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The role and regulation of VEGF-mediated ERK5 activity in 
endothelial cells 
Extracellular signal-regulated kinase 5 (ERK5) is the newest member of the mitogen-
activated protein kinase (MAPK) family following the discovery of ERK1/2, JNK and p38 
MAPK. ERK5 consists of an N-terminal kinase domain, similar to the other MAPK members, 
and a large C-terminal domain, which is unique in structure and function from the other 
MAPK members. ERK5 is activated in response to a multitude of extracellular stimuli, 
including pro-angiogenic factors in endothelial cells. The physiological importance of ERK5 
was highlighted following Erk5 gene ablation in mice, where a severe disruption to 
cardiovascular development and loss of vascular integrity was observed, resulting in 
embryonic lethality. 
This study investigated the differences in ERK5 activation between vascular endothelial 
growth factor (VEGF) stimulation of primary human dermal microvascular endothelial cells 
(HDMECs) compared to epidermal growth factor (EGF) stimulation of HeLa (immortalised 
epithelial cervical cancer cell line) cells. It was discovered that in contrast to other 
growth factors, VEGF appeared unique in its ability to induce ERK5 phosphorylation in 
HDMECs, stimulating ERK5 activity via a VEGFR-2/PLCγ-dependent pathway. Utilisation of 
the innovative Phos-tag™ reagent in SDS-PAGE facilitated the novel discovery that VEGF 
was only able to induce phosphorylation of the threonine (Thr)218/tyrosine (Tyr)220 residues 
present within the activation loop of the kinase domain. In contrast, EGF stimulation of 
HeLa cells resulted in phosphorylation of ERK5 on Thr218/Tyr220 as well as additional C-
terminal residues such as Thr732. It was further demonstrated that contrary to EGF, VEGF 
stimulation of HDMECs did not evoke a nuclear translocation of ERK5, instead, ERK5 
appeared to localise to the cytoplasm and plasma membrane. The analysis of intracellular 
signalling pathways following treatment with small-molecule inhibitors against MAPK/ERK 
kinase 5 (MEK5) and ERK5 kinase activity, revealed that VEGF-mediated ERK5 activation 
regulated phosphorylation of AKT in HDMECs. Furthermore, with an apparent co-
localisation of ERK5 and AKT in the cytoplasm and at the plasma membrane of HDMECs, it 
was hypothesised that the two proteins were interacting partners. Adenoviral-mediated 
expression of FLAG-tagged ERK5 revealed that VEGFR-2, ERK5 and AKT co-
immunoprecipitated in HDMECs, suggesting the possibility of a complex between these 
proteins at the cell periphery following VEGF stimulation and VEGFR-2 internalisation. 
Taken together, this study shows that VEGF appears to induce a unique activation of ERK5 
in endothelial cells, which facilitates its interaction with AKT and subsequent regulation of 
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1.1 Embryonic vascular development 
1.1.1  Vasculogenesis 
The de novo formation of the primitive vascular plexus during embryogenesis is referred to 
as vasculogenesis and is a multi-step process. The progression from the single-layered 
blastula into the tri-laminar gastrula gives rise to the three germ layers – the ectoderm, 
mesoderm and endoderm (Figure 1.1). Of these layers, cells derived from the mesoderm 
undergo differentiation to become angioblasts, which fuse together to form blood islands. 
Aggregation of these blood islands along with further differentiation into endothelial cells 
results in the primitive vascular network (Figure 1.1) (Risau and Flamme, 1995). In mice, 
aggregation of the angioblasts occur at embryonic day 6.5 (E6.5) and the primary vascular 
network is established at E8.0-E8.5 (Haar and Ackerman, 1971). It is essential that a 
functional plexus is constructed in order for murine embryos to survive beyond E9.5 
(Srivastava and Olson, 2000). 
 
 
Figure 1.1 Stages of vasculogenesis.  
(A) Structure of the gastrula. The tri-laminar gastrula is formed during gastrulation, in which the 
single-layered blastula undergoes cleavage at the primitive streak to result in the three germ layers – 
the ectoderm (teal), mesoderm (magenta) and endoderm (purple) – which envelop the archenteron 
(primitive gut; yellow). (B) Formation of the primitive vascular plexus. Mesoderm-derived cells 
differentiate into angioblasts. Fusion, aggregations and further differentiation of the blood islands 
give rise to the primitive vascular plexus in the yolk sac. Diagrams adapted from (A) (Brauckmann 
and Gilbert, 2004), and (B) (Heinke et al., 2012). 
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1.1.2  Angiogenesis 
Angiogenesis is defined as the formation of new blood vessels from pre-existing ones and 
occurs following the formation of the primary vascular network, therein remodelling the 
plexus to enable blood vessels to reach the extremities of the developing embryo (Risau, 
1997; Carmeliet, 2000). Normal embryonic development is dependent upon angiogenesis, 
however this process remains in a state of quiescence postpartum, with only a few 
physiological exceptions including wound reparation (Li et al., 2003) and endometriosis 
(Groothuis et al., 2005).  
Two distinct mechanisms of angiogenesis exist namely, intussusception and sprouting. 
During intussusceptive angiogenesis, interstitial cellular columns are inserted into the 
lumen of pre-existing vessels; the growth and stabilisation of these columns leads to a 
partitioning of the vessel and subsequent remodelling of the local vascular network (Risau, 
1997). Sprouting angiogenesis however is somewhat more dynamic, whereby several 
diverse processes coordinate neovessel growth and stabilisation, shown schematically in 
Figure 1.2 (Klagsbrun and Moses, 1999; Vailhe et al., 2001). 
The initial neovessel growth in angiogenesis is stimulated by the presence of factors such 
as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) in the 
immediate microenvironment surrounding the endothelial cells (Folkman and Shing, 1992; 
Klagsbrun and Moses, 1999; Pearson, 2000). The binding of these angiogenic growth factors 
to their cognate receptors present on the endothelial cells of pre-existing vessels, induces 
a loss of pericyte coverage, an increase in vascular permeability and secretion of 
proteases to degrade the basement membrane and the surrounding interstitial matrix 
(Bergers and Song, 2005; van Hinsbergh et al., 2006). The leading ‘tip’ endothelial cell 
migrates into the space created in the matrix along the concentration gradient of the 
angiogenic factor (Gerhardt and Betsholtz, 2003), succeeded by proliferating ‘stalk’ 
endothelial cells to collectively form an endothelial sprout with a lumen (Figure 1.2) 
(Vailhe et al., 2001). 
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Figure 1.2 Sprouting angiogenesis.  
Neovessel growth from a pre-existing blood vessel is stimulated by the presence of angiogenic 
factors in the microenvironment surrounding endothelial cells (ECs) (1). Upon binding of the growth 
factor to its cognate receptor on the EC, the cell becomes activated and secretes proteases (2). 
Degradation of the basement membrane and interstitial matrix creates a space into which the ‘tip’ 
EC migrates, followed by proliferating ‘stalk’ ECs to form an unstable vessel with a lumen (3). ECs 
secrete extracellular matrix proteins and growth factors in order to reconstruct the basement 
membrane and recruit pericytes for neovessel stabilisation (4). Diagram modified from (Klagsbrun 
and Moses, 1999). 
 
The lumen is formed though the anastomoses of two sprouts and neovessel stabilisation, 
whereby the secretion of extracellular matrix proteins reconstructs the basement 
membrane, and mural cells such as pericytes are recruited to support the immature vessel 
(Figure 1.2) (Carmeliet, 2000; Jain, 2003; Fantin et al., 2010). Vessel stabilisation is 
critical for survival of the vessel; its absence results in rapid apoptosis and as a 
consequence, vessel regression. This emphasises the equal importance of both the growth 
and stabilisation phases of sprouting angiogenesis (Benjamin et al., 1998). 
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1.1.3  The vascular system 
The vascular network that is generated as a consequence of vasculogenesis and 
angiogenesis is the first functional organ to develop during embryogenesis. It is a complex 
system that is of fundamental importance in all vertebrates as it facilitates the supply of 
oxygen and nutrients to their organs whilst simultaneously removing metabolic waste 
products. In addition to this, the vascular system permits the movement of immune cells 
to sites of infection or inflammation, as well as the rapid transport of endocrine signals to 
their effector organs (Rossant and Howard, 2002). 
 
 
Figure 1.3 Cross-section of blood vessel structure.  
Illustration of a large blood vessel such as an artery or vein (A) and a small vessel such as a capillary 
or arteriole (B). Diagrams adapted from (McGeachie, 2014) and (EducationalForum, 2014). 
 
The cardiovascular system is a highly branched tubular network of blood vessels. The 
vessel lumens are lined with a monolayer of endothelial cells. Large blood vessels such as 
arteries and veins have three layers: the outermost layer (adventitia) comprises loose 
connective tissue, smaller blood vessels and nerves, the middle layer (media) consisting of 
multiple sheets of vascular smooth muscle cells, and the inner layer (intima) lining the 
luminal surface with a single layer of macrovascular endothelial cells, which is surrounded 
by the basement membrane (Figure 1.3). Small blood vessels such as capillaries and 
arterioles however, are lined by a monolayer of microvascular endothelial cells, encased 
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in the basement membrane and stabilised by specialised smooth muscle cells known as 
pericytes (Figure 1.3) (Lafleur et al., 2003; Gallagher and van der Wal, 2006). 
Endothelial cells display a significant amount of heterogeneity across the vascular tree; 
the most apparent difference being their morphology (Aird, 2007). Typically, endothelial 
cell are flat in structure, however in high endothelial venules they exhibit a cuboidal or 
plump shape (Kumar et al., 1987; Girard and Springer, 1995; Miyasaka and Tanaka, 2004). 
In addition to this, endothelial cells from different organs also demonstrate diversity with 
regards to their function. For example, the basal and inducible permeability of 
endothelium are differentially regulated (Aird, 2007). The mechanisms of endothelial 
heterogeneity are mediated by spatial and time differences in the endothelium; blood 
vessels are located throughout the body, exposing the endothelial cells to a variety of 
tissue microenvironments (Aird, 2012). Furthermore, the molecular and biochemical 
properties of endothelial cells differ vastly across the vascular tree (Kumar et al., 1987; 
Garlanda and Dejana, 1997; Jackson and Nguyen, 1997; Conway and Carmeliet, 2004; 
Hewett, 2009). Thus, since the majority of the human vasculature (over 95%) is comprised 
of microvessel endothelium, the use of these cells is more physiologically relevant for in 
vitro models of endothelial cell function and angiogenesis (Hewett, 2009). 
1.1.4  Tumour angiogenesis and therapeutic targeting 
The strictly coordinated process of physiological angiogenesis as previously described in 
Section 1.1.2, is critical to normal embryonic development. However, the pathogenesis of 
numerous diseases has been shown to be associated with dysregulated angiogenesis 
(Folkman, 1995) and of these pathologies, the role of angiogenesis in tumour development 
has been of significant interest. Since the 1970s, Folkman et al. have proposed and 
substantiated the theory that neoangiogenesis was the crux for tumour growth and 
metastasis (Folkman, 1971; Folkman, 1990; Folkman and Shing, 1992). Today, it is well 
established that the growth of solid tumours over 1-2 mm3 requires an adequate blood 
supply to deliver nutrients and oxygen (Muthukkaruppan et al., 1982), without which 
tumours can become necrotic or apoptotic (Holmgren et al., 1995). Consequently, tumour 
angiogenesis has become one of the hallmarks of cancer (Hanahan and Weinberg, 2011). 
A hypoxic environment is created by the limited capacity of oxygen to diffuse through the 
tumour mass (Dor et al., 2001), and in response to this decreased concentration of oxygen, 
the transcription factor hypoxia-inducible factor-1 alpha (HIF-1α) is upregulated 
(Semenza, 2007). HIF-1α dimerises with HIF-1 beta (HIF-1β) and regulates the expression 
of numerous hypoxia responsive genes, such as VEGFR-1 and VEGF-A (Carmeliet, 2005; 
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Ferrara, 2009). Additionally, angiostatic factors like endostatin and thrombospondin-1 
(TSP-1) are decreased resulting in a phenotypic change referred to as the activation of the 
‘angiogenic switch’ (Kazerounian et al., 2008). This switch remains on, thus enabling and 
sustaining neoplasia (Hanahan and Folkman, 1996; Carmeliet, 2005). 
Although tumour-induced vessels are functionally similar to normal vasculature in that 
they transport metabolites, they are structurally distinct. Unlike normal vessels, 
characteristics of tumour vessels include thin leaky walls due to the presence of fenestrae, 
irregularly-shaped vessels that are convoluted, the absence of a complete basement 
membrane and vessel immaturity due to a lack of pericyte stabilisation (Carmeliet, 2000; 
Hashizume et al., 2000; Hellström et al., 2001; Morikawa et al., 2002). In addition to 
these attributes, endothelial cells derived from neoplasia display differential gene 
expression to those derived from normal vasculature (Seaman et al., 2007). In particular, 
high levels of expression of VEGF and its receptors have been observed in a wide variety of 
human cancers (Plate et al., 1993; Ferrara and Davis-Smyth, 1997; Nishida et al., 2006), 
hence the rationale to focus on these targets for anti-angiogenic therapies (Holmes et al., 
2007; Soltau and Drevs, 2009). 
The past decade has led to the introduction of numerous anti-VEGF(R) targeted therapies 
for a range of different carcinomas. The first U.S. Food and Drug Administration (FDA) 
approved anti-angiogenic agent was bevacizumab (Avastin®; a recombinant humanised 
monoclonal antibody against VEGF-A) in 2004, for the treatment of metastatic colorectal 
cancer (mCRC) in combination with chemotherapeutic agents (Hurwitz et al., 2004). It has 
since been approved for use in metastatic renal cell carcinomas (mRCC) combined with 
interferon-alpha (IFN-α) (Escudier et al., 2007b; Rini et al., 2010) and it is suggested that 
its success is partly due to the normalisation of tumour vasculature, thereby enhancing 
delivery of chemotherapeutic agents into the tumour mass (Jain, 2005; Kerbel, 2006). 
Subsequently, agents targeting receptor tyrosine kinases (RTKs) have been successfully 
developed; sorafanib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), axitinib 
(Inlyta®) were FDA approved in 2005, 2006, 2009 and 2012 respectively, for the treatment 
of various cancers including renal cell carcinoma (RCC), hepatocellular carcinoma and 
gastro-intestinal stroma tumours (GIST) (Escudier et al., 2007a; Motzer et al., 2007; 
Sonpavde and Hutson, 2007; Llovet et al., 2008; Sternberg et al., 2010; Rini et al., 2011). 
The main mode of action for these small-molecule RTK inhibitors is to block the VEGF 
receptors (VEGFR-1, -2, -3) thereby preventing subsequent activation of the downstream 
signalling pathways, however they are multi-targeting, acting on receptors such as the 
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platelet-derived growth factor receptors (PDGFRs), as well as other kinases including Raf 
and c-kit (Sonpavde and Hutson, 2007; Wilhelm et al., 2008). 
Despite the success of these anti-VEGF(R) therapies there are numerous hurdles that are 
frequently encountered. A major adverse effect of these treatments is hypertension; VEGF 
causes vasodilation and hypotension (Ku et al., 1993; Henry et al., 2003), which is 
considered to be mediated by VEGFR-2 stimulation of nitric oxide (Ferrara, 2004). 
Additional side effects have been observed with the anti-VEGF(R) inhibitors, which are 
attributed to changes in normal vasculature, in particular endothelial dysfunction and 
pruning of healthy vessels (Inai et al., 2004; Hayes, 2011). Furthermore, the benefits of 
these types of treatment are short-lived due to the rapid regrowth of tumour vasculature 
and consequently tumour growth, upon withdrawal of these therapies (Inai et al., 2004; 
Mancuso et al., 2006). Resistance to these treatments poses another challenge, as some 
patients are refractory to these therapies whereas others acquire resistance due to a 
substantial amount of redundant signalling and compensation mechanisms (Bergers and 
Hanahan, 2008; Eikesdal and Kalluri, 2009; Weis and Cheresh, 2011). These issues 
emphasise the importance for new anti-angiogenic targets to be identified and developed. 
Due to the significant cross-talk of intracellular signalling pathways upon the binding of 
angiogenic factors to their cognate receptors, rather than focussing efforts to inhibit 
multiple angiogenic signalling cascades, a more viable strategy of therapeutic inhibition 
may be to target the activity of intracellular signalling hubs where these pathways 
converge (Rossant and Howard, 2002; Weis and Cheresh, 2011). 
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1.2 VEGF/VEGFR-2 signalling in endothelial cells 
1.2.1  VEGF 
The term VEGF is a description of the family of homodimeric glycoproteins, as well as the 
prototypic growth factor which was first described as vascular-permeability factor (VPF) 
by Dvorak and colleagues (Senger et al., 1983). In mammals, there are five structurally 
related members, VEGF (also designated VEGF-A and VEGF-A165), VEGF-B, VEGF-C, VEGF-D 
and placenta growth factor (PlGF), with additional homologues such as the parapoxvirus 
Orf virus-encoded VEGF, denoted VEGF-E, and the snake venom VEGF, assigned VEGF-F 
(Lyttle et al., 1994; Yamazaki et al., 2003).  
Furthermore, alternative splicing of the VEGF-A gene in humans results in six variants of 
differing amino acid lengths (denoted as VEGFXXX) VEGF121, VEGF145, VEGF165, VEGF183, 
VEGF189 and VEGF206 (Houck et al., 1991; Tischer et al., 1991; Poltorak et al., 1997; 
Jingjing et al., 1999). With the exception of VEGF121, the other VEGF splice variants 
contain a heparin-binding domain enabling their binding to cell surface heparan sulphate 
proteoglycans (HSPGs) and/or the extracellular matrix, as encoded for by exons 6 and 7 of 
VEGF (Tischer et al., 1991; Park et al., 1993). VEGF121 lacks both exons 6 and 7 thus does 
not bind HSPGs, and as such is a freely diffusible acidic protein (Holmes et al., 2007). 
Additionally, there exists a family of VEGF-A splice variants as a result of alternative 
splicing of exon 8. These variants are denoted VEGF(XXX)b and are able to bind, but are 
unable to efficiently activate the cognate VEGF receptors, hence are described as anti-
angiogenic (Harper and Bates, 2008). 






VEGFR-3 VEGFR-3 NRP1 NRP2  
VEGF-A ! ! ! ! " ! ! 
VEGF-B ! " " " " ! " 
VEGF-C " " ! ! ! " ! 
VEGF-D " " ! ! ! " " 
VEGF-E " " ! ! " ! " 
PlGf ! ! " " " ! ! 
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VEGF165 is the most abundant and biologically active isoform in humans and is produced by 
a variety of cells such as macrophages, vascular smooth muscle cells and tumour cells 
(Berse et al., 1992). It is secreted as a homodimeric protein, linked by covalent bonds and 
stabilised by intra- and inter-chain disulphide bonds (Pötgens et al., 1994; Muller et al., 
1997). Under normal physiological conditions the expression of VEGF is low, however 
conditions such as growth factor stimulation (e.g. FGF-2), oxygen tension or an aberration 
in the pH level, result in increased VEGF levels (Shweiki et al., 1992; Stavri et al., 1995; 
Carmeliet and Jain, 2000). Furthermore, metabolic regulators and transcription factors 
such as reactive oxygen species (ROS) and the E26 transformation-specific (ETS) family are 
able to regulate VEGF expression (Ushio-Fukai and Nakamura, 2008; Randi et al., 2009).  
The VEGF family as a whole is essential for normal embryonic development via the 
processes of vasculogenesis, lymphangiogenesis and angiogenesis, however it is the 
original growth factor, VEGF-A, that plays a pivotal role (Coultas et al., 2005). It was 
concurrently observed by two separate groups, that Vegf-a-/- and Vegf-a+/- heterozygous 
mice both exhibited fatal defects in vascular development (Carmeliet et al., 1996; Ferrara 
et al., 1996). The Vegf-a-/- mice died at embryonic day 9.5-10.5 (E9.5-10.5) whereas the 
Vegf-a+/- heterozygous mice died at E11.0-12.0 suggesting that embryonic vessel 
development may in fact be VEGF dose-dependent (Carmeliet et al., 1996; Ferrara et al., 
1996; Holmes et al., 2007). This dependence on VEGF was discovered to be essential in the 
early postnatal life of mice and diminished as the animal matured, eventually being lost 
after the fourth postnatal week, potentially due to having more stable vessels covered 
with pericytes (Kitamoto et al., 1997; Gerber et al., 1999). Interestingly, the consequence 
of a three-fold VEGF overexpression in mice was normal early vascular development, 
however these embryos later died between E12.5-E14.5, with observations of larger than 
normal hearts and abnormally thin ventricular walls (Miquerol et al., 2000). 
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1.2.2  VEGF receptors 
The VEGF ligands signal through three structurally related cell surface RTKs, denoted VEGF 
receptor (VEGFR) -1, -2 and -3, as well as two transmembrane non-tyrosine kinase co-
receptors neuropilin (NRP) -1 and -2. The RTKs are expressed in a distinct manner – 
VEGFR-1 (Flt-1) is expressed on haematopoietic stem cells, macrophages and monocytes, 
VEGFR-2 (Flk-1/KDR) is expressed on vascular endothelial cells and VEGFR-3 (Flt-4) is 
expressed on lymphatic endothelial cells – however some overlap does occur with the 
expression of VEGFR-1 and -2 on other cell types (Holmes et al., 2007; Koch and Claesson-
Welsh, 2012). The various VEGF isoforms bind to different receptors, with VEGF-A binding 
to both VEGFR-1 and -2, whereas VEGF-B and PlGF exclusively bind to VEGFR-1. The pro-
peptide forms of VEGF-C and VEGF-D bind to VEGFR-3, however the mature forms of these 
ligands can bind to VEGFR-2 as well. Finally, the viral VEGF-E ligand solely binds to VEGFR-
2. Additionally, the binding of VEGFs to the NRP receptors has been shown to result in a 
complex with VEGFR-2 thus enhancing VEGFR-2 functionality (Whitaker et al., 2001; Soker 
et al., 2002; Holmes et al., 2007). 
1.2.2.1 VEGFR-1 
VEGFR-1 (Flt-1) is expressed on endothelial cells, haematopoietic cells and monocytes, 
with the ability to bind VEGF-A, -B and PlGF. It has been reported that a splice variant of 
VEGFR-1 exists; devoid of the transmembrane and internal signalling domains, it is termed 
soluble VEGR-1 (sVEGFR-1). It is proposed that sVEGFR-1 acts as a decoy receptor to 
sequester VEGF and negatively regulate VEGFR-2 signalling (Shibuya et al., 1990; Kendall 
and Thomas, 1993; Roberts et al., 2004). The physiological role of VEGFR-1 was uncovered 
when it was observed that Vegfr-1-/- mice died at E8.5-9.0 due to an overproduction of 
haemangioblasts, leading to disorganised vasculature (Fong et al., 1995; Fong et al., 
1999). Since then it has been demonstrated that in endothelial cells, ligand binding to 
VEGFR-1 as well as fixation of the extracellular domain of VEGFR-1 via the transmembrane 
domain, were essential for normal vascular development, whereas downstream signalling 
of VEGFR-1 was dispensable (Hiratsuka et al., 1998; Hiratsuka et al., 2005). Somewhat 
more recently it has been proposed that VEGFR-1 may act as a spatial control for VEGFR-2 
signalling and branching of angiogenic sprouts by capturing VEGF (Kappas et al., 2008). 
1.2.2.2 VEGFR-2 
VEGFR-2 is the main VEGF receptor on endothelial cells; 12,400 receptors/cell are 
reported to be present on human umbilical vein endothelial cells (HUVECs) (Chen et al., 
2001a) and 7,300 receptors/cell expressed on human dermal microvascular endothelial 
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cells (HDMECs) (Imoukhuede and Popel, 2011). Furthermore, a crucial role of VEGFR-2 in 
vascular development was emphasised when it was observed that VEGFR-2 null-mice died 
at E8.5-9.5 due to developmental defects of the haematopoietic cells, blood islands and 
endothelial cells (Shalaby et al., 1995). Thus the high levels of VEGFR-2 expression on 
endothelial cells, as well as its physiological significance, form the basis of focussing on 
this receptor in HDMEC. 
VEGFR-2, also known as kinase-insert domain receptor (KDR) in humans and foetal liver 
kinase (Flk)-1 in mice, is a class III transmembrane kinase receptor comprising of 1356 
amino acids (Terman et al., 1991). Flk-1 shares 85% sequence homology with KDR, 
however it is 2 amino acids shorter in length (Holmes et al., 2007). It has been observed 
that VEGFR-2 exists in two forms, an immature form without significant glycosylation and 
of 150 kDa molecular weight, as well as a mature glycosylated form of 230 kDa that is 
expressed on the surface of the cell (Takahashi and Shibuya, 1997). 
The extracellular domain of VEGFR-2 is made up of seven Ig-like domains, of which 
domains 2 and 3 bind VEGF (Figure 1.4) with a Kd of 75-125 pM (Fuh et al., 1998; Shinkai et 
al., 1998). The binding of VEGF to a VEGFR-2 monomer, induces a second VEGFR-2 
monomer to bind to the tethered ligand, holding the two receptors in close proximity to 
stabilise the dimerisation with additional low-affinity interactions between the Ig-like 
domains (Ruch et al., 2007; Yang et al., 2010b). Consequently, the intracellular kinase 
domains of the receptors are correctly positioned for trans-autophosphorylation of several 
tyrosine (Tyr; Y) residues. Studies using mammalian cells that overexpress KDR, 
established five major phosphorylation sites namely, Y951 within the kinase-insert domain, 
Y1054 and Y1059 present in the kinase domain, and Y1175 and Y1214 in the carboxyl (C)-
terminal tail of the receptor (Figure 1.4) (Takahashi et al., 2001; Matsumoto et al., 2005). 
These phosphorylated tyrosine residues create binding sites for specific proteins that 
contain an Src homology 2 (SH2) domain. VEGF-receptor associated protein (VRAP) also 
known as T-cell specific adaptor molecule (TSAd) binds to phosphorylated (p-) Y951 (Wu et 
al., 2000b; Matsumoto et al., 2005), whereas p-Y1214 is the binding site for the adaptor 
protein Nck (non-catalytic region of tyrosine kinase adaptor protein 1) (Lamalice et al., 
2006). Phosphorylated Y1175 provides a docking site for numerous signalling molecules, 
including SH2-containing (Shc)-like protein (Sck), phospholipase C-gamma (PLC-γ) and SH2 
protein B (Shb), (Cunningham et al., 1997; Warner et al., 2000; Takahashi et al., 2001; 
Holmqvist et al., 2004). 
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Figure 1.4 VEGFR-2 structure, tyrosine phosphorylation sites and dimerisation. 
VEGFR-2 is a class III receptor tyrosine kinase composed of 1356 amino acids. There exist seven Ig-
like domains (I-VII) on the extracellular domain, of which the domains II and III bind the ligand, 
VEGF-A. The intracellular domain comprises of two kinase domains, separated by a kinase insert 
domain. The five major phosphorylation sites identified, Y951, Y1054, Y1059, Y1175 and Y1214, 
along with their various binding proteins for downstream signalling, are highlighted. Figure adapted 
from (Holmes et al., 2007). 
 
1.2.2.3 VEGFR-3 
VEGFR-3 (Flt-4) is expressed on all endothelial cells during development, however its 
expression is restricted to lymphatic endothelial cells in adults (Olsson et al., 2006; Lohela 
et al., 2009). VEGFR-3 is only able to bind VEGF-C and –D, and gene targeting studies have 
shown that it is Vegfc that is vital for sprouting lymphangiogenesis (Karkkainen et al., 
2002; Karkkainen et al., 2004). The physiological role of VEGFR-3 was revealed upon Flt-4 
ablation in mice, which proved embryonically lethal at E9.5. Flt-4-/- embryos were 
observed to have an accumulation of fluid in the pericardium cause by leaky vasculature, 
prior to the onset of lymphangiogenesis (Dumont et al., 1998). 
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1.2.2.4 VEGF co-receptors: NRP-1 and NRP-2 
The transmembrane glycoproteins NRP-1 and NRP-2 are additional receptors for VEGF. 
NRPs are class III semaphorins with a conserved primary structure divided into four 
domains: CUB (a1/a2), FV/FVIII (b1/b2), MAM (c) and domain (d) comprising of a 
transmembranous and short cytoplasmic region (Figure 1.5a) (Parker et al., 2012; 
Kumanogoh and Kikutani, 2013). The NRPs require an additional transmembrane molecule 
to exhibit kinase activity and in the case of VEGF binding, the co-receptor is a VEGF 
receptor (Figure 1.5b). Furthermore, NRPs are able to act as an isoform specific co-
receptor for VEGF as they require the presence of exon 7 of the VEGF molecule, thus NRPs 
are able to bind VEGF165, but not VEGF121 (Neufeld et al., 2002). The expression of NRP-1 is 
restricted to the heart vasculature wherein it functions as a co-receptor with VEGFR-2 
(Soker et al., 1998; Whitaker et al., 2001). Rather interestingly, the VEGFR-2/NRP-1 
heterodimer binds VEGF165 with a four-fold greater affinity than the VEGFR-2 homodimer, 
and as a consequence, it has been shown to enhance VEGF-induced endothelial cell 
proliferation and migration (Soker et al., 1998; Soker et al., 2002). NRP-1 has been shown 
to be vital for normal vascular development, as global Nrp-1-/- mouse embryos die at E14.0 
presenting with cardiovascular defects (Kawasaki et al., 1999), and endothelial-specific 
Nrp-1 deletion leads to vascular abnormalities (Gu et al., 2003). NRP-2 plays an important 
role in lymphatic vessel development; Nrp-2-/- mice are viable but display decreased 
lymphatic growth (Yuan et al., 2002). NRP-2 has also been observed to act as a co-
receptor with VEGFR-2 and VEGFR-3 in endothelial cells, thereby enhancing VEGF-




Chapter One: General Introduction 
15 
 
Figure 1.5 Primary structure of Neuropilins and their binding with VEGFRs. 
(A) The NRPs consist of four domains, two repeats (a1/a2) of the CUB (complement C1r/C1s, Uegf, 
Bmp1) domain at the N-terminal, which are followed by two repeats (b1/b2) of the FV/FVIII 
(coagulation factor 5/8) domain, the MAM (Meprin, A-5 protein and receptor protein-tyrosine 
phosphatase µ) and a transmembrane/cytoplasmic region. NRP1 has an additional PDZ binding motif 
at the C-terminal. (B) A VEGF isoform containing exon 7 e.g. VEGF165, binds to the FV/FVIII domain of 
NRP1 and domains II and III of VEGFR. 
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1.2.3  Intracellular VEGFR-2 signalling and the regulation of endothelial cell 
physiology 
The propagation of the signal induced by VEGF-stimulated activation of VEGFR-2, confers a 
multitude of diverse functions in endothelial cells including proliferation, survival, 
migration, differentiation, transcriptional activation and permeability (Zachary, 2003; 
Holmes et al., 2007). Various intracellular signalling pathways downstream of VEGFR-2 
mediate these functions however only those implicated in cell proliferation and survival 
will be elaborated upon. 
1.2.3.1 PLC-γ-mediated proliferation in endothelial cells 
VEGFR-2 has a unique pathway through which it induces proliferation; it does not activate 
the extracellular signal-regulated kinases (ERKs, also known as mitogen-activated protein 
kinases or MAPKs) via the classical growth factor receptor-bound protein 2 (Grb2)-son of 
sevenless (Sos)-rat sarcoma (Ras) pathway, instead via PLC-γ activation and subsequently 
the protein kinase C (PKC) pathway (Takahashi et al., 2001).  
As previously mentioned in Section 1.2.2.2 p-Y1175 provides a docking site for PLC-γ, 
which in turn is phosphorylated prior to hydrolysing the membrane phospholipid, 
phosphatidylinositol (4,5)-bisphosphate (PIP2), into inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) (Wu et al., 2000a). The production of IP3 increases the concentration 
of intracellular calcium whereas DAG activates PKC. Thus, various PKC isoforms have been 
associated with VEGF-mediated proliferation, including PKC-α, -β, and –ζ (Xia et al., 1996; 
Takahashi et al., 1999; Wellner et al., 1999). 
Classically, the proliferation-inducing ERK1/2 pathway is activated by Ras, however the 
specific mechanism through which Ras is implicated in VEGFR-2 mediated signalling 
remains unclear. Initial studies suggested VEGF-stimulation of Ras occurred via a PKC and 
sphingosine kinase pathway in HUVECs (Meadows et al., 2001; Shu et al., 2002), however it 
remains possible that an unidentified adaptor molecule may be involved in coupling 
VEGFR-2 to the GrbB2-Sos-Ras pathway, as Ras hyperactivation has been shown to induce a 
pro-angiogenic phenotype (Meadows et al., 2004; Bajaj et al., 2010). 
The significance of PLC-γ in angiogenesis was revealed with the use of PLC-γ1 deficient 
mice embryos; a considerable decrease in vasculogenesis and erythropoiesis occurred 
resulting in death at E9.0 (Ji et al., 1997; Liao et al., 2002). In addition to this, it was 
observed that the VEGF/VEGFR-2/PLC-γ1 axis is required for arterial development, as PLC-
γ1 deficient zebrafish embryos did not respond to exogenous VEGF (Lawson et al., 2003).  
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Furthermore, after initial observations revealing the importance of Y1173 in Flk-1 (Y1175 
in KDR) (Takahashi et al., 2001), later studies utilised mice with a Y1173F mutation (F 
represents phenylalanine) knock-in to emphasise these findings; defects in the endothelial 
and haematopoietic cells resulted in embryonic lethality at E8.5-9.5 similar to Flk-1 null 
mice (Shalaby et al., 1995; Sakurai et al., 2005). However, whether this is a consequence 
of a lack of PLC-γ activation and subsequently the ERK1/2 cascade, is unclear as Shb and 
Sck also bind to this residue (Warner et al., 2000; Holmqvist et al., 2004). It may be that 
PLC-γ activation regulates the function of proliferation in angiogenesis, whereas Shb and 
Sck binding to Y1173 may mediate other critical functions of angiogenesis. Studies have 
shown that Shb deficient mice exhibit dysfunctional microvasculature with a decrease in 
VEGF-induced vascular permeability and increased density of the arterioles as well as a 
reduced number of microvasculature branch points, possibly due to decreased levels of VE-
cadherin (Funa et al., 2009; Christoffersson et al., 2012; Zang et al., 2013). The 
phenotypic analysis of Sck deficient mice has yet to be determined. 
1.2.3.2 PI3K/AKT-induced survival of endothelial cells 
Phosphotidylinositide 3’-kinases (phosphoinositide 3’ kinases or PI3Ks) are a family of 
related phosphate kinases capable of catalysing the phosphorylation of the 3-position 
hydroxyl group on the inositol ring of plasma membrane-associated phosphoinositides. 
Activation of PI3K occurs upon growth factor stimulation and generates membrane-bound 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) as a result of PIP2 phosphorylation. As a 
consequence, the phosphoinositide-dependent kinases 1 and 2 (PDK1 and PDK2) are 
recruited to membrane-bound PIP3 which subsequently phosphorylate the serine/threonine 
kinase protein kinase B (PKB/AKT) (Anderson et al., 1998; Cantley, 2002). The binding of 
PDK1 and AKT to PIP3 via their pleckstrin-homology (PH)-domains enables PDK1 to 
phosphorylate AKT on Thr308 in its catalytic domain (Alessi et al., 1997; Stokoe et al., 
1997). Additionally, full AKT activity is obtained upon phosphorylation of Ser473 situated on 
the regulatory C-terminal, which is thought to occur via autophosphorylation as well as 
phosphorylation by other kinases (Coffer et al., 1998; Lawlor and Alessi, 2001). Numerous 
potential kinases were reported to have PDK2 capabilities in phosphorylating AKT on 
Ser473, however it is mammalian target of rapamycin (mTOR)-complex 2 (mTORC2) that has 
been best characterised in this role (Dong and Liu, 2005; Sarbassov et al., 2005; Huang and 
Manning, 2009). In contrast, phosphatase and tensin homologue deleted on chromosome 10 
(PTEN) antagonises the PI3K/AKT pathway; loss of PTEN results in hyperactive PI3K 
signalling, leading to various cancers, thus it is one of the most important tumour 
suppressor genes (Suzuki et al., 2007; Salmena et al., 2008; Omerovic et al., 2010). 
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One of the most studied physiological consequences of the PI3K/AKT signalling pathway is 
cell survival, through phosphorylation and inhibition of pro-apoptotic proteins such as Bcl-
2 associated death promoter (BAD), caspase 9 and the Forkhead family of transcription 
factors (Datta et al., 1997; Cardone et al., 1998; Brunet et al., 1999). Additionally, it was 
shown that VEGF-mediated survival of HUVEC was dependent upon the VEGFR-2/PI3K/AKT 
axis (Gerber et al., 1998). Many potential mechanisms have been proposed to elucidate 
this mechanism, the first of which was that Shb binding to p-Y1175 may play a role 
(Holmqvist et al., 2004). Furthermore, the scaffold adaptor protein Grb2-associated 
binder-1 (Gab1) was initially observed to couple VEGFR-2 to PI3K/AKT via the p85 
regulatory subunit of PI3K, thereby activating PI3K (Dance et al., 2006), whereas Blanes et 
al. observed that autophosphorylation of Y801 on VEGFR-2 enabled direct binding of the 
p85 subunit of PI3K to induce its activation (Blanes et al., 2007). However, evidence has 
since been provided to show that Y801F/Y1214F mutations on VEGFR-2 inhibited Gab1 
phosphorylation, consequently impairing AKT activation in response to VEGF stimulation 
(Caron et al., 2009). In support of this, a more recent computational study recapitulated 
the finding that Gab1 knockdown decreased AKT phosphorylation (Tan et al., 2013). Thus 




1.3 Epidermal Growth Factor Receptor (EGFR) signalling  
1.3.1  Epidermal Growth Factor (EGF) 
In 1951 it was discovered that mouse tumours grafted onto chick embryos secreted a 
soluble, diffusible factor, which was able to stimulate the growth of nerve cells, thus 
termed nerve growth factor (NGF) (Levi-Montalcini and Hamburger, 1951). Purification of 
this crude NGF extract serendipitously revealed an additional growth factor that 
stimulated proliferation and keratinisation of epidermal cells, and was consequently 
termed epidermal growth factor (EGF) (Cohen and Levi-Montalcini, 1957; Cohen and Elliot, 
1963). Subsequent studies revealed a homologous human EGF polypeptide isolated from 
human urine (Cohen and Carpenter, 1975; Starkey et al., 1975). It was later discovered 
that urogastrone, a compound found in human urine that inhibits gastric acid secretion, 
was almost identical to EGF thus suggesting a potential new role for the growth factor 
(Gregory, 1975). 
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There are numerous other proteins that are structurally and functionally similar to EGF 
known as the EGF-like molecules including heparin-binding EGF-like growth factor (HB-
EGF), transforming growth factor-α (TGF-α), amphiregulin (AR), epiregulin (EPR), and 
epigen, amongst others (Shoyab et al., 1988; Massague, 1990; Higashiyama et al., 1992; 
Toyoda et al., 1995; Strachan et al., 2001; Harris et al., 2003). The mature forms of these 
growth factors are characterised by a conserved consensus sequence wherein 6 cysteine 
(cys; C) residues are spaced as follows: CX7CX4-5CX10-13CXCX8GXRC (G represents glycine, R 
is arginine and X represents any amino acid) and form three intramolecular disulphide 
bonds (Harris et al., 2003). The consensus sequence, known as the EGF motif, is essential 
for ligand binding to the family of EGF receptors. 
1.3.2  EGF receptors 
The EGF receptors (EGFRs), also known as the ErbB (derived from erythroblastic leukemia 
viral gene, to which these receptors are homologous) receptors, are similar to the VEGFRs 
in that they are transmembrane RTKs. In humans there are four structurally related 
members of the EGFR family: the original RTK ErbB1 (Her1, or EGFR-1 as it is referred to 
hereinafter), ErbB2 (Her2 in humans/Neu in rodents), ErbB3 (Her3) and ErbB4 (Her4) 
(Yarden and Sliwkowski, 2001). 
EGF and the EGF-like molecules can bind to the various receptors to result in homo- or 
hetero-oligomers with differing downstream signalling properties, however it is the 
ubiquitously expressed and prototypic EGFR-1 that will be discussed further. 
1.3.2.1 EGFR-1 
EGFR-1 is a glycoprotein of 170 kDa, comprising an extracellular receptor domain, a single 
membrane-spanning region as well as an intracellular tyrosine kinase domain (TKD) (Figure 
1.6) (Yarden and Sliwkowski, 2001). The extracellular region consists of four domains (I-
IV), of which domains I and III are leucine-rich repeat (LRR)-like and II and IV are cysteine-
rich. Prior to ligand binding, EGFR-1 exists in a tethered conformation, whereby 
intramolecular interactions between domains II and IV prevent dimerisation and activation 
(Ferguson et al., 2003). High-affinity EGF binding to EGFR-1 disrupts these intramolecular 
interactions, causing a conformational change to the extracellular region and subsequently 
revealing a previously concealed dimerisation arm in domain II. This dimerisation arm 
enables an intermolecular interaction with a second ligand-bound/activated receptor 
(Figure 1.6) (Ferguson et al., 2003; Dawson et al., 2005). 
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Unlike VEGFR-2, dimerised EGFR does not undergo trans-phosphorylation of tyrosine 
residues present on the cytoplasmic kinase domains. Instead, the intracellular TKDs form 
an asymmetric dimer whereby the C-lobe of one TKD acts as an “activator” and interacts 
with the N-lobe of the second TKD, called the “receiver” (Zhang et al., 2006) (Figure 1.6). 
This allosteric mechanism results in disruption of the monomeric cis-autoinhibitory 
interactions, enabling the “receiver” kinase to assume the active configuration with 
activation loop phosphorylation (Zhang et al., 2006). 
 
 
Figure 1.6 EGFR-1 structure, dimerisation and activation. 
EGFR-1 undergoes a structural change upon ligand binding and results in the activation of the 
intracellular kinase domain. The binding of ligands, such as EGF, leads to the exposure of a binding 
arm unique to EGFR-1, which facilitates dimerisation. The intracellular domains form an asymmetric 
dimer, whereby one receptor acts as an “activator” and the other as a “receiver”. Contact between 
the two receptors results in a conformational change in the N-lobe of the receiver receptor, 
consequently disrupting auto-inhibitory interactions present in the monomer. Figure adapted from 
(Lemmon and Schlessinger, 2010). 
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1.3.3  Downstream EGFR-1 signalling 
EGFR-1 is able to form heterodimers with other members of the ErbB family, preferentially 
ErbB2, thus it is difficult to unambiguously ascertain substrates of EGFR-1. Phosphorylation 
of the cytoplasmic kinase domains of EGFR-1 presents specific docking sites for the SH2 or 
phosphotyrosine-binding (PTB) domains of various scaffold/adaptor proteins. Recruitment 
and subsequent activation of these adaptor proteins in turn activate a multitude of 
downstream substrates, thereby forming a complex, interlinked signalling network, 
however it is the two canonical signalling pathways, Ras>ERK1/2 and PI3K/AKT, that will 
be discussed in more depth. 
1.3.3.1 Grb2, Shc and the Ras>ERK1/2 pathway 
Two proteins that play major roles in relaying EGF-induced EGFR signalling to activate the 
Ras/MAPK pathway are Grb2 and Shc (Lowenstein et al., 1992). Grb2 is found to have a 
cytosolic localisation and is constitutively bound to the Ras exchange factor, Sos. The SH2 
domain of Grb2 is able to bind to EGFR upon activation and phosphorylation of the kinase 
and there are reports of direct Grb2-EGFR association at residues Y1068 and Y1086 of the 
receptor (Batzer et al., 1994). Additionally, an indirect association of Grb2 and EGFR has 
been suggested through the binding of Shc to EGFR via its PTB domain, resulting in its 
tyrosine phosphorylation and consequent recruitment of the Grb2-Sos complex (Sasaoka et 
al., 1994). This latter mode of recruitment is proposed to play a dominant role in EGF-
stimulated Ras signalling (Sakaguchi et al., 1998), however findings contrary to this were 
observed in a different cellular system, whereby Ras activation was not affected by the 
loss of Shc (Hashimoto et al., 1999). The co-existence of these two pathways may be in 
order to perform different functional roles, or that cell-type specificity requires the 
dominance of one over the other. Nevertheless, the translocation of the Grb2-Sos complex 
to membrane-bound Ras assists the Ras-Sos interaction whereby Ras-bound GDP is 
exchanged for GTP, resulting in Ras activation, which subsequently activates the 
serine/threonine kinase, Raf-1 (Hallberg et al., 1994). A cascade of intermediate kinases 
enables Raf-1 to activate ERK1 and ERK2 via phosphorylation, leading to their nuclear 
translocation wherein transcription factors are phosphorylated (Johnson and Vaillancourt, 
1994). Furthermore, the Grb2-Sos complex undergoes dissociation due to ERK1/2 
phosphorylation of Sos, thereby acting as an inherent negative feedback loop (Langlois et 
al., 1995). 
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1.3.3.2 Gab1 and the PI3K/AKT activation 
Initial studies suggested that phosphorylation of EGFR could result in a direct association 
between the p85 regulatory subunit of PI3K and EGFR as a consequence of Src-induced 
phosphorylation of residue Y920 on the receptor (Stover et al., 1995). However it has since 
been reported that this interaction may in fact be due to EGFR/ErbB3 heterodimerisation, 
as the latter contains the required pYXXM motifs in order to bind the SH2 domains of the 
p85 subunit (Mattoon et al., 2004). Thus it has been established that EGF induction of the 
PI3K/AKT pathway occurring via EGFR homodimerisation, must occur through an indirect 
association mediated by the docking protein Gab1. 
It was observed that EGF stimulation of cells resulted in the tyrosine phosphorylation of 
Gab1, which facilitated the recruitment, binding (of the SH2 domains of the p85 
regulatory subunit) and subsequent activation of PI3K (Holgado-Madruga et al., 1996; 
Mattoon et al., 2004). Furthermore, Gab1 null mice presented significantly lower levels of 
PI3K activity, emphasising the importance of this adaptor protein in propagating the 
EGF/EGFR signal (Mattoon et al., 2004). 
1.3.4  EGFR-1 and carcinogenesis 
EGFR-1 activation usually leads to cellular growth, however its aberrant signalling plays a 
pivotal role in the onset and progression of numerous types of cancer (Salomon et al., 
1995; Normanno et al., 2001). Studies have shown that overexpression of EGFR-1, and the 
EGF-like peptides, can induce the neoplastic transformation of various cell types 
(Rosenthal et al., 1986; Watanabe et al., 1987; Di Marco et al., 1989; Shankar et al., 
1989; Ciardiello et al., 1990). More recently it has been demonstrated that EGFR-1 
overexpression can be induced by the hypoxic microenvironment of tumours as a result of 
increased EGFR-1 mRNA translation (Franovic et al., 2007), however it must also be noted 
that EGFR overexpression in the absence of gene amplification has also been observed 
(Salomon et al., 1995; Normanno et al., 2003). 
The involvement of EGFR-1 in carcinogenesis increases in complexity however, the 
receptor is able to form heterodimers with other members of the EGF family of receptors, 
namely ErbB-2, -3 and -4 (Yarden and Sliwkowski, 2001). Furthermore, mutations in the 
TKD of EGFRs have been discovered in patients with various types of cancer, which has 
facilitated the selection of the correct cohort of patients likely to respond to anti-EGFR 
agents (Normanno et al., 2006). Nevertheless, the integrated system through which an 
extracellular signal can be transmitted via other receptors, leads to the amplification and 
diversification of the signal (Normanno et al., 2006). Consequently, a multitude of cellular 
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functions required for tumour development are regulated by these receptors, including 




1.4 MAPK signalling 
1.4.1  MAPK modules: organisation, activation and physiological role 
The MAPKs are highly conserved enzymes expressed in all eukaryotic cells that are able to 
mediate a multitude of intracellular processes. A three-tiered hierarchical MAPK module 
exists, whereby the apical kinase, termed the MAPK kinase kinase (MAPKKK; MAPK/ERK 
kinase kinase; MEKK), first responds to extracellular stimuli such as growth factors, 
oxidative stresses and other stimuli (Boulton et al., 1991; Widmann et al., 1999) (Figure 
1.7). The MAPKKK phosphorylates its downstream target, the dual-specificity MAPK kinase 
(MAPKK; MAPK/ERK kinase; MEK) on specific serine (Ser; S) and threonine (Thr; T) 
residues, which in turn phosphorylates the threonine and tyrosine (Tyr; Y) residues of the 
conserved T-X-Y motif present within the activation loop of the terminal MAPK (Widmann 
et al., 1999; Zhang and Dong, 2007) (Figure 1.7). This sequential cascade enables 
phosphorylation and activation of the final MAPKs downstream effector proteins to 
generate a specific intracellular response (Lewis et al., 1998; Yang et al., 2003a; Yoon and 
Seger, 2006). These effector proteins include transcription factors, structural proteins, 
cytoplasmic enzymes and phospholipids (Chang and Karin, 2001), to regulate a variety of 
normal cellular function such as cell proliferation, differentiation, migration, survival and 
death (Yang et al., 2003a; Qi and Elion, 2005).  
As with most intracellular signalling pathways, MAPK signalling is also relatively complex 
and diverse; each MAPKK can be phosphorylated by more than one MAPKKK (Chang and 
Karin, 2001). Furthermore, there exists a cross-talk between the MAPKs to regulate critical 
functions, however the specificity of signal transfer to MAPKs is maintained by scaffold 
proteins and distinct docking interactions between individual components of each MAPK 
cascade (Whitmarsh and Davis, 1998; van Drogen and Peter, 2002; Morrison and Davis, 
2003). Consequently, an efficient signal transfer produces the required cellular response 
(Tanoue and Nishida, 2003; Raman et al., 2007). 
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Mammalian cells contain four distinct, classical MAPK cascades: extracellular signal-
regulated kinases (ERK) 1/2, c-Jun NH2-terminal kinases (JNK) 1/2/3, p38 proteins 
α/β/γ/δ and ERK5 (Nishida and Gotoh, 1993; Abe et al., 1996; Robinson and Cobb, 1997; 
Chang and Karin, 2001). Dual-phosphorylation of the Thr and Tyr residues within a T-X-Y 
motif in the activation loop of the kinase domain of the terminal MAPK results in its 
activation (X represents glutamic acid, proline, or glycine in the ERK, JNK and p38 
subfamilies respectively (Widmann et al., 1999)). ERK5 is the most recently identified 
MAPK and has been associated with a multitude of cellular processes including cellular 
proliferation, migration, survival and angiogenesis. 
 
Figure 1.7 Mitogen-activated protein kinase (MAPK) signalling cascades in mammalian cells. 
The four distinct MAPK cascades namely ERK1/2, ERK5, p38 MAPKs (α,β,γ,δ) and JNK 1/2/3, are 
arranged into a hierarchal three-tier system known as a MAPK module. Mitogens such as cytokines or 
growth factors, environmental stresses including oxidative or osmotic stress, as well as other 
extracellular stimuli, act via specific receptors to stimulate the MAPK cascade activation. The 
response begins with phosphorylation of an apical MAPKKK (or MEKK), activation of which 
sequentially phosphorylates and concomitantly activates the downstream MAPKK (or MEK). The 
MAPKK in turn dual-phosphorylates (denoted by a circled P) specific threonine (T) and tyrosine (Y) 
residues of the conserved T-X-Y motif present within the kinase domain, where X is glutamic acid (E) 
in ERK1/2 and ERK5; glycine (G) in p38 MAPKs and proline (P) in JNKs, to activate the terminal 
MAPK. A variety of downstream cytosolic or nuclear substrates, including other protein kinases such 
as p90RSK/SGK and transcription factors (MEF2C, Elk-1, Sap1a) are phosphorylated by the MAPKs to 
elicit a range of transcriptional or non-transcriptional changes that result in specific cellular 
responses e.g. cellular proliferation/differentiation, sustained cellular survival of the initiation of 
cell death by apoptosis. 
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1.4.2  Extracellular signal-regulated kinase 5 – ERK5 
1.4.2.1 Discovery of ERK5 
Nearly two decades ago, two independent research groups simultaneously cloned ERK5. 
Zhou et al. utilised a yeast two-hybrid screen, initially identifying the upstream MEK5 and 
consequently discovering a novel binding partner, ERK5 (Zhou et al., 1995). The second 
group, Lee and colleagues, screened a human placenta cDNA library using degenerate PCR 
to identify a novel MAPK gene; they termed this big MAPK (BMK)-1 due to its large size 
relative to ERK1/2 (Lee et al., 1995). ERK5 and BMK1 were later found to be identical. 
Both research groups demonstrated that ERK5 was ubiquitously expressed, but particularly 
abundant in the heart, skeletal muscle, placenta, lungs and kidneys (Lee et al., 1995; 
Zhou et al., 1995). Furthermore, it has since been documented that ERK5 is universally 
expressed in various different cell lines and is localised in both nuclear and cytoplasmic 
compartments (Buschbeck and Ullrich, 2005). 
1.4.2.2 Structure of ERK5 
The human ERK5 gene (also called MAPK7) is 5,824 bases in length, with an open reading 
frame of 2451 bp and encodes for a protein of 816 amino acids (Figure 1.8). There are four 
alternatively spliced transcript variants, which encode for two isoforms of ERK5. Variants 
1, 3 and 4 (also known as BMK1-α, -γ and -β respectively) all encode for the longer isoform 
(isoform 1). BMK1-α is the prototypic transcript from which BMK-γ and -β have a differing 
5’ untranslated region (UTR). Transcript variant 2 is deficient of a 5’ segment that 
includes the translation start codon, thus resulting in an N-terminal truncated isoform 
(isoform 2) at which transcription occurs at an in-frame start codon further downstream 
(NCBI, 2014). 
The N-terminus of isoform 1 (amino acids 1-406) begins with a region required for 
cytoplasmic targeting (a.a. 1-77), followed by the kinase domain (a.a. 78-406) which 
shares 66% sequence identity to the kinase domain of ERK2 (Zhou et al., 1995) (Figure 
1.8). The kinase domain can be further separated into a region essential for MEK5 
interaction (a.a. 78-139) and for oligomerisation (a.a. 140-406) (Yan et al., 2001) (Figure 
1.8). The dual-phosphorylation T-E-Y motif at which MEK5 is able to dual-phosphorylate 
ERK5, is positioned at a.a. 218-220. It is important to note that this numbering is 
historical, as an updated sequence situates these residues at a.a. 219-221. However, in 
line with the majority of published studies and commercially produced antibodies, this 
project will refer to these activation loop residues as Thr218/Tyr220.  
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ERK5 contains a common docking (CD) domain, similar to other MAPKs, consisting of a 
short sequence of negatively-charged amino acid residues (a.a. 350-358) (Figure 1.8), 
thereby allowing ERK5 to form associations with certain docking (D)-domain-containing 
substrates (Tanoue and Nishida, 2002). 
ERK5 is unique to the MAPK family as it contains an extended C-terminal tail of 410 amino 
acids (Figure 1.8), giving it a molecular weight of approximately 102kDa, consequently 
making it more than twice the molecular weight of many other MAPKs (Zhou et al., 1995).  
 
 
Figure 1.8 Structure of ERK5 and functional domains. 
ERK5 consists of 816 amino acid (a.a.) residues, with an N-terminal kinase domain and a large C-
terminal tail of approximately 400 a.a. The N-terminus contains a region for cytoplasmic targeting 
(a.a. 1-77), before the kinase domain (a.a. 78-406), which is comprised of a MEK5 binding region 
(a.a. 78-139), a common docking (CD) domain (a.a. 350-358) and the oligomerisation region, which 
spans over a.a. 140-406. It is within the kinase domain of ERK5 that the residues (Thr218/Tyr220), 
which are phosphorylated by MEK5, exist. The extended C-terminal tail contains two Proline-rich 
(PR) domains – PR1 (a.a. 434-465) and PR2 (a.a. 578-701) – a MEF2-interacting region (a.a. 440-501), 
the nuclear localisation signal (NLS) domain (a.a. 505-539) and a transcriptional activation domain 
(a.a. 664-789). 
 
Within this C-terminal domain exists a nuclear localisation signal (NLS) domain (a.a. 505-
539) important for ERK5 nuclear targeting (Yan et al., 2001; Buschbeck and Ullrich, 2005) 
(Figure 1.8), two proline-rich (PR) domains termed PR1 (a.a. 434-465) and PR2 (a.a. 578-
701) which are considered to be potential binding sites for Src-homology 3 (SH3)-domain-
containing proteins (Zhou et al., 1995; Yan et al., 2001) (Figure 1.8) and a myocyte 
enhancer factor 2 (MEF2)-interacting region (a.a. 440-501) (Yan et al., 2001). Recently, a 
potent transcriptional activation domain (a.a. 664-789) (Figure 1.8) was identified (Kasler 
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et al., 2000) This region undergoes autophosphorylation thus enabling it to directly 
regulate gene transcription; an additional unique trait of ERK5 compared to the other 
MAPKs (Morimoto et al., 2007). Furthermore, it has been shown that truncation of this C-
terminal tail gives rise to an increased kinase activity of ERK5, which previous studies have 
suggested might infer an auto-inhibitory function of the C-terminal tail (English et al., 
1998), however it is more likely that MEK5 activity is increased thereby increasing the 
number of activated ERK5 molecules (Buschbeck and Ullrich, 2005). 
Although it has been established that ERK5 has constant nuclear localising activity due to 
its bipartite NLS (Yan et al., 2001; Kondoh et al., 2006), it has recently been proposed 
that ERK5 also possesses nuclear export activity (Raviv et al., 2004; Buschbeck and Ullrich, 
2005). It is considered that ERK5 exists in a folded conformation in its quiescent 
unphosphorylated state whereby an intramolecular interaction between the N- and C-
terminals is facilitated. This interaction is suggested to either dampen the signal of the 
NLS due to the folded conformation of ERK5, or generate a nuclear export signal (NES) 
thereby sequestering ERK5 in the cytoplasm (Figure 1.9). 
However upon dual-phosphorylation of Thr218 and Tyr220 by MEK5, the presumed 
intramolecular NES interaction is disrupted resulting in ERK5 undergoing a conformational 
change and translocating to the nucleus (Kondoh et al., 2006) (Figure 1.9). 
Dephosphorylation reverts ERK5 to a folded conformation, increasing NES strength relative 
to NLS, and relocating ERK5 to the cytoplasm (Kondoh et al., 2006; Plotnikov et al., 2011). 
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Figure 1.9 ERK5 intracellular localisation. 
It has been proposed that ERK5 possesses nuclear export activity (Raviv et al., 2004; Buschbeck and 
Ullrich, 2005) and that in its unphosphorylated state, ERK5 exists in a folded conformation, thereby 
enabling a molecular interaction between the N- and C-terminals. It is considered that this 
conformation may either reduce the nuclear localisation signal (NLS) or generate a nuclear export 
signal (NES), causing ERK5 to be sequestered in the cytoplasm. Phosphorylation of ERK5 by MEK5 
results in a conformational change that disrupts the NES interaction and facilitates translocation of 
ERK5 into the nucleus (Kondoh et al., 2006). 
 
The intricacies and idiosyncrasies of ERK5 are continually being revealed, however 
progress in the field has been hampered by a lack of reagents, most notably a reliable 
phospho-Thr218/Tyr220 ERK5 antibody for western blotting and immunofluorescence. 
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1.5 The ERK5 signalling pathway 
1.5.1  ERK5 activation 
Since its initial identification as a stress-activated MAPK activated by both oxidative and 
osmotic stresses (Abe et al., 1996), evidence has shown ERK5 to be stimulated by a 
plethora of extracellular stimuli; such as VEGF, EGF, FGF-2 and platelet-derived growth 
factor (PDGF) (Kato et al., 1998; Hayashi and Lee, 2004; Kesavan et al., 2004). 
Additionally, ERK5 is activated by trophic factors in neurons, namely brain-derived 
neurotrophic factor (BDNF) (Cavanaugh et al., 2001) and nerve growth factor (NGF) 
(Watson et al., 2001; Finegan et al., 2009) as well as certain inflammatory cytokines, for 
example interleukin 6 (IL-6) (Carvajal-Vergara et al., 2005). Furthermore, physiological 
and pathological conditions including laminar shear-stress, ischaemia and hypoxia are also 
able to activate ERK5 (Takeishi et al., 1999; Yan et al., 1999; Sohn et al., 2002). 
The MAPKKKs activated by these extracellular stimuli and upstream of ERK5 are MEKK2 and 
MEKK3, which are able to specifically phosphorylate the Ser311/Thr315 residues of MEK5 
(Chao et al., 1999; Sun et al., 2001). MEKK2 and MEKK3 share 94% sequence identity (Blank 
et al., 1996), including the presence of Phox (PX) and Bem1p (PB1) domains in their N-
terminal regions. MEK5 also contains a PB1 domain; heterodimerisation of the PB1 domains 
of MEK5 and MEKK2/MEKK3 enables the transmission and maintenance of the specific 
signal transduction between MEKK2/MEKK3 and MEK5 (Nakamura and Johnson, 2003). 
MEKK2 and MEKK3 are sufficiently divergent in their N-terminals to permit differential 
regulation of the ERK5 signalling cascade (Lamark et al., 2003). MEKK2 has been shown to 
bind to the SH2-domain containing scaffold protein, Lck-associated adaptor (Lad), which 
then complexes with MEK5 to enhance ERK5 activation (Sun et al., 2001). Furthermore, 
the MEKK2-Lad complex is required for EGF-stimulated, Src-dependent activation of ERK5 
(Sun et al., 2003). MEK5 is the sole upstream MAPKK able to directly activate ERK5. This 
activation occurs by the preferential phosphorylation of the Thr218 residue of the T-E-Y 
motif present within the activation loop of the ERK5 kinase domain, by MEK5 (Mody et al., 
2003). MEK5 can only confer full catalytic activity to ERK5 by dual-phosphorylation of both 
the Thr218/Tyr220 residues of ERK5. Once activated, ERK5 is able to phosphorylate MEK5 
(Mody et al., 2003) and undergo autophosphorylation, in addition to potential 
phosphorylation by an alternative kinase, of numerous residues on its C-terminal thereby 
enhancing the transcriptional activity of ERK5 (Morimoto et al., 2007).  
The MEK5 phosphorylation motif S311XXXT315 bears great similarity to the phosphorylation 
motif of MEK1 (S218XXXS222), thus it was suggested that analogous to the canonical Ras>Raf-
1>MEK1/2>ERK1/2 signalling pathway, Ras/Raf-1 may also be able to activate MEK5 
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(English et al., 1998). Initial findings proposed a Ras-dependent, yet Raf-independent 
pathway of ERK5 activation upon co-transfection of HEK 293 cells with constitutively 
active Ras with ERK5 (English et al., 1998), however subsequent studies revealed the cell-
type specific nature of Ras-mediated activation of ERK5; ERK5 was strongly activated by 
constitutively active Ras in PC12 cells and C2C12 myoblasts, but not in HeLa or COS7 cells 
(English et al., 1998; Kato et al., 1998; Kamakura et al., 1999). An interesting observation 
was unearthed in 2005 however, whereby insulin-stimulated activation of ERK5 in 
adipocytes appeared to be inhibited by a dominant-negative farnesyltransferase, 
indicating a requirement for prenylation of Ras in order to activate ERK5 (Sharma and 
Goalstone, 2005). Thus until further clarification, Ras/Raf-1 activation of ERK5 remains 
dependent upon cell type. 
It has recently been shown that during mitosis, ERK5 is able to undergo MEK5-independent 
phosphorylation of alternative residues by cyclin-dependent kinases (CDK), thereby 
revealing potential novel modes of ERK5 activation (Diaz-Rodriguez and Pandiella, 2010; 
Inesta-Vaquera et al., 2010). 
1.5.2  Regulation of ERK5 activity 
MAPKs are typically inactivated by dephosphorylation of the T-X-Y motif by a MAP kinase 
phosphatase (MKP) subfamily of dual-specificity phosphatases (DUSPs) (Dickinson and 
Keyse, 2006). However, a DUSP that dephosphorylates Thr218/Tyr220 of ERK5 has yet to be 
identified. Instead, the phosphotyrosine-specific phosphatase PTP-SL (protein tyrosine 
phosphatase STEP-like) is proposed to dephosphorylate ERK5 at the Tyr220 residue, 
consequently hindering its translocation to the nucleus (Buschbeck and Ullrich, 2005). 
ERK5 was observed to phosphorylate PTP-SL, however this interaction appeared to be 
minor in comparison to the significantly increased phosphatase activity of PTP-SL upon its 
binding to ERK5 (Buschbeck and Ullrich, 2005). 
Furthermore, post-translational modifications have been shown to regulate ERK5 activity; 
in HUVECs, a small ubiquitin-like modifier 3 (SUMO3) protein covalently binds to ERK5 on 
Lys6 and Lys22 following exposure to advanced glycation end-products (AGE) or H2O2, 
thereby inhibiting its transcriptional promoter activity induced by sheer stress without 
affecting ERK5 phosphorylation (Woo et al., 2008). 
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1.5.3  ERK5 substrates 
The most significant role of ERK5 reportedly is to regulate a number of downstream 
transcription factors of which the myocyte enhancer factor (MEF) family, MEF2A, C, and D, 
are the best characterised (Kato et al., 1997; Yang et al., 1998; Kato et al., 2000). ERK5 
phosphorylates MEF2C on Ser387 (Kato et al., 1997), which increases MEF2C transcriptional 
activity and subsequently increases c-Jun gene expression (Kato et al., 1997). It has been 
shown that MEF2D is a substrate specific to ERK5 (Yang et al., 1998; Kato et al., 2000), 
whereas both ERK5 and the p38 MAPK control the activities of MEF2A and C (Han et al., 
1997; Ornatsky et al., 1999). As previously mentioned in Section 1.4.2.2 ERK5 contains a 
MEF2-interacting region and a transcriptional activation domain in its C-terminal tail, both 
of which are necessary for regulating MEF2 activity (Kasler et al., 2000); a truncated C-
terminal ERK5 mutant lacks the ability to stimulate MEF2 activity (Yan et al., 2001). 
In addition to the MEF2 family of substrates, ERK5 is also able to directly enhance the 
transcription of c-Myc, CREB and Sap1a (English et al., 1998; Kamakura et al., 1999), the 
latter of which occurs via a serum response element that may also be involved in 
activating the c-Fos promoter. Both ERK5 and ERK1/2 are capable of phosphorylating c-Fos 
on Ser387, however it has been observed that ERK5 activation leads to phosphorylation of 
alternative sites on c-Fos, leading to maximal c-Fos transactivation. Furthermore, 
phosphorylation of these sites in c-Fos requires the C-terminal tail of ERK5 (Terasawa et 
al., 2003).  
ERK5, like other MAPKs, phosphorylates substrates on Ser/Thr residues immediately 
preceding a Pro residue.  Interestingly, residue Thr28 in the ERK5 N-terminal domain and 
residues Ser421, Ser433, Ser496, Ser731 and Thr733 in the C-terminal tail are not followed by a 
Pro residue, but undergo phosphorylation (Mody et al., 2003) thus further suggesting the 
possible involvement of an additional kinase. In addition to this, MEK5 can be 
phosphorylated by ERK5 at specific non-proline directed residues Ser129, Ser137, Ser142 and 
Ser149 (Mody et al., 2003). Together these findings suggest that the substrate specificity of 
ERK5 may differ from that of other MAPK family members. 
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1.5.4  ERK5 and endothelial cells 
1.5.4.1 Knockout of ERK5 signalling axis components 
The physiological role of the ERK5 signalling cascade was determined in vivo, utilising gene 
ablation of specific components of the pathway in mice (Regan et al., 2002; Sohn et al., 
2002; Hayashi et al., 2004; Hayashi and Lee, 2004; Kesavan et al., 2004) (Table 1.2). 
Erk5-deficient mice died around E10.5 due to defects in normal cardiac development, 
maturation of vasculature and angiogenesis. In addition to this, an increased expression of 
VEGF was observed in these mice compared to the wild-type, however this was not 
considered to be the primary factor leading to death (Sohn et al., 2002); over-expression 
of VEGF resulted in normal development up to E12.5, with cardiovascular abnormalities 
leading to lethality only being evident at E12.5-14.5 (Miquerol et al., 2000).  
Furthermore, it is suggested that the increased VEGF expression may be due to 
deregulation of hypoxia-inducible factor-1 alpha (HIF-1α), preventing its ubiquitination 
and proteolysis and resulting in aberrant angiogenesis (Pi et al., 2005). Phenotypic 
abnormalities of Erk5 ablation include immature vasculature and rounded, disorganised 
endothelial cells (ECs) leading to loss of vascular integrity, with increased vessel leakiness, 
leading to death by haemorrhage (Regan et al., 2002; Sohn et al., 2002; Yan et al., 2003). 
Additionally, ablation of upstream genes of the ERK5 signalling axis resulted in similar 
phenotypic disruptions in Mek5-deficient (Wang et al., 2005) and Mekk3-deficient (Yang et 
al., 2000) mice, thus highlighting the critical function that the ERK5 signalling cascade 
plays in both vasculogenesis and angiogenesis (Table 1.2). 
1.5.4.2 Conditional knockouts and endothelial cell apoptosis 
Generation of endothelial-specific Erk5-knockout mice revealed that the initial defect 
upon Erk5 ablation occurs within the endothelium (Hayashi et al., 2004); these mice 
displayed cardiovascular defects and died around E10.0, analogous to the global Erk5-
knockout mice. However, cardiomyocyte-, hepatocyte- and neuronal-specific Erk5-
knockout mice did not exhibit developmental effects (Hayashi et al., 2004; Li et al., 2013) 
(Table 1.2). Ablation of Erk5 in adult mice resulted in decreased vascular integrity 
followed by death within 2-3 weeks owing to leaky blood vessels caused by EC apoptosis 
(Hayashi et al., 2004). 
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Table 1.2 Phenotypic consequences after gene ablation of components of the ERK5 signalling 
cascade in mice. 
Genotype Phenotype Reference 
Mekk3-/- Severe defects in early angiogenesis resulting in embryonic lethality at E11.0; vasculogenesis not affected 
(Yang et al., 
2000) 
Mekk2-/- 
Mice develop normally, are viable and fertile 
 
Mice develop normally and are viable, but display altered 
cytokine expression in thymocytes 
 
Mice develop normally and are viable, but demonstrate reduced 









et al., 2000) 
Mek5-/- 
Impaired cardiac development, decreased proliferation and 
increased apoptosis in the head, head and dorsal regions leading 




Embryonically fatal at E9.5-10.5 with stunted growth and 
underdeveloped vasculature within the yolk sac 
Defective cardiac development, heart looping, angiogenesis and 
vascular maturation; embryonic lethality at E9.5-10.5 
Embryonic death at E10.5-11.0 owing to angiogenic defects in 
the embryo and placenta; evidence of embryonic endothelial cell 
apoptosis 
Embryonic growth retardation, particularly of the head and 
lower trunk with dilated pericardial sacs; impaired angiogenesis 





(Yan et al., 
2003) 
 




Mice develop normally and are viable 
 
Pathophysiological challenges in adult mice result in reduced 
hypertrophic remodelling, are more vulnerable to hypertrophic 









Identical phenotype to that of global Erk5-/- mice; embryonically 










Degeneration of the cardiovascular system with apoptosis of 
endothelial cells resulting in lethality of adult mice within 2 





Significant reduction in the density of adult-born neurons in the 
granule cell layer of the olfactory bulb, delayed cell cycle exit of 
mitotic neuroblasts in the subventricular zone resulting in 
inhibited neuronal differentiation, disrupted neuronal 
maturation, migration and cell survival 
(Li et al., 
2013) 
Mef2c-/-  
Embryonic death at E9.5 owing to right ventricle malformation 
as a consequence of failed right loop morphogenesis of the heart 
tube; disorganisation of endothelial cells results in failure to 
form a vascular plexus 
Cardiac and vascular malformations leads to embryonic fatality 
at E9.5 
(Lin et al., 
1997) 
(Lin et al., 
1998) 
(Bi et al., 
1999) 
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The ability of ERK5 to protect ECs from apoptosis relies on ERK5 phosphorylation of MEF2C 
(Hayashi et al., 2004); the phenotype of Mef2c-/- mice is similar to that of Erk5-/- mice, 
with embryonic lethality as a consequence of cardiac and vascular malformations (Hayashi 
and Lee, 2004; Roberts et al., 2009). Interestingly, it was observed that Erk5-/- embryos 
infected with an adenovirus encoding a constitutively active Mef2c were only partially 
protected from EC apoptosis (Hayashi et al., 2004) suggesting the existence of additional 
downstream effectors of ERK5 that regulate apoptosis (Olson, 2004).  
Recent in vitro studies using HDMECs demonstrated that ERK5 is required for VEGF-induced 
phosphorylation of AKT to suppress apoptosis and facilitate cellular survival during tubular 
morphogenesis of the endothelial cells via VEGFR-2 (Roberts et al., 2010). Furthermore, 
ERK5 has also been implicated in PDGF-induced activation of AKT in porcine aortic 
endothelial cells (PAEs) (Lennartsson et al., 2010) and FLT3-mediated activation of AKT in 
the Ba/F3 pro-B-cell line (Razumovskaya et al., 2011). Taken together, these data suggest 
that ERK5 may play a critical role in coupling growth factor receptors to activation of AKT 
and regulating cell survival (Datta et al., 1997). It is unlikely that ERK5 directly 
phosphorylates AKT as it is well established that AKT is activated via phosphorylation of 
Thr308 in the activation loop via mammalian target of rapamycin complex 2 (mTORC2) 
(Jacinto et al., 2006; Sarbassov et al., 2006), as well as Ser473 in the C-terminus by 
phosphoinositide-dependent kinase-1 (PDK1) (Alessi et al., 1996). The precise mechanism 
through which ERK5 regulates AKT phosphorylation and activation remains obscure, 
however it may be that ERK5 regulates the activity of a phosphatase, such as protein 
phosphatase 2 (PP2A) (Pankov et al., 2003), or MAP-kinase phosphatase 3 (MKP3) (Razmara 
et al., 2012), which have been shown to regulate AKT dephosphorylation 
(Nithianandarajah-Jones et al., 2012). 
1.5.4.3 Shear-stress and atheroprotection 
Endothelial cell injury caused by various factors including tobacco smoke, diabetes and 
hypertension (Hayashi and Lee, 2004), can lead to endothelial dysfunction, reduced 
laminar shear stress, endothelial apoptosis and eventually atherosclerosis (Traub and Berk, 
1998). It was demonstrated that steady laminar shear stress resulted in an ERK5-mediated 
anti-apoptotic effect in bovine lung microvascular endothelial cells (BLMECs) (Pi et al., 
2005). This study revealed that activation of ERK5 by constitutively-active MEK5 (CA-MEK5) 
improved EC viability and reduced apoptosis, whereas dominant-negative ERK5 resulted in 
EC apoptosis, increased endothelial permeability and plaque destabilisation (Pi et al., 
2005). In HUVECs however, an atheroprotective effect was observed whereby ERK5 
activation negatively regulated TNF-α-mediated expression of adhesion molecules such as 
Chapter One: General Introduction 
35 
vascular adhesion molecule-1 (VCAM-1) and E-selectin (Akaike et al., 2004). Additionally, a 
more recent study utilised a novel MEK5 inhibitor, BIX 02188, to reveal that the 
MEK5>ERK5 pathway mediates flow-dependent inhibition of TNF-α signalling in BLMECs (Li 
et al., 2008).  
ERK5 was been observed to be required for flow-induced expression of Krüppel-like factor 
2 (KLF2) in HUVECs (Parmar et al., 2006) and human glomerular endothelial cells (Slater et 
al., 2012). KLF2 has been implicated in negatively regulating inflammation and promoting 
vascular stabilisation (Dekker et al., 2002; SenBanerjee et al., 2004; Boon and Horrevoets, 
2009). Further to KLF2, the expression of KLF4-dependent genes have been shown to be 
induced by ERK5 activation, which are also important in flow-dependent protective 
responses in endothelial cells (Ohnesorge et al., 2010; Clark et al., 2011). Furthermore, 
statins have been implicated in ERK5-mediated KLF4-dependent gene expression in 
endothelial cells, thereby suggesting that some of the pleiotropic vasoprotective effects of 
these drugs may act via ERK5 activation (Ohnesorge et al., 2010).  
In addition to this, it has been observed that the flow–induced activation of ERK5 conveys 
a cytoprotective response via activation of NF-E2 related factor 2 (Nrf2)-upregulated genes 
(Kim et al., 2012). Consequently, depletion of ERK5 expression using siRNA or a MEK5 
inhibitor (BIX02189, discussed in more detail in Section 1.5.5.4) resulted in a loss of Nrf2 
transcriptional activity (Kim et al., 2012). Even more recently, it has been shown that in 
HUVECs, MAPK-activated protein kinase-1 (MAPKAP-K1, also known as p90RSK) directly 
inhibits the transcriptional activity of ERK5 thereby inducing an inflammatory response in 
the ECs and promoting vascular dysfunction (Le et al., 2013). 
1.5.5  ERK5 and carcinogenesis 
1.5.5.1 Aberrant cell proliferation, migration and adhesion 
Cancer represents a progression from normal cellular homeostasis to a neoplastic condition 
with the cellular acquisition of a number of defined hallmarks: sustained proliferative 
signalling, evading suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis, reprogramming energy 
metabolism and evading immune destruction (Hanahan and Weinberg, 2011). The role of 
MAPKs, in particular ERK1/2, in cancer progression has been a focus of intense research 
over the last two decades (Dhillon et al., 2007) and attention is now also shifting to the 
potential role of ERK5 in the development of cancer and disease progression (Lochhead et 
al., 2012). 
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It was demonstrated by Kato and colleagues that EGF-induced proliferation of the non-
tumourigenic breast epithelial cell line MCF10A, and cervical cancer cell line HeLa, were 
dependent upon ERK5 activity (Kato et al., 1998). It was later found that EGF stimulation 
of ERK5 was essential for the phosphorylation of the serine-threonine kinase serum- and 
glucocorticoid-induced protein kinase (SGK) at Ser78 to allow entry into S-phase, and 
subsequent proliferation (Hayashi et al., 2001). Furthermore, it was observed that in a 
range of cells, ERK5 regulated cyclin D1 expression to allow cell-cycle progression from G1- 
to S-phase (Mulloy et al., 2003), yet it has since been shown that ERK5 activity peaks at 
G2-M phase and is necessary to regulate NF-кB activity prior to expression of mitosis-
promoting genes, to allow cell proliferation (Cude et al., 2007). 
Additional studies have shown a role for ERK5 in the proliferation of the breast cancer cell 
lines, MCF-7 and BT474 (Esparís-Ogando et al., 2002). More recently, it has been shown 
that ERK5 suppresses the promyelocytic leukaemia protein (PML) in the PML nuclear body 
by direct phosphorylation on Ser403 and Thr409; consequent upregulation of p21 expression 
is prevented – an important proliferation modulator (Yang et al., 2010a). This suppression 
has since been shown to enable the cells to overcome the G1-S transition checkpoint in 
cell-cycle progression, thereby reducing inhibition of tumour cell proliferation (Yang and 
Lee, 2011) (Figure 1.10). 
The RAS oncogene is mutated in approximately 20-30% of cancers (Prior et al., 2012). ERK5 
has been shown to be activated by Ras in PC12 and C2C12 cells (English et al., 1998; Kato 
et al., 1998; Kamakura et al., 1999) and it has been demonstrated that oncogenic forms of 
SRC activate the ERK5 pathway in fibroblasts, leading to a loss of actin stress fibres (Barros 
and Marshall, 2005) and formation of invasive adhesions also known as podosomes 
(Schramp et al., 2008). 
Cellular invasion and metastasis are critical for tumour spread. Sawhney et al. have shown 
that in breast cancer cells, ERK5 forms a complex with the avβ3 integrin and FAK to 
regulate adhesion and migration, and that overexpression of constitutively active MEK5 
leads to hyperphosphorylation of FAK (Sawhney et al., 2009). Furthermore, it has been 
demonstrated that overexpression of MEK5 in prostate cancer induces expression of matrix 
metalloproteinase-2 (MMP-2) (Ramsay et al., 2011) and MMP-9 (Mehta et al., 2003). 
Collectively, these data suggest that ERK5 may have an important role in cell attachment 
to the extracellular matrix (ECM) and in cell migration (Nithianandarajah-Jones et al., 
2012). 
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Figure 1.10 Mechanisms of ERK5-mediated cell survival. 
1. Various extracellular stimuli such as growth factors, oxidative and osmotic stresses as well as 
laminar shear-stress, can activate the ERK5 MAPK module; 2. ERK5 is directly phosphorylated on 
Thr218/Tyr220 in the kinase domain by MEK5. Inhibition of this phosphorylation can occur using the 
MEK5-selective inhibitor, BIX 02189; 3. Phosphorylation of ERK5 leads to a conformational change 
and results in disruption of the proposed N- and C-terminal nuclear export signal (NES) interaction; 
4. Active ERK5 undergoes autophosphorylation of the C-terminal non-kinase domain (NKD) and 
consequently translocates into the nucleus. Inhibition of ERK5 by XMD8-92 prevents this 
autophosphorylation and thus disrupts activation of the nuclear localisation signal; 5. Once in the 
nucleus, ERK5 is able to phosphorylate promyelocytic leukemia protein (PML) in the PML nuclear 
body (PML-NB); 6. Non-phosphorylated PML upregulates p21, which is necessary for G1/S cell cycle 
progress; 7. Nuclear ERK5 is also able to phosphorylate transcription factors such as CREB and MEF2 
resulting in a survival response; 8. ERK5 regulates phosphorylation of AKT on Thr308 and Ser473 by an 
unknown mechanism; 9. AKT phosphorylation of BAD, sequesters it to the 14-3-3 protein and inhibits 
its interaction with BCL2 and translocation to the mitochondria; 10. Phosphorylated FoxO3a by AKT, 
is also sequestered by the 14-3-3 protein in the cytoplasm, thus preventing it from upregulating the 
Fas ligand (FasL), which subsequently results in an apoptotic feedback loop and FasL-mediated 
caspase activation. 
 
1.5.5.2 Breast and prostate cancer 
The genesis and progression of breast carcinomas is linked to certain oncogenic stimuli, in 
particular the ErbB family of RTKs in response to binding with members of the EGF family 
of ligands (Wang and Tournier, 2006); HER2 overexpression is detected in 20-30% of breast 
carcinomas. ERK5 expression has been detected in the majority of patients during the 
early stages of breast cancer, with overexpression occurring in approximately 20% 
(Montero et al., 2009), supporting previous studies that demonstrate the upregulation of 
the ERK5 pathway in HER2 overexpressing cells (Hayashi and Lee, 2004). Montero et al. 
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also proposed ERK5 as an independent prognosis factor, as levels of ERK5 appeared to be 
inversely proportional to disease free survival time, thereby illustrating the potential of 
ERK5 as a biomarker to better predict the outcome of breast cancer in its early stages 
(Montero et al., 2009; Nithianandarajah-Jones et al., 2012). 
ERK5 expression in prostate cancer is similar to that of breast cancer, whereby it 
correlates to poor prognosis. There is an additional significant link between ERK5 
expression and bone metastases, leading to death (McCracken et al., 2008). Studies have 
shown that MEK5/ERK5 induces the transcription of activator protein (AP)-1, which in turn 
upregulates matrix metallopeptidase (MMP)-9 to degrade the extracellular matrix 
surrounding the cells, and enhance the metastatic potential of the cancer (Mehta et al., 
2003). Furthermore, PC3 cells overexpressing ERK5 had significantly increased levels of 
proliferation, motility and invasion, as well as being considerably more efficient in forming 
tumours, thus emphasising the relationship between the presence of ERK5 and the 
aggression of prostate cancer (McCracken et al., 2008). 
1.5.5.3 Tumour-associated angiogenesis 
As previously described in Section 1.1.4, tumour-associated angiogenesis is distinctly 
different from its physiological counterpart; the microvessels are leaky and twisted, blood 
flow can be intermittent, static and even reversed, and there is often a lack of supporting 
pericyte cells (De Bock et al., 2011). The critical role that ERK5 plays in physiological 
angiogenesis was demonstrated when Erk5-deficient mice exhibited defective vasculature 
(Hayashi et al., 2004; Hayashi and Lee, 2004). It was subsequently reported that the ERK5 
signalling pathway was essential for tumour-associated angiogenesis; vascular 
development was inhibited and exogenous tumour growth was reduced in mice with 
deleted ERK5 in human tumour xenograft models (Hayashi et al., 2005). Additionally, 
studies have demonstrated the ability of pro-angiogenic factors such as VEGF and FGF to 
stimulate ERK5 activation in HUVECs (Hayashi et al., 2004) and have shown the specific 
requirement for ERK5 to mediate VEGF-stimulated tubular morphogenesis, but not cellular 
proliferation in HDMEC (Roberts et al., 2010). Thus taken together, these data indicate the 
potential of ERK5 as an anti-angiogenic drug target. 
1.5.5.4 Small-molecule inhibitors of ERK5 
Studies into small-molecule kinase inhibitors of the MEK5/ERK5 pathway have recently 
uncovered two indolinone-6-carboxamides (developed by Boehringer Ingelheim) that 
selectively inhibit MEK5 over MEK1/2 (Tatake et al., 2008). In vitro, BIX02188 and 
BIX02189 are able to block MEK5 activity and have IC50s of 4.3 nmol/L and 1.5 nmol/L 
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respectively. In HeLa and HEK293 cells, both osmotic stress-induced ERK5 and MEF2C 
activation are inhibited (Tatake et al., 2008). The use of these compounds in PC12 cells 
implicate MEK5/ERK5 in NGF-induced neurite outgrowth and stabilisation of tyrosine 
hydroxylase (Obara et al., 2009). Currently no data is available with respect to growth 
factor-induced activation of ERK5, or of the pharmacodynamics or pharmacokinetics of 
these two carboxamides. Although MEK5 is the only upstream kinase to directly 
phosphorylate ERK5, recent findings that ERK5 phosphorylation occurs via a MEK5-
independent, CDK-dependent pathway (Inesta-Vaquera et al., 2010), implies that these 
MEK5-targeting BIX inhibitors may prove to be insufficient in inhibiting the ERK5 signalling 




Figure 1.11 Chemical structures of MEK5/ERK5 small-molecule inhibitors. 
(A) BIX 02188, Chemical name (3Z)-3-[[[3-[(Dimethylamino)methyl]phenyl]amino]phenylmethylene]-
2,3-dihydro-2-oxo-1H-indole-5-carboxamide, and (B) BIX 02189, Chemical name 3-[[[3-
[(Dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-N,N-dimethyl-2-oxo-1H-indole 
-6-carboxamide, both developed by Boehringer Ingelheim are selective MEK5 inhibitors, with an IC50 
of 4.3 nmol/L and 1.5 nmol/L, respectively; (C) XMD8-92, Chemical name 2-[[2-Ethoxy-4-(4-hydroxy-
1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimidol[4,5-b][1,4]benzodiazepine-6-
one, is a highly selective ERK5 inhibitor, with an IC50 of 240 nmol/L. 
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XMD8-92 is a highly-selective inhibitor of ERK5 activity, which arose after modifications 
were made to the ATP-competitive polo kinase inhibitor BI-2536 (Yang et al., 2010a). 
XMD8-92 inhibits EGF-stimulated ERK5 activation with an IC50 of 240 nmol/L in vitro and 
selectively inhibits EGF-induced phosphorylation of ERK5 over ERK1/2 up to a 
concentration of 5µM. Yang et al. utilised XMD8-92 in mice with lung and cervical 
xenograft tumours to show inhibition of tumour growth by 95%, through phosphorylation 
and suppression of PML as described in Section 1.5.5.1, thereby blocking tumour cell 
proliferation (Yang et al., 2010a). Furthermore, unlike the loss of vascular integrity caused 
by endothelial-specific ERK5 deletion (Hayashi et al., 2004), it has been observed that 
XMD8-92 treatment does not appear to affect vasculature stability in mice owing to the 
reversible nature of inhibition of ERK5 activity (Yang et al., 2010a). 
 
 
1.6 Project aims 
The objective of this study was to further elucidate the activation of ERK5 in VEGF-
stimulated primary human dermal microvascular endothelial cells (HDMECs) in contrast to 
EGF-stimulated HeLa cells. 
In order to achieve this objective, this project aimed to: 
1. Characterise, the, activation, and, phosphorylation, status, of, ERK5, in, response, to,
various,growth, factors, in, the, two,cell, types,, as,well, as,determining, the,potential,
tyrosine,residues,on,VEGFRA2,and,downstream,signalling,pathways,through,which,
ERK5,is,activated.,
2. Utilise, smallAmolecule, inhibitors, of, MEK5, and, ERK5, to, determine, the,
phosphorylation, status, of, ERK5, and, the, role, of, agonist, stimulated, ERK5, in,
regulating,AKT,activation,in,HDMECs,and,HeLa.,
3. Identify, the, intracellular, localisation, of, ERK5, in, HDMEC,, compared, to, HeLa,,
following,agonist,stimulation.,
4. Identify, potential, novel, binding, partners, of, ERK5, in, HDMECs, using,
immunoprecipitation,of,ERK5,,followed,by,mass,spectrometry,analysis.,
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2.1 Materials 
2.1.1  General reagents 
Full-range (12-225 kDa) rainbow molecular weight marker and Hybond ECL nitrocellulose 
membrane were purchased from GE Healthcare (Amersham, UK). Ultrapure ProtoGel® 
solution was bought from Geneflow Ltd. (National Diagnostics, Staffordshire, UK). 
ProLong® Gold antifade reagent, Lipofectamine™ RNAiMAX and Lipofectamine™ 2000 
transfection agents, as well as RNaseZap® were bought from Invitrogen™; NuPAGE® 4-12% 
Bis-Tris gels, LDS sample buffer [4X] and SilverQuest™ Silver Staining kit were purchased 
from Novex®. Invitrogen™ and Novex® products were sourced from Life Technologies™ 
(Paisley, UK).  
Aprotinin, leupeptin, pepstatin, phenylmethylsulphonyl fluoride (PMSF), agar, agarose 
(electrophoresis grade), glycerol, 3-(N-morpholino)-propanesulphonic acid (MOPS), 
polyoxyethylenesorbitan monolaurate (Tween-20) and sodium dodecyl sulphate (SDS) 20% 
(w/v) solution, were purchased from Melford (Ipswich, UK). Prestained protein marker 
(broad range 10-230 kDa) was bought from New England Biolabs (UK) Ltd. (Hitchin, UK).  
Ammonium chloride, ammonium peroxodisulphate (APS), ampicillin solution, bicinchoninic 
acid solution, copper (II) sulphate solution, dimethyl sulphoxide (DMSO), sterile DNase- 
and RNase-free dH2O, ethidium bromide (EtBr), ethylenediaminetetraacetic acid (EDTA), 
gelatin from porcine skin, kanamycin solution, Luria Bertani (LB) broth powder, manganese 
(II) chloride tetrahydrate, sodium orthovanadate (Na3VO4), N,N,N’,N’-
tetramethylethylenediamine (TEMED), Tris-EDTA (TE) buffer solution (pH 8.0) and Triton 
X-100 were bought from Sigma-Aldrich (Poole, UK).  
Enhanced chemiluminescence (ECL) western blotting detection reagents, glycine, sodium 
chloride (NaCl), Tris-Base were bought from Thermo Fisher Scientific™ (Loughborough, UK). 
Phos-tag™ AAL-107 was bought from Wako Chemicals GMBH (Neuss, Germany). 
2.1.2  Agonists and inhibitors 
Recombinant human vascular endothelial growth factor (VEGF)-A165 and basic fibroblast 
growth factor (FGF-2) were purchased from R&D Systems Inc. (Minneapolis, MN, USA). 
Recombinant human hepatocyte growth factor (HGF), epidermal growth factor (EGF), 
dimeric platelet-derived growth factor (PDGF)-BB and transforming growth factor (TGF)-α 
were bought from Peprotech EC (Rocky Hill, NJ, USA). BIX 02189 was purchased from 
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Selleck Chemicals (Stratech Scientific Ltd., Suffolk, UK). XMD 8-92 was bought from Tocris 
Bioscience (Bristol, UK). 
2.1.3  Antibodies 
Table 2.1 Primary antibodies against total proteins used in this study 
Antibody Source Cat. No. Dilution Host Species Appl. 
Actin 
(I-19) 
Santa Cruz Biotechnology (CA, 
USA) sc-1616-R 1:2000 Rabbit WB 
AKT New England Biolabs (Hitchin, UK) #9271 1:1000 1:50 Rabbit 
WB 
IP 
EGFR-#1 New England BioLabs (Hitchin, UK) #2232 1:1000 Rabbit WB 








ERK5 R&D Systems AF2848 1:40 Goat IP 
FLAG® M2 Sigma-Aldrich (Poole, UK) F1804 1:2000 Mouse WB 
FLAG® M2 
Affinity Gel Sigma-Aldrich (Poole, UK) A2220 1:25 Mouse IP 
GAPDH XP New England Biolabs (Hitchin, UK) #5174 1:2000 Rabbit WB 
Lamin B1 
(H-90) 
Santa Cruz Biotechnology (CA, 
USA) sc-20682 1:2000 Rabbit WB 
MEK5 Abcam (Cambridge, UK) ab45146 1:10000 Rabbit WB 
PECAM1 
(CD31) 
Santa Cruz Biotechnology (CA, 
USA) sc-1506 1:1000 Goat WB 




New England Biolabs (Hitchin, UK) #9102 1:1000 1:100 Rabbit 
WB 
IF 
c-Raf New England BioLabs (Hitchin, UK) #9422 1:1000 Rabbit WB 
H-Ras 
(C-20) 
Santa Cruz Biotechnology (CA, 
USA) sc-520 1:200 Rabbit WB 
K-Ras 
(C-19) 
Santa Cruz Biotechnology (CA, 
USA) sc-521 1:200 Rabbit WB 
N-Ras 
(F-155) 
Santa Cruz Biotechnology (CA, 




New England Biolabs (Hitchin, UK) #2479 1:1000 1:200 Rabbit 
WB 
IF 
Applications: WB – Western blotting; IF – Immunofluorescence; IP – Immunoprecipitation 
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Table 2.2 Primary antibodies against phosphorylated proteins used in this study 




New England Biolabs (Hitchin, UK) #4060 1:2000 Rabbit WB 
Phospho-








Dr. Atanasio Pandiella 
Instituto de Biolgia Molecular y 
Celular del Cancer, CSIC-
Universidad de Salamanca 
N/A 1:3000 Rabbit WB 
Phospho-
ERK5 (T732) Dr. Atanasio Pandiella (as above) N/A 1:1000 Rabbit WB 
Phospho-
PKC (pan) 
New England BIoLabs (Hitchin, 
UK) #9371 1:1000 Rabbit WB 
Phospho-










New England Biolabs (Hitchin, UK) #3770 1:1000 Rabbit WB 
Applications: WB – Western blotting 
Table 2.3 Secondary antibodies used in this study 
Antibody Source Cat. No. Dilution Appl. 
Alexa Fluor® 488 Donkey 
Anti-Rabbit IgG (H+L) 
Molecular Probes® (Life 
Technologies™; Paisley, UK) A21206 1:1000 IF 
Alexa Fluor® 568 Donkey 
Anti-Rabbit IgG (H+L) 
Molecular Probes® (Life 
Technologies™; Paisley, UK) A10042 1:1000 IF 
Hoechst 33342 Molecular Probes
® (Life 
Technologies™; Paisley, UK) H1399 1:5000 IF 
HRP-conjugated AffiniPure 
Donkey Anti-Goat IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, 
USA) 
705-035-
147 1:10000 WB 
HRP-conjugated AffiniPure 
Goat Anti-Mouse IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, 
USA) 
115-035-
166 1:5000 WB 
HRP-conjugated AffiniPure 
Goat Anti-Rabbit IgG (H+L) 
Jackson ImmunoResearch 
Laboratories, Inc. (PA, 
USA) 
111-035-
144 1:5000 WB 
Protein G Plus Agarose 
Suspension 
Calbiochem® (EMD 
Millipore; Feltham, UK) IP04 1:10 IP 
Applications: WB – Western blotting; IF – Immunofluorescence; IP - Immunoprecipitation 
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2.1.4  Bacterial strains and media 
Table 2.4 Bacterial strains and media used in this study 
Bacterial strain Source Media Application 
One Shot® ccdB 







LB broth / agar plates 
+ 50 µg/mL kanamycin 
 















LB broth / agar plates 
+ 50 µg/mL kanamycin 
 






2.1.5  Cell culture 
2.1.5.1 General materials 
Glass coverslips (16 mm diameter) were bought from Agar Scientific (Stansted, UK). All 
other cell culture materials were purchased from Greiner Bio-One (Stonehouse, UK), 
Starlab UK (Milton Keynes, UK) or Thermo Fisher Scientific™ (Loughborough, UK), unless 
otherwise stated. 
2.1.5.2 Cell types, culture media and solutions 
Table 2.5 Cell types used in this study 
Abbr. 
Name Cell type and details Source 
HDMEC 
Human dermal microvascular endothelial cells 
(Lot No. 6060707.1) 
Isolated from juvenile, Caucasian male 
PromoCell (Heidelberg, 
Germany) 
HeLa Human epithelial cervical cancer cell line Isolated from adult, African-American female 
European Collection of Cell 
Cultures supplied by Sigma-
Aldrich (Poole, UK)  
MAE Murine aortic endothelial cells Isolated from mouse aorta (vector cells) 
Prof. Lena Claesson-Welsh, 
Rudbeck Laboratory,  
Dept. Immunology, 
Genetics & Pathology, 




Murine aortic endothelial cells 
Isolated from mouse aorta, stably expressing 
transfected murine VEGFR-2 (Flk-1) 




Murine aortic endothelial cells 
Isolated from mouse aorta, stably expressing 
transfected murine VEGFR-2 (Flk-1) with a point 
mutation at Tyr949 to Phe949 in the cytoplasmic 
domain 
Prof. Lena Claesson-Welsh 
(as above) 




Murine aortic endothelial cells 
Isolated from mouse aorta, stably expressing 
transfected murine VEGFR-2 (Flk-1) with a point 
mutation at Tyr1173 to Phe1173 in the cytoplasmic 
domain 




Murine aortic endothelial cells 
Isolated from mouse aorta, stably expressing 
transfected murine VEGFR-2 (Flk-1) with a point 
mutation at Tyr1212 to Phe1212 in the cytoplasmic 
domain 
Prof. Lena Claesson-Welsh 
(as above) 
HEK 293A 
Human embryonal kidney cell line 





Table 2.6 Cell culture media and solutions used in this study 
Name Culture media composition Source 
Endothelial full 
growth medium 
EBM MV2 basal medium (Cat. No. C-22221) with 
SupplementPack (Cat. No. C-39221): 0.05 mL/mL FCS, 
5 ng/mL EGF, 10 ng/mL FGF-2, 20 ng/mL Long R3 IGF-1, 
0.5 ng/mL VEGF165, 1 µg/mL Ascorbic Acid, 







EBM MV2 basal medium 






Dulbecco’s Modified Eagle Medium (DMEM) (Cat. No. 
D6429) containing 4500 mg/L glucose, L-glutamine, 
sodium pyruvate and sodium bicarbonate 
 









0.1% low serum 
medium 
Dulbecco’s Modified Eagle Medium (DMEM) (Cat. No. 
D6429) containing 4500 mg/L glucose, L-glutamine, 
sodium pyruvate and sodium bicarbonate 














Opti-Minimal Essential Medium (Cat. No. 51985-0XX) 









Gelatin 0.5% (w/v) gelatin from porcine skin in ddH2O, autoclaved 
Sigma-Aldrich® 
(Poole, UK) 
Versene Dulbecco’s phosphate buffered saline without Ca
2+/Mg2+ 
supplemented with 0.001 mL/mL EDTA 
Lonza (Basel, 
Switzerland) 
PBS Cell Wash Dulbecco’s phosphate buffered saline with Ca2+/Mg2+ Lonza (Basel, Switzerland) 
Ice-cold 
PBS Lysis Wash 
Dulbecco’s phosphate buffered saline without Ca2+/Mg2+ 
stored at 4ºC 
Lonza (Basel, 
Switzerland) 
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2.1.6  Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) 
2.1.6.1 General materials 
siRNA duplexes were purchased from Dharmacon Inc. (Lafayette, USA). Gateway® entry 
vector, Gateway®-adapted ViraPower adenoviral expression vector, oligonucleotide 
primers and 2x Power SYBR® Green mastermix were bought from Life Technologies™ 
(Paisley, UK). RNeasy mini RNA extraction kit, QIAshredder kit, RNase-Free DNase set and 
QIAprep Spin Miniprep/Maxiprep kits were purchased from Qiagen (Crawley, UK). 
Vivapure® AdenoPACK™ 20 was bought from Sartorius UK (Surrey, UK). Optically clear heat-
sealing film was purchased from Starlab UK (Milton Keynes, UK) and Adeno-X Rapid Titer 
Kit was bought from Takara Bio Europe SAS (Clontech; Saint-Germain-en-Laye, France). 
2.1.6.2 Plasmid constructs 
Table 2.7 Plasmid constructs used in this study 
Plasmid Description Source 
pcDNA3.1-
ERK5(wt) 
pcDNA3.1 mammalian expression vector containing 
human wild-type ERK5 cDNA and a FLAG epitope tag 
at the N-terminus (Kato et al., 1997) 




Jolla, CA, USA 
pcDNA3.1-
ERK5(AEF) 
pcDNA3.1 mammalian expression vector containing 
dominant-negative mutant human ERK5 cDNA, 
whereby the T218 and Y220 activation domain 
phosphorylation sites were mutated to A218 and F220, 
and a FLAG epitope tag at the N-terminus (Kato et al., 
1997) 
Dr. J.D. Lee 
(as above) 
pCMV5-MEK5(D) 
pCMV5 mammalian expression vector containing a 
constitutively active rat MEK5α-1 cDNA, whereby the 
S313 and T317 phosphorylation sites were replaced with 
D313 and D317, and 3 copies of the HA epitope tag 
added to the C-terminus (Kato et al., 1997) 




Gateway® pENTR™1A entry clone containing human 





Gateway® pENTR™1A entry clone containing dominant-
negative mutant human ERK5 cDNA, whereby the T218 
and Y220 activation domain phosphorylation sites were 




Gateway® pENTR™1A entry clone containing a 
constitutively active rat MEK5α-1 cDNA, whereby the 
S313 and T317 phosphorylation sites were replaced with 




Gateway®-adapted ViraPower™ adenoviral expression 
clone containing human wild-type ERK5 cDNA and a 
FLAG epitope tag at the N-terminus 
This study. 




Gateway®-adapted ViraPower™ adenoviral expression 
clone containing dominant-negative mutant human 
ERK5 cDNA, whereby the T218 and Y220 activation 
domain phosphorylation sites were mutated to A218 




Gateway®-adapted ViraPower™ adenoviral expression 
clone containing a constitutively active rat MEK5α-1 
cDNA, whereby the S313 and T317 phosphorylation sites 
were replaced with D313 and D317, and a HA3 epitope 





2.2.1  Adenoviral expression clone construction 
2.2.1.1 Restriction digests, gel extraction and ligation reactions 
Restriction digests were performed in a volume of 100 µL on 5 µg of DNA, in the presence 
of bovine serum albumin (BSA) and a restriction enzyme buffer, with a 2- to 10- fold 
excess of the appropriate restriction enzymes, and made up to 100 µL with nuclease-free 
dH2O. The N-terminal FLAG-tagged ERK5(wt) and ERK5(AEF) cDNA sequences were cut out 
of the pcDNA3.1 expression vectors using the restriction enzymes XhoI and XbaI, and the 
C-terminal HA3-tagged MEK5(D) cDNA sequence was cut out of the pCMV5 expression 
vector using KpnI and XmaI. The pENTR™1a entry vector was cut open with the DraI and 
EcoRV restriction enzymes. Restriction digest mixtures were mixed by gentle pipetting and 
incubated at the enzyme’s optimum temperature for 4 h, prior to inactivating the enzymes 
by heating to 75ºC for 15 min. The 5’ and 3’ ends of the cDNA were blunted by incubating 
the 100 µL restriction digest mixtures with 20 µL of 10 mM dNTP mix and 5 µL of T4 
polymerase. The entry vector was treated with 5µL Calf Alkaline Phosphatase (CAP) for 1 h 
at 37ºC, to remove 5’ phosphates and prevent the religation of single digests thereby 
reducing false positives, and then heated to 75ºC for 15 min to inactivate the enzyme. 
The insert and vector restriction digests were run on a 1% (w/v) agarose gel and the 
appropriate bands were extracted using the Wizard® SV Gel Extraction Kit (Cat #9281; 
Promega, Southampton, UK). 
The digested insert was incubated with the digested vector in the presence of T4 ligase, 
ligase buffer and nuclease-free dH2O in a volume of 10 µL for 18 h at 21ºC in order to 
ligate the two products. The background level of self-ligated vector was checked by 
including a vector-only (no cDNA) ligation reaction. 
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2.2.1.2 Chemical transformation of competent cells 
One Shot® TOP10 Chemically Competent E.coli cells were transformed with the ligation 
reaction products. Competent cells were thawed on ice and 100 µL was added to each 
ligation reaction and placed on ice for 30 min. Each reaction was incubated at 42ºC for 90 
s and then placed on ice for 3 min. 900 µL of warm Luria Bertani (LB) media was then 
added to each reaction, which was then incubated for 1 h at 37ºC, under continuous 
rotation at 250 rpm. 200 µL of each transformed construct was streaked out onto 
kanamycin LB plates and incubated overnight at 37ºC. Three colonies for each construct 
were selected and incubated in separate 5 mL cultures for 8 h at 37ºC. DNA was then 
extracted from each culture using the QIAprep Spin Miniprep kit (described below), the 
concentration determined by spectrophotometric measurement of the absorbance at 260 
nm (A260) using a NanoDrop ND-1000 spectrophotometer and the associated software 
(Labtech International, Lewes, UK) and the sample sent to Source BioScience LifeSciences 
for sequencing. 
Once the correct sequence and alignment were confirmed, one DNA extraction product 
from each entry clone was selected and used to transform chemically competent cells as 
described above. Following this, the starter culture of each transformed construct was 
amplified in 100 mL of kanamycin LB media, the cells were harvested using the QIAprep 
Spin Maxiprep kit (described below) and the DNA concentration determined by 
spectrophotometry. 
QIAprep Spin Miniprep and Maxiprep kit 
The principles behind both the Miniprep and Maxiprep plasmid purification kits were the 
same, with the only difference being the volume of culture being purified. Initially, 
bacterial lysates were neutralised, cleared through centrifugation and the cleared lysate 
(supernatant) was then loaded directly onto an equilibrated, anion-exchange tip and 
allowed to enter the resin by gravity flow. Due to the low-salt and pH conditions, the 
plasmid DNA was able to selectively bind to the resin. Other impurities such as RNA and 
proteins were removed from the resin with a medium-salt wash, after which addition of a 
high-salt buffer to the resin eluted the ultrapure plasmid DNA. Isopropanol precipitation 
was then used to concentrate and desalt the DNA, which was then collected by 
centrifugation, air-dried and resuspended in sterile nuclease-free dH2O. 
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The following protocol states volumes for the Miniprep in normal font and those for the 
Maxiprep, in underlined font. All buffers indicated are those provided in the commercially 
available Qiagen kits. 
Bacterial cultures were centrifuged at 6000 x g for 15 min at 4ºC, the supernatant 
discarded and the bacterial pellet was resuspended in 0.3 mL or 10 mL of Buffer P1, by 
vortexing. To the suspension, 0.3 mL or 10 mL of Buffer P2 was added, mixed by vigorous 
inversion (not vortexing) of the capped tube and incubated at room temperature for 5 
min. The addition of 0.3 mL or 10 mL of chilled Buffer P3 prior to immediate mixing by 
vigorous inversion and incubation on ice for 5 min, enhanced the precipitation of 
contaminants such as genomic DNA and cell debris, which was separated by room 
temperature centrifugation at 13,300 rpm for 10 min or two 4ºC centrifugation steps, the 
first for 30 min, followed by transference of the supernatant to fresh capped tubes, and a 
second spin for 15 min. To equilibrate a QIAGEN-tip, 1 mL or 10 mL of Buffer QBT was 
added to the column and allowed to empty by gravity flow, after which the cleared 
sample supernatant was added to the column and allowed to enter the resin by gravity 
flow. Impurities were removed from the column with two washes of 2 mL or 30 mL Buffer 
QC, and the DNA was eluted with 0.8 mL or 15 mL Buffer QF into fresh tubes. The addition 
of 0.7 volumes of room temperature isopropanol to the eluted DNA, followed by 
centrifugation at 13,300 rpm for 30 min at room temperature or 4ºC, enabled precipitation 
of the DNA. The pelleted DNA was then washed with 1 mL or 5 mL of room temperature 
70% (v/v) ethanol, centrifuged at 13,300 rpm for 10 min and the resulting supernatant 
carefully removed and discarded. The pellet was air-dried for 5 min prior to redissolving 
the DNA in nuclease-free dH2O. 
2.2.1.3 LR recombination reaction and expression clone selection 
The entry clones (pENTR™1A + ERK5(wt)/ERK5(AEF)/MEK5(D)) underwent a LR 
recombination reaction with the pAd/CMV destination vector (Gateway®-adapted 
ViraPower™ adenoviral expression vector) prior to chemical transformation of competent 
cells and selection of an expression vector. In a final volume of 8 µL, 150 ng of the entry 
clone was mixed with 300 ng of the destination vector, in the presence of TE buffer (pH 
8.0). 2 µL of LR Clonase™ II enzyme mix (provided with the kit) was then added to each 
sample, mixed well by pipetting and incubated at 25ºC for 18 h. To each reaction, 1 µL 
Proteinase K solution (provided with the kit) was added and incubated at 37ºC for 10 min, 
after which competent E.coli were transformed as previously described in Section 2.2.1.2 
and streaked onto ampicillin LB plates. Colonies were then selected, grown and the 
extracted DNA (Miniprep kit) was sent off for sequencing, as before. One DNA extraction 
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product from each destination clone, with the correct sequence and alignment, was 
selected and used to transform chemically competent cells as described above, prior to 
amplification in 100 mL of ampicillin LB media and harvesting the cells using the Maxiprep 
kit. 
2.2.2  Preparing adenoviral stocks 
2.2.2.1 PacI digestion, phenol:chloroform extraction and ethanol precipitation 
Each destination clone (pAd/CMV + ERK5wt/ERK5(AEF)/MEK5(D)) and the empty 
destination vector (pAd/CMV) were digested with the PacI restriction enzyme to expose 
the viral inverted terminal repeats to enable proper viral replication and packaging, and 
remove the bacterial sequences (i.e. ampicillin resistance gene and pUC origin). 5 µg of 
plasmid was digested with PacI restriction enzyme in the presence of restriction enzyme 
buffer, BSA, made up to 100 µL with nuclease-free dH2O and mixed well with gentle 
pipetting. The mix was incubated at 37ºC for 4 hours after which the enzyme was 
inactivated by heating to 65ºC for 20 min. 
Each fragment was then purified using phenol:chloroform extraction. An equal volume 
(100 µL) of phenol:chloroform:isoamyl alcohol (or PCI; 25:24:1) was added to each 
restriction fragment, vortexed to mix and then centrifuged at 13,300 rpm for 1 min. The 
aqueous layer containing the DNA, was transferred into a fresh microcentrifuge tube and 1 
volume of PCI was added, vortexed and centrifuged as before. The transferred aqueous 
layer was further purified, first by incubating it with 2.5 volumes of 100% ice-cold ethanol 
and 1/10 volume of 3 M sodium acetate (pH 5.2) at -80ºC for 1 h. The products were then 
centrifuged at 13,300 rpm for 20 min at 4ºC and the supernatant was carefully removed. 
The pellet was rinsed with 70% ethanol, centrifuged at 13,300 rpm for 15 min at 4ºC and 
the supernatant was aspirated off. The pellet was then resuspended in 10 µL sterile, 
nuclease-free dH2O. 
2.2.2.2 Generating crude and secondary adenoviral stocks 
Table 2.8 Cell density of HEK 293A cell line 
12-well plate (cells/well) 6-well plate (cells/well) 10 cm dish (cells/dish) 
5.0 x 105 
(for viral titering) 5.0 x 10
5 3.0 x 106 
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Each well of a 6-well tissue culture plate was seeded with HEK 293A cells, at a density as 
mentioned in Table 2.8, in 2 mL complete medium and incubated in a humidified 37ºC, 5% 
(v/v) CO2 Sanyo MCO-17AC cell culture incubator for 24 h, after which the culture medium 
was replaced with fresh complete medium (1.5 mL). For each PacI-digested product, 1 µg 
of linearised plasmid was diluted with 250 µL of Opti-MEM® and gently mixed by pipetting. 
Separately, 3 µL of Lipofectamine™ 2000 was diluted in 250 µL of Opti-MEM® for each 
plasmid, mixed gently and incubated at room temperature for 5 min. After this, the 
diluted Lipofectamine™ 2000 solution was combined with each diluted plasmid to result in 
a 500 µL transfection mix and gently mixed, prior to incubation at room temperature for 
20 min, to enable the formation of liposome-nucleic acid complexes. The transfection mix 
was then added drop-wise to each well, the culture plate was gently swirled to ensure 
even distribution and the cells were incubated in the cell culture incubator for 24 h. After 
this incubation period, the transfection medium was removed from the cells and replaced 
with 2 mL complete medium. Every 48-72 h, cells were replenished with 2 mL fresh 
complete medium until approximately 80% cytopathic effect was observed at which point 
adenovirus-containing cells were harvested by squirting cells and media off the plate with 
a tissue culture pipette and transferred to a sterile, 15 mL capped tube. 
The harvested adenovirus-containing cells were then subjected to three freeze/thaw 
cycles (freeze at -80ºC for 30 min followed by thawing in a 37ºC water bath for 15 min) 
causing the cells to lyse and release the intracellular viral particles to result in a crude 
viral lysate. The viral lysate was then centrifuged at 3000 rpm for 15 min at room 
temperature to pellet the cell debris and the supernatant containing the crude viral 
particles was transferred into cryovials in 1 mL aliquots at stored at -80ºC. 
The crude viral lysate was used to generate an amplified secondary stock for purification 
and titering. For each adenovirus, HEK 293A cells were seeded at a density as mentioned 
in Table 2.8 on a 10 cm cell culture dish, in 10 mL of complete medium for 24 h at 37ºC. 
Each dish was then infected with the drop-wise addition of 100 µL of crude adenoviral 
stock, swirled gently to mix and then incubated at 37ºC for 72 h. The adenovirus-
containing cells were harvested with a tissue culture pipette and transferred with the 
media to a sterile, 15 mL capped tube, prior to three freeze/thaw cycles, centrifugation 
and transferring and storing the supernatant containing viral particles, as described above. 
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2.2.2.3 Purifying and concentrating adenoviral stocks 
To purify each adenovirus construct, HEK 293A cells were seeded on 6 x 10 cm cell culture 
dishes at a density as previously mentioned in Table 2.8, in 7 mL of complete medium per 
dish, for 24 h at 37ºC. Cells were then infected with the secondary adenoviral stock as 
described in Section 2.2.2.2 and incubated at 37ºC until 80-90% cytopathic effect was 
observed. Infected cells were harvested with a tissue culture pipette and centrifuged at 
3,500 x g for 15 min to pellet the cells. The supernatant was decanted into a sterile 
container and set aside, however 2 mL of the supernatant was used to resuspend the cell 
pellet prior to subjecting the cells to three freeze/thaw cycles. The cells were then 
centrifuged as before to pellet the cell debris and the viral supernatant was recombined 
with the original supernatant and gently mixed. 
The adenoviruses were purified using reagents and materials provided with the Vivapure® 
AdenoPACK™ 20 (Sartorius UK). Benzonase® was added to each culture to result in a final 
concentration of 12.5 U/mL, mixed well and incubated at 37ºC for 30 min to enable the 
digestion of cellular nucleic acids. The digested supernatant was then loaded onto a 
Vivaclear Maxi and centrifuged at 500 x g for 30 min at room temperature. The flow-
through was collected and measured, to which 1/9 volume of loading buffer (10x) was 
slowly added under agitation, to prevent osmotic shock to the viral particles. Each 
adenoviral sample was then added to separate, equilibrated AdenoPACK 20 Maxi columns, 
centrifuged at 500 x g for 30 min and the flow-through discarded. The columns were 
washed twice with Washing Buffer (1x; diluted from 10x) and centrifuged at 500 x g for 5 
min, removing the flow-through each time.  
The adenoviruses were eluted off the membrane, by addition of 1 mL Elution Buffer, 
centrifugation at 500 x g for 30 s, 10 min incubation, followed by centrifugation at 500 x g 
for 5 min. The adenoviruses were dialysed with 9 mL PBS containing 2.5% glycerol (v/v) on 
Vivaspin 20 centrifugal concentrators and centrifuged at 800 x g for 30 min, concentrating 
the adenoviruses to a volume of approximately 200 µL. 
2.2.2.4 Titering adenoviral stocks 
A viral titer of optical particle units (opu) was obtained by diluting 2 µL of each adenovirus 
with 8 µL PBS containing 0.1% (v/v) SDS, determining the absorbance at 260 nm (OD260) by 
spectrophotometry and using the following calculation: 
OD260 x 5 (dilution factor) x (1.1 x 10
9) = viral titer (opu/µL) 
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A viral titer of infectious units (ifu) was obtained by following the Adeno-X Rapid Titer Kit 
protocol. In brief, HEK 293A cells were seeded on a 12-well plate at a density as 
mentioned in Table 2.8, in 1 mL complete medium and infected with 100 µL of 10-fold 
serial dilutions of the viral samples for 48 h. Infected cells were then fixed with ice-cold 
100% methanol and probed with an anti-hexon antibody and its corresponding secondary 
(HRP-conjugated) antibody. Each well was then treated with DAB (3,3’-diaminobenzidine) 
substrate to develop the brown/black colour for positive-infected cells and washed with 
PBS Cell Wash (Table 2.6) before quantification using a 20X objective and applying the 
following calculation to result in a viral titer of ifu/µL: 
(# infected cells/field) x 594 (fields/well) 
100 µL (volume of virus) x 10-6 (dilution factor) 
Complete adenoviral FLAG-ERK5 sequence and final viral titer is provided in Appendix I. 
 
2.2.3  Cell culture 
2.2.3.1 Sterile cell culture technique 
Cells were cultured in sterile conditions at all times. A Howie coat and nitrile gloves were 
worn and sterile cell culture equipment were used within a TriMAT2 Class II microbiological 
safety cabinet. All work surfaces were disinfected using 70% (v/v) ethanol before and after 
cell culture work. Prior to use, culture media were warmed to 37ºC in a water bath. Cells 
were maintained at a humidified 37ºC, 5% (v/v) CO2 Sanyo MCO-17AC cell culture 
incubator. 
2.2.3.2 Gelatin-coating of cell culture materials 
HDMEC were cultured or seeded on gelatin-coated dishes, plates or coverslips. Sterile 
dishes, plates and 16 mm coverslips were coated with 0.5% (w/v) gelatin and incubated in 
the cell culture incubator for at least 5 min prior to use. Gelatin was aspirated prior to 
plating out HDMEC. 
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2.2.3.3 Thawing of cryopreserved cell stocks 
Cryopreserved cells were stored in vapour phase Nitrogen (approximately -135ºC). 
Cryovials were thawed for 2-3 min in a 37ºC water bath, disinfected with 70% (v/v) ethanol 
and the cells were transferred into a 15ml capped tube containing 9 mL of pre-warmed, 
appropriate culture medium (full growth/complete medium). Cells were pelleted by 
centrifugation at 1000 rpm for 5 min, the supernatant was aspirated off and the cells were 
resuspended in 10 mL culture medium. Cells were transferred to a 10 cm gelatin-coated 
dish (HDMEC) or non-gelatinised T-75 cm2 flask (all other cell types) then incubated for 24 
h, after which the cell culture medium was replaced with 10 mL fresh culture medium. 
2.2.3.4 Routine culture of cells 
As previously mentioned, cells were maintained in their appropriate full growth/complete 
medium in a cell culture incubator. HDMEC were cultured on gelatin-coated 10 cm2 dishes, 
whereas all other cells were cultured in T75 cm2 flasks. 
Cells that reached 80-90% confluency, approximately 2-3 days after seeding, were split to 
the next passage. Each 10 cm2 dish or T75 cm2 flask of cells was washed with 6-10 mL 
Versene (Table 2.6) and treated with 1-3 mL of Trypsin (Table 2.6), respectively and 
returned to the incubator for 3-5 min. After this time, 95-100% of the cells will have 
detached (which can be observed under a light microscope) and cells were resuspended in 
their appropriate cell culture medium, homogenised with vigorous pipetting and reseeded 
in the splitting ratio as described in Table 2.9. 
Table 2.9 Cell splitting ratio 
Cell type Culture medium Splitting ratio  
HDMEC Full growth medium 1:6 
HeLa Complete medium 1:5 
MAE 
(all variants) Complete medium 1:10 
HEK 293A Complete medium 1:5 
 
2.2.3.5 Cell counting and seeding 
Cells were counted to ensure an accurate number of cells were seeded for experiments. 
Trypsin was used to detach cells from the culture dish or flask, as described in Section 
2.2.3.4 and cells were resuspended in 7 mL of their appropriate culture medium. 100 µL of 
cells was pipetted onto a Neubauer haemocytometer (Sondheim, Germany) for counting.  
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The original cell density was calculated as follows: 
Number (#) of cells counted = cells per 0.1 mm3 
∴ # of cells counted x 10,000 = cells per 1 cm3 i.e. cells / mL 
Multiply by 8 mL = total # of cells 
The cell number for experiments may then be calculated. Cells were then transferred into 
a fresh capped tube, centrifuged at 1000 rpm for 5 min, the medium aspirated and cells 
resuspended in the required volume of appropriate culture medium. 
To ensure reproducibility, cells were seeded for protein analysis experiments as denoted 
in Table 2.10 and immunofluorescence analysis experiments in Table 2.11. 
Table 2.10 Cell density for protein analysis experiments 
Cell type 12-well plate (cells/well) in 1 mL of media 
6-well plate (cells/well) 
in 2 mL of media 
10 cm dish (cells/dish) 
in 8 mL of media 
HDMEC 5.0 x 104 1.0 x 105 4.0 x 105 
HeLa 6.5 x 104 1.3 x 105 5.2 x 105 
MAE (all) 5.0 x 104 1.0 x 105 N/A 
 
Table 2.11 Cell density for immunofluorescence experiments 
Cell type 12-well plate (cells/well) in 1 mL of media 
HDMEC 3.0 x 104 
HeLa 4.0 x 104 
 
2.2.4  Cell treatments 
2.2.4.1 Cell infection with adenoviral expression vectors 
HDMEC and HeLa were routinely infected in 6-well plates for Western immunoblotting 
(Section 2.2.9), or 10 cm dishes for mass spectrometry (Section 2.2.8). Cells were seeded 
at the appropriate density as described in Table 2.10 in full growth medium or complete 
medium respectively, and incubated for 24 h at 37ºC. Adenoviral expression vectors were 
diluted from their stock solution in full growth medium or complete medium to the desired 
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multiplicity of infection (MOI; ratio of infectious units to the number of cells) using the 
following calculation: 
# cells x desired MOI = # infectious units (ifu) 
# ifu / viral titer (ifu/µL) = # µL stock virus needed for desired MOI 
Cells were then infected with drop-wise addition of the diluted virus, the cell culture 
plates were gently swirled to ensure even distribution, and incubated at 37ºC for 30 h. 
Following this incubation, cells were washed with PBS Cell Wash and serum starved 
overnight in 1% low serum medium or 0.1% low serum medium respectively, prior to 
agonist stimulation (Section 2.2.4.4) and cell lysis (Section 2.2.4.5). 
2.2.4.2 Cell transfection with small interfering RNA (siRNA) 
A list of siRNA duplexes used in this study can be found in Appendix II. 
HDMEC and HeLa were routinely transfected in 6-well plates for protein analysis by 
Western immunoblotting and thus were seeded at a density as described in Table 2.10 in 
their appropriate culture medium respectively, and incubated at 37ºC for 24 h. 
Lipofectamine™ RNAiMAX transfection reagent was diluted to give a final concentration of 
0.2% (v/v) in 250 µL of Opti-MEM® and in a separate microcentrifuge tube, siRNA stock 
solution (20 µM) was diluted to a final concentration of 10 nM in 250 µL of Opti-MEM®. 
These two components were incubated separately for 5 min at room temperature, then 
combined and mixed by gentle pipetting to result in a 500 µL transfection mix which was 
then incubated at room temperature for 30 min to enable the formation of the liposome-
nucleic acid complexes. Media on the cells was replaced accordingly with 2 mL of fresh 
full growth medium or complete medium, prior to drop-wise addition of the siRNA 
transfection mix and gentle swirling of the cell culture plate to ensure even distribution. 
Cells were incubated at 37ºC for 6 h with the transfection mix, after which they were 
washed twice with 2 mL PBS Cell Wash, and incubated with 2 mL full growth medium or 
complete medium for a further 24 h at 37ºC. Following this 24 h incubation, cells were 
washed with PBS Cell Wash and serum starved overnight in 1% low serum medium or 0.1% 
low serum medium respectively, prior to treatment with inhibitors (Section 2.2.4.3) 
and/or agonist stimulation (Section 2.2.4.4) and cell lysis (Section 2.2.4.5). 
For experiments conducted on 12-well plates, all volumes were halved i.e. 125 µL of Opti-
MEM® per incubation, resulting in a 250 µL transfection mix in 1 mL of media. 
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2.2.4.3 Intracellular kinase inhibition using small-molecule inhibitors 
The small-molecule kinase inhibitors used in this study, BIX 02189 and XMD8-92, were 
diluted in sterile dimethylsulphoxide (DMSO) into stock solutions of 50 mM and 30 mM 
respectively, and stored in aliquots at -80ºC. For experimental use, the inhibitors were 
thawed and either diluted in DMSO or appropriate low serum medium to result in 0.1% 
(v/v) final concentration of DMSO in each case. Furthermore, 0.1% (v/v) DMSO in 
appropriate low serum medium was utilised as a vehicle control, as DMSO had no observed 
effects on the cells at this concentration. Cells were pre-incubated with vehicle control or 
inhibitor medium for 1 h, prior to agonist stimulation (Section 2.2.4.4) and cell lysis 
(Section 2.2.4.5). Cells were treated with varying concentrations of inhibitors, the 
specifics of which are provided in the text for individual experiments. 
2.2.4.4 Agonist stimulation of cells 
As previously mentioned, prior to agonist stimulation, cells were serum starved overnight 
at 37ºC, in their appropriate low serum medium. A list of the growth factors used in 
experiments can be found in Section 2.1.2. The two most commonly used growth factors in 
these experiments were vascular endothelial growth factor (VEGF) to stimulate HDMEC and 
epidermal growth factor (EGF) to stimulate HeLa cells. All growth factors were initially 
diluted in sterile-filtered PBS containing 0.1% (w/v) BSA to 100 mg/mL stock 
concentrations and stored in aliquots at -80ºC. For experimental use, growth factors were 
thawed and diluted in appropriate low serum medium to 50 ng/mL final concentration, 
unless otherwise stated in the text. Cells were incubated with various agonists for 
different lengths of time, thus the specifics of these are provided in the text for each 
experiment. 
2.2.4.5 Cell lysis – Protein extraction 
Protein lysates were prepared by placing cell culture plates on ice, prior to washing cells 
twice with ice-cold PBS Lysis Wash (Table 2.6). Unless otherwise stated in the text, lysates 
for Western immunoblotting were generated with the addition of modified radio-
immunoprecipitation assay (RIPA) lysis buffer and lysed cells were scraped and transferred 
into microcentrifuge tubes. Protein lysates were centrifuged at 14,000 rpm for 20 min at 
4ºC, prior to being transferred into fresh, pre-chilled microcentrifuge tubes and mixing 
samples with 1/3 volumes of 4x LDS. Protein samples were then boiled at 90ºC for 5 min, 
vortexed and frozen at -80ºC for at least 1 h before their use in Western immunoblotting 
(Section 2.2.9). 
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Constituents of RIPA lysis buffer: 
20 mM Tris-HCl; pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (v/v) glycerol, 1% Triton-X-100, 1 
mM Na3VO4, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 1 mM PMSF, 
0.1% (w/v) SDS and 0.5% (w/v) sodium deoxycholate. 
Protein lysates for immunoprecipitation and mass spectrometry were produced with the 
addition of sucrose lysis buffer and lysed cells were scraped and transferred into 
microcentrifuge tubes. Lysates were then centrifuged at 14,000 rpm for 20 min at 4ºC, 
prior to being transferred into fresh, pre-chilled microcentrifuge tubes and proceeding 
with the immunoprecipitation protocol (Section 2.2.7). 
Constituents of sucrose lysis buffer: 
250 mM Tris-HCl; pH 7.6, 1 mM MgCl2, 1 mM β-mercaptoethanol, 0.1% (v/v) Triton-X-100, 1 
mM Na3VO4, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin, 1 mM PMSF. 
2.2.5  Subcellular protein fractionation 
HDMEC and HeLa were seeded on sterile 10 cm dishes at a density as denoted in Table 
2.10 for 48 h in full growth medium or complete medium, respectively. Cells were then 
serum starved overnight in their appropriate low serum medium, prior to agonist 
stimulation, washing with ice-cold PBS Lysis Wash and harvesting cells with Trypsin. Cells 
were then pelleted by centrifugation at 500 x g for 5 min at 4ºC, washed with ice-cold PBS 
Lysis Wash, repelleted in fresh, pre-chilled microcentrifuge tubes and the supernatant 
discarded. The cell pellet was kept on ice prior to commencing with the protocol as 
provided in the Subcellular Protein Fractionation Kit for Cultured cells (purchased from 
Thermo Fisher Scientific™; Loughborough, UK).  
Unless otherwise stated, all extraction buffers contained protease inhibitors, all 
incubations and centrifugations were at 4ºC, incubations involved gentle, rotary mixing 
and all extraction samples were kept on ice in fresh, pre-chilled microcentrifuge tubes. In 
brief, the procedure involved ice-cold cytoplasmic extraction buffer (CEB) being added to 
and incubated with the cell pellet for 10 min, after which the sample was centrifuged at 
500 x g for 5 min and the supernatant (cytoplasmic extract) was transferred to a fresh 
tube. Ice-cold membrane extraction buffer (MEB) was then added to the pellet, vortexed 
for 5 s and incubated for 10 min prior to centrifugation at 3000 x g for 5 min. The 
supernatant (membrane extract) was transferred to a fresh tube, and nuclear extraction 
buffer (NEB) was added to the pellet, vortexed for 15 s and incubated for 30 min. 
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Centrifugation of the sample at 5000 x g for 5 min, separated the soluble nuclear extract 
into the supernatant and was transferred to a fresh tube, after which chromatin-bound 
extraction buffer (room temperature NEB containing 100 mM CaCl2 and 300 units 
Micrococcal Nuclease – both provided in the kit) was added to the pellet, vortexed for 15 s 
and incubated in a 37ºC water bath for 5 min. Further vortexing for 15 s, followed by 
centrifugation at 16,000 x g for 5 min, enabled the supernatant (chromatin-bound nuclear 
extract) to be transferred to a fresh tube prior to adding room temperature pellet 
extraction buffer to the cell pellet, vortexing for 15 s and incubation at room temperature 
for 10 min. A final centrifugation at 16,000 x g for 5 min separated the cytoskeletal 
extract into the supernatant which was transferred to a fresh tube. Subcellular protein 
fractions were mixed with 1/3 volumes of 4x LDS, boiled at 90ºC for 5 min, vortexed and 
frozen at -80ºC for at least 1 h before their use in Western immunoblotting. 
 
2.2.6  Immunofluorescence 
2.2.6.1 Cell staining 
HDMEC and HeLa cells were seeded on sterile 16 mm glass coverslips, placed within wells 
of a 12-well plate, at a density as mentioned in  
Table 2.11, for 48 h in full growth medium or complete medium respectively. Cells were 
then serum starved overnight in their appropriate low serum medium, prior to agonist 
stimulation, washing cells with ice-cold PBS Lysis Wash and cell fixation and 
permeabilisation with ice-cold methanol for 10 min at -20ºC. Unless otherwise stated in 
the text, all subsequent washes were with Tris-buffered saline (TBS; 20mM Tris, 0.137M 
NaCl) containing 0.1% (v/v) Tween-20 (TBS-T) and all washes and incubations were at room 
temperature with gentle rotation. Each well was initially washed three times with PBS Cell 
Wash, 5 min each, after which cells were incubated with blocking buffer (TBS-T containing 
1% (w/v) BSA and 5% (v/v) donkey serum) for 1 h. Cells were washed once prior to their 
incubation with primary antibodies, which were made up in TBS-T containing 1% (w/v) 
BSA, at a dilution as denoted in Table 2.1 and Table 2.2, for 1 h. Each well was then 
washed three times and incubated with the appropriate fluorescent-labelled secondary 
antibodies, which were made up in TBS-T containing 1% (w/v) BSA at a dilution as 
mentioned in Table 2.3 for 1 h in the dark. Cells were then washed twice, and Hoechst 
diluted in TBS-T containing 1% (w/v) BSA (Table 2.3) was added to the cells and incubated 
for 10 min in the dark, after which cells were washed three times.  
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2.2.6.2 Image acquisition and analysis 
The glass coverslips were then carefully removed from the wells using forceps and 
mounted onto glass slides, using ProLong® Gold antifade reagent and sealed with clear nail 
varnish. Samples were stored in the dark at 4ºC until observation using an inverted Zeiss 
Axio Observer microscope, with Filter Sets 49 (DAPI/Hoechst; #488049-9901=000), 38 
(GFP/FITC/Alexa 488; #000000-1031-346) and 31 (Alexa 568; #000000-1031-350) and the 
associated Zen software for image acquisition. 
2.2.7  Immunoprecipitation 
Unless otherwise stated, all incubations and washes were conducted at 4ºC, under rotation 
and all centrifugations were at 4ºC. Primary antibodies that were not pre-conjugated to 
agarose beads, were incubated for 8 h with Protein G Plus in Wash/Binding buffer (25 mM 
Tris, 150 mM NaCl; pH 7.2) containing 0.1% (w/v) BSA, at the dilutions mentioned in Table 
2.1 and Table 2.2. Primary antibody-coupled-agarose beads were then centrifuged at 
13,300 rpm for 1 min and the blocking buffer supernatant discarded. Protein lysates 
generated as described in Section 2.2.4.5, were then added to the primary antibody-
coupled-agarose beads and incubated overnight, with end-over-end mixing at 4ºC. The 
samples were centrifuged at 13,300 rpm for 5 min, the supernatant removed and kept 
aside on ice, and the beads were then washed three times with Wash buffer for 5 min 
each. Samples for mass spectrometry were further washed twice with 25 mM ammonium 
bicarbonate, a fraction taken out for Western blotting and silver staining, and stored in 
100 µL of ammonium bicarbonate at -80ºC prior to running samples on a mass 
spectrometer (Ultimate 3000 RSLC™ nano system coupled to a QExactive™ mass 
spectrometer; both Thermo Scientific). Samples for Western blotting were mixed with 1 
volume of 2x LDS sample buffer, boiled at 90ºC for 5 min, vortexed, centrifuged for 30 s 
and stored at -80ºC for at least 1 h, prior to use. 
2.2.8  Mass spectrometry (LC-MS/MS) 
In order to identify proteins prior to analysis by mass spectrometry, samples were initially 
evaluated using SDS-PAGE (2.2.9.1), followed by Western blotting (0) and silver staining 
(2.2.8.1). 
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2.2.8.1 Silver staining 
The SilverQuest™ Silver Staining kit (Life Technologies) was utilised, only ultrapure water 
was used and all incubations were performed on a rotary shaker at a speed of 1 
revolution/sec at room temperature. 
After electrophoresis, the gel was removed from the cassette and placed in a clean 
staining tray. The gel was briefly rinsed with water prior to incubating it with 100 mL of 
fixative (40% (v/v) ethanol, 10% (v/v) acetic acid) for 20 min. The fixative was discarded 
and the gel was washed with 30% (v/v) ethanol for 10 min, after which the gel was 
incubated with 100 mL of Sensitizing solution for 10 min. The Sensitizing solution was then 
removed and the gel was washed with 100 mL of 30% (v/v) ethanol for 10 min, followed by 
100 mL of water for 10 min. The gel was then incubated with 100 mL of Staining solution 
for 15 min, after which the gel was washed with 100 mL of water for 30 sec. To develop 
the gel, 100 mL of Developing solution was added to the gel and incubated for up to 8 min 
until the desired band intensity had been reached, at which point 10 mL of Stopper 
solution was added to the gel (still submerged in Developing solution) and the colour 
change from pink to colourless indicated the development had stopped. The gel was 
washed with 100 mL of water for 10 min and scanned using an Epson® 4490 photo scanner. 
2.2.8.2 Proteomic analysis 
The label-free analysis was performed by Professor Rob Beynon’s Proteomics Group 
(Institute of Integrative Biology, University of Liverpool, Crown Street, Liverpool L69 7ZB) 
using an UltiMate 3000 RSLC™ nano system (Thermo Scientific) coupled to a QExactive™ 
mass spectrometer (Thermo Scientific). The sample was loaded onto the trapping column 
(Thermo Scientific, PepMap100, C18, 75 µm x 20 mm) using partial loop injection for seven 
minutes at a flow rate of 4 µL/min with 0.1% (v/v) formic acid (FA). The sample was 
resolved on the analytical column (Easy-Spray, C18, 75 µm x 500 mm, 2 µm column) using 
a gradient of 97% solution A (0.1% FA) : 3% solution B (99.9% acetonitrile (ACN), 0.1% FA) to 
60% solution A : 40% solution B over 240 min at a flow rate of 300 nL/min. The program 
used for data acquisition consisted of 70,000 resolution full-scan MS scan and the 10 most 
abundant peaks were selected for MS/MS. Database searching was performed using 
MASCOT (Matrix Science). A p-value of 0.05, the built in MASCOT decoy search, reported a 
peptide false discovery rate (FDR) of 0.5%. The data was processed with Progenesis 
(version 4, Nonlinear Dynamics, Newcastle-upon-Tyne, UK). 
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2.2.9  Western immunoblotting 
2.2.9.1 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
using pre-cast, 15-well NuPAGE® Novex® 4-12% Bis-Tris polyacrylamide gels in the XCell 
SureLock™ Mini-Cell electrophoresis system, with 800 mL 1x MOPS running buffer (0.05 M 
MOPS, 0.05 M Tris, 1 mM EDTA, 0.1% (v/v) SDS). The Mini-Cell running unit was loaded with 
1 or 2 pre-cast gels, placed into the tank and secured into position by locking the tension 
wedge. The loading chamber was then filled with MOPS buffer to ensure there were no 
leaks, after which the combs were removed and each well rinsed out with MOPS buffer to 
remove any unpolymerised acrylamide. Protein lysates in LDS were prepared as previously 
described in Section 2.2.4.5, of which up to 25 µL was loaded into each well, with the first 
well of every gel being loaded with 3 µL of full-range rainbow marker mixed with 22 µL 1x 
LDS sample buffer. After all the samples were loaded, the remaining MOPS buffer was 
poured into the tank, the lid was placed on to the running unit and the tank connected to 
a power supply prior to running the gels at constant amperage of 50 mA, 250 V, 15 W for 
up to 2 h. 
Following electrophoresis, the Mini-Cell was disassembled, the plastic cassettes containing 
electrophoresed NuPAGE® gels were opened and the stacking gel and ‘foot’ of the gel 
discarded. The resolving gel was then allowed to equilibrate in 25 mL 1x Tris-Glycine 
transfer buffer (12 mM Tris, 96 mM glycine, 20% (v/v) methanol) prior to transferring the 
proteins onto nitrocellulose membrane. 
2.2.9.2 Phos-tag™ SDS-PAGE 
The Phos-tag™ Acrylamide reagent was utilised in order to enable specific monitoring of 
phosphorylated proteins. This resulted in a retarded mobility and a distinct upward band 
shift of the phosphorylated form, from the non-phosphorylated protein, thus permitting 
the use of a total antibody to detect both the phosphorylated and non-phosphorylated 
forms. 
Phos-tag™ gels were set up and run using the Bio-Rad Mini-PROTEAN® Tetra Cell 
electrophoresis system, whereby a 1.5 mm glass spacer plate was assembled with a glass 
short plate in the gel casting unit. Each Phos-tag™ resolving gel was made up in the order 
as mentioned in Table 2.12, leaving the addition of the APS and TEMED solutions, until just 
prior to the resolving gel solution being poured between the glass plates. 
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Table 2.12 Composition of 7% Phos-tag™ SDS-PAGE gels 
 Resolving gel Stacking gel 
Resolving gel buffer 
(1.5 M Tris-HCl, pH 8.8, 0.4% (v/v) SDS 2.5 mL N/A 
Stacking gel buffer 
(0.5 M Tris-HCl, pH 6.8, 0.4% (v/v) SDS N/A 2.5 mL 
Ultrapure Protogel® solution 
(30% (w/v) Acrylamide, 0.8% (w/v) Bis-
Acrylamide (37.5:1)) 
2.3 mL 1.3 mL 
MnCl2 (10mM) 210 µL N/A 
Phos-tag™ Acrylamide reagent 
(5mM; 3% (v/v) MeOH) 140 µL N/A 
dH2O 4.85 mL 6.2 mL 
APS 
(10% (w/v) in dH2O) 
100 µL 100 µL 
TEMED 10 µL 10 µL 
On top of each gel, 300 µL dH2O was gently pipetted to eliminate air bubbles and ensure 
an even edge to the top of the gel, and the gel was left to polymerise for 1 h. Following 
polymerisation, the dH2O was poured off and the excess blotted, before adding the 
stacking gel (Table 2.12) and immediately inserting a 15-well, 1.5 mm comb. The stacking 
gel was then allowed to polymerise for 1 h. The Tetra Cell running units were loaded with 
2 gels or 4 gels, positioned within the tank and each loading chamber filled with 1x SDS 
running buffer (0.025 M Tris-HCl, 0.192 M glycine, 0.1% (v/v) SDS; pH 8.3) to ensure there 
were no leaks. Following this, the combs were removed and each well flushed out with 
SDS buffer to remove any unpolymerised acrylamide, prior to loading the samples in each 
well, with the first well of every gel being loaded with 12.5 µL prestained protein marker. 
After loading all the samples, the remaining SDS buffer was poured into the tank, the lid 
placed on to the running unit and connected to a power supply, prior to running the gels 
at constant amperage of 8 mA or 16 mA, 250V, 15 W for 22 h. 
The manganese ions present in the Phos-tag™ gels act as a cofactor and enable the 
formation of a stable complex with the phosphate group of the proteins during 
electrophoresis. However, after electrophoresis these ions must be eliminated from the 
gel in order to increase the efficiency at which the proteins can be transferred onto 
nitrocellulose membrane. 
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The Tetra Cell was disassembled, the glass plates containing electrophoresed Phos-tag™ 
gels were opened and the stacking gel and ‘foot’ of the gel discarded. The resolving gel 
was carefully placed into 25 mL 1x transfer buffer containing 100 mM EDTA and gently 
agitated for 10 min. Following this, the EDTA transfer buffer was poured off and the gel 
was gently agitated for a further 10 min in 25 mL fresh 1x transfer buffer. 
2.2.9.3 Western blot analysis 
Proteins resolved by SDS-PAGE or Phos-tag™ SDS-PAGE, were transferred onto nitrocellulose 
membrane using the XCell II™ Blot Module.  Sponges provided with the blotting unit were 
pre-soaked in 1x transfer buffer, along with nitrocellulose membrane cut to 7.5 cm x 8.5 
cm. The two electrophoresed gels were sandwiched between pre-soaked filter papers cut 
to 7.5 cm x 8.5 cm, and these two stacks were placed on top of one another but separated 
by a pre-soaked sponge. This stack in turn was placed upon another pre-soaked sponge 
within the blotting unit. A further three pre-soaked sponges were placed on top of the 
stack, followed by the unit lid, after which the blotting unit was placed into the Mini-Cell 
tank and secured into position with the tension wedge. The blotting chamber was then 
filled with 1x transfer buffer, the rest of the tank with cold dH2O and the lid was placed 
on top prior to transferring the proteins at a constant amperage of 140 mA or 125 mA, 300 
V, 15 W for 2 h. 
Nitrocellulose membranes with transferred proteins were briefly washed with 1x TBS-T to 
remove any traces of methanol, which would impede antibody binding. Membranes were 
then incubated, with gentle rocking, in 25 mL of blocking buffer (5% (w/v) BSA in TBST) at 
room temperature for 1 h to block non-specific antibody binding sites. Membranes were 
then incubated with the appropriate primary antibody diluted in 2% (w/v) BSA in TBS-T (as 
described in Table 2.1 and Table 2.2) at 4ºC for 16 h with gentle agitation. Following 
incubation with the primary antibody, membranes were washed six times with 1x TBS-T 
for 10 min with gentle rocking, prior to incubation with the appropriate horseradish 
peroxidase (HRP)-linked secondary antibody diluted in 2% (w/v) BSA in TBS-T (Table 2.3) at 
4ºC for 1.5 h, with gentle agitation. Membranes were then washed for 10 min each time – 
five washes with 1x TBS-T, followed by a wash with 1x TBS, prior to incubating the 
membrane with a 1:1 mixture of enhanced chemiluminescence (ECL) reagent 1 and 
reagent 2 at room temperature for 2 min. The membranes were then encased in a plastic 
sleeve within an X-ray film cassette and taken into a darkroom before exposing them to X-
ray films for various lengths of time, developing and fixing the films. 
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2.2.9.4 Quantification of protein expression by densitometry 
Developed X-ray films were scanned using an Epson® 4490 photo scanner and the image 
imported into ImageJ (http://imagej.nih.gov/ij/). The image was grey-scaled and the 
colour inverted to remove any background interference, after which a box set to the size 
of the largest band was positioned over each band to measure the relative intensity (a 
setting within the program). To correct for protein loading, the quantified protein of 
interest band was then related back to its corresponding, quantified Actin band. The 
untreated control sample in each experiment was assigned an arbitrary value of 1.0, to 
which bands from all other conditions were relatively expressed. 
2.2.9.5 Statistical analysis 
Densitometric values from Western blot experiments that had been repeated three or 
more times were subjected to statistical analysis. A repeated measures ANOVA was 
performed in SPSS 20 on densitometric values to determine the overall significant 
difference in the means of the experimental conditions. In the case of sphericity violation 
(p<0.05 in Mauchly’s Test of Sphericity), a Greenhouse-Geisser correction was utilised. A 
post hoc test using the Bonferroni correction allowed for pair-wise comparison of each 
experimental condition to the basal control condition, in order to determine which 
specific means significantly differed. The means are presented as bar charts with standard 
deviation bars. The significance levels p<0.05, p<0.01 or p<0.001 were applied accordingly 
to each experiment and any significant differences were indicated with asterisks. 
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3.1 Introduction 
The ERK5 protein is ubiquitously expressed in various tissues and cell lines (Regan et al., 
2002; Yan et al., 2003; Buschbeck and Ullrich, 2005) but studies suggest that ERK5 may 
play different, yet specific roles in particular cell types (Sohn et al., 2002; Hayashi and 
Lee, 2004; Wang et al., 2005; Wang and Tournier, 2006; Spiering et al., 2009). As such, 
ERK5 has been implicated in the regulation of cell adhesion, differentiation, migration, 
proliferation and survival in various cellular contexts (Kato et al., 1998; Dinev et al., 2001; 
Wang and Tournier, 2006; Carter et al., 2009; Sawhney et al., 2009). Additionally, the 
progression of certain pathologies including cancer, cardiac hypertrophy and ischemia 
implicate a pivotal role for ERK5 (Takeishi et al., 1999; Wang and Tournier, 2006; Montero 
et al., 2009). 
The physiological role of ERK5 was highlighted with experiments utilising gene ablation of 
components of the ERK5 signalling pathway in mice (Hayashi and Lee, 2004), and as 
previously discussed, it was apparent that Erk5-/- (Regan et al., 2002; Sohn et al., 2002; 
Yan et al., 2003), Mek5-/- (Wang et al., 2005) and Mekk3-/- (Yang et al., 2000) deficient 
mice died around E9.5-11.5 due to severe defects in the vasculature. Subsequent studies 
utilised conditional tissue-specific Erk5 knockout mice; developmental defects similar to 
those observed in the global Erk5-/- mice were also detected with endothelial-specific Erk5 
knockout mice (Hayashi et al., 2004). However, the cardiomyocyte and hepatocyte Erk5 
knockouts did not affect development (Hayashi et al., 2004; Hayashi and Lee, 2004), thus 
revealing the significant role of ERK5 in endothelial cell development and survival. 
The activation of ERK5 in endothelial cells was initially investigated using H2O2 to 
stimulate HUVECs whereby it was demonstrated that oxidative stress was able to activate 
ERK5 (Abe et al., 1996). Following this, Yan and colleagues showed that ERK5 could be 
stimulated by fluid shear stress in bovine aortic endothelial cells (BAECs) (Yan et al., 
1999). In the same study, the pro-angiogenic molecules VEGF and FGF-2 were unable to 
induce ERK5 activity in the BAECs; however, it has since been shown in HUVECs that these 
same growth factors are able to stimulate ERK5 activation (Hayashi et al., 2004). It has 
more recently been observed that ERK5 plays a unique role in HDMEC, regulating VEGF-
mediated AKT activation and suppressing apoptosis to facilitate tubular morphogenesis of 
cells in a collagen gel (Roberts et al., 2010). 
Due to the vast structural and functional heterogeneity of endothelial cells across the 
vascular bed, studies into the role of ERK5 in endothelial cell function often present with 
conflicting data. Furthermore, EGF-stimulated HeLa cells have been utilised to date as a 
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benchmark for ERK5 activation in the context of tumour cell proliferation, suggesting a 
profound difference in ERK5 function between endothelial cells and HeLa cells. Thus, this 
chapter describes experiments performed in order to analyse the regulation of ERK5 
activity between these two cell types. 
This project utilises conventional and innovative methods of SDS-PAGE to identify the key 
differences in the intracellular ERK5 signalling of these cell types. Additionally, murine 
aortic endothelial (MAE) cell lines stably transfected with various Flk-1 receptor mutants, 
as well as small-molecule kinase inhibitors, were employed to define potential regulators 
and effectors of ERK5 and elucidate differences in agonist-dependent ERK5 
phosphorylation. 
3.2 Characterisation of ERK5 activation  
3.2.1  Detection of ERK5 activity 
After the initial discovery of ERK5 in 1995, the detection of ERK5 activation predominantly 
involved protein separation by SDS-PAGE with an 8% (w/v) acrylamide gel, followed by 
Western blotting using a polyclonal anti-ERK5 antibody (Duff et al., 1995; Abe et al., 1996; 
Abe et al., 1997). This resulted in a ‘bandshift’ whereby phosphorylated ERK5 exhibited 
reduced electrophoretic mobility, thus migrating slower than the non-phosphorylated form 
of ERK5. However since then, many commercial antibodies against ERK5 have become 
readily available, as have pre-cast, gradient percentage acrylamide gels for SDS-PAGE. 
A range of pro-angiogenic growth factors - VEGF, FGF-2, HGF, EGF, PDGF-BB and TGF-α – 
were utilised in order to assess the profile of ERK5 activation in HeLa and HDMEC, by 
means of a mobility bandshift. Following cell stimulation with the pro-angiogenic factors, 
cells were lysed with RIPA, and analysed by SDS-PAGE and Western blotting using an 8% 
(w/v) acrylamide gel and the commercially available ERK5 antibody (#3372; New England 
BioLabs, Hitchin, UK) respectively (Figure 3.1).  
It was found that in HeLa cells, VEGF, FGF-2 and PDGF-BB did not stimulate ERK5 
activation as only a single ERK5 band was detected, similar to that of the control basal 
condition (Figure 3.1a). However, stimulation with HGF, EGF and TGF-α resulted in an 
ERK5 mobility bandshift. 
Individual quantification of the stimulated lower ERK5 and upper p–ERK5 mobility bands 
were compared to an arbitrary value of 1.0, set for both the ERK5 and p-ERK5 bands in the 
basal condition. 








Figure 3.1 Characterisation of ERK5 activation by electrophoretic mobility bandshift.  
(A) HeLa cells were seeded on 6-well plates for 24 h, prior to overnight serum starvation. Cells were 
stimulated with 50 ng/mL of VEGF, FGF-2, HGF, EGF, PDGF-BB or TGF-α for 10 min, followed by RIPA 
lysis. (B) HDMEC were seeded gelatin-coated 6-well plates for 24 h, followed by overnight serum 
starvation. Cells were stimulated with 50 ng/mL of VEGF, FGF-2, HGF, EGF, PDGF-BB or TGF-α for 10 
min, and lysed with RIPA. Protein lysates from (A) and (B) were resolved on an 8% (w/v) acrylamide 
gel, followed by Western blotting (WB) with antibodies against ERK5 (#3372, NEB) and Actin (I-19, 
SCB) as a loading control. Densitometric analysis of protein phosphorylation or protein expression 
relative to Actin is displayed beneath each blot. The basal control condition was set arbitrarily as 
1.0. This result is representative of three independent experiments (*p<0.05). 
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EGF stimulated ERK5 activation in HeLa to a greater degree than any other agonist (Figure 
3.1a) and was statistically significant (p<0.05). HGF and TGF-α addition also led to 
increased ERK5 phosphorylation, but these two agonists did not activate ERK5 as 
effectively as EGF (Figure 3.1a). 
In stark contrast to the HeLa cells, agonist stimulation of HDMEC followed by separation by 
SDS-PAGE and Western blotting, did not result in a mobility bandshift of ERK5 activation 
with any of the pro-angiogenic factors (Figure 3.1b). Therefore, in order to detect ERK5 
activation in this cell type, phosphorylation of the Thr218/Tyr220 residues of the T-E-Y motif 
present in the ERK5 activation loop (Zhou et al., 1995) were probed with a commercially 
produced phospho-specific ERK5 (p-ERK5) antibody (#3371 New England Biolabs, Hitchin, 
UK).  
3.2.2  Dual-phosphorylation of ERK5 
The same agonist-stimulated HeLa and HDMEC lysates used in Figure 3.1 underwent SDS-
PAGE on a 4-12% NuPAGE gel prior to Western blotting with the aforementioned 
Thr218/Tyr220-specific p-ERK5 antibody (Figure 3.2). 
The use of this p-ERK5 antibody on the HeLa lysates confirmed the previous ERK5 
activation results produced with the mobility bandshift, i.e. EGF was a potent activator of 
ERK5, as demonstrated by a two-fold increase compared to the control basal condition 
(Figure 3.2a).  
Furthermore, HGF and TGF-α also stimulated ERK5 phosphorylation, but to a lesser 
degree. Once again, stimulation of HeLa with VEGF, FGF-2 and PDGF-BB had a negligible 
effect on the phosphorylation of ERK5. 
The activation of ERK5 in HDMEC as detected by the p-ERK5 antibody, was only noticeably 
induced upon stimulation with VEGF (Figure 3.2b). VEGF stimulation evoked ERK5 
phosphorylation 1.6 times that of the basal condition, whereas FGF-2, HGF, EGF, PDGF-BB 
and TGF-α only marginally phosphorylated ERK5. 
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Figure 3.2 Characterisation of ERK5 activation using phospho-specific antibodies.  
(A) HeLa protein lysates used in Figure 3.1a and (B) HDMEC protein lysates used in Figure 3.1b were 
resolved on a 4-12% NuPAGE® gel, followed by Western blotting (WB) with an antibody against 
phospho-ERK5 (p-ERK5) (T218/Y220) (#3371, NEB). Densitometric analysis of protein phosphorylation 
or protein expression relative to actin is displayed beneath each blot. The basal control condition 
was set arbitrarily as 1.0. This result is representative of three independent experiments.  
 
As this ERK5 activation was not detected by mobility bandshift, it was considered that 
ERK5 might be differentially phosphorylated in HeLa cells and HDMEC, however it was 
necessary to initially exclude the possibility that different isoforms of ERK5 might be 
present in the two cell types. As previously discussed in Section 1.4.2.2, four alternatively 
spliced transcript variants of ERK5 exist, which encode for two different isoforms of ERK5. 
Thus, total RNA was extracted from HeLa cells and HDMEC grown in their normal growth 
medium and sent to Dr Jürgen Müller (Warwick Medical School, University of Warwick, 
Coventry, CV4 7AL, UK) for sequence analysis. Sequencing data from the mRNA revealed 
that the ERK5 transcripts in both cell types were in fact identical. The full sequence data 
can be found in Appendix III. 
Subsequently, due to the clear evidence that Thr218/Tyr220 are phosphorylated in response 
to VEGF in the HDMEC and EGF in the HeLa (Figure 3.2), it was hypothesised that the 
enhanced mobility bandshift observed in HeLa but not in HDMEC, was instead due to the 
phosphorylation of the numerous serine and threonine residues in the C-terminal tail of 
ERK5. Thus, Thr218/Tyr220 phosphorylation alone is not sufficient in decreasing the 
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electrophoretic mobility of p-ERK5 compared to non-phosphorylated ERK5; a result 
previously reported in HEK293 cells (Mody et al., 2003). Therefore, in order to ascertain 
the potential differences in phosphorylation between the two cell types, the innovative 
Phos-tag™ reagent was utilised in an acrylamide gel. 
3.2.3  Phosphorylation events of ERK5 
Kinoshita and colleagues reported that phosphorylated proteins could be visualised with 
the use of an alkoxide-bridged dinuclear metal (Mn2+) complex as a novel phosphate-
binding tag molecule (Phos-tag™) (Kinoshita et al., 2006). This Phos-tag™ reagent has a 
vacancy on the two metal ions, which provides suitable access for capturing 
phosphomonoester dianions bound to Ser, Thr and Tyr residues. Thus, phosphorylated 
proteins bound to Phos-tag™ migrate slower through a polyacrylamide gel than their 
corresponding non-phosphorylated proteins, resulting in the visualisation of multiple bands 
during Western blotting (Figure 3.3) (Kinoshita et al., 2006). 
 
 
Figure 3.3 Mode of action of Phos-tag acrylamide 
Image from: http://www.wako-chem.co.jp/english/labchem/product/life/Phos-tag/Acrylamide.htm 
 
The recommended concentrations for the Phos-tag™ reagent were 10% (w/v) acrylamide, 
100 µM Phos-tag and 140 µM MnCl2. However, with the equipment available – XCell 
SureLock™ and XCell II™ Blot system – the substantial heat produced during electrophoresis 
rendered the gel unusable. Hence it was necessary to optimise the conditions for protein 
electrophoresis and transfer. During optimisation of these conditions, it became apparent 
that a lower total concentration of acrylamide present (%T; see Table 3.1) in the gel 
would enhance the electrophoretic mobility of both the non-phosphorylated and 
phosphorylated protein bands, whilst enabling the reduction in the amount of Phos-tag™ 
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reagent used. Furthermore, it proved valuable to increase the ratio of Mn2+ ion to Phos-
tag™ to an excess of 3:1, thus ensuring all reagent molecules were primed to capture 
phosphorylated proteins. 
The Phos-tag™ optimisation conditions that were unsuccessful in distinctly separating the 
phosphorylation events of ERK5, are indicated in normal type font in Table 3.1 (data not 
shown). 
 







concn (µM)  
Electrophoresis 
system, amperage & 
time 
Western blot 
system, amperage & 
time 
10% 100 200 XCell SureLock
™; 
30mA, 2h 
XCell II™ Blot; 
125mA, 2h 
8% 100 200 XCell SureLock
™; 
10mA, 6h 
XCell II™ Blot; 
125mA, 2h 
8% 70 210 XCell SureLock
™; 
10mA, 6h 
XCell II™ Blot; 
125mA, 2h 
8% 70 210 XCell SureLock
™; 
8mA, 22h 
XCell II™ Blot; 
125mA, 2h 
7% 70 210 XCell SureLock
™; 
8mA, 22h 
XCell II™ Blot; 
125mA, 2h 





7% 70 210 Mini-PROTEAN
®; 
8mA, 22h 
XCell II™ Blot; 
125mA, 2h 
 
After these initial experiments, it was evident that the XCell II™ Blot Module enabled 
clearer transfer of proteins onto the nitrocellulose membrane than the Mini Trans-Blot®. 
Thus, the XCell II™ Blot was utilised in an experiment that compared the quality of ERK5 
phosphorylation band separation using the XCell SureLock™ and Mini-PROTEAN® 
electrophoresis systems, and the optimised conditions indicated in bold type font in Table 
3.1 (Figure 3.4). 
EGF-stimulated HeLa and VEGF-stimulated HDMEC protein lysates were separated for 22 h 
at 8 mA on a 7% (w/v) acrylamide, 70 µM Phos-tag™, 210 µM MnCl2 gel either using the 
XCell SureLock electrophoresis system or the Mini-PROTEAN system. However, both gels 
were transferred using the XCell II Blot Module at 125 mA for 2h prior to Western blotting 
with an antibody against ERK5 (Figure 3.4).  
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Using the XCell SureLock system, it was apparent that the protein lysates did not migrate 
through their lanes in a stable manner, as the bands were not horizontally aligned (Figure 
3.4a). This was attributed to inefficient heat conduction from the plastic cassettes to the 
surrounding buffer, produced during electrophoresis. Nevertheless, in both cell types and 
all conditions, a higher migrating band (*) that did not fully resolve from the ERK5 band 
was observed and was termed “p-ERK5” in Figure 3.4a. 
 
Figure 3.4 Optimisation of Phos-tag™ gel SDS-PAGE to detect ERK5 activation. 
HeLa cells and HDMEC were seeded on 6-well plates for 24 h, prior to overnight serum starvation. 
HeLa were stimulated with EGF (50 ng/mL) and HDMEC with VEGF (50 ng/mL), for 10 or 30 min, 
followed by RIPA lysis. Lysates were separated for 22 h at 8 mA on a 7% (w/v) acrylamide, 70 µM 
Phos-tag™, 210 µM MnCl2 gel using either (A) an Invitrogen XCell SureLock
™ Mini-Cell electrophoresis 
system or, (B) a Bio-Rad Mini-PROTEAN® Tetra Cell electrophoresis system. Both gels were 
transferred for 2 h at 125 mA, using an Invitrogen XCell II™ Blot Module prior to Western blotting 
(WB) with an antibody against ERK5. Densitometric analysis of protein phosphorylation or protein 
expression relative to the basal control condition of each cell type, is displayed beneath each blot. 
The basal control condition for each cell type and each migrated form of ERK5 was set arbitrarily as 
1.0. 
 
The HeLa cells exhibited an additional band migrating much slower than the p-ERK5 band 
suggesting this represented a hyper-phosphorylated ERK5 and was designated the “hyper 
p-ERK5” band (Figure 3.4a). This band was present in unstimulated HeLa, but significantly 
increased in intensity at 10 min EGF stimulation and then somewhat decreased again at 30 
min stimulation, yet still remained more intense than the unstimulated condition. 
Importantly, this hyper p-ERK5 band was not detected in unstimulated or VEGF-stimulated 
HDMEC (Figure 3.4a). 
Chapter Three: Characterisation of ERK5 activation 
76 
Protein separation using the Mini-PROTEAN® system appeared to result in greater stability 
of migration, as all detected bands were horizontally aligned. Furthermore, all observed 
bands were distinct from one another, making it possible to quantify their intensity 
relative to the respective basal condition migration band for each cell type (Figure 3.4b). 
EGF stimulation of HeLa for 10 min resulted in a faint band that migrated slower than that 
of ERK5, suggestive of a phosphorylation event and was termed “p-ERK5” (Figure 3.4b), 
however at 30 min post-stimulation, this band disappeared. This p-ERK5 band was also 
present in VEGF-stimulated HDMEC at 10 min, remaining sustained for 30 min.  
A clear hyper p-ERK5 band was observed in all conditions of HeLa cells whilst using the 
Mini-PROTEAN® system (Figure 3.4b), the intensity of which, followed that observed in 
Figure 3.4a. Once again however, this band was not detected in either the unstimulated or 
VEGF-stimulated HDMEC conditions (Figure 3.4b). Overall these data suggested a potential 
difference in the agonist-stimulated phosphorylation of ERK5 in HeLa and HDMEC.  
3.2.4  ERK5 activation in HeLa cells 
The same agonist stimulated HeLa lysates used in Figure 3.1a and Figure 3.2a were 
separated on a 7% (w/v) acrylamide, 70 µM Phos-tag™, 210 µM MnCl2 gel for 22 h at 8 mA, 
after which an antibody against ERK5 was used for Western blotting. In addition to this, 
the same lysates were resolved on a 4-12% NuPAGE® gel prior to Western blotting with 
antibodies against phospho-AKT (#4060) and phospho-ERK1/2 (#4370) (Figure 3.5). 
Similar to results observed in Figure 3.1a and Figure 3.2a, stimulation of HeLa cells with 
VEGF, FGF-2 or PDGF-BB did not induce any phosphorylation of ERK5 as detected by Phos-
tag™ SDS-PAGE, compared to the basal condition (Figure 3.5). Furthermore, VEGF and FGF-
2 did not elicit phosphorylation of AKT or ERK1/2 compared to the unstimulated basal 
condition, whereas PDGF-BB evoked AKT phosphorylation 2.3 times that of the basal 
condition and slightly lower phosphorylation of ERK1/2. 
HeLa stimulated with HGF, EGF and TGF-α all resulted in hyper p-ERK5, with a significant 
decrease in p-ERK5 (p<0.05) (Figure 3.5). EGF stimulation of ERK5 was much greater than 
with HGF and TGF-α, however hyper p-ERK5 stimulation with both EGF and TGF-α 
appeared to be statistically significant (p<0.01). In addition to this, HGF stimulation 
resulted in an increase in AKT phosphorylation to a higher degree than EGF and TGF-α, and 
these three agonists phosphorylated ERK1/2 to a lesser degree. 




Figure 3.5 Characterisation of ERK5 activation in HeLa cells using Phos-tag™ SDS-PAGE.  
HeLa protein lysates used in Figure 3.1a and Figure 3.2a were separated on a 7% (w/v) acrylamide 
Phos-tag™ gel, followed by Western blotting (WB) with an antibody against ERK5. Lysates were also 
resolved on a 4-12% NuPAGE® gel prior to Western blotting (WB) with antibodies against phospho-AKT 
(#4060, NEB) and phospho-ERK1/2 (#4370, NEB). Densitometric analysis of protein phosphorylation 
or protein expression relative to the basal control condition, is displayed beneath each blot. The 
basal control condition was set arbitrarily as 1.0 for each protein. This result is representative of 
three independent experiments (*p<0.05, **p<0.01). 
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3.2.5  VEGF stimulates ERK5 activation in HDMEC 
Agonist stimulated HDMEC lysates used in Figure 3.1b and Figure 3.2b were also resolved 
on a 7% (w/v) acrylamide, 70 µM Phos-tag™, 210 µM MnCl2 gel for 22 h at 8 mA, followed by 
Western blotting using an antibody against ERK5. The same lysates were also separated on 
a 4-12% NuPAGE® gel prior to Western blotting with antibodies against phospho-PLCγ 
(#2821), phospho-PKC (pan) (#9371), phospho-AKT and phospho-ERK1/2 (Figure 3.6). 
The Phos-tag™ gel revealed ERK5 activation results in a similar pattern of bands to that 
seen in Figure 3.2b, namely that VEGF was the most potent stimulator of ERK5 
phosphorylation in HDMEC, resulting in a significant increase in p-ERK5 (p<0.01) (Figure 
3.6). The only other agonist that marginally activated ERK5 was HGF. Interestingly, both 
VEGF and HGF also stimulated AKT phosphorylation in HDMEC to a strong degree, as well 
as phosphorylation of four identifiable PKC isoforms – α, δ, ε and η. 
Additionally, ERK1/2 appeared to be phosphorylated upon stimulation with VEGF, FGF-2 
and HGF, with increased band intensities of 1.9, 1.7 and 1.6 respectively (Figure 3.6). 
Interestingly, VEGF was unique in its ability to phosphorylate PLCγ (Figure 3.6) compared 
to the negligible values for the other agonists, suggesting VEGF-mediated ERK5 activity 
may exist downstream of, and thus be linked to, PLCγ activation. 
 




Figure 3.6 Characterisation of ERK5 activation in HDMEC using Phos-tag™ SDS-PAGE.  
HDMEC protein lysates used in Figure 3.1b and Figure 3.2b were separated on a 7% (w/v) acrylamide 
Phos-tag™ gel, followed by Western blotting (WB) with an antibody against ERK5. Lysates were also 
resolved on a 4-12% NuPAGE® gel prior to Western blotting (WB) with antibodies against phospho-
PLCγ (#2821), phospho-PKC (pan) (#9371, NEB) phospho-AKT and phospho-ERK1/2. Densitometric 
analysis of protein phosphorylation or protein expression relative to the basal control condition, is 
displayed beneath each blot. The basal control condition was set arbitrarily as 1.0 for each protein. 
This result is representative of three independent experiments (*p<0.01). 
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3.3 VEGF-induced activation of ERK5 occurs via Tyr1175 
residue on VEGFR-2 
VEGF-A is known to activate VEGFR-1 and VEGFR-2 in endothelial cells, however it is the 
binding to VEGFR-2 that stimulates a plethora of downstream signalling pathways resulting 
in a multitude of cellular functions (Holmes et al., 2010). The Tyr1175 residue located on 
the intracellular C-terminal domain of VEGFR-2 undergoes trans-autophosphorylation upon 
VEGF binding to the extracellular region of the receptor. Furthermore, phosphorylated 
Tyr1175 acts as a docking site for PLCγ which itself is phosphorylated and activated 
(Cunningham et al., 1997; Takahashi et al., 2001). To determine the role of VEGFR-2 in 
the activation of ERK5, murine aortic endothelial (MAE) cells stably expressing a range of 
murine VEGFR-2 (Flk-1) mutants were obtained from Prof. Claesson-Welsh, Rudbeck 
Laboratory, Uppsala University, Sweden. The original MAE cells (designated MAE vector) 
had been stably transfected with wild-type Flk-1 (assigned MAE WT) or Flk-1 point mutants 
known to affect downstream signalling pathways. Flk-1 is two amino acids shorter in 
length than human VEGFR-2, thus the Flk-1 receptor mutants contained point mutations at 
Tyr949, Tyr1173, Tyr1212 residues (corresponding to the human Tyr951, Tyr1175, Tyr1214 residues) 
to give Phe949, Phe1173, Phe1212. 
An initial experiment screened the MAE vector cells with the same pro-angiogenic growth 
factors that were used to stimulate HeLa and HDMEC in Section 3.2, alongside a positive 
control of VEGF-stimulated HDMEC (Figure 3.7). It was confirmed that the MAE vector cells 
did not express endogenous Flk-1, as stimulation with VEGF and subsequent Western 
blotting with a p-VEGFR2 antibody did not result in a phosphorylation band comparable to 
that of the VEGF-stimulated HDMEC positive control. Interestingly however, the MAE 
vector cells appeared to be strongly stimulated by EGF, with the presence of an intense p-
EGFR1 band migrating at an apparent molecular weight of 175 kDa suggesting the presence 
of EGFR-1 on these cells. 
In addition to this, it was observed that HGF, EGF, PDGF-BB and TGF-α stimulation 
resulted in the phosphorylation of AKT and ERK1/2 in the MAE vector cells, whereas VEGF 
and FGF-2 had negligible effects on the phosphorylation of these two proteins, thereby 
reflecting the absence of the cognate receptors of these latter agonists on the MAE vector 
cells. 
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Figure 3.7 Agonist screen on MAE vector cells. 
MAE vector cells were seeded on 6-well plates for 24 h, prior to overnight serum starvation. Cells 
were stimulated with 50 ng/mL of VEGF, FGF-2, HGF, EGF, PDGF-BB or TGF-α for 10 min, followed 
by RIPA lysis. Proteins were separated on a 4-12% SDS-PAGE gel as well as on a 7% (w/v) acrylamide 
Phos-tag™ gel, alongside a positive control of HDMEC stimulated with 50 ng/mL of VEGF. Membranes 
were incubated with antibodies against phospho-VEGFR2 (#3770, NEB)+phospho-EGFR (#2234, NEB), 
ERK5, phospho-AKT, phospho-ERK1/2 and Actin as a loading control. Densitometric analysis of 
protein phosphorylation or protein expression relative to the basal control condition, is displayed 
beneath each blot. The basal control condition was set arbitrarily as 1.0 for each protein. This 
result is representative of two independent experiments. 
 
The MAE vector cells were screened alongside the MAE WT and receptor mutant cells 
following VEGF stimulation for 10 and 30 min, to confirm the presence of Flk-1 on the 
stably transfected cells as well as observe the phosphorylation kinetics of ERK5 and various 
other proteins (Figure 3.8). It is important to note that each cell type was 
densitometrically compared to its own basal condition, which was set at an arbitrary value 
of 1.0. 
 




Figure 3.8 Screen of MAE mutant cell lines.  
MAE vector cells and MAE cells expressing the Flk-1 WT, Y949F, Y1173F or Y1212F receptors were seeded 
on 6-well plates alongside HDMEC as a positive control. Cells were incubated for 24 h, prior to 
overnight serum starvation, VEGF stimulation (50 ng/mL) for 10 or 30 min and RIPA lysis. Proteins 
were separated on a 4-12% SDS-PAGE gel, as well as on a 7% (w/v) acrylamide Phos-tag™ gel, 
alongside the 10 min VEGF (50 ng/mL) stimulated HDMEC positive control. Membranes were then 
incubated with antibodies against phospho-VEGFR2, VEGFR-2 (#2479 NEB), phospho-PLCγ, ERK5, 
phospho-AKT, phospho-ERK1/2 and Actin, for Western blotting (WB). Densitometric analysis of 
protein phosphorylation or protein expression relative to the basal control condition of each cell 
type, is displayed beneath each blot. The basal control condition was set arbitrarily as 1.0 for each 
protein and each cell type. This result is representative of three independent experiments 
(*p<0.05). 
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It was evident that the MAE WT and mutant receptor cells expressed VEGFR-2, as both the 
mature and immature forms of the receptor were observed in these cells in comparison to 
the absence of the receptor in the MAE vector cells (Figure 3.8). In addition to this, with 
the use of the p-VEGFR2 (Tyr1175) antibody, it was possible to confirm the inability of the 
MAE cells expressing Flk-1 Y1173F, to be phosphorylated on this site.  
The phosphorylation of PLCγ was significantly increased with 10 min VEGF stimulation in 
both the MAE WT and MAE cells expressing Flk-1 Y949F, and a two-fold increase in 
phosphorylation was observed in the MAE cells expressing Flk-1 Y1212F. As expected, the 
lack of phosphorylation of the MAE cells expressing Flk-1 Y1173F prevented the docking and 
subsequent phosphorylation of PLCγ (Figure 3.8). 
Rather interestingly, this deficiency in PLCγ phosphorylation in the MAE cells expressing 
Flk-1 Y1173F resulted in a statistically significant lack of ERK5 phosphorylation as detected 
by Phos-tag™ SDS-PAGE (p<0.05) (Figure 3.8), whereas the MAE cells expressing Flk-1 Y949F 
and Flk-1 Y1212F were shown to phosphorylate ERK5 at 10 min VEGF stimulation, compared 
to the MAE WT. 
AKT phosphorylation at 10 min in the MAE WT cells upon VEGF stimulation was nearly 
three times that of its basal condition and sustained p-AKT was observed at 30 min. 
Although at 10 min VEGF stimulation the MAE cells expressing Flk-1 Y949F and Y1212F also 
had increased p-AKT compared to their respective basal conditions, the increase was not 
as marked as the MAE WT cells. Additionally, some sustained p-AKT was observed in the 
MAE cells expressing Flk-1 Y1212F. The MAE cells expressing Flk-1 Y1173F appeared to have 
little, if any, AKT phosphorylation at both the 10 min or 30 min stimulation time points 
(Figure 3.8), with a significant difference at 10 min (p<0.05). 
Furthermore, VEGF appeared to stimulate ERK1/2 phosphorylation in the MAE WT and the 
three mutant receptors at 10 min relative to their respective basal conditions, with 
sustained phosphorylation at 30 min within each cell type. 
These results are suggestive of both ERK5 and AKT lying downstream of VEGFR-2 and that 
phosphorylation of the Tyr1175 residue was required in order for these two kinases to be 
activated in endothelial cells.  
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3.4 ERK5 undergoes differential phosphorylation following 
VEGF and EGF stimulation in murine endothelial cells 
Due to the apparent difference in ERK5 activation in HeLa and HDMEC, it was considered 
that this may be attributable to the activation of ERK5 via the separate EGF- and VEGF- 
stimulated intracellular signalling pathways, rather than differences in cell type. Thus, the 
presence of both EGFR-1 and murine VEGFR-2 on the MAE WT cells was exploited in order 
to ascertain whether the differential activation of ERK5 was characteristic of cell type, as 
well as extracellular stimuli. 
MAE vector and MAE WT cells were stimulated with VEGF, EGF, or VEGF+EGF for 10 min 
alongside positive controls of basal and VEGF-stimulated HDMEC and basal and EGF-
stimulated HeLa (Figure 3.9) and protein lysates were separated on both conventional and 
Phos-tag™ SDS-PAGE. 
In corroboration with previous results in Section 3.3, it was observed that EGF stimulated 
ERK5 phosphorylation in the MAE vector cells, as only a hyper p-ERK5 band was detected 
(Figure 3.9) similar to the EGF-stimulated HeLa cells. VEGF was unable to induce ERK5 
activity in the MAE vector cells due to their lack of VEGFR-2 expression. Stimulation of the 
MAE WT cells with VEGF resulted in a p-ERK5 band 1.5 times that of its basal condition, 
whereas EGF stimulation of these cells led to a hyper p-ERK5 band 2.5 times greater than 
its respective basal condition. Interestingly however, the co-stimulation of the MAE WT 
cells with VEGF and EGF appeared to slightly increase the intensity of the p-ERK5 band yet 
decrease the hyper p-ERK5 band (Figure 3.9). 
The use of conventional SDS-PAGE to ascertain ERK5 activation by mobility bandshift 
illustrated that only the EGF stimulation of the MAE vector, MAE WT and HeLa cells 
resulted in a bandshift denoting ERK5 activation (Figure 3.9). Thus, the stimulation of the 
MAE WT and HDMEC with VEGF did not lead to a mobility bandshift and in addition to this, 
the co-stimulation of the MAE WT cells appeared to restrict the ability of ERK5 to undergo 
a mobility bandshift as observed with EGF alone (Figure 3.9). 
The phosphorylation of AKT in the MAE WT cells upon individual agonist stimulation was 
observed to be much greater with EGF rather than VEGF (Figure 3.9). Furthermore, the co-
stimulation condition appeared to present phosphorylated AKT as a cumulative of the 
separate agonist conditions. 
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Figure 3.9 ERK5 is differentially activated by VEGF and EGF. 
MAE vector and MAE WT cells were seeded on 6-well plates with HDMEC and HeLa plated alongside. 
Cells were incubated for 24 h, serum starved overnight, stimulated with VEGF, EGF or VEGF+EGF 
(50ng/mL for each agonist) for 10 min and RIPA lysed. Proteins were separated on an 8% (w/v) 
acrylamide gel, as well as on a 7% (w/v) acrylamide Phos-tag™ gel, alongside HDMEC and HeLa basal 
and stimulated conditions (50 ng/mL of VEGF and EGF respectively). Membranes were incubated 
with antibodies against p-VEGFR2+p-EGFR1, ERK5, p-AKT and Actin. Densitometric analysis of 
protein phosphorylation or protein expression relative to the basal control condition of each cell 
type (set arbitrarily as 1.0), is displayed beneath each blot. This result is typical of three 
independent experiments. 
 
Altogether, these findings indicate that VEGF and EGF stimulate differential ERK5 
phosphorylation within the same cell type. Additionally, co-stimulation with these agonists 
appears to affect ERK5 phosphorylation, not in a cumulative manner as would be 
expected, but instead in a mode where VEGF stimulation of ERK5 seems to decrease the 
effect of EGF-stimulated hyper p-ERK5 compared to that of EGF stimulation alone. 
 
3.5 Small-molecule kinase inhibitors 
The two small-molecule kinase inhibitors commonly used in blocking MEK5 and ERK5 
activity are BIX 02189 and XMD8-92 respectively. The indolinone-6-carboxamide, BIX 02189 
selectively inhibits MEK5 over MEK1/2 and has an IC50 of 1.5 nmol/L (Tatake et al., 2008), 
whilst the highly-selective ATP-competitive kinase inhibitor XMD8-92 inhibits EGF-
stimulated ERK5 activation with an IC50 of 240 nmol/L (Yang et al., 2010a). Interestingly, 
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XMD8-92 has been shown to phosphorylate and consequently suppress PML, thereby 
blocking tumour cell proliferation; the growth of lung and cervical xenograft tumours were 
inhibited by 95% (Yang et al., 2010a). These two inhibitors were validated by dose 
response experiments conducted in HDMEC and HeLa cells to ensure receptor activation, 
as well as other intracellular signalling pathways, were not affected in a non-specific 
manner with these agents (Figure 3.10, Figure 3.11, Figure 3.12, and Figure 3.13). 
3.5.1  BIX 02189 inhibits ERK5, but not ERK1/2, activity 
In HDMEC, the addition of 0.1 µM BIX 02189 appeared to marginally increase the p-ERK5 
band as detected in the Phos-tag™ gel, compared to the basal or 0.1% (v/v) DMSO vehicle 
control. The subsequent doses of 0.3 µM, 1 µM and 3 µM reduced this phosphorylation to 
below those of the controls (Figure 3.10). Furthermore, the higher concentrations of 10 µM 
and 30 µM were able to decrease p-ERK5 to that of the unstimulated control conditions, 
with the 10 µM condition yielding a significant decrease (p<0.05) (Figure 3.10). 
The phosphorylation of ERK1/2 was not affected by the addition of BIX 02189 up to a 
concentration of 10 µM, thereby suggesting that VEGF-mediated ERK1/2 activity occurs 
independently of the ERK5 signalling pathway (Figure 3.10). In spite of this, the 30 µM 
dose of BIX 02189 decreased p-ERK1/2 and p-AKT indicating a more global, toxic effect of 
the drug at this concentration (Figure 3.10). 
BIX 02189 did not appear to have an effect on p-AKT up to 0.3 µM, with 1 µM and 3 µM only 
marginally decreasing its phosphorylation (Figure 3.10). However the 10 µM concentration 
decreased p-AKT to half that of the stimulated controls, suggesting that VEGF-mediated 
ERK5 phosphorylation may be required for AKT activity (Figure 3.10). 
A rather interesting result was the increase in p-VEGFR2 with the addition of 10 µM BIX 
02189, suggesting that MEK5 may either play a role in the internalisation of VEGFR-2, or it 
activates phosphatases that dephosphorylate the receptor. 
 




Figure 3.10 BIX 02189 dose response in HDMEC. 
HDMEC were plated on 6-well plates for 48 h prior to overnight serum starvation. Cells were then 
pre-incubated with 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM BIX 02189 or 0.1% DMSO for 1 h, 
prior to VEGF stimulation (50 ng/mL) for 10 min and RIPA lysis. Proteins were separated on 4-12% 
NuPAGE® gel as well as on a 7% (w/v) acrylamide Phos-tag™ gel followed by incubating with 
antibodies against p-VEGFR2, VEGFR-2, ERK5, p-AKT, p-ERK1/2 and Actin for Western blotting (WB). 
Densitometric analysis of protein phosphorylation or protein expression relative to the basal control 
condition (set arbitrarily as 1.0), is displayed beneath each blot. This result is representative of 
four independent experiments (p<0.05). 
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In the HeLa cells, the stimulation of the basal and 0.1% (v/v) DMSO vehicle controls with 
EGF resulted in a slight decrease in p-ERK5, but a three-fold increase in hyper p-ERK5 as 
detected by Phos-tag™ gel. This result was interpreted as a single, slower electrophoretic 
band (p-ERK5) on a conventional SDS-PAGE (Figure 3.11). 
The addition of 0.1 µM or 0.3 µM BIX 02189 appeared to reduce hyper p-ERK5 (p<0.01) yet 
slightly increase p-ERK5, possibly in an attempt to abrogate the inhibition of MEK5 by the 
drug. This result was reflected on conventional SDS-PAGE, as the p-ERK5 band was also 
affected (Figure 3.11). The subsequent doses of 1 µM, 3 µM, 10 µM and 30 µM, all 
decreased p-ERK5 and significantly decreased hyper p-ERK5 (p<0.001) in the Phos-tag™ gel, 
as well as the p-ERK5 band in SDS-PAGE (Figure 3.11). 
BIX 02189 did not have an effect on ERK1/2 phosphorylation at any of the concentrations, 
however there was a noticeable increase of p-AKT at 30 µM (Figure 3.11).  
These data demonstrate that the phosphorylation of additional residues of ERK5 is 
dependent upon EGF-mediated MEK5 dual-phosphorylation of ERK5. Furthermore, these 
data have revealed that a BIX 02189 dose of 10 µM was sufficient in inhibiting MEK5/ERK5 
activity without affecting the parallel ERK1/2 pathway in both HDMEC and HeLa cells. 
 




Figure 3.11 BIX 02189 dose response in HeLa. 
HeLa were plated on 6-well plates for 48 h prior to overnight serum starvation. Cells were then pre-
incubated with 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM BIX 02189 or 0.1% DMSO for 1 h, prior to 
EGF stimulation (50 ng/mL) for 10 min and RIPA lysis. Proteins were separated on 4-12% NuPAGE® gel 
as well as on a 7% (w/v) acrylamide Phos-tag™ gel followed by incubating with antibodies against p-
EGFR1, ERK5, p-AKT, p-ERK1/2 and Actin for Western blotting (WB). Densitometric analysis of 
protein phosphorylation or protein expression relative to the basal control condition (set arbitrarily 
as 1.0), is displayed beneath each blot. This result is typical of four independent experiments 
(*p<0.05, **p<0.01, ***p<0.001). 
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3.5.2  XMD8-92 inhibits hyper phosphorylation of ERK5 
It was observed that upon adding XMD8-92 to HDMEC and utilising Phos-tag™ SDS-PAGE, 
VEGF-mediated phosphorylation of ERK5 was not inhibited even at 30 µM (Figure 3.12). 
Alongside this, ERK1/2 activity remained unaffected by the addition of this drug, whereas 
the phosphorylation of AKT was slightly increased at concentrations up to 3 µM, above 
which AKT activity decreased back to levels akin to the control conditions (Figure 3.12). 
In HeLa cells, the addition of 0.1 and 0.3 µM resulted in a slight decrease in hyper p-ERK5, 
which became somewhat more apparent at the 1 µM and 3 µM concentrations and 
significantly decreased at the 10 µM and 30 µM concentrations (p<0.01), as observed by 
Phos-tag™ gel (Figure 3.13). Conventional SDS-PAGE was able to detect a decrease in p-
ERK5 from 0.3 µM and was reduced to a level similar to that of the unstimulated controls 
at 3 µM. Once again, alongside the Phos-tag™ decreases in hyper p-ERK5, the p-ERK5 band 
appeared to increase, perhaps in an attempt to reinstate phosphorylation of the additional 
residues (Figure 3.13). 
The phosphorylation of both ERK1/2 and AKT were unaffected by any concentrations of 
XMD8-92. Altogether, these data illustrate that XMD8-92 inhibits the hyper phosphorylation 
of ERK5 at a concentration between 10 µM and 30 µM and in addition to this, AKT activity 
is not dependent upon ERK5 hyper phosphorylation. 




Figure 3.12 XMD8-92 dose response in HDMEC. 
HDMEC were plated on 6-well plates for 48 h prior to overnight serum starvation. Cells were then 
pre-incubated with 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM XMD8-92 or 0.1% DMSO for 1 h, 
prior to VEGF stimulation (50 ng/mL) for 10 min and RIPA lysis. Proteins were separated on 4-12% 
NuPAGE® gel as well as on a 7% (w/v) acrylamide Phos-tag™ gel followed by incubating with 
antibodies against p-VEGFR2, VEGFR-2, ERK5, p-AKT, p-ERK1/2 and Actin for Western blotting (WB). 
Densitometric analysis of protein phosphorylation or protein expression relative to the basal control 
condition (set arbitrarily as 1.0), is displayed beneath each blot. This result is representative of 




























Figure 3.13 XMD8-92 dose response in HeLa. 
HeLa were plated on 6-well plates for 48 h prior to overnight serum starvation. Cells were then pre-
incubated with 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM XMD8-92 or 0.1% DMSO for 1 h, prior to 
EGF stimulation (50 ng/mL) for 10 min and RIPA lysis. Proteins were separated on 4-12% NuPAGE® gel 
as well as on a 7% (w/v) acrylamide Phos-tag™ gel followed by incubating with antibodies against p-
EGFR1, ERK5, p-AKT, p-ERK1/2 and Actin for Western blotting (WB). Densitometric analysis of 
protein phosphorylation or protein expression relative to the basal control condition (set arbitrarily 
as 1.0), is displayed beneath each blot. This result is typical of three independent experiments 
(p<0.01). 
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3.6 Discussion 
The strong activation of ERK5 in HeLa seen upon EGF stimulation (Figure 3.1a, Figure 3.2a 
and Figure 3.5) corroborates findings from previous studies although these include a 
variety of cell types (Kato et al., 1998; Kamakura et al., 1999; Hayashi et al., 2004; 
Kondoh et al., 2006). With the use of conventional SDS-PAGE, a phospho-specific ERK5 
antibody against the Thr218/Tyr220 residues and Phos-tag™ SDS-PAGE, it was possible to 
ascertain that in HeLa cells, ERK5 not only undergoes phosphorylation in the activation 
loop of the kinase domain (Figure 3.2a), but also at additional residues. As a consequence 
of this extensive phosphorylation, ERK5 was able to produce a mobility bandshift with 
conventional SDS-PAGE (Figure 3.1a), as well as a dual bandshift (p-ERK5 and hyper p-
ERK5) with Phos-tag™ SDS-PAGE (Figure 3.5) in the HeLa cells. 
TGF-α possesses some structural similarity to EGF and is able to bind to the EGF receptor 
(Tam et al., 1984; Schreiber et al., 1986) with an affinity indistinguishable from EGF in an 
equilibrium competition assay (Ebner and Derynck, 1991), consequently potentiating the 
activation of ERK5 in HeLa cells through EGFR-1. In addition to this, it has recently been 
shown that although the HGF receptor (cMET) is usually expressed in cells of an epithelial 
origin, they are also expressed in HeLa cells and dimerise upon ligand binding (Dietz et al., 
2013). The number of cMET receptors on the surface of HeLa cells is significantly lower 
than that of the EGF receptor (4600-8700 cMET receptors/HeLa (Dietz et al., 2013) 
compared to 22,000 high affinity EGFR/HeLa and 25,000 low affinity EGFR/HeLa (Berkers 
et al., 1991)). Thus, the activation of ERK5 upon HGF stimulation is less than that of EGF, 
which can be seen by the presence of a less intense phosphorylation band for HGF 
compared to that of EGF (Figure 3.1a, Figure 3.2a and Figure 3.5). Furthermore, the Phos-
tag™ SDS-PAGE revealed that although TGF-α may bind to EGFR-1 with a similar affinity as 
EGF, the former agonist did not appear to phosphorylate ERK5 to the same extent as EGF, 
highlighting the potency of EGF-mediated ERK5 activation. 
In stark contrast to ERK5 activation in HeLa cells, it was impossible to detect ERK5 
activation in HDMEC using the mobility bandshift method with conventional SDS-PAGE 
(Figure 3.1b). However, the use of the p-Thr218/Tyr220 antibody and Phos-tag™ SDS-PAGE 
enabled the detection of ERK5 phosphorylation in HDMEC upon stimulation with VEGF 
(Figure 3.2b and Figure 3.6).  
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Interestingly, this study revealed that both VEGF and HGF were able to stimulate AKT 
phosphorylation with much more potency than other agonists in HDMEC (Figure 3.6). It has 
previously been reported that in human malignant mesothelioma cells both AKT and ERK5 
are activated by HGF stimulation (Altomare et al., 2005; Ramos-Nino et al., 2008), 
whereas in human aortic endothelial cells (HAEC), AKT and ERK1/2 are phosphorylated 
(Nakagami et al., 2001). 
Studies have associated the cMET signalling pathway in tumour growth, survival, and 
metastasis; additionally promoting angiogenesis by acting synergistically with VEGF (van 
Belle et al., 1998; Xin et al., 2001). Furthermore, stimulation with VEGF has been 
reported to lead to increased tyrosine phosphorylation of PI3K and AKT (Guo et al., 1995).  
Although there is evidence that FGF-2, HGF and EGF are able to phosphorylate PLCγ in 
other cell lines (Nishibe et al., 1990; Mohammadi et al., 1991; Okano et al., 1993), it was 
observed in this study that VEGF was unique in its ability to stimulate PLCγ amongst 
growth factors (Figure 3.6); a finding which has previously been observed in HDMEC 
(Holmes et al., 2010). 
Utilisation of MAE cells stably expressing Flk-1 receptor mutants confirmed that the Tyr1173 
residue (Tyr1175 in humans) was essential for PLCγ phosphorylation (Figure 3.8), which 
corroborates previous studies (Takahashi et al., 2001). Additionally, this residue was also 
responsible for the activation of ERK5, implying the presence of ERK5 downstream of 
VEGFR-2 (Tyr1175) and PLCγ (Figure 3.8). With the knowledge that p-PLCγ hydrolyses PIP2 
into IP3 which increases intracellular Ca2+, and DAG an activator of PKC (Wu et al., 2000a), 
it is possible that ERK5 activity may be regulated by various PKC isoforms, which has 
previously been shown in a multitude of cell types (Diaz-Meco and Moscat, 2001; Li et al., 
2005; Zhao et al., 2010). Contrary to these studies however, other groups have shown that 
ERK5 activation does not occur via PKC (Abe et al., 1996; Kato et al., 1998; Yan et al., 
1999) suggesting that activation of this pathway is highly dependent on cell type. 
Further to this, the MAE Tyr1173Phe mutant displayed reduced p-AKT, which may be 
attributed to decreased activation of PI3K in response to the hindered binding of Shb to 
the Tyr1173 residue (Holmqvist et al., 2004), whereas ERK1/2 activity remained unaffected 
demonstrating that ERK5 and ERK1/2 activity are independent of one another and 
regulated separately. 
With the suggestions that VEGFR-2 and PLCγ are required for the VEGF-mediated 
phosphorylation of ERK5 in endothelial cells, attention turned to the apparent difference 
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in ERK5 phosphorylation in HeLa cells namely, the hyper p-ERK5 band. The MAE WT cells 
enabled exploitation of the presence of both the VEGF and EGF cognate receptors on an 
endothelial cell type. Furthermore, utilising both Phos-tag™ and conventional SDS-PAGE 
allowed for discrimination of the different phosphorylation events of ERK5 amongst 
agonists and cell types (Figure 3.9). 
This study revealed for the first time that observed differences in ERK5 phosphorylation 
were not dependent upon cell type, instead upon agonist. The data presented in this 
chapter show that VEGF is able to phosphorylate ERK5 at the very least on the 
Thr218/Tyr220 residues within the activation loop, resulting in a p-ERK5 band on Phos-tag™ 
SDS-PAGE (Figure 3.9). However, this phosphorylation event alone is not substantial 
enough to generate a mobility bandshift on conventional SDS-PAGE (Figure 3.9); a similar 
discovery was made in HEK293 cells (Mody et al., 2003). In contrast to this, EGF is able to 
phosphorylate ERK5 at Thr218/Tyr220 as well as additional residues, most probably in the C-
terminal tail, and as a consequence gives rise to a hyper p-ERK5 band on Phos-tag™ SDS-
PAGE and a mobility bandshift on conventional SDS-PAGE (Figure 3.9). An additional 
interesting discovery amongst these results is that of ERK5 phosphorylation upon VEGF and 
EGF co-stimulation; there is an apparent decrease in hyper p-ERK5 compared to that of 
EGF stimulation alone. One theory may be that VEGFR-2 and EGFR-1 activate different 
intracellular pools of ERK5, whereby VEGFR-2 sequesters ERK5 in an intracellular 
localisation that precludes it from being further phosphorylated by EGFR-1. 
The data generated with the use of the small-molecule kinase inhibitors targeting MEK5 
and ERK5, further demonstrated these VEGF- and EGF-mediated differences in ERK5 
phosphorylation (Figure 3.10, Figure 3.11, Figure 3.12, and Figure 3.13). It was evident 
that inhibition of MEK5 kinase activity with BIX 02189 prevented dual-phosphorylation of 
ERK5 in both VEGF-stimulated HDMEC and EGF-stimulated HeLa (Figure 3.10 and Figure 
3.11), as well as the subsequent phosphorylation of additional C-terminal residues in HeLa 
(Figure 3.11). XMD8-92 appears to be a type I, ATP-competitive inhibitor that affects the 
kinase activity of ERK5 i.e. hyper p-ERK5 in EGF-stimulated HeLa (Figure 3.12 and Figure 
3.13) and not activation of the T-E-Y motif, a finding that has previously been reported by 
way of mobility band shift (Deng et al., 2011). Thus, data from this project provides 
evidence to support findings from previous studies that have demonstrated no effect on 
vasculature stability upon XMD8-92 treatment (Yang et al., 2010a). Further elucidation of 
VEGF and EGF-mediated differences in ERK5 phosphorylation and the effect this may have 
on its intracellular localisation, as well as on cell survival, is discussed in the next chapter. 
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4.1 Introduction 
VEGF has been shown to activate ERK5 in HUVECs (Hayashi et al., 2004) and HDMECs 
(Roberts et al., 2010), yet numerous studies have utilised the stimulation of ERK5 by EGF 
to determine ERK5 activation, intracellular localisation and subsequently, develop small-
molecule inhibitors of ERK5 (Kato et al., 1998; Kamakura et al., 1999; Hayashi et al., 
2001; Raviv et al., 2004; Kondoh et al., 2006; Tatake et al., 2008; Yang et al., 2010a). As 
a consequence, EGF-mediated ERK5 activation and its function in tumour cell proliferation 
is perceived to be the dogma. However, the discovery that the initial defect of Erk5 
ablation occurs within the endothelium (Hayashi et al., 2004), along with the finding that 
ERK5 is required for VEGF-induced AKT phosphorylation during tubular morphogenesis in 
HDMEC (Roberts et al., 2010), emphasised the physiological relevance of characterising 
ERK5 activation in endothelial cells. Hence, it was hypothesised that EGF- and VEGF-
mediated ERK5 activation and function differed.  
Data from the previous chapter revealed an important discovery with respect to VEGF- and 
EGF-mediated activation of ERK5 in HDMEC and HeLa, whereby the two growth factors 
were able to induce differential phosphorylation events of ERK5 (Chapter 3). VEGF-
stimulated HDMEC resulted in phosphorylation of the Thr218/Tyr220 residues of ERK5, 
whereas EGF was able to induce this dual-phosphorylation, as well as phosphorylation of 
additional residues thought to be in the C-terminal. 
It was possible to discriminate these phosphorylation events with the use of Phos-tag™ SDS-
PAGE, a technique that will be further utilised in this chapter, along with small interfering 
RNA (siRNA) to identify the differences in the role and regulation of VEGF- and EGF-
induced phosphorylation of ERK5 in HDMEC and HeLa.  
The use of RNA interference (RNAi) technology has been demonstrated to be an effective 
method of post-transcriptional gene silencing (Sharp, 2001). This method introduces 
foreign small double-stranded RNA (dsRNA), complementary to the sequence of the gene 
of interest, which is recognised by an RNA III nuclease (termed Dicer) and cleaved into 
short RNA duplexes measuring 21-28 nucleotides (hence the term small interfering RNA) 
(Bernstein et al., 2001; Zhang et al., 2002). The siRNAs are incorporated into a silencing 
complex termed RISC (RNA-induced silencing complex), enabling the complex to be guided 
to the target mRNA sequence, resulting in the degradation of the mRNA sequence and 
subsequently preventing the translation of the mRNA (Hammond et al., 2000). 
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Additionally, with the use of immunofluorescence and subcellular protein fractionation, 
the effect this differential ERK5 activation has on the intracellular localisation of ERK5 will 
be explored. 
Furthermore, the use of the specific small-molecule inhibitors of MEK5 and ERK5, BIX 
02189 and XMD8-92 will be utilised in order to determine the role of VEGF- and EGF-
mediated AKT activity as a result of ERK5 phosphorylation. 
 
4.2 VEGF fails to induce C-terminal phosphorylation of ERK5 
The differential phosphorylation of ERK5 by VEGF and EGF was further investigated with 
the use of phospho-specific antibodies against the Thr218/Tyr220 residues in the activation 
loop of the kinase domain as well as against Thr732, a residue present on the C-terminal 
tail of ERK5. These antibodies were generated and kindly gifted by Dr. Atanasio Pandiella 
and his lab group (Instituto de Biolgia Molecular y Celular del Cancer, CSIC-Universidad de 
Salamanca, Spain). HDMEC and HeLa were stimulated with VEGF and EGF respectively for 
different times and the protein lysates were run on Phos-tag™ gels in order to assign 
specific phosphorylation events to the individual bands. 
 
 
Figure 4.1 VEGF fails to induce C-terminal phosphorylation of ERK5. 
HDMEC and HeLa were plated on 12-well plates for 24 h prior to overnight serum starvation. Cells 
were then stimulated with VEGF or EGF accordingly, for 1, 5, 10, 30 and 60 min after which they 
were lysed with RIPA. HDMEC and HeLa lysates were run alongside each other and separated on a 7% 
(w/v) acrylamide, 70 µM Phos-tag™, 210 µM MnCl2 gel at 8 mA for 22 h, followed by Western blotting 
(WB) with antibodies against (A) phospho-Thr218/Tyr220 or (B) phospho-Thr732, prior to being stripped 
and re-incubated with an antibody against ERK5. This result is representative of two independent 
experiments. 
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It was observed that with the p-Thr218/Tyr220 antibody, these residues were phosphorylated 
by VEGF from 1 min, with the highest phosphorylation seen at 5 min and 10 min. However, 
phosphorylation of these residues was somewhat sustained through to 60 min (Figure 4.1a 
- left). EGF stimulation of these kinase domain residues in HeLa also resulted in 
phosphorylation at 1 min and once again, the 5 min and 10 min time points possessed the 
strongest phosphorylation (Figure 4.1a - left). These residues did appear to be 
phosphorylated at 30 and 60 min but less so than at the earlier time points. There are two 
distinct bands evident in HeLa cells with the p-Thr218/Tyr220 antibody, the lower band (*) 
denotes the phosphorylation of the T-E-Y residues, whereas (**) represents 
phosphorylation of C-terminal residues in addition to the T-E-Y residues (Figure 4.1a - 
left). 
Stripping this phospho-specific antibody off the membrane and re-probing with the ERK5 
antibody enabled determination of the migration distance of these specific residues 
(Figure 4.1 - right). Thus, the ERK5 antibody revealed that the band designated “p-ERK5” 
in Phos-tag™ gels from the previous chapter, i.e. the only species of phosphorylated band 
in HDMEC and the “faster” of the two phosphorylated bands in HeLa could be attributed to 
phosphorylation of the Thr218/Tyr220 residues (marked * in Figure 4.1a - right). 
Comparing the p-ERK5 band in HDMEC to that of the phospho-specific antibody, similar 
results were observed – strong phosphorylation at the 1, 5, and 10 min time points, with 
less intensity at 30 and 60 min (Figure 4.1 - right). However, the kinetics of the p-ERK5 
band in HeLa differ to that seen using the phospho-specific antibody, due to the ability of 
ERK5 to undergo hyper-phosphorylation due to EGF stimulation. 
The use of the p-Thr732 antibody on the same lysates uncovered an interesting and novel 
discovery. Stimulation of HDMEC with VEGF did not appear to phosphorylate the Thr732 
residue at any of the time points, however EGF-stimulated HeLa revealed phosphorylation 
of this C-terminal residue at 5 min which increased at 10 min (Figure 4.1 - left). Once 
again, stripping and re-probing the membrane with the ERK5 antibody, and measuring the 
migration distance of this phosphorylation band showed the “hyper p-ERK5” band (as 
assigned in the previous chapter) could be attributable to phosphorylation of C-terminal 
residues of ERK5 in addition to phosphorylation of the Thr218/Tyr220 residues (Figure 4.1 - 
right). 
Taken together, these data show that VEGF only evokes phosphorylation of Thr218/Tyr220 in 
the kinase domain, whereas EGF can stimulate phosphorylation of these residues in the 
kinase domain as well as residues present in the C-terminal tail. 
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4.3 EGF-mediated C-terminal phosphorylation of ERK5 
requires HRAS 
The previous data suggest that VEGFR-2 couples to ERK5 activation in a manner distinct to 
EGFR-1 and that phosphorylation of the Thr218/Tyr220 motif in the activation loop of the 
kinase domain does not necessarily facilitate autophosphorylation of subsequent C-
terminal residues. In an attempt to explain this, specific signalling proteins differentially 
activated downstream of EGFR-1 and VEGFR-2, in particular the RAF-1/RAS molecules 
(Hallberg et al., 1994; Sasaoka et al., 1994; Sakaguchi et al., 1998; Doanes et al., 1999; 
Takahashi et al., 2001; Zachary, 2003), were knocked down using siRNA to determine 
which protein would affect ERK5 phosphorylation. 
RAF-1 activation has been implicated downstream of EGFR-1 and RAS activation, leading to 
phosphorylation of ERK1/2 (Hallberg et al., 1994; Johnson and Vaillancourt, 1994), thus its 
potential role in VEGF-/EGF-mediated ERK5 phosphorylation was examined. In HDMEC, p-
ERK5 was not affected by siRNA knockdown of RAF-1 (Figure 4.2a). However in HeLa cells, 
a slight decrease in hyper p-ERK5 was detected compared to that of the 
untransfected/non-targeting siRNA EGF-stimulated control (Figure 4.2b). 
The abundance of the RAS isoforms differs greatly amongst cell types. In a variety of 
endothelial cells (HAEC and murine microvascular lung and cardiac cells) H-RAS is the 
major isoform (60-70% of the total), followed by N-RAS (approximately 20%) and the K-RAS 
comprising of the remainder (Haeussler et al., 2013). In HeLa cells, K- and N-RAS occur in 
relatively equal quantities, each comprising about 40-45% of the total amount of RAS, with 
H-RAS only accounting for <10% of the total (Omerovic et al., 2008). Despite this stark 
disparity in RAS isoform abundance, siRNA knockdown of any of the RAS isoforms did not 
affect p-ERK5 in HDMEC (Figure 4.2a). Interestingly, only siRNA knockdown of H-RAS in 
HeLa cells (the lowest abundant isoform) resulted in a notable decrease in hyper p-ERK5 
compared to the EGF-stimulated control conditions (Figure 4.2b). 
 




Figure 4.2a C-terminal phosphorylation of ERK5 requires HRAS activation. 
(A) HDMEC were plated on 6-well plates for 24 h, prior to a 6 hr siRNA transfection with the 
appropriate control and target duplexes. Cells were then serum starved overnight, stimulated with 
50 ng/mL VEGF for 10 min and RIPA lysed. Lysates were separated on a 4-12% NuPAGE® gel, 15% SDS-
PAGE as well as a 7% (w/v) acrylamide, 70 µM Phos-tag™ gel, followed by Western blotting (WB) with 
antibodies against ERK5, RAF-1 (#9422, NEB), HRAS (sc-520), KRAS (sc-521) and NRAS (sc-31). Bar 
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Figure 4.2b C-terminal phosphorylation of ERK5 requires HRAS activation. 
(B) HeLa were plated on 6-well plates for 24 h, prior to a 6 hr siRNA transfection with the 
appropriate control and target duplexes. Cells were then serum starved overnight, stimulated with 
50 ng/mL EGF for 10 min and RIPA lysed. Lysates were separated on a 4-12% NuPAGE® gel, 15% SDS-
PAGE as well as a 7% (w/v) acrylamide, 70 µM Phos-tag™ gel, followed by Western blotting (WB) with 
antibodies against ERK5, RAF-1 (#9422, NEB), HRAS (sc-520), KRAS (sc-521) and NRAS (sc-31). Bar 
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4.4 Thr218/Tyr220 phosphorylation alone is not sufficient to 
facilitate nuclear localisation 
The intracellular localisation of ERK5 has been suggested to alter according to the 
phosphorylation status, and hence the conformation, of ERK5. Kondoh and colleagues 
proposed that in its quiescent unphosphorylated state, ERK5 is tethered in a folded 
configuration due to an intramolecular interaction between the N- and C-terminals 
(Kondoh et al., 2006). It is considered that this conformation either generates a nuclear 
export signal (NES), or dampens the signal of the nuclear localisation signal (NLS) domain, 
thus sequestering ERK5 in the cytoplasm. Dual-phosphorylation of the Thr218/Tyr220 
residues by MEK5 is thought to disrupt the intramolecular NES interaction enabling the 
translocation of ERK5 to the nucleus (Kondoh et al., 2006). 
The aforementioned data in this project portrays a key difference in VEGF- and EGF-
mediated ERK5 phosphorylation, thus the possible effect on the intracellular localisation 
of ERK5 was investigated with the use of immunofluorescence.  
HeLa cells were stimulated with EGF (Figure 4.3) and HDMEC stimulated with VEGF, for 10 
or 30 min (Figure 4.4). In HeLa cells, ERK5 translocated from the cytoplasm to the nucleus 
upon stimulation with EGF at 10 min (Figure 4.3). Furthermore, 30 min stimulation with 
EGF resulted in almost complete translocation of ERK5 into the nucleus (Figure 4.3). 
Interestingly in HDMEC, 10 min VEGF stimulation did not appear to have any effect on 
ERK5 localisation, remaining sequestered in the cytoplasm (Figure 4.4). In spite of ERK5 
still having a cytoplasmic localisation upon 30 min VEGF stimulation, a somewhat more 
plasma membranous localisation was observed, with the presence of clusters of ERK5 on 
the cell periphery (Figure 4.4). 
 




Figure 4.3 Intracellular localisation of ERK5 in HeLa cells. 
HeLa were plated on 16 mm coverslips for 24 h, prior to overnight serum starvation and stimulation with 50 ng/mL EGF for 10 or 30 min. Cells were then fixed with ice-cold 
MeOH, blocked in 5% BSA/PBS with donkey serum and stained with an antibody against ERK5, prior to staining with a fluorescent secondary antibody and image acquisition 
with an inverted Zeiss Axio Observer microscope and the associated Zen software. 
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Figure 4.4 Intracellular localisation of ERK5 in HDMEC. 
HDMEC were plated on 16 mm coverslips for 24 h, prior to overnight serum starvation and stimulation with 50 ng/mL VEGF for 10 or 30 min. Cells were then fixed with ice-
cold MeOH, blocked in 5% BSA/PBS with donkey serum and stained with an antibody against ERK5, prior to staining with a fluorescent secondary antibody and image 
acquisition with an inverted Zeiss Axio Observer microscope and the associated Zen software. 
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To further explore the potential localisation of ERK5 in VEGF-stimulated HDMEC, a 
subcellular protein fractionation kit was utilised to separate the cellular compartments 
over various stimulation time points (Figure 4.5). 
 
 
Figure 4.5 Subcellular protein fractionation of HDMEC. 
HDMEC were seeded on 10 cm plates for 24 h prior to overnight serum starvation and stimulation 
with 50 ng/mL VEGF for 10, 30 and 60 min. Cells were then lysed with the appropriate buffers from 
the Thermo Fisher Subcellular Fractionation Kit. Lysates were separated on a 4-12% NuPAGE gel as 
well as a 7% (w/v) acrylamide, 70 µM Phos-tag™ gel, followed by Western blotting (WB) with 
antibodies against VEGFR-2, ERK5, AKT and ERK1/2. Densitometric analysis of protein 
phosphorylation or protein expression relative to the basal control condition of each subcellular 
region, is displayed beneath each blot. The basal control condition was set arbitrarily as 1.0 for 
each protein and each subcellular region. This result is representative of two independent 
experiments. 
 
The use of subcellular controls (CD31 - membrane, GAPDH - cytoplasm and Lamin - 
nuclear) established that each fraction contained some presence of contaminants from 
other compartments, however the enrichment of each subcellular protein in comparison to 
the whole cell lysate was evident (Appendix IV). Following this, the localisation of VEGFR-
2, ERK5, AKT and ERK1/2 was studied. 
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As expected, VEGFR-2 localised predominantly to the membrane during the 10, 30 and 60 
min stimulation time points (Figure 4.5). Small amounts were detected in the nucleus 
upon VEGF stimulation, which may be attributable to internalisation and translocation of 
the receptor to the nucleus; a phenomenon observed to occur in endothelial cells (Santos 
et al., 2007) and has since been shown to be a dynamic process (Domingues et al., 2011). 
From the 0 min basal to the 10 min stimulation time point, the amount of ERK5 in the 
cytoplasm decreased, yet in the same time frame the ERK5 quantity increased in the 
membranous fraction nearly two-fold (Figure 4.5). The presence of ERK5 at the membrane 
decreased slightly, yet remained somewhat sustained at the expense of its existence in 
the cytoplasm.  
The use of Phos-tag™ SDS-PAGE with these fraction lysates similarly highlighted the 
increase of both the unphosphorylated and phosphorylated forms of ERK5 at the 
membrane after 10 min VEGF stimulation, with a noticeable decrease of both forms in the 
cytoplasm at the same time point (Figure 4.5). Once again, the amounts of both ERK5 and 
p-ERK5 at the membrane slightly decreased at the 30 and 60 min time points, however 
they still remained higher than the basal condition. Dissimilar to previous observations, 
the 30 min time point in the cytoplasm revealed a replenishment in the amount of ERK5 
which decreased again at 60 min, however at both time points p-ERK5 was lower than that 
of the basal condition (Figure 4.5). 
Interestingly, the levels of AKT follow a pattern similar to that of ERK5. Over the time 
points, the amount of AKT in the cytoplasm decreases however at the membrane, there is 
a peak of AKT at 10 min, followed by a slight decrease at the 30 min time point. The 
difference to this trend is at 60 min, where the level of AKT drops to just below that of 
the basal condition (Figure 4.5).  
The intracellular localisation of p-AKT differed to that of AKT; a three-fold increase in p-
AKT was observed at the 10 min and 30 min time points in the cytoplasm, followed by a 
decrease to below basal levels at 60 min (Figure 4.5). Additionally the increased levels of 
AKT previously observed at the membrane resulted in increased p-AKT at 10 min and 30 
min and a decreased, yet somewhat sustained, phosphorylation at 60 min (Figure 4.5). 
The constant levels of ERK1/2 throughout all time points and in each cellular fraction 
suggest that VEGF does not affect its intracellular localisation (Figure 4.5). 
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Taken together, these data suggest that the inability of VEGF to induce C-terminal 
phosphorylation of ERK5 affects the intracellular localisation of ERK5, subsequently 
resulting in a more cytoplasmic/plasma membranous rather than nuclear localisation as 
observed with EGF stimulation of HeLa. 
 
4.5 ERK5 co-localises with AKT in HDMEC but not HeLa 
The earlier subcellular fractionation data suggested that the localisation of AKT appeared 
to mimic that of ERK5, thus utilising co-staining and immunofluorescence, the intracellular 
localisation of ERK5 and phosphorylated AKT were investigated in HDMEC (Figure 4.6) and 
HeLa cells (Figure 4.7). 
VEGF-stimulated HDMEC revealed an increase in p-AKT fluorescence in the cytoplasm at 10 
min and this further increased at 30 min, compared to the basal (Figure 4.6). The high 
fluorescence of p-AKT detected in the nucleus of HDMEC was surprising considering the 
low levels detected in the subcellular fractionation. 
The merged images highlight that although increased p-AKT is detected in the cytoplasm 
at the 10 min time point, it does not co-localise with ERK5 until 30 min, visualised as 
white fluorescence in the cytoplasm and at the cell periphery (Figure 4.6). 
In HeLa cells, the levels of p-AKT increased in the cytoplasm at 10 min EGF stimulation, 
but this decreased back to basal levels at 30 min stimulation (Figure 4.7). Consequently, 
the co-staining reveals that at the 10 min time point there is no co-localisation evident, as 
the punctate green and magenta fluorescence remain distinct from one another in the 
merged image (Figure 4.7). Once again due to the pre-existing nuclear p-AKT staining in 
the basal condition as well as in the stimulated conditions, the apparent co-localisation of 
ERK5 and AKT at the 30 min time point may be a circumstantial observation (Figure 4.7). 
Furthermore, it must be considered that the presence of numerous proteins within the 
confined area of the nucleus may be incorrectly interpreted as co-localisation. 
These data draw attention to the key difference that sustained stimulation of HDMEC with 
VEGF results in an intracellular co-localisation of ERK5 and phosphorylated AKT within the 
cytoplasm and at the fringes of the cell, whereas neither acute, nor sustained EGF 
stimulation of HeLa cells produces co-localisation of these two proteins. 





Figure 4.6 ERK5 and AKT co-staining in HDMEC reveals co-localisation within the cytoplasm and the cell periphery. 
HDMEC were seeded at 3.0 x 104 cells per 16 mm coverslips for 24 h. Cells were serum started overnight, then stimulated for 10 or 30 min with 50 ng/mL VEGF. Cells were 
then stained with an antibody against ERK5 (green), p-AKT (magenta) and the nucleus with Hoechst (blue) for detection of intracellular co-localisation. 





Figure 4.7 ERK5 and AKT co-staining in HeLa reveals a lack of co-localisation. 
HeLa were seeded at 4.0 x 104 cells per 16 mm coverslips for 24 h. Cells were serum starved overnight, then stimulated for 10 or 30 min with 50 ng/mL EGF. Cells were 
then stained with an antibody against ERK5 (green), p-AKT (magenta) and the nucleus with Hoechst (blue) for detection of intracellular localisation. 
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4.6 MEK5 kinase activity is required for VEGF-stimulated AKT 
activity in HDMEC 
It has recently been observed that ERK5 is required for VEGF-induced phosphorylation of 
AKT in HDMEC during tubular morphogenesis (Roberts et al., 2010) and additional studies 
implicate ERK5 in growth-factor induced activation of AKT in other cells (Lennartsson et 
al., 2010; Razumovskaya et al., 2011). Taken together with the subcellular fractionation 
and co-localisation data shown earlier in this study, this suggests that ERK5 may play a 
role in coupling growth factor receptors to AKT, leading to its activation and subsequently 
regulating cellular survival. To further investigate the potential involvement of VEGF, EGF 
as well as activated ERK5, in the regulation of AKT activity, the commercially available 
MEK5 and ERK5 inhibitors were pre-incubated with HDMEC or HeLa prior to acute agonist 
stimulation. 
The dose-response data for these inhibitors from the previous chapter (Figure 3.10 - Figure 
3.13), determined the optimum concentration of the MEK5 inhibitor BIX 02189 was 10 µM 
and the ERK5 in HDMEC and HeLa without affecting other pathways such as ERK1/2 
phosphorylation in a non-specific manner. 
VEGF stimulation of the untreated HDMEC and 0.1% (v/v) DMSO vehicle control gave rise to 
the phosphorylation of VEGFR-2, ERK5, AKT and ERK1/2 to similar levels, thus confirming 
that the signalling pathways were not affected by the presence of DMSO at this 
concentration (Figure 4.8). 
The MEK5 inhibitor, BIX 02189, significantly reduced VEGF-induced phosphorylation of 
ERK5 as detected by Phos-tag™ SDS-PAGE (p<0.05), with no observed effects on ERK1/2 
phosphorylation (Figure 4.8). Two important observations were highlighted with this BIX-
treated, VEGF-stimulated condition – there was a marked increase in VEGFR-2 
phosphorylation and a significant decrease in AKT phosphorylation (p<0.01). Thus, it is 
proposed that the inhibition of MEK5 kinase activity with BIX 02189 prevents MEK5 from 
dual-phosphorylating the Thr218/Tyr220 residues of ERK5 and as a consequence, ERK5 
activation and p-AKT is decreased (Figure 4.8). The increase in p-VEGFR2 is thought to 
occur in response to a decrease in receptor internalisation and degradation, due to MEK5 
inhibition by BIX 02189. In the presence of BIX 02189, the levels of VEGFR-2 after VEGF 
stimulation are maintained, suggesting that MEK5 may play a role in the internalisation of 
the receptor (Figure 4.8). 
 




Figure 4.8 VEGF-stimulated AKT activity in HDMEC is dependent upon MEK5 kinase activity. 
HDMEC were plated on 12-well plates for 24 hours, followed by overnight serum starvation. Cells 
were pre-incubated with 0.1% (v/v) DMSO as a vehicle control, BIX 02189 (10 µM) or XMD8-92 (20 µM) 
for 1 hour, prior to addition of VEGF (50 ng/mL final concentration) for 10 min and RIPA lysis. 
Protein lysates were separated on 4-12% NuPAGE® gels as well as a 7% (w/v) acrylamide, 70 µM Phos-
tag™ gel. Membranes were incubated with antibodies against p-VEGFR2, VEGFR-2 ERK5, p-AKT, p-
ERK1/2 and Actin. This experiment is representative of four individual experiments (*p<0.05, 
**p<0.01). 
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Treatment with the ERK5 inhibitor, XMD8-92 did not appear to have any effect on the 
phosphorylation of VEGFR-2, ERK5, AKT or ERK1/2, further confirming the hypothesis that 
C-terminal phosphorylation of ERK5 does not occur in VEGF-stimulated HDMEC, but also 





Figure 4.9 EGF-induced hyper phosphorylation of ERK5 is not required for AKT activity in HeLa. 
HeLa were plated on 12-well plates for 24 hours, followed by overnight serum starvation. Cells were 
pre-incubated with 0.1% (v/v) DMSO as a vehicle control, BIX 02189 (10 µM) or XMD8-92 (20 µM) for 1 
hour, prior to addition of EGF (50 ng/mL final concentration) for 10 min and RIPA lysis. Protein 
lysates were separated on 4-12% NuPAGE® gels as well as a 7% (w/v) acrylamide, 70 µM Phos-tag™ gel. 
Membranes were incubated with antibodies against p-EGFR1, ERK5, p-AKT, p-ERK1/2 and Actin. This 
experiment is representative of four individual experiments (*p<0.05, **p<0.01). 
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The use of BIX 02189 in HeLa cells significantly reduced EGF-induced p-ERK5 and hyper p-
ERK5 (p<0.01). However, in contrast to results observed in the HDMEC, AKT 
phosphorylation increased 1.5-fold (p<0.05) with no notable effect on EGFR-1 
phosphorylation observed (Figure 4.9), suggesting a potential negative feedback loop with 
EGF, which is inhibited by BIX 02189. 
As expected, inhibition with XMD8-92 prevented EGF-induced hyper-phosphorylation of 
ERK5, yet p-ERK5 was still evident (Figure 4.9). No other significant differences were 
observed, implying C-terminal phosphorylation is not required for AKT activity. 
These results suggest that VEGF- and EGF-induced AKT activity have opposing 
dependencies regarding MEK5 kinase activity. In HDMEC, phosphorylation of AKT requires 
VEGF-mediated MEK5 kinase activity and consequently ERK5 activation. In HeLa however, 
AKT activation may exist within a negative feedback loop with EGF, which is inhibited by 
the presence of BIX 02189. Nevertheless, it is apparent that C-terminal phosphorylation of 
ERK5 does not play a role in AKT activity. 
 
4.7 Discussion 
Current literature reports that phosphorylation of the Thr218/Tyr220 residues of ERK5 leads 
to kinase activity and concomitant autophosphorylation of C-terminal Ser/Thr residues 
(Mody et al., 2003; Buschbeck and Ullrich, 2005; Morimoto et al., 2007). This study has 
uncovered a novel discovery in that VEGFR-2 activation of ERK5 shows that kinase activity 
and phosphorylation of C-terminal residues are not necessarily mutually inclusive events. 
VEGF induces phosphorylation of the Thr218/Tyr220 residues, however it fails to induce 
phosphorylation of C-terminal residues of ERK5 (Figure 4.1). Dual-phosphorylation of T-E-Y 
alone is insufficient to decrease the electrophoretic mobility on conventional SDS-PAGE, 
hence the lack of mobility bandshift observed in VEGF-stimulated HDMEC in the previous 
chapter (Section 3.2.1) – a finding which has previously been observed in HEK293 cells 
(Mody et al., 2003). 
In contrast, this study has shown that EGF stimulation of ERK5 activity results in 
phosphorylation of Thr218/Tyr220, as well as C-terminal residues including Thr732 (Figure 
4.1). Interestingly, although this Thr732 residue directly precedes a proline residue, VEGF 
was unable to induce its phosphorylation, suggesting that an alternative pathway may feed 
into the phosphorylation of C-terminal residues upon EGF stimulation. 
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Subsequent experiments aimed to further identify potential downstream signalling 
proteins that may contribute to this difference in growth factor-induced ERK5 
phosphorylation, thus siRNA was utilised against RAF-1, HRAS, KRAS and NRAS – molecules 
known to be differentially activated by VEGFR-2 and EGFR-1 (Hallberg et al., 1994; 
Sasaoka et al., 1994; Sakaguchi et al., 1998; Doanes et al., 1999; Takahashi et al., 2001; 
Zachary, 2003). Results from these experiments uncovered the possible involvement of 
HRAS in EGF-mediated C-terminal phosphorylation of ERK5, as a significant decrease in 
hyper p-ERK5 was observed upon HRAS knockdown (Figure 4.2). It is important to note that 
although the protein level of KRAS appeared to be knocked-down by approximately 85% in 
both HDMEC and HeLa, the non-specific nature of the antibody used to detect the protein 
in Western blotting, makes this result somewhat unreliable. Thus additional evidence 
would be required to ensure the lack of KRAS involvement in EGF-mediated C-terminal 
phosphorylation of ERK5.  A previous study reported no effect on EGF-induced ERK5 
activation in HeLa cells in the presence of a dominant-active (G12V) RAS (Kato et al., 
1998), the mutation favoured by HRAS (Prior et al., 2012), however with the hypothesis 
that dominant-active HRAS would only induce C-terminal phosphorylation of ERK5, it 
would not affect the EGF-mediated phosphorylation of T-E-Y. Nevertheless, as EGF 
activation of the various RAS isoforms has already been demonstrated in HeLa (Omerovic 
et al., 2008), the use of a RAS activation assay would confirm the involvement, or lack 
thereof, of VEGF-activated RAS in HDMEC. 
Despite the aforementioned differences in VEGF- and EGF-mediated phosphorylation of 
ERK5, it was observed that phosphorylation of both Thr218/Tyr220 in the activation loop, as 
well as residues present on the C-terminal, was required for nuclear localisation of ERK5. 
Thus, as EGF was able to phosphorylate all these residues in HeLa, ERK5 translocated from 
the cytoplasm into the nucleus after 10 min stimulation, with translocation more evident 
at 30 min (Figure 4.3). However, VEGF-mediated phosphorylation of ERK5 on Thr218/Tyr220 
in the absence of C-terminal phosphorylation renders the protein unable to undergo 
translocation to the nucleus, instead localising in the cytoplasm and at the plasma 
membrane (Figure 4.4, Figure 4.5) in HDMEC. The data produced from the subcellular 
fractionation experiment revealed an interesting finding in that along with ERK5 having a 
more cytoplasmic/plasma membranous localisation, AKT also appeared to follow suit 
(Figure 4.5). It is important to consider the purity of these subcellular fractions in this 
interpretation however, as the subcellular controls in Appendix IV demonstrated some 
presence of contaminants from other compartments. Nevertheless, the co-localisation of 
the two proteins was investigated using immunofluorescence co-staining (Figure 4.6 and 
Figure 4.7). 
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The data from these co-staining experiments revealed that upon sustained VEGF 
stimulation (30 min), ERK5 and p-AKT appeared to co-localise as visualised by white 
fluorescence in the cytoplasm and at the periphery of the cell (Figure 4.6), a result also 
observed in the subcellular fractionation (Figure 4.5). Interestingly however, this co-
localisation was not evident in acute or sustained EGF-stimulated HeLa cells, as separate 
punctate fluorescence for each protein was observed (Figure 4.7). This disparity in VEGF- 
and EGF- induced co-localisation with p-AKT suggests that ERK5 may play different roles in 
various cell types dependent upon growth factor stimulus. 
With the use of specific MEK5 and ERK5 small-molecule inhibitors, the association between 
ERK5 and AKT was further exposed; it was apparent that VEGF-mediated AKT activity in 
HDMEC required MEK5 kinase activity, but not ERK5 kinase activity (Figure 4.8), whereas 
EGF-mediated AKT activity appeared to increase upon addition of BIX 02189 (Figure 4.9). 
The positive correlation between ERK5 and AKT upon VEGF stimulation is one that has 
been previously observed in HDMEC with respect to cell survival and tubular 
morphogenesis (Roberts et al., 2010). Additional studies have implicated ERK5 in PDGFR-β-
mediated activation of AKT in PAE cells (Lennartsson et al., 2010) and FLT3-mediated 
activation of AKT in the Ba/F3 pro-B-cell line (Razumovskaya et al., 2011), however a very 
recent study has proposed a novel, positive feedback loop between ERK5 and AKT in PDGF-
stimulated mesangial cells (Bera et al., 2014). This feedback loop is suggested to lie 
downstream of PI3K, yet in parallel to the ERK1/2 signalling pathway, however no data are 
shown with respect to the phosphorylation levels of the receptor upon inhibition of PI3K, 
AKT or ERK5 (Bera et al., 2014).  
Small-molecule inhibitor data from this chapter and Chapter 3 have revealed an 
interesting association between VEGFR-2 and MEK5 (Figure 4.8 and Figure 3.10). The 
addition of BIX 02189 in VEGF-stimulated HDMEC resulted in increased receptor 
phosphorylation compared to that of the untreated stimulated condition (Figure 4.8). It 
has been established that VEGFR-2 is internalised upon VEGF stimulation (Santos et al., 
2007), hence the observed decrease in receptor levels between the untreated basal and 
untreated stimulated condition (Figure 4.8). However in the presence of BIX 02189, 
VEGFR-2 levels are maintained upon VEGF stimulation, suggesting the possible involvement 
of MEK5 kinase activity in VEGFR-2 internalisation. 
Intriguingly, EGF-mediated AKT activity in HeLa was observed to increase upon MEK5 
kinase inhibition (Figure 4.9), whereas the inhibition of ERK5 C-terminal phosphorylation 
with XMD 8-92 did not appear to have any effect on p-AKT levels (Figure 4.9). These data 
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suggest that ERK5 and AKT may exist within a negative feedback loop with EGF which is 
inhibited by the presence of BIX 02189 but not XMD8-92.  
The specific mechanism through which ERK5 regulates VEGF-induced AKT phosphorylation 
still remains unclear. It has been considered that ERK5 may phosphorylate and 
consequently inactivate a phosphatase that regulates AKT phosphorylation, e.g. PP2A or 
MKP3 (Pankov et al., 2003; Razmara et al., 2012), rather than ERK5 directly 
phosphorylating AKT, as it is well established that mTORC2 and PDK1 are responsible for 
AKT activation via phosphorylation at Thr308 and Ser473 (Alessi et al., 1996; Jacinto et al., 
2006; Sarbassov et al., 2006). A recent study demonstrated the requirement of ERK5 in 
VEGF-mediated AKT phosphorylation in HDMEC, whereby siRNA against ERK5 resulted in a 
decrease in p-AKT (Roberts et al., 2010). This finding is supported by novel data from this 
study; inhibition of VEGF-induced ERK5 phosphorylation of Thr218/Tyr220 with BIX 02189 
leads to a 50% decrease in AKT phosphorylation (Figure 4.8). However the inability of the 
ERK5 kinase inhibitor XMD8-92 to affect VEGF-stimulated AKT activation (Figure 4.8) 
suggests that only the Thr218/Tyr220 phosphorylation of ERK5 is critical for VEGF-mediated 
AKT regulation, rather than the ability of ERK5 to subsequently phosphorylate downstream 
targets. Additionally, the intracellular localisation of ERK5 and AKT is significant, as this 
reveals a potential interaction between the two proteins, which may result in either a 
direct or indirect mode of AKT phosphorylation by ERK5. Thus in an attempt to further 
investigate the association between ERK5 and AKT in VEGF- and EGF- stimulated cells, 
experiments in the next chapter utilise adenoviral gene transduction to overexpress FLAG-
epitope tagged ERK5 in the primary HDMECs followed by immunoprecipitation and mass 
spectrometry analysis. 
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5.1 Introduction 
The data from Chapter 4 revealed a potential link between ERK5 and AKT in VEGF-
stimulated HDMEC; immunofluorescence highlighted an intracellular co-localisation of the 
two proteins and small-molecule inhibitors uncovered the dependency of AKT 
phosphorylation on MEK5 kinase activity. In contrast, with EGF-stimulated HeLa cells, AKT 
did not appear to co-localise with ERK5 and inhibition of MEK5 kinase activity did not 
inhibit EGF-stimulated AKT activity. 
Previous studies have identified MEF2D as an ERK5-interacting protein using yeast ‘two-
hybrid’ screen, in vitro GST-pull down assays, as well as antiserum to detect 
immunoprecipitation of MEF2 associated proteins in vivo (Yang et al., 1998; Kasler et al., 
2000). However, as it is unclear if ERK5 is able to directly phosphorylate AKT on Thr308 and 
Ser473, there remains a distinct possibility that unidentified ancillary proteins interact with 
ERK5 to facilitate AKT phosphorylation. A complex containing multiple proteins could 
prove difficult to detect at endogenous levels, thus overexpression of ERK5 using 
adenoviral-mediated gene delivery was utilised to express a FLAG-epitope tagged ERK5 in 
HDMEC and HeLa. The FLAG-tag could then be exploited during immunoprecipitation prior 
to Western blotting. In addition to this, mass spectrometry was utilised to further confirm 
potential binding partners of ERK5. Achieving high transfection efficiency in primary 
human cells such as endothelial cells is known to be notoriously difficult. The discontinued 
transfection reagent TransPass™ HUVEC transfection reagent (NEB®, 2013) reports to have 
been able to achieve a 40% transfection efficiency in HDMEC, whereas the current 
Lipofectamine™ 2000 transfection (LifeTechnologies™) reports to achieve <2% transfection 
efficiency in HUVECs. The study from which this project has progressed previously utilised 
Amaxa® Nucleofector® technology (Lonza, 2014) to transfect HDMECs, but this led to low 
cell viability. 
Recombinant adenoviruses are the most commonly used vectors utilised as gene transfer 
vectors in vivo and in vitro. They are advantageous due to their high transduction 
efficiency and ability to infect both dividing as well as resting cells without actively 
integrating into the host genome, therein resulting in transient gene expression (Anton et 
al., 2012). Adenoviruses enter the target cells by binding to the Coxsackie/Adenovirus 
receptor (CAR) (Bergelson et al., 1997) prior to being internalised via integrin-mediated 
endocytosis (Russell, 2000) and transported into the nucleus. Here, transcription and 
translation of E1 proteins occurs, two early phase events that are essential for the 
subsequent expression of adenoviral late genes and viral replication.  
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The ViraPower™ adenoviral expression system utilised in this project generates a 
replication-incompetent adenovirus due to the deletion of E1 and E3 in the destination 
vector (pAd/CMV-DEST) capable of delivering a gene of interest, i.e. FLAG-ERK5. The 
HEK293A producer cells contain a stably integrated copy of E1, thus they are infected with 
the pAd/CMV-DEST thereby supplying it with the E1 proteins required to facilitate early 
phase transcription and translation of the adenovirus. The pAd/CMV-DEST contains the 
human cytomegalovirus (CMV) promoter, which controls the expression of FLAG-ERK5, 
hence it is termed pAd/CMV/FLAG-ERK5. The adenoviral FLAG-ERK5 was used as a gene 
delivery vehicle, whereby HDMEC and HeLa cells were transduced with the adenovirus, 
with no occurrence of viral replication. 
Mass spectrometry (MS) of small molecules has been used for over 50 years in combination 
with a wide variety of ionisation techniques such as chemical ionisation, electron 
ionisation and fast atom bombardment. However, these methods of ionisation were not 
readily applicable to larger molecules such as peptides and proteins, hence the 
introduction of mild ionisation technologies. 
The original concept of matrix-assisted laser desorption/ionization (MALDI) was developed 
in 1988, whereby a laser bombards sample molecules in an absorbing matrix, resulting in 
an ionised sample (Karas and Hillenkamp, 1988). Since then, MS-based technologies have 
become much more sophisticated enabling the identification and quantification of low-
abundance proteins. Methods such as electrospray ionisation (ESI) (Fenn et al., 1989), 
isotope-coded affinity tags (ICATs) (Gygi et al., 1999), stable-isotope labelling by amino 
acids in cell culture (SILAC) (Ong et al., 2002), isotope-coded protein label (ICPL) (Schmidt 
et al., 2005), isobaric tags for relative and absolute quantification (iTRAQ) (Ross et al., 
2004) have all aided in the detection of previously undetectable, low-abundance proteins. 
This project utilised label-free analysis using an UltiMate 3000 RSLC™ nano system (Thermo 
Scientific) coupled to a QExactive™ mass spectrometer (Thermo Scientific). 
This chapter details experiments conducted to characterise the potential interaction of 
ERK5 and AKT in both HDMEC and HeLa cells and the further analysis of potential VEGF-
stimulated ERK5-interacting proteins in HDMEC. 
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5.2 RIPA vs sucrose lysis buffer for immunoprecipitation 
Radio-immunoprecipitation assay (RIPA) buffer is a commonly used cell lysis reagent, due 
to its robustness in lysis and extracting proteins (abcam®). Nowadays, the original isotopic 
assay method is rarely performed, however the acronym for this buffer endured. The 
presence of three non-ionic and ionic detergents results in a vigorous lysis buffer. As RIPA 
buffer was utilised in the preparation of protein lysates for Western blotting, it was also 
initially used in the preparation of immunoprecipitation lysates (Figure 5.1). 
Immunoprecipitation was conducted in order to initially precipitate, isolate and 
concentrate ERK5 out of the HDMEC or HeLa protein lysates with the use of an antibody 
previously bound to agarose beads. Subsequently, SDS-PAGE and Western blotting was 
utilised in an attempt to ascertain potential interacting partners of ERK5. MEK5 has 
previously been shown to bind ERK5, via the PB1 domain and 34 amino acid C-terminal 
extension of MEK5 (Nakamura et al., 2006), hence blotting for MEK5 acts as a positive 
control for the ERK5 IP experiments. 
Furthermore, data from the previous chapter highlighted a potential role for MEK5 in 
VEGFR-2 internalisation and degradation in HDMEC and as a consequence, the receptor 
may also be in close proximity to ERK5. In contrast, no association was observed between 
MEK5 kinase activity and EGFR-1 in the previous chapter, thus blotting for EGFR-1 after IP 
could provide evidence to confirm this theory. Additionally, an antibody against AKT was 
also utilised in order to further elucidate the potential interaction between ERK5 and AKT 
in HDMEC. 
It was evident that in both the HeLa and HDMEC, relatively low levels of ERK5 expression 
were detected in both the IP and total lysates after RIPA lysis (Figure 5.1). The high 
detergent content of RIPA results in a highly denaturing lysis buffer, deeming it somewhat 
incompatible for its use in IP. Consequently, a sucrose lysis buffer was considered for the 
preparation of IP lysates as it stabilises lysosymal membranes and reduces the release of 
proteases (Figure 5.2). 
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Figure 5.1 Immunoprecipitation of endogenous ERK5 after lysis with RIPA buffer. 
HeLa and HDMEC were seeded on 10 cm dishes for 24 h, prior to overnight serum starvation. Cells 
were then stimulated with EGF or VEGF (50 ng/mL) for 10 or 30 min, followed by RIPA lysis. Lysates 
were immunoprecipitated (IP) overnight, at 4°C with an antibody against ERK5 (AF2848) that had 
been previously bound to Protein G Plus agarose beads. The beads were then spun down and 
washed, prior to the addition of 1 volume of LDS and boiling at 90°C. Samples were separated on 4-
12% NuPAGE® gels and membranes were incubated with antibodies against VEGFR-2+EGFR-1, ERK5, 
AKT and MEK5 for Western blotting (WB). Arrows indicate the protein band of interest amongst other 
non-specific bands. This result is representative of three individual experiments. 
 
Cells lysed with the sucrose lysis buffer displayed higher levels of ERK5 in both the IP and 
total lysates, compared to that detected after RIPA lysis (Figure 5.2). The presence of 
proteins additional to AKT and MEK5 detected in the total lysates, were not considered 
problematic due to the enhanced detection of our proteins of interest. However, in both 
lysis methods, the presence of the heavy IgG-γ chains from the un-coupled ERK5 antibody 
(50-55 kDa) obscured the detection of AKT and MEK5 in the IP lysates (Figure 5.1 and 
Figure 5.2). 
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Figure 5.2 Immunoprecipitation of endogenous ERK5 after lysis with sucrose buffer. 
HeLa and HDMEC were seeded on 10 cm dishes for 24 h, prior to overnight serum starvation. Cells 
were then stimulated with EGF or VEGF (50 ng/mL) for 10 or 30 min, followed by sucrose lysis. 
Lysates were immunoprecipitated (IP) overnight, at 4°C with an antibody against ERK5 (AF2848) that 
had been previously bound to Protein G Plus agarose beads. The beads were then spun down and 
washed, prior to the addition of 1 volume of LDS and boiling at 90°C. Samples were separated on 4-
12% NuPAGE® gels and membranes were incubated with antibodies against VEGFR-2+EGFR-1, ERK5, 
AKT and MEK5 for Western blotting (WB). Arrows indicate the protein band of interest amongst other 
non-specific bands. This result is representative of three individual experiments. 
 
This could be overcome with the use of an agarose conjugated ERK5 antibody (sc-1284 AC) 
to prevent free antibody, and subsequently free IgG-γ chains, from concealing the 50kDa 
region. However, this pre-conjugated antibody proved somewhat less effective in 
immunoprecipitating ERK5 than the one originally used (AF2848) (Figure 5.3). Additionally, 
very low expressions of co-precipitating proteins were detected in endogenous levels (data 
not shown). Figure 5.3 illustrates the various antibodies tested for efficient IP of ERK5, as 
well as the Protein G Plus agarose beads control. 
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Figure 5.3 Antibodies against ERK5 utilised to ascertain immunoprecipitation efficiency. 
HDMEC were seeded on 10 cm dishes for 24 h, prior to overnight serum starvation. Cells were then 
stimulated with VEGF (50 ng/mL) for 10 min, followed by sucrose lysis. Lysates were 
immunoprecipitated (IP) overnight, at 4°C with antibodies against ERK5 (#3372 NEB, sc-1284 AC SC, 
AF2848 R&D, sc-1284 SC and sc-1286 SC) that had been previously bound to Protein G Plus agarose 
beads, alongside a Protein G plus agarose beads only control. The beads were then spun down and 
washed, prior to the addition of 1 volume of LDS and boiling at 90°C. Samples were separated on 4-
12% NuPAGE® gels and membranes were incubated with an antibody against ERK5 (#3372 NEB). 
 
5.3 Overexpression of ERK5, reveals AKT as a potential 
interacting partner in HDMEC but not HeLa 
The use of adenoviral-mediated gene delivery to overexpress FLAG-tagged ERK5 in HDMEC 
and HeLa cells offered a two-fold advantage: ERK5 could be overexpressed in an attempt 
to increase the binding of potential ERK5-interacting proteins, and the FLAG-epitope tag 
could be utilised for efficient immunoprecipitation with an anti-FLAG antibody covalently 
coupled to agarose beads, reducing the potential presence of the heavy IgG-γ chains. 
In order to determine the level of ERK5 expression required for subsequent experiments, 
HeLa and HDMEC were transduced with a range of adenoviral multiplicity of infection 
(MOI) and analysed using Western blotting (Figure 5.4 and Figure 5.5). It was evident that 
the adenovirus efficiently transduced overexpression of ERK5 in both cell types, with 
overexpression noticeable from a MOI of 5 in HeLa (Figure 5.4) and as little as MOI of 1 in 
HDMEC (Figure 5.5). The use of an anti-FLAG® M2 antibody enabled confirmation of the 
expression of the FLAG-epitope tag, and in both cell types the tag was first detected at a 
MOI of 5 (Figure 5.4 and Figure 5.5). 
 
Chapter Five: Proteomic analysis of ERK5-interacting proteins in HDMEC 
125 
 
Figure 5.4 Adenoviral MOI response of adenoviral FLAG-ERK5 in HeLa. 
HeLa were plated on 12-well plates for 24 h. Cells were either left untransduced, or transduced with 
adenoviral FLAG-ERK5 with a range of MOI: 1, 5, 10, 20, 30, 40, 50 or 100 for 30 h, prior to overnight 
serum starvation. Cells were then stimulated with EGF (50 ng/mL) for 10 min and lysed. Protein 
lysates were separated on 4-12% NuPAGE® gels and incubated with antibodies against ERK5, FLAG® 
M2, p-AKT, pERK1/2 and Actin. This result is representative of two individual experiments. 
 
 
Figure 5.5 Adenoviral MOI response of adenoviral FLAG-ERK5 in HDMEC. 
HDMEC were plated on 12-well plates for 24 h. Cells were either left untransduced, or transduced 
with adenoviral FLAG-ERK5 with a range of MOI: 1, 5, 10, 20, 30, 40, 50 or 100 for 30 h, prior to 
overnight serum starvation. Cells were then stimulated with VEGF (50 ng/mL) for 10 min and lysed. 
Protein lysates were separated on 4-12% NuPAGE® gels and incubated with antibodies against ERK5, 
FLAG® M2, p-AKT, pERK1/2 and Actin. This result is representative of two individual experiments. 
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From these adenoviral MOI response experiments, it was important to ascertain a MOI that 
would enable sufficient ERK5 overexpression, without inducing artefacts, or affecting 
other parallel signalling pathways such as ERK1/2; thus a MOI of 20 was utilised for 
subsequent IP experiments. 
HeLa and HDMEC transduced with adenoviral FLAG-ERK5 and stimulated with EGF or VEGF 
(50 ng/mL) for 10 min or 30 min were precipitated with an anti-FLAG® M2 antibody 
covalently coupled to agarose beads (A2220) (Figure 5.6).  
Western blotting with an antibody against AKT revealed that this protein was co-
precipitated along with FLAG-tagged ERK5 in HDMEC but not in HeLa cells. AKT appeared 
to co-precipitate with ERK5 in the unstimulated condition, however the amount increased 
upon stimulation with VEGF for 10 min and 30 min (Figure 5.6). These results support the 
subcellular fractionation data from the previous chapter whereby an increase in ERK5 at 
the membrane after VEGF stimulation, resulted in increased levels of AKT (Figure 4.5). 
 
Figure 5.6 Immunoprecipitation of overexpressed ERK5 in HeLa and HDMEC. 
HeLa and HDMEC were seeded on 10 cm dishes for 24 h, prior to 48 h incubation with adenoviral 
FLAG-ERK5 MOI 20. Cells were then serum starved overnight, then stimulated with EGF or VEGF (50 
ng/mL) for 10 or 30 min, followed by sucrose lysis. Lysates were immunoprecipitated (IP) overnight, 
at 4°C with an anti-FLAG® M2 antibody covalently coupled to agarose beads (A2220). The beads were 
then spun down and washed, prior to the addition of 1 volume of LDS and boiling at 90°C. Samples 
were separated on 4-12% NuPAGE® gels and membranes were incubated with antibodies against 
VEGFR-2+EGFR-1, ERK5, AKT and MEK5 for Western blotting (WB). Arrows indicate the protein band 
of interest amongst other non-specific bands. This result is representative of two individual 
experiments. 
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A rather interesting discovery during this IP experiment was the co-immunoprecipitation of 
the relevant RTKS. In HeLa cells, EGFR-1 appeared to co-precipitate with ERK5 in the 
unstimulated condition, whereas in HDMEC, VEGFR-2 co-precipitated with ERK5 in all 
conditions, with a noticeable increase at 10 min following VEGF stimulation (Figure 5.6). 
The reciprocal IP using an antibody against AKT for precipitation was conducted in order to 
validate the co-precipitation of AKT with ERK5 (Figure 5.7). Although the heavy IgG-γ 
chains yet again masked the 50 kDa region, Western blotting against ERK5 demonstrated 
that HeLa cells did not reveal an ERK5-AKT interaction, whereas once more ERK5 co-
precipitated with AKT in HDMEC (Figure 5.7). It was observed that in the two VEGF-
stimulated conditions, the levels of ERK5 was more than that of the unstimulated 
condition, with the 30 min stimulation revealing the greatest amount of ERK5 (Figure 5.7). 
  
 
Figure 5.7 Immunoprecipitation of AKT in HeLa and HDMEC overexpressing ERK5. 
HeLa and HDMEC were seeded on 10 cm dishes for 24 h, prior to 48 h incubation with adenoviral 
FLAG-ERK5 MOI 20. Cells were then serum starved overnight, then stimulated with EGF or VEGF (50 
ng/mL) for 10 or 30 min, followed by sucrose lysis. Lysates were immunoprecipitated (IP) overnight, 
at 4°C with an antibody against AKT that had been previously bound to Protein G Plus agarose beads. 
The beads were then spun down and washed, prior to the addition of 1 volume of LDS and boiling at 
90°C. Samples were separated on 4-12% NuPAGE® gels and membranes were incubated with 
antibodies against VEGFR-2+EGFR, ERK5, AKT and MEK5 for Western blotting (WB). Arrows indicate 
the protein band of interest amongst other non-specific bands. This result is representative of one 
experiment. 
 
5.4 Discovery proteomics 
In an attempt to further substantiate the novel finding that ERK5 and AKT may interact 
with one another in HDMEC, this protein-protein interaction was examined with the use of 
mass spectrometry (LC-MS/MS). HDMEC were transduced with adenoviral FLAG-ERK5 for 30 
h in order to induce ERK5 overexpression. Three conditions of HDMEC were investigated: 1. 
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Untransduced, basal control, 2. Transduced, basal control and 3. Transduced, 30 min 
VEGF-stimulated condition. HDMEC samples prepared for analysis by mass spectrometry, 
were initially immunoprecipitated with an antibody against FLAG® M2 and evaluated using 
SDS-PAGE and Western blotting (Figure 5.8), as well as with silver staining (Figure 5.9). 
 
 
Figure 5.8 Western blot of samples to be run on LC-MS/MS. 
HDMEC were seeded on multiple 10 cm dishes for 24 h, prior to 30 h incubation with adenoviral 
FLAG-ERK5 MOI 20. Cells were then serum starved overnight, then stimulated with VEGF (50 ng/mL) 
for 30 min, followed by sucrose lysis. Lysates were immunoprecipitated (IP) overnight, at 4°C C with 
an agarose conjugated antibody against FLAG® tag. The beads were then spun down and washed, 
prior to the removal of a fraction of bead lysates, addition of 1 volume of LDS and boiling at 90°C. 
Protein samples were separated on 4-12% NuPAGE® gels and membranes were incubated with 
antibodies against ERK5 for Western blotting (WB). This result is representative of three individual 
experiments. 
 
It was evident that in both the Western blot (Figure 5.8) and silver stain (Figure 5.9), 
proteins in addition to ERK5 were detected in these samples and consequently sent to 
Professor Rob Beynon (Proteomics Group, Institute of Integrative Biology, University of 
Liverpool, Crown Street, Liverpool L69 7ZB) for proteomic analysis. 
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Figure 5.9 Silver stain of samples to be run on LC-MS/MS. 
Protein samples used in Figure 5.8 were separated on 4-12% NuPAGE® gels prior to membrane 
fixation, sensitisation and development, as per the SilverQuest™ Silver Staining kit (Life 
Technologies™) protocol. 
 
The results obtained from the three separate runs were consolidated. Proteins present in 
the untransduced basal condition were subtracted from each transduced condition, after 
which only proteins present in two out of the three independent runs were retained 
(Figure 5.10). The remaining proteins were further whittled down according to the number 
of unique peptides, with a cut-off point of 2 unique peptides (Figure 5.10). The protein 
hits for each experimental condition, after applying the aforementioned restrictions are 
summarised in Table 5.1, Table 5.2 and Table 5.3, with the comprehensive tables 
available to view in Appendix V. 
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Figure 5.10 Flowchart of resultant proteins from proteomic analysis for the transduced, 30 min 
VEGF-stimulated condition. 
Proteins initially detected in the transduced, 30 min VEGF-stimulated condition, were subjected to 
subtraction of proteins present in the untranduced, basal condition, then restricted to those only 
present in two of the three independent runs conducted, followed by elimination of proteins with <2 
unique peptides. 
It was evident that of the remaining candidate proteins detected in the transduced 30 min 
VEGF-stimulated condition, ERK5 (termed MAPK7 in the proteomic readout) was noticeably 
present with an average of 10 unique peptides across the three runs (Table 5.3). The use 
of STRING 9.1 (http://string-db.org), a network analysis program, enabled the creation of 
Figure 5.11 providing known and predicted protein-protein interactions for the resultant 
candidate proteins. 
 
Figure 5.11 Original STRING network analysis. 
Resultant candidate proteins in the transduced, 30 min VEGF-stimulated condition were interpreted 
by STRING 9.1 to produce a visual network analysis. Key: KRT9 (Keratin), ACTB (Actin), HIST1H4H 
(Histone), TUBA1B (Tubulin), MAPK7 (Mitogen-activated protein kinase 7; ERK5). 
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Table 5.1 Readout of proteins discovered in the untransduced, basal condition after LC-MS/MS 
# Peptides: total number of peptides identified as belonging to each protein; # Unique Peptides: number of peptides identified with high confidence for each protein 





# Peptides # Unique Peptides # Peptides 
# Unique 






Protein arginine N-methyltransferase 5 
OS=Homo sapiens GN=PRMT5 PE=1 SV=4 - 
[ANM5_HUMAN] 
2 7 2 8 2 9 2 8 
O60814 Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] 1 2 1 1 N/A N/A 1 2 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 SV=1 - [KV203_HUMAN] 1 1 1 1 1 1 1 1 
P01859 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 - [IGHG2_HUMAN] 1 1 1 1 N/A N/A 1 1 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - [ALBU_HUMAN] 2 6 N/A N/A 3 5 3 6 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 2 6 13 17 2 5 6 9 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 1 4 6 14 N/A N/A 4 9 
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo sapiens GN=TRIM21 PE=1 SV=1 - [RO52_HUMAN] N/A N/A 1 1 1 1 1 1 
P35908 
Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
N/A N/A 3 9 1 3 2 6 
P52732 Kinesin-like protein KIF11 OS=Homo sapiens GN=KIF11 PE=1 SV=2 - [KIF11_HUMAN] N/A N/A 1 2 1 12 1 7 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - [H4_HUMAN] N/A N/A 1 3 1 3 1 3 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 SV=3 - [CASPA_HUMAN] N/A N/A 1 1 1 1 1 1 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 1 2 1 3 2 4 1 3 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 - [TBA1C_HUMAN] 1 5 N/A N/A 3 4 2 5 
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Table 5.2 Readout of proteins discovered in the transduced, basal condition after LC-MS/MS 
# Peptides: total number of peptides identified as belonging to each protein; # Unique Peptides: number of peptides identified with high confidence for each protein 
 Run 1 Run 2 Run 3   















P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - [TBB5_HUMAN] N/A N/A 3 4 2 7 3 6 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] N/A N/A 1 6 1 8 1 7 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 - [TBA1B_HUMAN] N/A N/A 4 6 5 6 5 6 
Q13164 
Mitogen-activated protein kinase 7 
OS=Homo sapiens GN=MAPK7 PE=1 SV=2 - 
[MK07_HUMAN] 
2 14 12 21 12 26 9 20 
 
 
Table 5.3 Readout of proteins discovered in the transduced, 30 min VEGF stimulated condition after LC-MS/MS 
# Peptides: total number of peptides identified as belonging to each protein; # Unique Peptides: number of peptides identified with high confidence for each protein 
 Run 1 Run 2 Run 3   
















Keratin, type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 - 
[K1C9_HUMAN] 
1 4 3 6 N/A N/A 2 5 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 2 5 1 6 1 6 1 6 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - [H4_HUMAN] 1 2 1 2 1 3 1 2 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 - [TBA1B_HUMAN] 5 5 2 5 5 6 4 5 
Q13164 
Mitogen-activated protein kinase 7 
OS=Homo sapiens GN=MAPK7 PE=1 SV=2 - 
[MK07_HUMAN] 
9 22 9 26 11 25 10 24 
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ERK5 was present in the original network analysis, however there were no immediate 
protein-protein interactions (either known or predicted) with any of the other candidate 
proteins. Thus, an expanded network was created to include 10 additional predicted 
partners (Figure 5.12). 
 
Figure 5.12 Expanded STRING network analysis. 
STRING 9.1 included an additional 10 protein partners into the original network analysis to produce 
an expanded network. Key: KRT9 (Keratin), HIST1H4H (Histone), MAPK7 (ERK5), TUBA1B (Tubulin), 
ACTB (Actin), MEF2C (Myocyte enhancer factor 2C), MEF2A (Myocyte enhancer factor 2A), PFN1 
(Profilin 1), GJA1 (Gap junction protein, alpha 1), ACTN2 (Actinin, alpha 2), KAT5 (Lysine 
acetyltransferase 5), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4), TMSB4X (Thymosin beta 4, X-linked), MYC (v-myc 
myelocytomatosis viral oncogene homolog), MAP2K5 (Mitogen-activated protein kinase kinase 5; 
MEK5). 
 
The expanded network analysis provided a new and rather interesting association between 
ERK5 and tubulin alpha-1B chain, via gap junction alpha-1 protein (GJA1). Thus, the 
inclusion of GJA1 as an intermediary junction increases the scope of additional proteins 
acting as interacting partners of ERK5. 
 
5.5 Discussion 
Early data from this chapter (Figure 5.6 and Figure 5.7) provides additional evidence to 
support the intriguing association between ERK5 and AKT in HDMEC, initially uncovered in 
Chapter 3. This chapter utilised an adenovirus generated to encode for FLAG-ERK5, which 
could then be added to HDMEC and HeLa cells to transduce an overexpression of ERK5. As 
previously mentioned, primary human cells are particularly difficult to transfect with high 
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efficiency. The use of a current, commercially available transfection reagent is only able 
to achieve <2% transfection efficiency in HUVECs, thus adenovirus-mediated gene delivery 
was preferred. 
Immunoprecipitation experiments revealed the presence of AKT upon ERK5 overexpression 
and precipitation in HDMEC (Figure 5.6). Additionally, a greater amount of AKT appeared 
to co-precipitate at the 30 min stimulation time point rather than the 10 min time point. 
The subsequent experiment conducting a reciprocal IP (IP: AKT and WB: ERK5), further 
confirmed that ERK5 could also be detected as co-precipitating with AKT in HDMEC, and 
once again a larger amount was observed at the 30 min time point (Figure 5.7). There 
appeared to be no association evident between ERK5 and AKT in HeLa (Figure 5.6 and 
Figure 5.7) potentially suggesting a differential role for VEGF- and EGF- stimulation of 
ERK5 and AKT activity. Few studies have investigated the role of VEGF-mediated ERK5 
phosphorylation in regulating AKT activity, however the study from which this project has 
progressed, initially highlighted the requirement for ERK5 in VEGF-stimulated AKT 
phosphorylation in HDMEC (Roberts et al., 2010). Instead, data from this project suggest a 
possible co-localisation (Figure 4.5) and interaction between ERK5 and AKT in HDMEC 
(Figure 5.6 and Figure 5.7). 
Subsequently, mass spectrometry was utilised in conjunction with ERK5 overexpression, in 
an attempt to further confirm AKT as a potential binding partner of activated ERK5 in 
HDMEC (Table 5.3). The results obtained from the proteomic analysis however, did not 
identify AKT in the immunoprecipitated proteins, which may have been due to the binding 
of ERK5 and AKT being transient. Thus, in an attempt to ascertain this potential transient 
interaction between ERK5 and AKT, additional proteomic experiments would require the 
inclusion of extra VEGF-stimulated time points such as 1, 5, 10 and 20 mins.  
However, with the ERK5-AKT interaction evident during Western blotting (Figure 5.8), it 
may suggest that it is instead necessary to optimise the sample conditions for mass 
spectrometry, especially considering the somewhat disconcerting lack of known binding 
partners such as MEK5, which would be expected to be identified by mass spectrometry 
following ERK5 immunoprecipitation. It is apparent that the conditions were correct for 
the mass spectrometry process, as our bait protein, ERK5, was present in the proteomic 
readout. Nevertheless, these conditions may not have been appropriate for the interacting 
complex itself. The samples were frozen at -80°C after preparation, however they were 
only processed 6 weeks later, enabling the potential occurrence of protein degradation. 
This remains a possibility as the average number of ERK5 peptides discovered was only 24, 
a relatively low quantity considering the protein appeared to be adequately overexpressed 
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as detected by Western blotting and silver staining (Figure 5.8 and Figure 5.9). Thus, 
bearing in mind that AKT itself was not overexpressed, the endogenous number of 
peptides may have been degraded to levels undetectable by the mass spectrometry 
instrument. Consequently, the overexpression of both ERK5 and AKT with two different 
epitope tags, may be required to ascertain the nature of the interaction either as direct 
binding of the two proteins, or their existence as a complex. 
The network analysis program STRING 9.1 was used to process candidate proteins originally 
discovered during mass spectrometry. This analysis schematic displayed ERK5 and tubulin 
alpha-1B chain present, yet with no direct association with one another, or any of the 
other resultant proteins (Figure 5.11). However, by including additional interacting 
partners into the network, these two proteins were connected via the intermediary 
protein, gap junction alpha-1 protein (GJA1). 
GJA1, also known as Connexin43 or Cx43, is a membrane-spanning protein that is able to 
form channels between adjacent cells, thereby bridging the gap and enabling intercellular 
exchange of information. Initial studies involving ERK5 and Cx43, reported the 
phosphorylation of Cx43 on Ser255 by ERK5 both in vitro and in vivo in EGF-stimulated 
HEK293 cells (Cameron et al., 2003), however in 2006 Park and colleagues demonstrated a 
“mode-1” interaction of 14-3-3 θ with phospho-Ser373 of Cx43 (Park et al., 2006). Previous 
evidence has shown AKT to often mediate 14-3-3 interactions by phosphorylating target 
proteins (Kovacina et al., 2003), thus Park et al., were subsequently able to demonstrate 
Cx43 as being a substrate for AKT in EGF-stimulated Rat-1 fibroblasts (Park et al., 2007). 
In the context of these previous studies, data from this project may provide an additional 
aspect whereby VEGF-stimulated ERK5 initially presents in the cytoplasm followed by an 
interaction with, and consequent phosphorylation of, Cx43 at the plasma membrane. Cx43 
in turn may complex with AKT either directly as a substrate, or indirectly via 14-3-3. It is 
important to note that although data from this project did not demonstrate a direct ERK5-
AKT interaction, the possibility of these two proteins interacting in this manner must not 
be neglected. In view of the possible connection of Cx43 occurring between ERK5 and AKT, 
it may be that the presence of the transmembranous protein, Cx43, has obscured the 
proteomic result. The hydrophobic domains of the membrane protein would not have 
solubilised appropriately in the sucrose lysis buffer, resulting in its precipitation prior to 
being processed by mass spectrometry. Therefore, it would be necessary to optimise the 
conditions to include membrane proteins, such as the addition of a mass spectrometry-
compatible detergent. 









6  Chapter Six 
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6.1 The role and regulation of ERK5 in endothelial cells 
The ubiquitously expressed ERK5 protein plays different, yet specific roles in various cell 
types (Sohn et al., 2002; Hayashi et al., 2004; Wang and Tournier, 2006; Spiering et al., 
2009) and in addition to regulating normal cellular processes such as proliferation, 
differentiation and survival (Kato et al., 1998; Dinev et al., 2001; Wang and Tournier, 
2006), ERK5 has been implicated in the progression of pathologies such as cancer and 
ischaemia (Takeishi et al., 1999; Montero et al., 2009). 
Global gene ablation techniques highlighted the critical role of ERK5 in normal vascular 
development (Hayashi and Lee, 2004), with the initial defect discovered to occur within 
the endothelium (Hayashi et al., 2004). Since these findings however, only a handful of 
studies have characterised the activation of ERK5 within endothelial cells (Abe et al., 
1996; Yan et al., 1999; Roberts et al., 2010), yet numerous studies focussed on EGF-
stimulated ERK5 activation in the context of tumour cell proliferation and intracellular 
localisation, thus leading to the development of small-molecule inhibitors (Kato et al., 
1998; Kamakura et al., 1999; Hayashi et al., 2001; Raviv et al., 2004; Kondoh et al., 2006; 
Tatake et al., 2008; Yang et al., 2010a).  
This thesis has addressed key differences in ERK5 activation by different growth factors in 
both endothelial and HeLa cells, and as a consequence several novel discoveries have been 
revealed, which are discussed forthwith. 
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6.1.1  VEGF appears unique in its ability to stimulate ERK5 phosphorylation 
in HDMECs 
The characterisation of ERK5 activation in HDMEC was initially investigated with the use of 
various growth factors, however it was VEGF that appeared to be unique in its ability to 
stimulate ERK5 phosphorylation in this cell type. Interestingly, VEGF was also able to 
induce phosphorylation of AKT (Figure 3.6) and with the use of the MEK5 inhibitor BIX 
02189 (Figure 4.8), it was later discovered that ERK5 might play a role in the regulation of 
AKT activity. The association between AKT and ERK5 became more evident as subcellular 
protein fractionation experiments revealed a cytoplasmic/plasma membranous 
intracellular localisation of the two proteins (Figure 4.5), which was further supported by 
immunofluorescence experiments showing co-localisation of p-AKT and ERK5 in the 
cytoplasm and at the cell periphery (Figure 4.6). 
It is important to note however, that the activation of both ERK5 and AKT in HDMEC are 
not events that are mutually inclusive of one another; stimulation with HGF acting through 
the c-Met receptor, demonstrates AKT activation in the absence of ERK5 phosphorylation 
(Figure 3.6). Instead, it appears that VEGF-mediated ERK5 activation requires the 
phosphorylation of PLCγ, as data utilising MAE cells stably expressing the Flk-1 Y1173F 
mutant receptor highlighted the significant decrease in ERK5 activation upon loss of PLCγ 
phosphorylation (Figure 3.8). 
PLCγ phosphorylation hydrolyses IP3 from PIP2, which in turn mediates intracellular levels 
Ca2+ and DAG, a PKC activator; thus, it is possible that ERK5 activity maybe regulated by 
PKC. Numerous studies have implicated various PKC isoforms in the regulation of ERK5 
activity (Diaz-Meco and Moscat, 2001; Li et al., 2005; Zhao et al., 2010), however others 
have shown that ERK5 activation does not occur via PKC (Abe et al., 1996; Kato et al., 
1998; Yan et al., 1999), thereby suggesting cell dependency with regards to activation of 
this pathway. VEGF-mediated proliferation in HDMEC has been shown to act through a 
PLCγ>PKC pathway, consequently activating ERK1/2 (Xia et al., 1996; Wellner et al., 1999; 
Takahashi et al., 2001); the observed decrease in ERK1/2 activation in the MAE cells stably 
expressing Flk-1 Y1173F reflects this (Figure 3.8), however the presence of some residual 
ERK1/2 phosphorylation suggests the possibility of an alternative pathway feeding into its 
activation. Ras hyperactivation has been shown to induce a pro-angiogenic phenotype 
(Meadows et al., 2004; Bajaj et al., 2010), therefore it may be that an unidentified 
adaptor molecule directly couples VEGFR-2 to the GrbB2-Sos-Ras pathway thereby 
activating ERK1/2. 
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6.1.2  VEGF and EGF induce differential phosphorylation of ERK5 and 
intracellular localisation 
Thus far, the majority of studies have adhered to the initial characterisation of ERK5 
activation whereby the Thr218/Tyr220 residues in the kinase domain are dual-
phosphorylated, followed by the autophosphorylation of numerous C-terminal tail residues 
(Mody et al., 2003). In light of the fact that reliable reagents for the detection of ERK5 
activation are lacking, in particular a consistent phospho-ERK5 (Thr218/Tyr220) antibody for 
Western blotting and immunofluorescence, progress in the field has been limited to 
detecting ERK5 activation through electrophoretic mobility bandshift on conventional SDS-
PAGE. This however presented a significant issue, as ERK5 activation in HDMEC could not 
be detected by mobility bandshift (Figure 3.1b). This project was able to overcome this 
hurdle with the use of the novel Phos-tag™ reagent in SDS-PAGE, and as a consequence this 
study revealed a novel difference in the phosphorylation events of ERK5 in VEGF-
stimulated HDMEC and EGF-stimulated HeLa. 
The activation of ERK5 resembles that of JNK, whereby phosphorylation by its upstream 
MAPKK preferentially phosphorylates the threonine residue of the T-X-Y motif (Lawler et 
al., 1998; Mody et al., 2003), in contrast to p38 MAPK and ERK1/2, which are 
preferentially phosphorylated on the tyrosine residue of the T-X-Y motif (Haystead et al., 
1992; Fleming et al., 2000). However, unlike JNK, p38 MAPK and ERK1/2, in addition to 
dual-phosphorylation of the Thr/Tyr residues of the T-X-Y motif, ERK5 is able to undergo 
autophosphorylation of multiple residues of its C-terminal tail (Mody et al., 2003; 
Buschbeck and Ullrich, 2005; Morimoto et al., 2007).  
This project discovered that in line with current literature regarding ERK5 activation, EGF-
stimulated HeLa cells undergo phosphorylation of the Thr218/Tyr220 residues in the 
activation loop of the kinase domain, but also at additional residues, such as Thr732, 
thought to be in the C-terminal tail. This resulted in a mobility bandshift with 
conventional SDS-PAGE (Figure 3.1a) and a dual bandshift with Phos-tag™ SDS-PAGE (p-
ERK5 and hyper p-ERK5) (Figure 3.5). It was subsequently ascertained that the p-ERK5 
band corresponded to phosphorylation of Thr218/Tyr220 (Figure 4.1a), and that the hyper p-
ERK5 band comprised of phosphorylation of these same two residues as well as additional 
C-terminal residues (Figure 4.1b).  
VEGF-stimulation of HDMEC did not induce an ERK5 mobility bandshift using conventional 
SDS-PAGE (Figure 3.1b, however a single bandshift was detected with Phos-tag™ SDS-PAGE 
(Figure 3.6), which was subsequently shown to correspond to phosphorylation of 
Thr218/Tyr220 (Figure 4.1a). These data suggest that VEGF was only able to induce dual-
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phosphorylation of the kinase domain residues (p-ERK5) with no apparent phosphorylation 
of C-terminal residues (Figure 4.1b). Taken together, these data infer that kinase activity 
and phosphorylation of C-terminal residues are not necessarily mutually inclusive events. 
Furthermore, this result along with dose-response data of the ERK5 inhibitor XMD8-92 on 
HeLa, proposed the possibility that an alternative pathway may feed in the 
phosphorylation of C-terminal residues upon EGF stimulation (Figure 3.13). If ERK5 alone 
was responsible for autophosphorylation of its C-terminal residues, the hyper p-ERK5 band 
should not be evident upon XMD8-92 inhibition, however the observed partial reduction in 
intensity of this hyper p-ERK5 band suggests that both ERK5-dependent and –independent 
pathways contribute towards the phosphorylation of the C-terminal tail (Figure 3.13). The 
novel discovery that XMD8-92 inhibits C-terminal autophosphorylation, but not ERK5-
independent C-terminal phosphorylation, would not have been detected on conventional 
SDS-PAGE; inhibition with XMD8-92 resulted in a loss of mobility bandshift, indicating 
conventional SDS-PAGE is unable to fully discriminate between the ERK5-dependent and –
independent phosphorylation events. 
This project utilised siRNA against signalling proteins, known to be differentially activated 
by VEGFR-2 and EGFR-1, to reveal the possible involvement of HRAS in EGF-mediated C-
terminal phosphorylation of ERK5 (Figure 4.2b). Recent studies have linked 
phosphorylation of the C-terminal residues of ERK5 to a MEK5-independent pathway during 
mitosis via CDK activity (Diaz-Rodriguez and Pandiella, 2010; Inesta-Vaquera et al., 2010). 
Focussing on Thr732, as this residue was investigated in this project, it is unlikely that RAS 
activates CDK-1 and as a consequence phosphorylates Thr732, as numerous studies have 
highlighted the ability of RAS to induce cell cycle arrest in primary mammalian cells (Land 
et al., 1983; Hirakawa and Ruley, 1988; Daar et al., 1991). More recently, albeit in a 
different system of Xenopus egg extracts, RAS has been shown to suppress CDK-1 (Huang 
et al., 2013). 
Utilising the kinase-specific phosphorylation profiling tool NetPhosK 1.0 (CBS, 2014) 
revealed p38 MAPK, CDK5 and GSK3 as possible kinases that may phosphorylate this 
specific residue. These kinases are predicted with a low confidence (0.51-0.58) and in 
conjunction with the knowledge that this profiling tool does not cover an exhaustive list of 
kinases, further delineation of the potential pathways feeding into C-terminal 
phosphorylation would be necessary. p38 MAPK activity has previously been implicated in 
increased vascular permeability and shear stress-induced angiogenesis upon VEGF 
stimulation of VEGFR-2 in endothelial cells (Issbrucker et al., 2003; Gee et al., 2010), thus 
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any potential involvement of this pathway in ERK5 phosphorylation would prove an 
interesting future avenue. 
The ERK5 signalling pathway is one that is associated with cancers of the breast and 
prostate, and additionally, tumours presenting with a strong nuclear localisation of ERK5 
often result in poor disease prognosis (Esparís-Ogando et al., 2002; Mehta et al., 2003; 
McCracken et al., 2008; Montero et al., 2009). This project revealed that the nuclear 
localisation of ERK5 required phosphorylation of its numerous C-terminal residues, in 
addition to its Thr218/Tyr220 residues (Figure 4.3). Consequently, VEGF-mediated dual-
phosphorylation of ERK5 did not undergo translocation to the nucleus, but instead 
appeared to localise in the cytoplasm and at the plasma membrane (Figure 4.4 and Figure 
4.5). 
6.1.3  VEGF-mediated ERK5 activation regulates AKT phosphorylation in 
HDMECs 
The discovery that VEGF-stimulated ERK5 activity was required in mediating AKT activity 
in HDMEC (Roberts et al., 2010), as well as the implication of ERK5 in growth factor-
mediated activation of AKT in other cell types (Lennartsson et al., 2010; Razumovskaya et 
al., 2011), led to the investigation of AKT activity with respect to ERK5 phosphorylation in 
this project. 
Experiments utilising the specific MEK5 inhibitor (BIX 02189) revealed a novel discovery in 
that VEGF-mediated AKT activity was dependent upon MEK5 kinase activity (Figure 4.8). 
The previous finding that the ERK5 kinase inhibitor (XMD8-92) blocked phosphorylation of 
ERK5-dependent C-terminal residues, but not that of Thr218/Tyr220 (Figure 3.12 and Figure 
3.13), supported the data highlighting the inability of XMD8-92 to affect VEGF-stimulated 
AKT activation; phosphorylation of Thr218/Tyr220 alone was sufficient in regulating VEGF-
mediated AKT activity (Figure 4.8). 
It was evident that the role ERK5 played in regulating the phosphorylation of AKT was 
specific to VEGF-stimulated HDMEC; inhibiting EGF-mediated ERK5 phosphorylation in HeLa 
with the use of BIX 02189 and XMD8-92 did not appear to affect AKT activity (Figure 4.9). 
This significant discovery provides a rationale behind the lack of vascular toxicity seen 
with XMD8-92 on the human tumour xenograft study in mice (Yang et al., 2010a); VEGF-
stimulated ERK5 regulation of AKT activity remains unaffected by XMD8-92, whereas BIX 
02189 could potentially induce vascular toxicity due to blocking VEGF-mediated AKT 
activity and consequently endothelial cell survival. It remains to be determined what the 
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extent of in vivo toxicity is with BIX 02189 as to date, no animal studies have utilised this, 
or any other MEK5 inhibitor. 
AKT appeared to have a similar intracellular localisation to that of ERK5, i.e. a 
cytoplasmic/plasma membranous localisation (Figure 4.5 and Figure 4.6) in HDMEC, with 
no apparent co-localisation between the two proteins in HeLa (Figure 4.7). Thus it was 
proposed that a potential interaction between ERK5 and AKT might exist in HDMEC. It is 
important to note however, that the antibody used in this study to detect the presence of 
AKT, recognised all three isoforms of AKT, i.e. AKT1, AKT2 and AKT3, therefore 
elucidation of which isoform interacts with ERK5 remains to be determined. 
6.1.4  VEGFR-2, ERK5 and AKT co-immunoprecipitate in HDMECs 
Immunoprecipitation experiments provided evidence to support the hypothesis that ERK5 
and AKT might interact with one another; HDMEC transduced with adenoviral FLAG-ERK5, 
revealed a co-immunoprecipitation of AKT along with FLAG-ERK5 upon VEGF stimulation 
(Figure 5.6) as well as the reciprocal result of FLAG-ERK5 co-precipitating with AKT (Figure 
5.7). As previously mentioned, the lack of association between ERK5 and AKT in HeLa was 
once again observed during both these immunoprecipitation experiments (Figure 5.6 and 
Figure 5.7), thus providing further evidence to suggest a differential role for EGF-mediated 
ERK5 phosphorylation in this cell type. 
A considerably interesting finding was the co-precipitation of the relevant receptors in 
each cell type with FLAG-ERK5 (Figure 5.6). Unstimulated HeLa demonstrated co-
precipitation of EGFR-1 with ERK5, whereas all conditions of HDMEC resulted in VEGFR-2 
co-precipitating with ERK5, with an evident increase at 10 min post-VEGF stimulation 
(Figure 5.6). These data, along with previous intracellular localisation results (Figure 4.4 
and Figure 4.5 suggest that VEGF may induce ERK5 activation via VEGFR-2 internalisation, 
thereby enabling it to complex with, and consequently activate, ERK5. Findings from co-
stimulation experiments that utilised MAE cells stably expressing the Flk-1 receptor, 
revealed the hyper p-ERK5 generated by EGF stimulation alone decreased upon co-
stimulation with VEGF (Figure 3.9). This provides additional evidence that VEGFR-2 and 
EGFR-1 may be able to activate different intracellular pools of ERK5, possibly due to 
VEGFR-2 sequestering ERK5 in an intracellular localisation that precludes it from being 
further phosphorylated by EGFR-1. 
VEGFR-2 internalisation is similar to that of EGFR-1 in that it undergoes clathrin-
dependent endocytosis upon binding to VEGF-A (Lampugnani et al., 2006), however the 
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ability of VEGFR-2 to signal in cooperation with the non-catalytic co-receptor NRP-1, lends 
itself to a difference in internalisation compared to EGFR-1 (Horowitz and Seerappu, 
2012). Consequently, this difference in internalisation may enable VEGFR-2, ERK5 and AKT 
to exist in a complex, possibly linked via the membrane-spanning protein Cx43, at a region 
between the plasma membrane and cytoplasm. 
Cx43 has previously been shown to be phosphorylated on Ser255 by ERK5, but not ERK1/2, 
both in vitro and in vivo in EGF-stimulated HEK293 cells (Cameron et al., 2003). 
Furthermore, with the observation of a “mode-1” interaction of 14-3-3 θ with phospho-
Ser373 of Cx43 (Park et al., 2006), and evidence showing AKT as a mediator of 14-3-3 
interactions by phosphorylation of target proteins (Kovacina et al., 2003), Cx43 has since 
been shown to be a substrate for AKT (Park et al., 2007). Thus VEGF-stimulated ERK5 
activity may phosphorylate and interact with Cx43 at the plasma membrane, which in turn 
may complex with AKT either directly as a substrate, or indirectly via 14-3-3. If this is the 
case, endothelial cell apoptosis in Erk5 knockout mice reported to be due to a lack of 
MEF2C phosphorylation by ERK5 (Hayashi et al., 2004), may in fact be due to a decrease in 
AKT activity. 
Interestingly, Akt1-/- mice show increased neonatal mortality (Chen et al., 2001b; Cho et 
al., 2001) due to defects in placental function such as fewer blood vessels and scarce 
vascular branching (Yang et al., 2003b). These phenotypes have been observed in vitro as 
a decrease in tubular morphogenesis and cellular survival in HDMEC, upon ERK5 knockdown 
with siRNA (Roberts et al., 2010). Furthermore, the study from which this project has 
progressed showed that PI3K inhibition affected VEGF-mediated AKT phosphorylation but 
not ERK5 phosphorylation, suggesting that PI3K may lie downstream of, or parallel to, the 
ERK5 pathway in HDMEC (Roberts et al., 2010). The role of EGF-mediated AKT activity in 
HeLa cells remains to be elucidated; a previous study has implicated EGFR in playing an 
important role in mediating oxidative stress-induced AKT activation (Wang et al., 2000).  
Figure 6.1 and Figure 6.2 demonstrates the proposed mechanisms though which ERK5 is 
differentially phosphorylated upon EGF or VEGF stimulation in HeLa or HDMEC. 
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Figure 6.1 EGF-mediated ERK5 activity in HeLa. 
EGF stimulation of HeLa results in phosphorylation of Thr218/Tyr220 in the kinase domain by MEK5. 
Inhibition of this phosphorylation can occur using the MEK5-selective inhibitor, BIX 02189. 
Phosphorylation of C-terminal residues of ERK5 may occur by ERK5-dependent and –independent 
pathways. The ERK5-selective inhibitor, XMD8-92 is able to inhibit autophosphorylation of ERK5 C-
terminal residues. ERK5-independent phosphorylation of C-terminal residues is thought to occur via 
EGF-mediated HRAS activation. Phosphorylation of C-terminal residues enables nuclear shuttling of 
ERK5 wherein phosphorylation of promyelocytic leukemia protein (PML) occurs in the PML-nuclear 
body (PML-NB). Phosphorylated PML is unable to upregulated p21, which is required for G1/S cell 
cycle progression. Additionally, nuclear ERK5 is able to phosphorylate transcription factors such as 
CREB and MEF2, leading to a survival response. 
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Figure 6.2 VEGF-mediated ERK5 activity in HDMEC. 
VEGF stimulation of HDMEC results in phosphorylation of Thr218/Tyr220 in the kinase domain by MEK5. 
BIX 02189 is able to inhibit this phosphorylation. VEGF is unable to induce C-terminal 
phosphorylation of ERK5. Instead, ERK5 phosphorylated at Thr218/Tyr220, is thought to complex with 
VEGFR-2 and MEK5 at the plasma membrane whereby it is able to complex with, and mediate AKT 
activation, possibly via Cx43, or via an unknown direct mechanism. Phosphorylated AKT is 
consequently able to phosphorylate BAD, sequestering it to the 14-3-3 protein, inhibiting its 
interaction with BCL2 and its translocation to the mitochondria. FoxO3a phosphorylation by AKT is 
also sequestered by the 14-3-3 protein in the cytoplasm, thereby preventing it from upregulating the 
Fas ligand (FasL), which subsequently results in an apoptotic feedback loop and FasL-mediated 
caspase activation. 
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6.2 Future perspectives 
This novel discovery that ERK5 is differentially phosphorylated by EGF and VEGF, which in 
turn leads to a divergence in downstream activation, provides key insight into the diverse 
functional role of ERK5 in various cell types upon growth factor simulation. 
The observation that C-terminal phosphorylation was required for the nuclear 
translocation of ERK5, could be further investigated regarding ERK5-dependent and ERK5-
independent phosphorylation of these C-terminal residues. Future studies should aim to 
observe the effect of reduced C-terminal phosphorylation on nuclear translocation; HeLa 
cells treated with XMD8-92 would inhibit ERK5-dependent C-terminal phosphorylation and 
intracellular localisation could then be observed using immunofluorescent staining. 
Furthermore, aberrations in the transcriptional activity of ERK5 as a result of decreased C-
terminal phosphorylation would be revealed by investigating levels of transcription factors 
such as CREB and MEF2, c-Myc and Sap1a with qRT-PCR. 
Thus far, studies have not observed the activation of RAS isoforms in response to VEGF 
stimulation in HDMEC; a future line of investigation would require a VEGF-activated RAS 
assay to determine potential RAS isoforms activated in HDMEC. Further to this, with the 
knowledge that HRAS plays a potential role in EGF-stimulated C-terminal phosphorylation, 
it may then be possible to utilise a dominant-active (G12V) RAS in VEGF-stimulated HDMEC 
to force phosphorylation of certain C-terminal residues. Immunofluorescent staining could 
be utilised in order to detect whether this results in a change in the intracellular 
localisation of VEGF-stimulated ERK5. Consequently, it would be necessary to determine 
any changes in downstream signalling, i.e. from VEGF-induced, ERK5-mediated AKT 
activity to EGF-stimulated, ERK5-mediated cell proliferation. 
As previously mentioned, VEGFR-2 is able to signal in cooperation with the co-receptor 
NRP-1. It may be that dimerisation of these two receptors and their subsequent 
internalisation may play a role in activating a different intracellular pool of ERK5 
compared to that of EGFR-1. To determine whether or not this may be the case, the use of 
VEGF-A121 an isoform that does not bind NRP-1, would provide further insight into the 
potential role NRP-1 plays in the activation of ERK5. Prior to this however, it would be 
necessary to assess the ability and extent of ERK5 phosphorylation in response to VEGF-A121 
stimulation. 
The interesting discovery that ERK5 may exist within a complex with VEGFR-2 and AKT 
near the plasma membrane would require much further exploration; time and funding 
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constraints limited further investigation in this project. As mentioned in Chapter 5, a more 
detailed proteomic study with additional VEGF-stimulated time-points, such as 1, 5, 10 
and 20 min would benefit the proteomic analysis in order to ascertain the potential 
transiency of the interaction between ERK5 and AKT. Additionally, in view of the relatively 
low quantity of the bait protein (FLAG-ERK5) after transduced overexpression, it would be 
necessary to ensure that proteomic samples are processed immediately, to prevent 
protein degradation upon freezing. Furthermore, with the possibility that the 
transmembrane protein Cx43, may be an intermediary molecule in the ERK5-AKT complex, 
optimisation of the proteomic lysis buffer would be required to take account of the 
insoluble, hydrophobic domains of the membrane protein. 
Finally, phospho-proteomics would potentially be the major line of future investigation, 
whereby point mutations of ERK5 could be overexpressed in both VEGF-stimulated HDMEC 
and EGF-stimulated HeLa. An adenoviral FLAG-ERK5(AEF) mutant, in which Thr218/Tyr220 
are mutated to Ala218/Phe220 respectively, and a constitutively-active HA3-MEK5(D), in 
which Ser311/Thr315 are mutated to Asp311/Asp315, were generated during this project, 
however time constraints prevented their use in proteomic experiments. The use of the 
adenoviral HA3-MEK5(D) in conjunction with adenoviral FLAG-ERK5(wt), would enable their 
overexpression, but also the constitutive phosphorylation of the Thr218/Tyr220 residues. 
This would overcome the transient nature of phosphorylated events, thereby facilitating 
detection of ERK5-interacting proteins. Phospho-proteomic profiling would reveal the 
specific residues phosphorylated following VEGF and EGF stimulation. Furthermore, point 
mutations of C-terminal phosphorylation residues in EGF-stimulated HeLa cells would 
facilitate identification of the precise kinase implicated in phosphorylating the ERK5-
independent C-terminal residues. 
This thesis has revealed a hitherto unknown difference in ERK5 phosphorylation and 
consequently its intracellular localisation in endothelial cells. These findings taken 
together with the discovery of novel interacting partners of ERK5, has brought to light 
several new interesting avenues for future investigation. One in particular involves the 
novel finding that C-terminal residues of ERK5 may be phosphorylated by ERK5-dependent 
and –independent pathways. The selective ERK5 inhibitor XMD8-92, although able to 
prevent autophosphorylation of C-terminal residues of ERK5, cannot inhibit other potential 
kinases from phosphorylating alternative C-terminal residues. Thus, in order to prevent 
ERK5-independent pathways from offering a compensatory mechanism for C-terminal 
phosphorylation in the presence of promising drugs such as XMD8-92, it is essential that 
these kinases are identified; hence, the critical component of pathological ERK5 activation 










7  References 
References 
149 
abcam®. (2014). "http://www.abcam.com/index.html?pageconfig=resource&rid=11379."   
Retrieved 11th November 2014. 
Abe, J., Kusuhara, M., Ulevitch, R. J., Berk, B. C. and Lee, J. D. (1996). Big mitogen-
activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem, 
271(28): 16586-16590. 
Abe, J., Takahashi, M., Ishida, M., Lee, J. D. and Berk, B. C. (1997). c-Src Is Required for 
Oxidative Stress-mediated Activation of Big Mitogen-activated Protein Kinase 1 
(BMK1). J Biol Chem, 272: 20389-20394. 
Aird, W. C. (2007). Phenotypic heterogeneity of the endothlium: I. Structure, function and 
mechanisms. Circulation research, 100: 158-173. 
Aird, W. C. (2012). Endothelial cell heterogeneity. Cold Spring Harb Perspect Med, 2: 
a006429. 
Akaike, M., Che, W., Marmarosh, N. L., Ohta, S., Osawa, M., Ding, B., Berk, B. C., Yan, C. 
and Abe, J. (2004). The hinge-helix 1 region of peroxisome proliferator-activated 
receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-
regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in 
flow-induced PPARgamma activation in endothelial cells. Mol Cell Biol, 24(19): 
8691-8704. 
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and 
Hemmings, B. A. (1996). Mechanism of activation of protein kinase B by insulin and 
IGF-1. Embo J, 15: 6541-6551. 
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B. and 
Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein 
kinase which phosphorylates and activates protein kinase B alpha. Curr Biol, 7: 
261-269. 
Altomare, D. A., You, H., Xiao, G. H., Ramos-Nino, M. E., Skele, K. L., De Rienzo, A., 
Jhanwar, S. C., Mossman, B. T., Kane, A. B. and Testa, J. R. (2005). Human and 
mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted 
pharmacologically to inhibit tumor cell growth. Oncogene, 24: 6080-6089. 
Anderson, K. E., Coadwell, J., Stephens, L. R. and Hawkins, P. T. (1998). Translocation of 
PDK-1 to the plasma membrane is important in allowing PDK-1 to activated protein 
kinase B. Curr Biol, 8: 684-691. 
Anton, M., Wolf, A., Mykhaylyk, O., Koch, C., Gansbacher, B. and Plank, C. (2012). 
Optimizing adenoviral transduction of endothelial cells under flow conditions. 
Pharm Res, 29: 1219-1231. 
Bajaj, A., Zheng, Q., Adam, A., Vincent, P. and Pumiglia, K. (2010). Activation of 
endothelial Ras signaling bypasses senescence and causes abnormal vascular 
morphogenesis. Cancer Res, 70: 3803-3812. 
References 
150 
Barros, J. C. and Marshall, C. J. (2005). Activation of either ERK1/2 or ERK5 MAP kinase 
pathways can lead to disruption of the actin cytoskeleton. J Cell Sci, 118: 1663-
1671. 
Batzer, A. G., Rotin, D., Urena, J. M., Skolnik, E. Y. and Schlessinger, J. (1994). Hierarchy 
of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol 
Cell Biol, 14: 5192-5201. 
Benjamin, L. E., Hemo, I. and Keshet, E. (1998). A plasticity window for blood vessel 
remodelling is defined by pericyte coverage of the preformed endothelial network 
and is regulated by PDGF-B and VEGF. Development, 125: 1591-1598. 
Bera, A., Das, F., Ghosh-Choudhry, N., Li, X., Pal, S., Gorin, Y., Kasinath, B. S., Abboud, 
H. E. and Ghosh Choudhury, G. (2014). A positive feedback loop involving Erk5 and 
Akt turns on mesangial cell proliferation in response to PDGF. Am J Physiol Cell 
Physiol, 306: C1089-C1100. 
Bergelson, J. M., cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, 
J. S., Horwitz, M. S., Crowell, R. L. and Finberg, R. W. (1997). Isolation of a 
common receptor for Coxsackie B viruses and Adenoviruses 2 and 5. Science, 275: 
1320-1323. 
Bergers, G. and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat 
Rev Cancer, 8: 592-603. 
Bergers, G. and Song, S. (2005). The role of pericytes in blood-vessel formation and 
maintenance. Neuro Oncol, 7: 452-464. 
Berkers, J. A., van Bergen en Henegouwen, P. M. and Boonstra, J. (1991). Three classes of 
epidermal growth factor receptors on HeLa cells. J Biol Chem, 266: 922-927. 
Bernstein, E., Caudy, A. A., Hammond, S. M. and Hannon, G. J. (2001). Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature, 409: 
363-366. 
Berse, B., Brown, L. F., Van De Water, L., Dvorak, H. F. and Senger, D. R. (1992). Vascular 
permeability factor (vascular endothelial growth factor) gene is expressed 
differentially in normal tissues, macrophages, and tumors. Mol Biol Cell, 3: 211-
220. 
Bi, W., Drake, C. J. and Schwarz, J. J. (1999). The transcription factor MEF2C-null mouse 
exhibits complex vascular malformations and reduced cardiac expression of 
angiopoietin 1 and VEGF. Dev Biol, 211: 255-267. 
Blanes, M. G., Oubaha, M., Rautureau, Y. and Gratton, J. P. (2007). Phosphorylation of 
tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-
dependent endothelial nitric-oxide synthase activation and nitric oxide release 
from endothelial cells. J Biol Chem, 282: 10660-10669. 
References 
151 
Blank, J. L., Gerwins, P., Elliott, E. M., Sather, S. and Johnson, G. L. (1996). Molecular 
cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. 
Regulation of sequential phosphorylation pathways involving mitogen-activated 
protein kinase and c-Jun kinase. J Biol Chem, 271(10): 5361-5368. 
Boon, R. A. and Horrevoets, A. J. (2009). Key transcriptional regulators of the 
vasoprotective effects of shear stress. Hamostaseologie, 29: 39-43. 
Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. 
D., DePinho, R. A., Panayotatos, N., Cobb, M. H. and Yancopoulos, G. D. (1991). 
ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine 
phosphorylated in response to insulin and NGF. Cell, 65(4): 663-675. 
Brauckmann, S. and Gilbert, S. F. (2004). Gastrulation: From Cells to Embryo, Cold Spring 
Harbor Laboratory Press. 
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., 
Arden, K. C., Blenis, J. and Greenberg, M. E. (1999). Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96: 857-868. 
Buschbeck, M. and Ullrich, A. (2005). The unique C-terminal tail of the mitogen-activated 
protein kinase ERK5 regulates its activation and nuclear shuttling. J Biol Chem, 
280(4): 2659-2667. 
Cameron, S. J., Malik, S., Akaike, M., Lerner-Marmarosh, N., Yan, C., Lee, J. D., Abe, J. 
and Yang, J. (2003). Regulation of epidermal growth factor-induced connexin 43 
gap junction communication by big mitogen-activated protein kinase 1/ERK5 but 
not ERK1/2 kinase activation. J Biol Chem, 278: 18682-18688. 
Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296: 1655-1657. 
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., 
Frisch, S. and Reed, J. C. (1998). Regulation of cell death protease caspase-9 by 
phosphorylation. Science, 282: 1318-1321. 
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat Med, 6: 389-395. 
Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438: 932-936. 
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., 
Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., 
Moons, L., Collen, D., Risau, W. and Nagy, A. (1996). Abnormal blood vessel 
development and lethality in embryos lacking a single VEGF allele. Nature, 380: 
435-439. 
Carmeliet, P. and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 
407: 249-257. 
Caron, C., Spring, K., Laramée, M., Chabot, C., Cloutier, M., Gu, H. and Royal, I. (2009). 
Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated 
References 
152 
signalling, migration, and survival of endothelial cells. Cellular signalling, 21: 943-
953. 
Carter, E. J., Cosgrove, R. A., Gonzalez, I., Eisemann, J. H., Lovett, F. A., Cobb, L. J. and 
Pell, J. M. (2009). MEK5 and ERK5 are mediators of the pro-myogenic actions of 
IGF-2. J Cell Sci, 122: 3104-3112. 
Carvajal-Vergara, X., Tabera, S., Montero, J. C., Esparis-Ogando, A., Lopez-Perez, R., 
Mateo, G., Gutierrez, N., Parmo-Cabanas, M., Teixido, J., San Miguel, J. F. and 
Pandiella, A. (2005). Multifunctional role of Erk5 in multiple myeloma. Blood, 
105(11): 4492-4499. 
Cavanaugh, J. E., Ham, J., Hetman, M., Poser, S., Yan, C. and Xia, Z. (2001). Differential 
regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by 
neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci, 21(2): 434-443. 
CBS. (2014). "http://www.cbs.dtu.dk/services/NetPhosK/."   Retrieved 22nd October 
2014. 
Chang, L. and Karin, M. (2001). Mammalian MAP kinase signalling cascades. Nature, 
410(6824): 37-40. 
Chao, T. H., Hayashi, M., Tapping, R. I., Kato, Y. and Lee, J. D. (1999). MEKK3 directly 
regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 
(BMK1) signaling pathway. J Biol Chem, 274(51): 36035-36038. 
Chen, J.-H., Wang, X.-C., Kan, M. and Sato, J. D. (2001a). Effect of FGF-1 and FGF-2 on 
VEGF binding to human umbilical vein endothelial cells. Cell Biol Int, 25: 257-260. 
Chen, W. S., Xu, P.-Z., Gottlob, K., Chen, M.-L., Sokol, K., Shiyanova, T., Roninson, I., 
Weng, W., Suzuki, R., Tobe, K., Kadowaki, T. and Hay, N. (2001b). Growth 
retardation and increased apoptosis in mice with homozygous disruption of the 
akt1 gene. Genes Dev, 15: 2203-2208. 
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. and Birnbaum, M. J. (2001). Akt1/PKBalpha 
is required for normal growth but dispensible for maintenance of glucose 
homeostasis in mice. J Biol Chem, 276: 38349-38352. 
Christoffersson, G., Zang, G., Zhuang, Z. W., Vågesjö, E., Simons, M., Phillipson, M. and 
Welsh, M. (2012). Vascular adaptation to a dysfunctional endothelium as a 
consequence of Shb deficiency. Angiogenesis, 15: 469-480. 
Ciardiello, F., McGeady, M. L., Kim, N., Basolo, F., Hynes, N., Langton, B. C., Yokozaki, 
H., Saeki, T., Elliott, J. W., Masui, H. and al., e. (1990). Transforming growth 
factor-alpha expression is enhanced in human mammary epithelial cells 
transformed by an activated c-Ha-ras protooncogene but not by the c-neu 
protooncogene, and overexpression of the transforming growth factor-alpha 
complementary DNA leads to transformation. Cell Growth Diff, 1: 407-420. 
References 
153 
Clark, P. R., Jensen, T. J., Kluger, M. S., Morelock, M., Hanidu, A., Qi, Z., Tatake, R. J. 
and Pober, J. S. (2011). MEK5 is activated by shear stress, activates ERK5 and 
induces KLF4 to modulate TNF responses in human dermal microvascular 
endothelial cells. Microcirculation, 18: 102-117. 
Coffer, P. J., Jin, J. and Woodgett, J. R. (1998). Protein kinase B (c-Akt): a 
multifunctional mediator of phosphatidylinositol 3-kinase activation. The 
Biochemical journal, 335: 1-13. 
Cohen, S. and Carpenter, G. (1975). Human epidermal growth factor: isolation and 
chemical and biological properties. Proc Natl Acad Sci U S A, 72: 1317-1321. 
Cohen, S. and Elliot, G. A. (1963). The stimulation of epidermal keratinization by a protein 
isolated from the submaxillary gland of the mouse. J Invest Dermatol, 40: 1-5. 
Cohen, S. and Levi-Montalcini, R. (1957). Purification and properties of a nerve growth-
promoting factor isolated from mouse sarcoma 180. Cancer Res, 17: 15-20. 
Conway, E. M. and Carmeliet, P. (2004). The diversity of endothelial cells: a challenge for 
therapeutic angiogenesis. J Clin Invest, 84: 1470-1478. 
Coultas, L., Chawengsaksophak, K. and Rossant, J. (2005). Endothelial cells and VEGF in 
vascular development. Nature, 438: 937-945. 
Cude, K., Wang, Y., Choi, H. J., Hsuan, S. L., Zhang, H., Wang, C. Y. and Xia, Z. (2007). 
Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling 
pathway. The Journal of cell biology, 177(2): 253-264. 
Cunningham, S. A., Arrate, M. P., Brock, T. A. and Waxham, M. N. (1997). Interactions of 
FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine 
binding sites. Biochem Biophys Res Commun, 240: 635-639. 
Daar, I., Nebreda, A. R., Yew, N., Sass, P., Paules, R., Santos, E., Wigler, M. and Vande 
Woude, G. F. (1991). The ras oncoprotein and M-phase activity. Science, 253: 74-
76. 
Dance, M., Montagner, A., Yart, A., Masri, B., Audigier, Y., Perret, B., Salles, J. P. and 
Raynal, P. (2006). The adaptor protein Gab1 couples the stimulation of vascular 
endothelial growth factor receptor-2 to the activation of phophoinositide 3-kinase. 
J Biol Chem, 281: 23285-23295. 
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M. E. 
(1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic 
death machinery. Cell, 91: 231-241. 
Dawson, J. P., Berger, M. B., Lin, C. C., Schlessinger, J., Lemmon, M. A. and Ferguson, K. 
M. (2005). Epidermal growth factor receptor dimerization and activation require 




De Bock, K., Cauwenberghs, S. and Carmeliet, P. (2011). Vessel abnormalization: another 
hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin 
Genet Dev, 21: 73-79. 
Dekker, R. J., van Soest, S., Fontijn, R. D., Salamanca, S., de Groot, P. G., VanBavel, E., 
Pannekoek, H. and Horrevoets, A. J. (2002). Prolonged fluid shear stress induces a 
distinct set of endothelial cell genes, most specifically lung Krüppel-like factor 
(KLF2). Blood, 100: 1689-1698. 
Deng, X., Yang, Q., Kwiatkowski, N., Sim, T., McDermott, U., Settleman, J. E., Lee, J. D. 
and Gray, N. S. (2011). Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-
6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med Chem 
Lett, 2: 195-200. 
Dhillon, A. S., Hagan, S., Rath, O. and Kolch, W. (2007). MAP kinase signalling pathways in 
cancer. Oncogene, 26: 3279-3290. 
Di Marco, E., Pierce, J. H., Fleming, T. P., Kraus, M. H., Molloy, C. J., Aaronson, S. A. and 
Di Fiore, P. P. (1989). Autocrine interaction between TGF alpha and the EGF-
receptor: quantitative requirements for induction of the malignant phenotype. 
Oncogene, 4: 831-838. 
Diaz-Meco, M. T. and Moscat, J. (2001). MEK5, a new target of the atypical protein kinase 
C isoforms in mitogenic signaling. Mol Cell Biol, 21: 1218-1227. 
Diaz-Rodriguez, E. and Pandiella, A. (2010). Multisite phosphorylation of Erk5 in mitosis. J 
Cell Sci, 123: 3146-3156. 
Dickinson, R. J. and Keyse, S. M. (2006). Diverse physiological functions for dual-specificity 
MAP kinase phosphatases. J Cell Sci, 119(Pt 22): 4607-4615. 
Dietz, M. S., HaBe, D., Ferraris, D. M., Gohler, A., Niemann, H. H. and Heilemann, M. 
(2013). Single-molecule photobleaching reveals increased MET receptor 
dimerization upon ligand binding in intact cells. BMC Biophysics, 6(6): 
http://www.biomedcentral.com/2046-1682/2046/2046. 
Dinev, D., Jordan, B. W., Neufeld, B., Lee, J. D., Lindemann, D., Rapp, U. R. and Ludwig, 
S. (2001). Extracellular signal regulated kinase 5 (ERK5) is required for the 
differentiation of muscle cells. EMBO Rep, 2: 829-834. 
Doanes, A. M., Hegland, D. D., Sethi, R., Kovesdi, I., Bruder, J. T. and Finkel, T. (1999). 
VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine 
kinases. Biochem Biophys Res Commun, 255: 545-548. 
Domingues, I., Rino, J., Demmers, J. A. A., de Lanerolle, P. and Santos, S. C. (2011). 
VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS ONE, 6: 
e25668. 
Dong, L. Q. and Liu, F. (2005). PDK2: the missing piece in the receptor tyrosine kinase 
signaling pathway puzzle. Am J Physiol Endocrinol Metab, 289: E187-196. 
References 
155 
Dor, Y., Porat, R. and Keshet, E. (2001). Vascular endothelial growth factor and vascular 
adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol, 
280: C1367-1374. 
Duff, J. L., Monia, B. P. and Berk, B. C. (1995). Mitogen-activated Protein (MAP) Kinase Is 
Regulated by the MAP Kinase Phosphatase (MKP-1) in Vascular Smooth Muscle 
Cells. J Biol Chem, 270: 7161-7166. 
Dumont, D. J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., 
Breitman, M. L. and Alitalo, K. (1998). Cardiovascular failure in mouse embryos 
deficient in VEGFR receptor-3. Science, 282: 946-949. 
Ebner, R. and Derynck, R. (1991). Epidermal growth factor and transforming growth 
factor-alpha: differential intracellular routing and processing of ligand-receptor 
complexes. Cell Regul, 2: 599-612. 
EducationalForum. (2014). "Caring for diabetes: 
http://www.caringfordiabetes.com/impdemo/hyper_artilce.html."   Retrieved 
10th November 2014. 
Eikesdal, H. P. and Kalluri, R. (2009). Drug resistance associated with antiangiogenesis 
therapy. Semin Cancer Biol, 19: 310-317. 
English, J. M., Pearson, G., Baer, R. and Cobb, M. H. (1998). Identification of substrates 
and regulators of the mitogen-activated protein kinase ERK5 using chimeric 
protein kinases. J Biol Chem, 273(7): 3854-3860. 
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., 
Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., 
Gore, M., S., F., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R. M. 
(2007a). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356: 
125-134. 
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., 
Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., Gorbunova, V., Bay, J. O., 
Bodrogi, I., Jagiello-Gruszfeld, A. and Moore, N. (2007b). Bevacizumab plus 
interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, 
double-blind phase III trial. Lancet, 370: 2103-2111. 
Esparís-Ogando, A., Díaz-Rodríguez, E., Montero, J. C., Yuste, L., Crespo, P. and 
Pandiella, A. (2002). Erk5 participates in neuregulin signal transduction and is 
constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol, 22: 
270-285. 
Fantin, A., Vieira, J. M., Gestri, G., Denti, L., Schwarz, Q., Prykhozhij, S., Peri, F., 
Wilson, S. W. and Ruhrberg, C. (2010). Tissue macrophages act as cellular 
chaperones for vascular anastomosis downstream of VEGF-mediated endothelial 
tip cell induction. Blood, 116: 829-840. 
Favier, B., Alam, A., Barron, P., Bonnin, J., Laboudie, P., Fons, P., Mandron, M., Herault, 
J. P., Neufeld, G., Savi, P., Herbert, J. M. and Bono, F. (2006). Neuropilin-2 
References 
156 
interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival 
and migration. Blood, 108: 1243-1250. 
Fenn, J. B., Mann, M., Meng, c. K., Wong, S. F. and Whitehouse, C. M. (1989). Electrospray 
ionization for mass spectrometry of large biomolecules. Science, 246: 64-71. 
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H. S., Leahy, D. J. and Lemmon, M. 
A. (2003). EGF activates its receptor by removing interactions that autoinhibit 
ectodomain dimerization. Mol Cell, 11: 507-517. 
Ferrara, N. (2004). Vascular endothelial growth factor: basic science and clinical progress. 
Endocr Rev, 25: 581-611. 
Ferrara, N. (2009). Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol, 29: 
789-791. 
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, 
L., Hillan, K. J. and Moore, M. W. (1996). Heterozygous embryonic lethality 
induced by targeted inactivation of the VEGF gene. Nature, 380: 439-442. 
Ferrara, N. and Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. 
Endocr Rev, 18: 4-25. 
Finegan, K. G., Wang, X., Lee, E. J., Robinson, A. C. and Tournier, C. (2009). Regulation 
of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell 
death and differentiation, 16(5): 674-683. 
Fleming, Y., Armstrong, C. G., Morrice, N., Paterson, A., Goedert, M. and Cohen, P. 
(2000). Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal 
kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) 
and MKK7. The Biochemical journal, 352: 145-154. 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285: 
1182-1186. 
Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl 
Cancer Inst, 82: 4-6. 
Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat 
Med, 1: 27-31. 
Folkman, J. and Shing, Y. (1992). Angiogenesis. J Biol Chem, 267: 10931-10934. 
Fong, G. H., Rossant, J., Gertsenstein, M. and Breitman, M. L. (1995). Role of the Flt-1 
receptor tyrosine kinase in regulating the assembly of vascular endothelium. 
Nature, 376: 66-70. 
References 
157 
Fong, G. H., Zhang, L., Bryce, D. M. and Peng, J. (1999). Increased hemangioblast 
commitment, not vascular disorganization, is the primary defect in flt-1 knock-out 
mice. Development, 126: 3015-3025. 
Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D. and Lee, S. C. (2007). 
Translational up-regulation of the EGFR by tumor hypoxia provides a 
nonmutational explanation for its overexpression in human cancer. Proc Natl Acad 
Sci U S A, 104: 13092-13097. 
Fuh, G., Li, B., Crowley, C., Cunningham, B. and Wells, J. A. (1998). Requirements for 
binding and signaling of the kinase domain receptor for vascular endothelial 
growth factor. J Biol Chem, 273: 11197-11204. 
Funa, N. S., Kriz, V., Zang, G., Calounova, G., Åkerblomg, B., Mares, J., Larsson, E., Sun, 
Y., Betsholtz, C. and Welsh, M. (2009). Dysfunctional microvasculature as a 
consequnce of Shb gene inactivation causes impaired tumor growth. Cancer Res, 
69: 2141-2148. 
Gallagher, P. J. and van der Wal, A. C. (2006). Blood vessels. Philadelphia, Lippincott, 
Williams and Wilkins. 
Garlanda, C. and Dejana, E. (1997). Heterogeneity of endothelial cells: specific markers. 
Arterioscler Thromb Vasc Biol, 17: 1193-1202. 
Garrington, T. P., Ishizuka, T., Papst, P. J., Chayama, K., Webb, S., Yujiri, T., Sun, W., 
Sather, S., Russell, D. M., Gibson, S. B., Keller, G., Gelfand, E. W. and Johnson, G. 
L. (2000). MEKK2 gene disruption causes loss of cytokine production in response to 
IgE and c-Kit ligand stimulation of ES cell-derived mast cells. Embo J, 19: 5387-
5395. 
Gee, E., Milkiewicz, M. and Haas, T. L. (2010). p38 MAPK is activated by vascular 
endothelial growth factor receptor 2 and is essential for shear stress-induced 
angiogenesis. Journal of cellular physiology, 222: 120-126. 
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G. A., Rangell, L., Wright, B. 
D., Radtke, F., Aguet, M. and Ferrara, N. (1999). VEGF is required for growth and 
survival in neonatal mice. Development, 126: 1149-1159. 
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V. and Ferrara, N. 
(1998). Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival 
through the Phosphatidylinositol 3'-Kinase/Akt Signal Transduction Pathway. J Biol 
Chem, 273: 30336-30343. 
Gerhardt, H. and Betsholtz, C. (2003). Endothelial-pericyte interactions in angiogenesis. 
Cell Tissue Res, 314: 15-23. 
Girard, J. P. and Springer, t. A. (1995). High endothelial venules (HEVs): specialized 
endothelium for lymphocyte migration. Immunol Today, 16: 449-457. 
References 
158 
Gregory, H. (1975). Isolation and structure of urogastrone and its relationship to epidermal 
growth factor. Nature, 257: 325-327. 
Groothuis, P. G., Nap, A. W., Winterhager, E. and Grummer, R. (2005). Vascular 
development in endometriosis. Angiogenesis, 8: 147-156. 
Gu, C., Rodriguez, E. R., Reimert, D. V., Shu, T., Fritsch, B., Richards, L. J., Kolodkin, A. 
L. and Ginty, D. D. (2003). Neuropilin-1 conveys semaphorin and VEGF signaling 
during neural and cardiovascular development. Developmental cell, 5: 45-57. 
Guo, D., Jia, Q., Song, H.-Y., Warren, R. S. and Donner, D. B. (1995). Vascular Endothelial 
Cell Growth Factor Promotes Tyrosine Phosphorylation of Mediators of Signal 
Transduction That Contain SH2 Domains. J Biol Chem, 270: 6729-6733. 
Guo, Z., Clydesdale, G., Cheng, J., Kim, K., Gan, L., McConkey, D. J., Ullrich, S. E., 
Zhuang, Y. and Su, B. (2002). Disruption of Mekk2 in mice reveals an unexpected 
role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol, 22: 
5761-5768. 
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H. and Aebersold, R. (1999). 
Quantitative analysis of complex protein mixtures using isotope-coded affinity 
tags. Nat Biotechnol, 17: 994-999. 
Haar, J. L. and Ackerman, G. A. (1971). A phase and electron microscopic study of 
vasculogenesis and erythropoiesis in the yolk sac of the mouse. Anat Rec, 170: 
199-224. 
Haeussler, D. J., Pimentel, D. R., Hou, X., Burgoyne, J. R., Cohen, R. A. and Bachschmid, 
M. M. (2013). Endomembrane H-Ras controls vascular endothelial growth factor-
induced nitric-oxide synthase-mediated endothelial cell migration. J Biol Chem, 
288: 15380-15389. 
Hallberg, B., Rayter, S. I. and Downward, J. (1994). Interaction of Ras and Raf in intact 
mammalian cells upon extracellular stimulation. J Biol Chem, 269: 3913-3916. 
Hammond, S. M., Bernstein, E., Beach, D. and Hannon, G. J. (2000). An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature, 
404: 293-296. 
Han, J., Jiang, Y., Li, Z., Kravchenko, V. V. and Ulevitch, R. J. (1997). Activation of the 
transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature, 
386(6622): 296-299. 
Hanahan, D. and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell, 86: 353-364. 




Harper, S. J. and Bates, D. O. (2008). VEGF-A splicing: The key to anti-angiogenic 
therapeutics? Nat Rev Cancer, 8: 880-887. 
Harris, R. C., Chung, E. and Coffey, R. J. (2003). EGF receptor ligands. Experimental cell 
research, 284: 2-13. 
Hashimoto, A., Kurosaki, M., Gotoh, N., Shibuya, M. and Kurosaki, T. (1999). Shc regulates 
epidermal growth factor-induced activation of the JNK signaling pathway. J Biol 
Chem, 274: 20139-20143. 
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. 
K. and McDonald, D. M. (2000). Openings between defective endothelial cells 
explain tumor vessel leakiness. Am J Pathol, 156: 1363-1380. 
Hayashi, M., Fearns, C., Eliceiri, B., Yang, Y. and Lee, J. D. (2005). Big mitogen-activated 
protein kinase 1/Extracellular signal-regulated kinase 5 signaling pathway is 
essential for tumor-associated angiogenesis. Cancer Res, 65: 7699-7706. 
Hayashi, M., Kim, S. W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, B., Yang, 
Y., Ulevitch, R. J. and Lee, J. D. (2004). Targeted deletion of BMK1/ERK5 in adult 
mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest, 
113(8): 1138-1148. 
Hayashi, M. and Lee, J. D. (2004). Role of the BMK1/ERK5 signaling pathway: lessons from 
knockout mice. J Mol Med (Berl), 82(12): 800-808. 
Hayashi, M., Tapping, R. I., Chao, T. H., Lo, J. F., King, C. C., Yang, Y. and Lee, J. D. 
(2001). BMK1 mediates growth factor-induced cell proliferation through direct 
cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem, 
276(12): 8631-8634. 
Hayes, D. F. (2011). Bevacizumab treatment for solid tumors: boon or bust? JAMA, 305: 
506-508. 
Haystead, T. A., Dent, P., Wu, J., Haystead, C. and Sturgill, T. W. (1992). Ordered 
phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett, 305: 17-22. 
Heinke, J., Patterson, C. and Moser, M. (2012). Life is a pattern: vascular assembly within 
the embryo. Front Biosci, E4: 2269-2288. 
Hellström, M., Gerhardt, H., Kalén, M., Li, X., Eriksson, U., Wolburg, H. and Betsholtz, C. 
(2001). Lack of pericytes leads to endothelial hyperplasia and abnormal vascular 
morphogenesis. The Journal of cell biology, 153: 543-554. 
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., 
Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., Gibson, C. M., 
Bajamonde, A., Rundle, A. C., Fine, J. and McCluskey, E. R. (2003). The VIVA trial: 
Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. 
Circulation, 107: 1359-1365. 
References 
160 
Hewett, P. W. (2009). Vascular endothelial cells from human micro- and macrovessels: 
isolation, characterisation and culture. Methods Mol Biol, 467: 95-111. 
Higashiyama, S., Lau, K. E., Besner, G. A., Abraham, J. and Klagsbrun, M. (1992). 
Structure of heparin-binding EGF-like growth factor. Multiple forms, primary 
structure, and glycosylation of the mature protein. J Biol Chem, 267: 6205-6212. 
Hirakawa, T. and Ruley, H. E. (1988). Rescue of cells from ras oncogene-induced growth 
arrest by a second, complementing, oncogene. Proc Natl Acad Sci U S A, 85: 19-
23. 
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. and Shibuya, M. (1998). Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogenesis in 
mice. Proc Natl Acad Sci U S A, 95: 9349-9354. 
Hiratsuka, S., Nakao, K., Nakamura, K., Katsuki, M., Maru, Y. and Shibuya, M. (2005). 
Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding 
domain is important for vasculogenesis and angiogenesis in mice. Mol Cell Biol, 
25: 346-354. 
Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K. and Wong, A. J. 
(1996). A Grb2-associated docking protein in EGF- and insulin-receptor signalling. 
Nature, 379: 560-564. 
Holmes, K., Chapman, E., See, V. and Cross, M. J. (2010). VEGF stimulates RCAN1.4 
expression in endothelial cells via a pathway requiring Ca2+/Calcineurin and 
Protein Kinase C-d. PLoS ONE, 5: e11435. 
Holmes, K., Roberts, O. L., Thomas, A. M. and Cross, M. J. (2007). Vascular endothelial 
growth factor receptor-2: Structure, function, intracellular signalling and 
therapeutic inhibition. Cellular signalling, 19: 2003-2012. 
Holmgren, L., O'Reilly, M. S. and Folkman, J. (1995). Dormancy of micrometastases: 
balanced proliferation and apoptosis in the presence of angiogenesis suppression. 
Nat Med, 1: 149-153. 
Holmqvist, K., Cross, M. J., Rolny, C., Hagerkvist, R., Rahimi, N., Matsumoto, T., 
Claesson-Welsh, L. and Welsh, M. (2004). The adaptor protein Shb binds to 
tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and 
regulates VEGF-dependent cellular migration. J Biol Chem, 279: 22267-22275. 
Horowitz, A. and Seerappu, H. R. (2012). Regulation of VEGF signaling by membrane 
traffic. Cellular signalling, 24: 1810-1820. 
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991). The 
vascular endothelial growth factor family - identification of a fourth molecular 




Huang, J. and Manning, B. D. (2009). A complex interplay between Akt, TSC2, and the two 
mTOR complexes. Biochem Soc Trans, 37: 217-222. 
Huang, T.-L., Pian, J. P. and Pan, B.-T. (2013). Oncogenic Ras suprresses Cdk1 in a 
complex manner during the incubation of activated Xenopus egg extracts. Arch 
Biochem Biophys, 532: 10.1016/j.abb.2013.1001.1006. 
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., 
Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., 
Ross, R. and Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335-2342. 
Imoukhuede, P. I. and Popel, A. S. (2011). Quantification and cell-to-cell variation of 
vascular endothelial growth factor receptors. Experimental cell research, 317: 
955-965. 
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., 
Shalinsky, D. R., Thurston, G., Yancopoulos, G. D. and McDonald, D. M. (2004). 
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes 
loss of endothelial fenestrations, regression of tumor vessels, and appearance of 
basement membrane ghosts. Am J Pathol, 165: 35-52. 
Inesta-Vaquera, F. A., Campbell, D. G., Tournier, C., Gomez, N., Lizcano, J. M. and 
Cuenda, A. (2010). Alternative ERK5 regulation by phosphorylation during the cell 
cycle. Cellular signalling, 22(12): 1829-1837. 
Issbrucker, K., Marti, H. H., Hippenstiel, S., Springmann, G., Voswinckel, R., Gaumann, A., 
Breier, G., Drexler, H. C. A., Suttorp, N. and Clauss, M. (2003). p38 MAP kinase - a 
molecular switch between VEGF-induced angiogenesis and vascular 
hyperpermeability. Faseb J, 17: 262-264. 
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and 
Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates 
Akt phosphorylation and substrate specificity. Cell, 127: 125-137. 
Jackson, C. J. and Nguyen, M. (1997). Human microvascular endothelial cells differ from 
macrovascular endothelial cells in their expression of matrix metalloproteinases. 
Int J Biochem Cell Biol, 29: 1167-1177. 
Jain, R. K. (2003). Molecular regulation of vessel maturation. Nat Med, 9: 685-693. 
Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science, 307: 58-62. 
Ji, Q. S., Winnier, G. E., Niswender, K. D., Horstman, D., Wisdom, R., Magnuson, M. A. 
and Carpenter, G. (1997). Essential role of the tyrosine kinase substrate 
phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad 
Sci U S A, 94: 2999-3003. 
References 
162 
Jingjing, L., Xue, Y., Agarwal, N. and Roque, R. S. (1999). Human Muller cells express 
VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest 
Opthalmol Vis Sci, 40: 752-759. 
Johnson, G. L. and Vaillancourt, R. R. (1994). Sequential protein kinase reactions 
controlling cell growth and differentiation. Curr Opin Cell Biol, 6: 230-238. 
Kamakura, S., Moriguchi, T. and Nishida, E. (1999). Activation of the protein kinase 
ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a 
signaling pathway to the nucleus. J Biol Chem, 274(37): 26563-26571. 
Kappas, N. C., Zeng, G., Chappell, J. C., Kearney, J. B., Hazarika, S., Kallianos, K. G., 
Patterson, C., Annex, B. H. and Bautch, V. L. (2008). The VEGF receptor Flt-1 
spatially modulates Flk-1 signaling and blood vessel branching. The Journal of cell 
biology, 181: 847-858. 
Karas, M. and Hillenkamp, F. (1988). Laser desorption ionization of proteins with 
molecular masses exceeding 10,000 daltons. Anal Chem, 60: 2299-2301. 
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., Jeltsch, 
M., Jackson, D. G., Talikka, M., Rauvala, H., Betsholtz, C. and Alitalo, K. (2004). 
Vascular endothelial growth factor C is required for sprouting of the first 
lymphatic vessels from embryonic veins. Nat Immunol, 5: 74-80. 
Karkkainen, M. J., Makinen, T. and Alitalo, K. (2002). Lymphatic endothelium: a new 
frontier of metastasis research. Nat Cell Biol, 4: E2-E5. 
Kasler, H. G., Victoria, J., Duramad, O. and Winoto, A. (2000). ERK5 is a novel type of 
mitogen-activated protein kinase containing a transcriptional activation domain. 
Mol Cell Biol, 20(22): 8382-8389. 
Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J. and Lee, J. D. (1997). 
BMK1/ERK5 regulates serum-induced early gene expression through transcription 
factor MEF2C. Embo J, 16(23): 7054-7066. 
Kato, Y., Tapping, R. I., Huang, S., Watson, M. H., Ulevitch, R. J. and Lee, J. D. (1998). 
Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. 
Nature, 395(6703): 713-716. 
Kato, Y., Zhao, M., Morikawa, A., Sugiyama, T., Chakravortty, D., Koide, N., Yoshida, T., 
Tapping, R. I., Yang, Y., Yokochi, T. and Lee, J. D. (2000). Big mitogen-activated 
kinase regulates multiple members of the MEF2 protein family. J Biol Chem, 
275(24): 18534-18540. 
Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T. and Fujisawa, H. 
(1999). A requirement for neuropilin-1 in embryonic vessel formation. 
Development, 126: 4895-4902. 
Kazerounian, S., Yee, K. O. and Lawler, J. (2008). Thrombospondins in cancer. Cellular 
and molecular life sciences : CMLS, 65: 700-712. 
References 
163 
Kendall, R. L. and Thomas, K. A. (1993). Inhibition of vascular endothelial cell growth 
factor activity by an endogenously encoded soluble recepotr. Proc Natl Acad Sci U 
S A, 90: 10705-10709. 
Kerbel, R. S. (2006). Antiangiogenic therapy: a universal chemosensitization strategy for 
cancer? Science, 312: 1171-1175. 
Kesavan, K., Lobel-Rice, K., Sun, W., Lapadat, R., Webb, S., Johnson, G. L. and 
Garrington, T. P. (2004). MEKK2 regulates the coordinate activation of ERK5 and 
JNK in response to FGF-2 in fibroblasts. Journal of cellular physiology, 199(1): 
140-148. 
Kim, M., Kim, S., Lim, J. H., Lee, C. M., Choi, H. C. and Woo, C. H. (2012). Laminar flow 
activation of ERK5 in vascular endothelium leads to atheroprotective effect via NF-
E2-related factor2 (Nrf2) activation. J Biol Chem, 287: 40722-40731. 
Kimura, T. E., Jin, J., Zi, M., Prehar, S., Liu, W., Oceandy, D., Abe, J., Neyses, L., 
Weston, A. H., Cartwright, E. J. and Wang, X. (2010). Targeted deletion of the 
extracellular signal-regulated protein kinase 5 attenuates hypertrophic response 
and promotes pressure overload-induced apoptosis in the heart. Circulation 
research, 106(5): 961-970. 
Kinoshita, E., Kinoshita-Kikuta, E., Takiyama, K. and Koike, T. (2006). Phosphate-binding 
tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics, 5: 749-
757. 
Kitamoto, Y., Tokunaga, H. and Tomita, K. (1997). Vascular endothelial growth factor is an 
essential molecule for mouse kidney development: glomerulogenesis and 
nephrogenesis. J Clin Invest, 99: 2351-2357. 
Klagsbrun, M. and Moses, M. A. (1999). Molecular angiogenesis. Chem BIol, 6: R217-224. 
Koch, S. and Claesson-Welsh, L. (2012). Signal transduction by vascular endothelial growth 
factor receptors. Cold Spring Harb Perspect Med, 2: a006502. 
Kondoh, K., Terasawa, K., Morimoto, H. and Nishida, E. (2006). Regulation of nuclear 
translocation of extracellular signal-regulated kinase 5 by active nuclear import 
and export mechanisms. Mol Cell Biol, 26(5): 1679-1690. 
Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J. and 
Roth, R. A. (2003). Identification of a proline-rich AKT substrate as a 14-3-3 
binding partner. J Biol Chem, 278: 10189-10194. 
Ku, D. D., Zaleski, J. K., Liu, S. and Brock, T. A. (1993). Vascular endothelial gorwht 
factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol, 265: 
H586-592. 
Kumanogoh, A. and Kikutani, H. (2013). Immunological functions of the neuropilins and 
plexins as receptors for semaphorins. Nature Reviews Immunology, 13: 802-814. 
References 
164 
Kumar, S., West, D. C. and Ager, A. (1987). Heterogeneity in endothelial cells from large 
vessels and microvessels. Differentiation, 36: 57-70. 
Lafleur, M. A., Handsley, M. M. and Edwards, D. R. (2003). Metalloproteinases and their 
inhibitors in angiogenesis. Expert Rev Mol Med, 5: 1-39. 
Lamalice, L., Houle, F. and Huot, J. (2006). Phosphorylation of Tyr1214 within VEGFR-2 
triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 
activation and endothelial cell migration in response to VEGF. 
Lamark, T., Perander, M., Outzen, H., Kristiansen, K., Overvatn, A., Michaelsen, E., 
Bjorkoy, G. and Johansen, T. (2003). Interaction codes within the family of 
mammalian Phox and Bem1p domain-containing proteins. J Biol Chem, 278(36): 
34568-34581. 
Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. and Dejana, E. (2006). 
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from 
intracellular compartments. The Journal of cell biology, 174: 593-604. 
Land, H., Parada, L. F. and Weinberg, R. A. (1983). Tumorigenic conversion of primary 
embryo fibroblasts require at least two cooperating oncogenes. Nature, 304: 596-
602. 
Langlois, W. J., Sasaoka, T., Saltiel, A. R. and Olefsky, J. M. (1995). Negative feedback 
regulation and desensitization of insulin- and epidermal growth factor-stimulated 
p21ras activation. J Biol Chem, 270: 25320-25323. 
Lawler, S., Fleming, Y., Goedert, M. and Cohen, P. (1998). Synergistic activation of 
SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr BIol, 8: 1387-1390. 
Lawlor, M. A. and Alessi, D. R. (2001). PKB/Akt: a key mediator of cell proliferation, 
survival and insulin responses? J Cell Sci, 114: 2903-2910. 
Lawson, N. D., Mugford, J. W., Diamond, B. A. and Weinstein, B. M. (2003). Phospholipase 
C gamma-1 is required downstream of vascular endothelial growth factor during 
arterial development. Genes Dev, 17: 1346-1351. 
Le, N. T., Heo, K. S., Takei, Y., Lee, H., Woo, C. H., Chang, E., McClain, C., Hurley, C., 
Wang, X., Li, F., Xu, H., Morrell, C., Sullivan, M. A., Cohen, M. S., Serafimova, I. 
M., Taunton, J., Fujiwara, K. and Abe, J. (2013). A crucial role for p90RSK-
mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and 
atherosclerosis. Circulation, 127: 486-499. 
Lee, J. D., Ulevitch, R. J. and Han, J. (1995). Primary structure of BMK1: a new 
mammalian map kinase. Biochem Biophys Res Commun, 213(2): 715-724. 
Lemmon, M. A. and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. 
Cell, 141: 1117-1134. 
References 
165 
Lennartsson, J., Burovic, F., Witek, B., Jurek, A. and Heldin, C. H. (2010). Erk 5 is 
necessary for sustained PDGF-induced Akt phosphorylation and inhibition of 
apoptosis. Cellular signalling, 22: 955-960. 
Levi-Montalcini, R. and Hamburger, V. (1951). Selective growth stimulating effects of 
mouse sarcoma on the sensory and sympathetic nervous system of the chick 
embryos. J Exp Zool, 116: 321-362. 
Lewis, T. S., Shapiro, P. S. and Ahn, N. G. (1998). Signal transduction through MAP kinase 
cascades. Advances in cancer research, 74: 49-139. 
Li, G., Lucas, J. J. and Gelfand, E. W. (2005). Protein kinase C alpha, betaI, and betaII 
isozymes regulate cytokine production in mast cells through MEKK2/ERK5-
dependent and -independent pathways. Cell Immunol, 238: 10-18. 
Li, J., Zhang, Y. P. and Kirsner, R. S. (2003). Angiogeneis in wound repair: angiogenic 
growth factors and the extracellular matrix. Microsc Res Tech, 2003: 107-114. 
Li, L., Tatake, R. J., Natarajan, K., Taba, Y., Garin, G., Tai, C., Leung, E., Surapisitchat, 
J., Yoshiziumi, M., Yan, C., Abe, J. and Berk, B. C. (2008). Fluid shear stress 
inhibits TNF-mediated JNK activation via MEK5-BMK1 in endothelial cells. Biochem 
Biophys Res Commun, 370: 159-163. 
Li, T., Pan, Y.-W., Wang, W., Abel, G., Zou, J., Xu, L., Storm, D. R. and Xia, Z. (2013). 
Targeted deletion of the ERK5 MAP kinase impairs neuronal differentiation, 
migration, and survival during adult neurogenesis in the olfactory bulb. PLoS ONE, 
8: e61948. 
Liao, H. J., Kume, T., McKay, C., Xu, M. J., Ihle, J. N. and Carpenter, G. (2002). Absence 




tp://www.lifetechnologies.com/order/catalog/product/11668027."   Retrieved 
9th November 2014. 
Lin, Q., Lu, J., Yanagisawa, H., Webb, R., Lyons, G. E., Richardson, J. A. and Olson, E. N. 
(1998). Requirement of the MADS-box transcription factor MEF2C for vascular 
development. Development, 125: 4565-4574. 
Lin, Q., Schwarz, J., Bucana, C. and Olson, E. N. (1997). Control of mouse cardiac 
morphogenesis and myogenesis by transcription factor MEF2C. Science, 276: 1404-
1407. 
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. 
C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzum, S., 
Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Haussinger, D., 
Giannaris, T., Shan, M., Moscovici, M., Voliotis, D. and Bruix, J. (2008). Sorafenib 
in advanced hepatocellular carcinoma. N Engl J Med, 359: 378-390. 
References 
166 
Lochhead, P. A., Gilley, R. and Cook, S. J. (2012). ERK5 and its role in tumour 
development. Biochem Soc Trans, 40: 251-256. 
Lohela, M., Bry, M., Tammela, T. and Alitalo, K. (2009). VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol, 21: 154-164. 
Lonza. (2014). "http://www.lonza.com/products-services/bio-
research/transfection/nucleofector-technology.aspx."   Retrieved 11th November 
2014. 
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, A., Ullrich, A., 
Skolnik, E. Y., Bar-Sagi, D. and Schlessinger, J. (1992). The SH2 and SH3 domain-
containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell, 70: 
431-442. 
Lyttle, D. J., Fraser, K. M., Fleming, S. B., Mercer, A. A. and Robinson, A. J. (1994). 
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf 
virus. J Virol, 68: 84-92. 
Mancuso, M., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., 
Inai, T., Brooks, P., Freimark, B., Shalinsky, D. R., Hu-Lowe, D. D. and McDonald, 
D. M. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. 
J Clin Invest, 116: 2610-2621. 
Massague, J. (1990). Transforming growth factors-α. J Biol Chem, 265: 21393-21396. 
Matsumoto, T., Bohman, S., Dixellus, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., 
Wikner, C., Qi, J. H., Wernstedt, C., Wu, J., Bruheim, S., Mugishima, H., 
Mukhopadhyay, D., Spurkland, A. and Claesson-Welsh, L. (2005). VEGF receptor-2 
Y951 signaling and a role for the adaptor molecule TSAd in tumor angiogenesis. 
Embo J, 24: 2342-2353. 
Mattoon, D. R., Lamothe, B., Lax, I. and Schlessinger, J. (2004). The docking protein Gab1 
is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival 
pathway. BMC Biology, 2(24). 
McCracken, S. R., Ramsay, A., Heer, R., Mathers, M. E., Jenkins, B. L., Edwards, J., 
Robson, C. N., Marquez, R., Cohen, P. and Leung, H. Y. (2008). Aberrant 
expression of extracellular signal-regulated kinase 5 in human prostate cancer. 
Oncogene, 27: 2978-2988. 
McGeachie, J. (2014). "Vascular system: 
http://www.lab.anhb.uwa.edu.au/mb140/corepages/vascular/vascular.htm."   
Retrieved 10th November 2014. 
Meadows, K. N., Bryant, P. and Pumiglia, K. (2001). Vascular endothelial growth factor 




Meadows, K. N., Bryant, P., Vincent, P. A. and Pumiglia, K. M. (2004). Activated Ras 
induces a proangiogenic phenotype in primary endothelial cells. Oncogene, 23: 
192-200. 
Mehta, P. B., Jenkins, B. I., McCarthy, L., Thilak, L., Robson, C. N., Neal, D. E. and Leung, 
H. Y. (2003). MEK5 overexpression is associated with metastatic prostate cancer, 
and stimulates proliferation, MMP-9 expression and invasion. Oncogene, 22: 1381-
1389. 
Miquerol, L., Langille, B. L. and Nagy, A. (2000). Embryonic development is disrupted by 
modest increases in vascular endothelial growth factor gene expression. 
Development, 127(18): 3941-3946. 
Miyasaka, M. and Tanaka, T. (2004). Lymphocyte trafficking across high endothelial 
venules: dogmas and enigmas. Nat Rev Immunol, 4: 360-370. 
Mody, N., Campbell, D. G., Morrice, N., Peggie, M. and Cohen, P. (2003). An analysis of 
the phosphorylation and activation of extracellular-signal-regulated protein kinase 
5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. The 
Biochemical journal, 372(Pt 2): 567-575. 
Mohammadi, M., Honegger, A. M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C. A., 
Jaye, M., Rubinstein, M. and Schlessinger, J. (1991). A tyrosine-phosphorylated 
carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding 
site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol, 11: 5068-
5078. 
Montero, J. C., Ocaña, A., Abad, M., Ortiz-Ruiz, M. J., Pandiella, A. and Esparís-Ogando, 
A. (2009). Expression of Erk5 in early stage breast cancer and association with 
disease free survival identifies this kinase as a potential therapeutic target. PLoS 
ONE, 4: e5565. 
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K. and McDonald, D. M. (2002). 
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am 
J Pathol, 160: 985-1000. 
Morimoto, H., Kondoh, K., Nishimoto, S., Terasawa, K. and Nishida, E. (2007). Activation 
of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. 
J Biol Chem, 282(49): 35449-35456. 
Morrison, D. K. and Davis, R. J. (2003). Regulation of MAP kinase signaling modules by 
scaffold proteins in mammals. Annual review of cell and developmental biology, 
19: 91-118. 
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., 
Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. 
M. and Figlin, R. A. (2007). Sunitinib versus interferon alfa in metastatic renal-cell 
carcinoma. N Engl J Med, 356(115-124). 
Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C. and de Vos, A. M. 
(1997). Vascular endothelial growth factor: crystal structure and functional 
References 
168 
mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A, 94: 
7192-7197. 
Mulloy, R., Salinas, S., Philips, A. and Hipskind, R. A. (2003). Activation of cyclin D1 
expression by the ERK5 cascade. Oncogene, 22(35): 5387-5398. 
Muthukkaruppan, V. R., Kubai, L. and Auerbach, R. (1982). Tumor-induced 
neovascularization in the mouse eye. J Natl Cancer Inst, 69: 699-708. 
Nakagami, H., Morishita, R., Yamamoto, K., Taniyama, Y., Aoki, M., Matsumoto, K., 
Nakamura, T., Kaneda, Y., Horiuchi, M. and Ogihara, T. (2001). Mitogenic and 
antiapoptotic action of hepatocyte growth factor through ERK, STAT3 and Akt in 
endothelial cells. Hypertension, 37(581-586). 
Nakamura, K. and Johnson, G. L. (2003). PB1 domains of MEKK2 and MEKK3 interact with 
the MEK5 PB1 domain for activation of the ERK5 pathway. J Biol Chem, 278(39): 
36989-36992. 
Nakamura, K., Uhlik, M. T., Johnson, N. L., Hahn, K. M. and Johnson, G. L. (2006). PB1 
domain-dependent signaling complex is required for extracellular signal-regulated 
kinase 5 activation. Mol Cell Biol, 26: 2065-2079. 
NCBI. (2014). "http://www.ncbi.nlm.nih.gov/gene/5598 MAPK7 mitogen-activated protein 
kinase 7 [Homo sapiens (human)] - Gene ID: 5598."   Retrieved 15th June 2014. 
NEB®. (2013). "https://www.neb.com/products/m2558-transpass-huvec-transfection-
reagent."   Retrieved 9th November 2014. 
Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O. and Herzog, Y. (2002). The 
neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon 
guidance and angiogenesis. Trends Cardiovasc Med, 12: 13-19. 
Nishibe, S., Wahl, M. I., Hernández-Sotomayor, S. M., Tonks, N. K., Rhee, S. G. and 
Carpenter, G. (1990). Increase of the catalytic activity of phospholipase C-gamma 
1 by tyrosine phosphorylation. Science, 250: 1253-1256. 
Nishida, E. and Gotoh, Y. (1993). The MAP kinase cascade is essential for diverse signal 
transduction pathways. Trends Biochem Sci, 18(4): 128-131. 
Nishida, N., Yano, H., Nishida, T., Kamura, T. and Kojiro, M. (2006). Angiogenesis in 
Cancer. Vasc Health Risk Manag, 2: 213-219. 
Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E. P., Muller, J. and Cross, M. J. 
(2012). ERK5: Structure, regulation and function. Cellular signalling, 24: 2187-
2196. 
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R. and Salomon, D. S. (2003). Target-
based agents against ErbB receptors and their ligands: a novel approach to cancer 
treatment. Endocr Relat Cancer, 10: 1-21. 
References 
169 
Normanno, N., Bianco, C., De Luca, A. and Salomon, D. S. (2001). The role of EGF-related 
peptides in tumor growth. Front Biosci, 6: d685-d707. 
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., 
Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D. S. (2006). Epidermal 
growth factor receptor (EGFR) signaling in cancer. Gene, 366: 2-16. 
Obara, Y., Yamauchi, A., Takehara, S., Nemoto, W., Takahashi, M., Stork, P. J. and 
Nakahata, N. (2009). ERK5 activity is required for nerve growth factor-induced 
neurite outgrowth and stabilization of tyrosine hydroxylase in PC12 cells. J Biol 
Chem, 284: 23564-23573. 
Ohnesorge, N., Viemann, D., Schmidt, N., Czymai, T., Spiering, D., Schmolke, M., Ludwig, 
S., Roth, J., Goebeler, M. and Schmidt, M. (2010). Erk5 activation elicits a 
vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). 
J Biol Chem, 285: 26199-26210. 
Okano, Y., Mizuno, K., Osada, S., Nakamura, T. and Nozawa, Y. (1993). Tyrosine 
phosphorylation of phospholipase C gamma in c-met/HGF receptor-stimulated 
hepatocytes: comparison with HepG2 hepatocarcinoma cells. Biochem Biophys Res 
Commun, 190: 842-848. 
Olson, E. N. (2004). Undermining the endothelium by ablation of MAPK-MEF2 signaling. J 
Clin Invest, 113: 1110-1112. 
Olsson, A. K., Dimberg, A., Kreuger, L. and Claesson-Welsh, L. (2006). VEGF receptor 
signalling - in control of vascular function. Nat Rev Mol Cell Biol, 7: 359-371. 
Omerovic, J., Clague, M. J. and Prior, I. A. (2010). Phosphatome profiling reveals PTPN2, 
PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-
mutated cancer cells. The Biochemical journal, 426: 65-72. 
Omerovic, J., Hammond, D. E., Clague, M. J. and Prior, I. A. (2008). Ras isoform 
abundance and signalling in human cancer cell lines. Oncogene, 27: 2754-2762. 
Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A. and 
Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a 
simple and accurate approach to expression proteomics. Mol Cell Proteomics, 1: 
376-386. 
Ornatsky, O. I., Cox, D. M., Tangirala, P., Andreucci, J. J., Quinn, Z. A., Wrana, J. L., 
Prywes, R., Yu, Y. T. and McDermott, J. C. (1999). Post-translational control of 
the MEF2A transcriptional regulatory protein. Nucleic Acids Res, 27(13): 2646-
2654. 
Pankov, R., Cukierman, E., Clark, K., Matsumoto, K., Hahn, C., Poulin, B. and Yamada, K. 
M. (2003). Specific beta1 integrin site selectively regulates Akt/protein kinase B 




Park, D. J., Freitas, T. A., Wallick, C. J., Guyette, C. V. and Warn-Cramer, B. J. (2006). 
Molecular dyamics and in vitro analysis of Connexin43: a new 14-3-3 mode-1 
interacting protein. Protein Sci, 15: 2344-2355. 
Park, D. J., Wallick, C. J., Martyn, K. D., Lau, A. F., Jin, C. and Warn-Cramer, B. J. 
(2007). Akt phosphorylates Connexin43 on Ser373, a "mode-1" binding site for 14-3-
3. Cell Commun Adhes, 14: 211-226. 
Park, J. E., Keller, G. A. and Ferrara, N. (1993). Vascular endothelial growth factor (VEGF) 
isoforms - differential deposition into the subepithelial extracellular matrix and 
bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell, 4: 1317-1326. 
Parker, M. W., Xu, P., Li, X. and Vander Kooi, C. W. (2012). Structural basis for selective 
vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol 
Chem, 287(14): 11082-11089. 
Parmar, K. M., Larman, H. B., Dai, G., Zhang, Y., Wang, E. T., Moorthy, S. N., Kratz, J. R., 
Lin, Z., Jain, M. K., Gimbrone Jr, M. A. and Garcia-Cardena, G. (2006). Integration 
of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest, 
116: 49-58. 
Pearson, J. D. (2000). Normal endothelial cell function. Lupus, 9: 183-188. 
Pi, X., Garin, G., Xie, L., Zheng, Q., Wei, H., Abe, J., Yan, C. and Berk, B. C. (2005). 
BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible 
factor 1alpha. Circulation research, 96(11): 1145-1151. 
Plate, K. H., Breier, G., Millauer, B., Ullrich, A. and Risau, W. (1993). Up-regulation of 
vascular endothelial growth factor and its cognate receptors in a rat glioma model 
of tumor angiogenesis. Cancer Res, 53: 5822-5827. 
Plotnikov, A., Zehorai, E., Procaccia, S. and Seger, R. (2011). The MAPK cascades: 
Signaling components, nuclear roles and mechanisms of nuclear translocation. 
Biochim Biophys Acta, 1813: 1619-1633. 
Poltorak, Z., Cohen, T., Sivan, R., Kandelis, Y., Spira, G., Vlodavsky, I., Keshet, E. and 
Neufeld, G. (1997). VEGF145: a secreted VEGF form that binds to extracellular 
matrix. J Biol Chem, 72: 7151-7158. 
Pötgens, A. J. G., Lubsen, N. H., van Altena, M. C., Vermeulen, R., Bakker, A., 
Schoenmakers, J. G. G., Ruiter, D. J. and de Waal, R. M. W. (1994). Covalent 
dimerization of vascular permeability factor/vascular endothelial growth factor is 
essential for its biological activity. J Biol Chem, 269: 32879-32885. 
Prior, I., Lewis, P. D. and Mattos, C. (2012). A comprehensive survey of Ras mutations in 
cancer. Cancer Research, 72: 2457-2467. 
Qi, M. and Elion, E. A. (2005). MAP kinase pathways. J Cell Sci, 118(Pt 16): 3569-3572. 
References 
171 
Raman, M., Chen, W. and Cobb, M. H. (2007). Differential regulation and properties of 
MAPKs. Oncogene, 26(22): 3100-3112. 
Ramos-Nino, M. E., Blumen, S. R., Sabo-Attwood, T., Pass, H., Carbone, M., Testa, J. R., 
Altomare, D. A. and Mossman, B. T. (2008). HGF mediates cell proliferation of 
human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. American Journal 
of Respiratory Cell and Molecular Biology, 38: 209-217. 
Ramsay, A. K., McCracken, S. R., Soofi, M., Fleming, J., Yu, A. X., Ahmad, I., Morland, R., 
Machesky, L., Nixon, C., Edwards, D. R., Nuttall, R. K., Seywright, M., Marquez, 
R., Keller, E. and Leung, H. Y. (2011). ERK5 signalling in prostate cancer promotes 
an invasive phenotype. Br J Cancer, 104: 664-672. 
Randi, A. M., Sperone, A., Dryden, N. H. and Birdsey, G. M. (2009). Regulation of 
angiogenesis by ETS transcription factors. Biochem Soc Trans, 37: 1248-1253. 
Raviv, Z., Kalie, E. and Seger, R. (2004). MEK5 and ERK5 are localized in the nuclei of 
resting as well as stimulated cells, while MEKK2 translocates from the cytosol to 
the nucleus upon stimulation. J Cell Sci, 117(Pt 9): 1773-1784. 
Razmara, M., Eger, G., Rorsman, C., Heldin, C. H. and Lennartsson, J. (2012). MKP3 
negatively modulates PDGF-induced Akt and Erk5 phosphorylation as well as 
chemotaxis. Cellular signalling, 24: 635-640. 
Razumovskaya, E., Sun, J. and Rönnstrand, L. (2011). Inhibition of MEK5 by BIX02188 
induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. Biochem 
Biophys Res Commun, 412: 307-312. 
Regan, C. P., Li, W., Boucher, D. M., Spatz, S., Su, M. S. and Kuida, K. (2002). Erk5 null 
mice display multiple extraembryonic vascular and embryonic cardiovascular 
defects. Proc Natl Acad Sci U S A, 99(14): 9248-9253. 
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, 
M. D., Gorbunova, V., Gore, M. E., Rusakov, I. G., Negrier, S., Ou, Y. C., 
Castellano, D., Lim, H. Y., Uemura, H., Tarazi, J., Cella, D., Chen, C., Rosbrook, 
B., Kim, S. and Motzer, R. J. (2011). Comparative effectiveness of axitinib versus 
sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. 
Lancet, 378: 1931-1939. 
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. 
N., Picus, J., Czaykowski, P., Dutcher, J. and Small, E. J. (2010). Phase III trial of 
bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients 
with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 
28: 2137-2143. 
Risau, W. (1997). Mechanisms of angiogenesis. Nature, 386: 671-674. 
Risau, W. and Flamme, I. (1995). Vasculogenesis. Annual review of cell and developmental 
biology, 11: 73-91. 
References 
172 
Roberts, D. M., Kearney, J. B., Johnson, J. H., Rosenberg, M. P., Kumar, R. and Bautch, V. 
L. (2004). The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) 
modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol, 
164: 1531-1535. 
Roberts, O. L., Holmes, K., Muller, J., Cross, D. A. and Cross, M. J. (2009). ERK5 and the 
regulation of endothelial cell function. Biochem Soc Trans, 37(Pt 6): 1254-1259. 
Roberts, O. L., Holmes, K., Muller, J., Cross, D. A. and Cross, M. J. (2010). ERK5 is 
required for VEGF-mediated survival and tubular morphogenesis of primary human 
microvascular endothelial cells. J Cell Sci, 123: 3189-3200. 
Robinson, M. J. and Cobb, M. H. (1997). Mitogen-activated protein kinase pathways. Curr 
Opin Cell Biol, 9(2): 180-186. 
Rosenthal, A., Lindquist, P. B., Bringman, T. S., Goeddel, D. V. and Derynck, R. (1986). 
Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA 
results in transformation. Cell, 46: 301-309. 
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., 
Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S., Juhasz, P., Martin, 
S., Bartlet-Jones, M., He, F., Jacobson, A. and Pappin, D. J. (2004). Multiplexed 
protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric 
tagging reagents. Mol Cell Proteomics, 3: 1154-1169. 
Rossant, J. and Howard, L. (2002). Signaling pathways in vascular development. Annual 
review of cell and developmental biology, 18: 541-573. 
Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. and Ballmer-Hofer, K. (2007). Structure 
of a VEGF-VEGF receptor complex determined by electon microscopy. Nat Struct 
Mol Biol, 14: 249-250. 
Russell, W. C. (2000). Update on Adenovirus and its Vectors. J Gen Virol, 81: 2573-2604. 
Sakaguchi, K., Okabayashi, Y., Kido, Y., Kimura, S., Matsumura, Y., Inushima, K. and 
Kasuga, M. (1998). Shc phosphotyrosine-binding domain dominantly interacts with 
epidermal growth factor receptors and mediates Ras activation in intact cells. Mol 
Endocrinol, 12: 536-543. 
Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. and Shibuya, M. (2005). Essential role 
of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc 
Natl Acad Sci U S A, 102: 1076-1081. 
Salmena, L., Carracedo, A. and Pandolfi, P. P. (2008). Tenets of PTEN tumor suppression. 
Cell, 133(403-414). 
Salomon, D. S., Brandt, R., Ciardiello, F. and Normanno, N. (1995). Epidermal growth 
factor-related peptides and their receptors in human malignancies. Crit Rev Oncol 
Hematol, 19: 183-232. 
References 
173 
Santos, S. C., Miguel, C., Domingues, I., Calado, A., Zhu, Z., Wu, Y. and Dias, S. (2007). 
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during 
wound healing. Experimental cell research, 313: 1561-1574. 
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., 
Markhard, A. L. and Sabatini, D. M. (2006). Prolonged rapamycin treatment 
inhibits mTORC2 assembly and Akt/PKB. Mol Cell, 22: 159-168. 
Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005). Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science, 307: 1098-1101. 
Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B. and Olefsky, J. M. (1994). The 
signaling pathway coupling epidermal growth factor receptors to activation of 
p21ras. J Biol Chem, 269: 32621-32625. 
Sawhney, R. S., Liu, W. and Brattain, M. G. (2009). A novel role of ERK5 in integrin-
mediated cell adhesion and motility in cancer cells via Fak signaling. Journal of 
cellular physiology, 219(1): 152-161. 
Schmidt, A., Kellermann, J. and Lottspeich, F. (2005). A novel strategy for quantitative 
proteomics using isotop-coded protein labels. Proteomics, 5: 4-15. 
Schramp, M., Ying, O., Kim, T. Y. and Martin, G. S. (2008). ERK5 promotes Src-induced 
podosome formation by limiting Rho activation. The Journal of cell biology, 181: 
1195-1210. 
Schreiber, A. B., Winkler, M. E. and Derynck, R. (1986). Transforming Growth Factor-
alpha: A More Potent Angiogenic Mediator Than Epidermal Growth Factor. Science. 
232: 1250-1253. 
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C. and St Croix, B. (2007). 
Genes that distinguish physiological and pathological angiogenesis. Cancer Cell, 
11: 539-554. 
Semenza, G. L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE, 2007: cm8. 
SenBanerjee, S., Lin, Z., Atkins, G. B., Greif, D. M., Rao, R. M., Kumar, A., Feinberg, M. 
W., Chen, Z., Simon, D. I., Luscinskas, F. W., Michel, T. M., Gimbrone Jr, M. A., 
Garcia-Cardena, G. and Jain, M. K. (2004). KLF2 Is a novel transcriptional 
regulator of endothelial proinflammatory activation. J Exp Med, 199: 1305-1315. 
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. 
(1983). Tumor cells secrete a vascular permeability factor that promotes 
accumulation of ascites fluid. Science, 219: 983-985. 
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L. 
and Schuh, A. C. (1995). Failure of blood-island formation and vasculaogenesis in 
Flk-1 deficient mice. Nature, 376: 62-66. 
References 
174 
Shankar, V., Ciardiello, F., Kim, N., Derynck, R., Liscia, D. S., Merlo, G., Langton, B. C., 
Sheer, D., Callahan, R., Bassin, R. H. and et al. (1989). Transformation of an 
established mouse mammary epithelial cell line following transfection with a 
human transforming growth factor alpha cDNA. Mol Carcinog, 2: 1-11. 
Sharma, G. and Goalstone, M. L. (2005). Dominant negative FTase (DNFTα) inhibits ERK5, 
MEF2C and CREB activation in adipogenesis. Mol Cell Endocrinol, 245: 93-104. 
Sharp, P. A. (2001). RNA interference--2001. Genes Dev, 15: 485-490. 
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H. and Sato, M. 
(1990). Nucleotide sequence and expression of a novel human receptor-type 
tyrosine kinase gene (flt) closely related to the fms family. Oncogene, 5: 519-524. 
Shinkai, A., Ito, M., Anazawa, H., Yamaguchi, S., Shitara, K. and Shibuya, M. (1998). 
Mapping of the sites involved in ligand association and dissociation at the 
extracellular domain of the kinase insert domain-containing receptor for vascular 
endothelial growth factor. J Biol Chem, 273: 31283-31288. 
Shoyab, M., McDonald, V. L., Bradley, J. G. and Todaro, G. J. (1988). Amphiregulin: a 
bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 
13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad 
Sci U S A, 85: 6528-6532. 
Shu, X., Wu, W., Mosteller, R. D. and Broek, D. (2002). Sphingosine kinase mediates 
vascular endothelial growth factor-induced activation of ras and mitogen-activated 
protein kinases. Mol Cell Biol, 22: 7758-7768. 
Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992). Vascular endothelial growth factor 
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359: 843-
845. 
Slater, S. C., Ramnath, R. D., Uttridge, K., Saleem, M. A., Cahill, P. A., Mathieson, P. W., 
Welsh, G. I. and Satchell, S. C. (2012). Chronic exposure to laminar shear stress 
induces Kruppel-like factor 2 in glomerular endothelial cells and modulates 
interactions with co-cultured podocytes. Int J Biochem Cell Biol, 44: 1482-1490. 
Sohn, S. J., Sarvis, B. K., Cado, D. and Winoto, A. (2002). ERK5 MAPK regulates embryonic 
angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial 
growth factor expression. J Biol Chem, 277(45): 43344-43351. 
Soker, S., Miao, H. Q., Nomi, M., Takashima, S. and Klagsbrun, M. (2002). VEGF165 
mediates formation of complexes containing VEGFR-2 and neuropilin-1 that 
enhance VEGF165-receptor binding. 2002, J Cell Biochem(85). 
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. and Klagsbrun, M. (1998). Neuropilin-1 
is expressed by endothelial and tumour cells as an isoform-specific receptor for 
vascular endothelial growth factor. Cell, 92(735-745). 
References 
175 
Soltau, J. and Drevs, J. (2009). Mode of action and clinical impact of VEGF signaling 
inhibitors. Expert Rev Anticancer Ther, 9: 649-662. 
Sonpavde, G. and Hutson, T. E. (2007). Pazopanib: a novel multitargeted tyrosine kinase 
inhibitor. Curr Oncol Rep, 9: 115-119. 
Spiering, D., Schmolke, M., Ohnesorge, N., Schmidt, M., Goebeler, M., Wegener, J., 
Wixler, V. and Ludwig, S. (2009). MEK5/ERK5 signaling modulates endothelial cell 
migration and focal contact turnover. J Biol Chem, 284: 24972-24980. 
Srivastava, D. and Olson, E. N. (2000). A genetic blueprint for cardiac development. 
Nature, 407: 221-226. 
Starkey, R. H., Cohen, S. and Orth, D. N. (1975). Epidermal growth factor: identification 
of a new hormone in human urine. Science, 189: 800-802. 
Stavri, G. T., Zachary, I. C., Baskerville, P. A., Martin, J. F. and Erusalimsky, J. D. (1995). 
Basic fibroblast growth factor upregulates the expression of vascular endothelial 
growth factor in vascular smooth muscle cells. Synergistic interaction with 
hypoxia. Circulation, 92: 11-14. 
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. 
H., Salman, P., Gladkov, O. A., Kavina, A., Zarbá, J. J., Chen, M., McCann, L., 
Pandite, L., Roychowdhury, D. F. and Hawkins, R. E. (2010). Pazopanib in locally 
advanced or metastatic renal cell carcinoma: results of a randomized phase III 
trial. J Clin Oncol, 28: 1061-1068. 
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., 
Holmes, A. B., McCormick, F. and Hawkins, P. T. (1997). Dual role of 
phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. 
Science, 277: 567-570. 
Stover, D. R., Becker, M., Liebetanz, J. and Lydon, N. B. (1995). Src phosphorylation of 
the epidermal growth factor receptor at novel sites mediates receptor interaction 
with Src and P85 alpha. J Biol Chem, 270: 15591-15597. 
Strachan, L., Murison, J. G., Prestidge, R. L., Sleeman, M. A., Watson, J. D. and Kumble, 
K. D. (2001). Cloning and biological activity of epigen, a novel member of the 
epidermal growth factor superfamily. J Biol Chem, 276: 18265-18271. 
Sun, W., Kesavan, K., Schaefer, B. C., Garrington, T. P., Ware, M., Johnson, N. L., 
Gelfand, E. W. and Johnson, G. L. (2001). MEKK2 associates with the adapter 
protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J Biol Chem, 
276(7): 5093-5100. 
Sun, W., Wei, X., Kesavan, K., Garrington, T. P., Fan, R., Mei, J., Anderson, S. M., 
Gelfand, E. W. and Johnson, G. L. (2003). MEK kinase 2 and the adaptor protein 
Lad regulate extracellular signal-regulated kinase 5 activation by epidermal 
growth factor via Src. Mol Cell Biol, 23(7): 2298-2308. 
References 
176 
Suzuki, A., Hamada, K., Sasaki, T., Mak, T. W. and Nakano, T. (2007). Role of PTEN/PI3K 
pathway in endothelial cells. Biochem Soc Trans, 35: 172-176. 
Takahashi, H., Ueno, H. and Shibuya, M. (1999). VEGF activates protein kinase C-
dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in 
primary endothelial cells. Oncogene, 18: 2221-2230. 
Takahashi, T. and Shibuya, M. (1997). The 230 kDa mature form of KDR/Flk-1 (VEGF 
receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals 
in NIH3T3 fibroblasts. Oncogene, 14: 2079-2089. 
Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001). A single 
autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent 
activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J, 
20: 2768-2778. 
Takeishi, Y., Abe, J., Lee, J. D., Kawakatsu, H., Walsh, R. A. and Berk, B. C. (1999). 
Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated 
protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused guinea 
pig hearts. Circulation research, 85(12): 1164-1172. 
Tam, J. P., Marquardt, H., Rosberger, D. F., Wong, T. W. and Todaro, G. J. (1984). 
Synthesis of biologically active rat transforming growth factor I. Nature, 309: 376-
378. 
Tan, W. H., Popel, A. S. and Mac Gabhann, F. (2013). Computational model of Gab1/2-
dependent VEGFR2 pathway to Akt activation. PLoS ONE, 8: e67438. 
Tanoue, T. and Nishida, E. (2002). Docking interactions in the mitogen-activated protein 
kinase cascades. Pharmacology & therapeutics, 93(2-3): 193-202. 
Tanoue, T. and Nishida, E. (2003). Molecular recognitions in the MAP kinase cascades. 
Cellular signalling, 15(5): 455-462. 
Tatake, R. J., O'Neill, M. M., Kennedy, C. A., Wayne, A. L., Jakes, S., Wu, D., Kugler Jr, S. 
Z., Kashem, M. A., Kaplita, P. and Snow, R. J. (2008). Identification of 
pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res 
Commun, 377: 120-125. 
Terasawa, K., Okazaki, K. and Nishida, E. (2003). Regulation of c-Fos and Fra-1 by the 
MEK5-ERK5 pathway. Genes to cells : devoted to molecular & cellular 
mechanisms, 8(3): 263-273. 
Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L. and Shows, T. B. 
(1991). Identification of a new endothelial cell growth factor receptor tyrosine 
kinase. Oncogene, 6: 1677-1683. 
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C. and 
Abraham, J. A. (1991). The human gene for vascular endothelial growth factor. 
References 
177 
Multiple protein forms are encoded through alternative exon splicing. J Biol Chem, 
266: 11947-11954. 
Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T. and 
Hanada, K. (1995). Epiregulin. A novel epidermal growth factor with mitogenic 
activity for rat primary hepatocytes. J Biol Chem, 270: 7495-7500. 
Traub, O. and Berk, B. C. (1998). Laminar shear stress: mechanisms by which endothelial 
cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol, 18: 677-
685. 
Ushio-Fukai, M. and Nakamura, Y. (2008). Reactive oxygen species and angiogenesis: 
NADPH oxidase as target for cancer therapy. Cancer Lett, 266: 37-52. 
Vailhe, B., Vittet, D. and Feige, J.-J. (2001). In vitro models of vasculogenesis and 
angiogenesis. Lab Invest, 81: 439-452. 
van Belle, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R. and Isner, J. 
M. (1998). Potentiated angiogeneic effect of scatter factor/hepatocyte growth 
factor via induction of vascular endothelial growth factor. Circulation, 97: 381-
390. 
van Drogen, F. and Peter, M. (2002). MAP kinase cascades: scaffolding signal specificity. 
Curr Biol, 12(2): R53-55. 
van Hinsbergh, V. W. M., Engelse, M. A. and Quax, P. H. (2006). Pericellular proteases in 
angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol, 26(716-728). 
Wang, X., McCullough, K. D., Franke, T. F. and Holbrook, N. J. (2000). Epidermal growth 
factor receptor-dependent Akt activation by oxidative stress enhances cell 
survival. J Biol Chem, 275: 14626-14631. 
Wang, X., Merritt, A. J., Seyfried, J., Guo, C., Papadakis, E. S., Finegan, K. G., Kayahara, 
M., Dixon, J., Boot-Handford, R. P., Cartwright, E. J., Mayer, U. and Tournier, C. 
(2005). Targeted deletion of Mek5 causes early embryonic death and defects in the 
extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival 
pathway. Mol Cell Biol, 25(1): 336-345. 
Wang, X. and Tournier, C. (2006). Regulation of cellular functions by the ERK5 signalling 
pathway. Cellular signalling, 18(6): 753-760. 
Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. and Prigent, S. A. (2000). The 
Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-
growth-factor receptor KDR in transfected cells. Biochemical Journal, 347: 501-
509. 
Watanabe, S., Lazar, E. and Sporn, M. B. (1987). Transformation of normal rat kidney 
(NRK) cells by an infectious retrovirus carrying a synthetic rat type alpha 
transforming growth factor gene. Proc Natl Acad Sci U S A, 84: 1258-1262. 
References 
178 
Watson, F. L., Heerssen, H. M., Bhattacharyya, A., Klesse, L., Lin, M. Z. and Segal, R. A. 
(2001). Neurotrophins use the Erk5 pathway to mediate a retrograde survival 
response. Nature neuroscience, 4(10): 981-988. 
Weis, S. M. and Cheresh, D. A. (2011). Tumor angiogenesis: molecular pathways and 
therapeutic targets. Nat Med, 17: 1359-1370. 
Wellner, M., Maasch, C., Kupprion, C., Lindschau, C., Luft, F. C. and Haller, H. (1999). 
The proliferative effect of vascular endothelial growth factor requires protein 
kinase C-alpha and protein kinase C-zeta. Arterioscler Thromb Vasc Biol, 19: 178-
185. 
Whitaker, G. B., Limberg, B. J. and Rosenbaum, J. S. (2001). Vascular endothelial growth 
factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for 
the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem, 276: 
25520-25531. 
Whitmarsh, A. J. and Davis, R. J. (1998). Structural organization of MAP-kinase signaling 
modules by scaffold proteins in yeast and mammals. Trends Biochem Sci, 23(12): 
481-485. 
Widmann, C., Gibson, S., Jarpe, M. B. and Johnson, G. L. (1999). Mitogen-activated 
protein kinase: conservation of a three-kinase module from yeast to human. 
Physiol Rev, 79(1): 143-180. 
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M. and Lynch, M. (2008). 
Preclinical overview of sorafenib, a multikinase inhibitor that target both Raf and 
VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 7: 3129-3140. 
Woo, C. H., Shishido, T., McClain, C., Lim, J. H., Li, J. D., Yang, J., Yan, C. and Abe, J. 
(2008). Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear 
stress-induced antiinflammatory response and endothelial nitric oxide synthase 
expression in endothelial cells. Circulation research, 102(5): 538-545. 
Wu, L. W., Mayo, L. D., Dunbar, J. D., Kessler, K. M., Baerwald, M. R., Jaffe, E. A., Wang, 
D., Warren, R. S. and Donner, D. B. (2000a). Utilization of distinct signaling 
pathways by receptors for vascular endothelial cell growth factor and other 
mitogens in the induction of endothelial cell proliferation. J Biol Chem, 275: 
5096-5103. 
Wu, L. W., Mayo, L. D., Dunbar, J. D., Kessler, K. M., Ozes, O. N., Warren, R. S. and 
Donner, D. B. (2000b). VRAP is an adaptor protein that binds KDR, a receptor for 
vascular endothelial cell growth factor. J Biol Chem, 275: 6059-6062. 
Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., 
Newsome, W. P., Jirousek, M. R. and King, G. L. (1996). Characterization of 
vascular endothelial growth factor's effect on the activation of protein kinase C, 
its isoforms, and endothelial cell growth. J Clin Invest, 98: 2018-2026. 
Xin, X., Yang, S. H., Ingle, G., Ziot, C., Rangell, L., Kowalski, J., Schwall, R., Ferrara, N. 
and Gerritsen, M. E. (2001). Hepatocyte growth factor enhances vascular 
References 
179 
endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol, 
158: 1111-1120. 
Yamazaki, Y., Takani, K., Atoda, H. and Morita, T. (2003). Snake venom vascular 
endothelial growth factors (VEGFs) exhibit potent activity through their specific 
recognition of KDR (VEGF receptor 2). J Biol Chem, 278: 51985-51988. 
Yan, C., Luo, H., Lee, J. D., Abe, J. and Berk, B. C. (2001). Molecular cloning of mouse 
ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol 
Chem, 276(14): 10870-10878. 
Yan, C., Takahashi, M., Okuda, M., Lee, J. D. and Berk, B. C. (1999). Fluid shear stress 
stimulates big mitogen-activated protein kinase 1 (BMK1) activity in endothelial 
cells. Dependence on tyrosine kinases and intracellular calcium. J Biol Chem, 
274(1): 143-150. 
Yan, L., Carr, J., Ashby, P. R., Murry-Tait, V., Thompson, C. and Arthur, J. S. (2003). 
Knockout of ERK5 causes multiple defects in placental and embryonic 
development. BMC developmental biology, 3: 11. 
Yang, C. C., Ornatsky, O. I., McDermott, J. C., Cruz, T. F. and Prody, C. A. (1998). 
Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein 
kinase, ERK5/BMK1. Nucleic Acids Res, 26(20): 4771-4777. 
Yang, J., Boerm, M., McCarty, M., Bucana, C., Fidler, I. J., Zhuang, Y. and Su, B. (2000). 
Mekk3 is essential for early embryonic cardiovascular development. Nature 
genetics, 24(3): 309-313. 
Yang, Q., Deng, X., Lu, B., Cameron, M., Fearns, C., Patricelli, M. P., Yates III, J. R., 
Gray, N. S. and Lee, J. D. (2010a). Pharmacological inhibition of BMK1 suppresses 
tumor growth through PML. Cancer Cell, 18: 258-267. 
Yang, Q. and Lee, J. D. (2011). Targeting the BMK1 MAP Kinase pathway in cancer therapy. 
Clin Cancer Res, 17: 3527-3532. 
Yang, S. H., Sharrocks, A. D. and Whitmarsh, A. J. (2003a). Transcriptional regulation by 
the MAP kinase signaling cascades. Gene, 320: 3-21. 
Yang, Y., Xie, P., Opatowsky, Y. and Schlessinger, J. (2010b). Direct contacts between 
extracellular membrane-proximal domains are required for VEGF receptor 
activation and cell signaling. Proc Natl Acad Sci U S A, 107: 1906-1911. 
Yang, Z.-Z., Tschopp, O., Hemmings-Mieszczak, M., Feng, J., Brodbeck, D., Perentes, E. 
and Hemmings, B. A. (2003b). Protein kinase Ba/Akt1 regulates placental 
development and fetal growth. J Biol Chem, 278: 32124-32131. 
Yarden, Y. and Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nat Rev 
Mol Cell Biol, 2: 127-137. 
References 
180 
Yoon, S. and Seger, R. (2006). The extracellular signal-regulated kinase: multiple 
substrates regulate diverse cellular functions. Growth Factors, 24(1): 21-44. 
Yuan, L., Moyon, D., Pardanaud, L., Breant, C., Karkkainen, M. J., Alitalo, K. and 
Eichmann, A. (2002). Abnormal lymphatic vessel development in neuropilin-2 
mutant mice. Development, 129: 4797-4806. 
Zachary, I. (2003). VEGF signalling: integration and multi-tasking in endothelial cell 
biology. Biochem Soc Trans, 31: 1171-1177. 
Zang, G., Christoffersson, G., Tian, G., Harun-Or-Rashid, M., Vågesjö, E., Phillipson, M., 
Barg, S., Tengholm, A. and Welsh, M. (2013). Aberrant association between 
vascular endothelial growth factor receptor-2 and VE-cadherin in response to 
vascular endothelial growth factor-a in Shb-deficient lung endothelial cells. 
Cellular signalling, 25: 85-92. 
Zhang, H., Kolb, F. A., Brondani, V., Billy, E. and Filipowicz, W. (2002). Human Dicer 
preferentially cleaves dsRNAs at their termini without a requirement for ATP. 
Embo J, 21: 5875-5885. 
Zhang, X., Gureasko, J., Shen, K., Cole, P. A. and Kuriyan, J. (2006). An allosteric 
mechanism for activation of the kinase domain of epidermal growth factor 
receptor. Cell, 125: 1137-1149. 
Zhang, Y. and Dong, C. (2007). Regulatory mechanisms of mitogen-activated kinase 
signaling. Cellular and molecular life sciences : CMLS, 64(21): 2771-2789. 
Zhao, Z., Wang, W., Geng, J., Wang, L., Su, G., Zhang, Y., Ge, Z. and Kang, W. (2010). 
Protein kinase C epsilon-dependent extracellular signal-regulated kinase 5 
phosphorylation and nuclear translocation involved in cardiomyocyte hypertrophy 
with angiotensin II stimulation. J Cell Biochem, 109: 653-662. 
Zhou, G., Bao, Z. Q. and Dixon, J. E. (1995). Components of a new human protein kinase 












8  Appendices 
Appendices 
182 
Appendix I – Complete adenoviral FLAG-ERK5 sequence 
Final viral titer: 7.72 x 109 ifu/mL 
Black: pAd/CMV/V5 DEST 
Pink: pENTR1a region transferred following recombination 
Blue: FLAG tag (Start codon in BOLD) 
Green: ERK5 sequence (T218/Y220 in BOLD)  













































































































































































































































































































































































































































































































































































































Appendix II – siRNA duplexes 
Protein Dharmacon product Catalogue Number Target (NCBI accession) 
Non-targeting control siGENOME Non-Targeting siRNA #3 D-001210-03 N/A 






NM_139034, NM_139032 (ORF) 






HRAS ON-TARGETplus HRAS siRNA 
J-004142-07 
J-004142-10 
NM_001130442, NM_005343 (ORF), 
NM_176795 (3’UTR) 








NM_004985, NM_033360 (ORF) 
 
NM_004985 (ORF), NM_033360 
(3’UTR) 
 
NM_004985, NM_033360 (3’UTR) 








Appendix III – ERK5 mRNA sequence data 
ERK5 mRNA sequence data for HeLa and HDMEC, compared against ERK5 NCBI reference 
sequence: NM_139033.2. Highlighted codons represent start (green) and stop codon (red). 
ERK5  AGCGTGGCCTTGGGAGGCGGGGCGGAGGGGGACGGACAGGGCAGCTCAAGACGCTGAGGT 
HeLa  ------------------------------------------------------------ 
HDMEC ------------------------------------------------------------ 
                                                                   
 
ERK5  GGTGGCTGCGGCCTTTGAACAAGTAAGTGAGCCACCCTCGGAGACCCCCGCGCTGGGGAC 
HeLa  ------------------------------------------------------------ 
HDMEC -----------------------------------------------------TGGGGAC 
                                                                   
 
ERK5  GGGAGGCCGGCGAGCCTCGGGACCTCTGAAAGCCTTGAGGAGGCGCGGGGACACCATGGC 
HeLa  ---------------CTCGGGACCTCTGAAAGCCTTGAGGAGGCGCGGGGACACCATGGC 
HDMEC GGGAGGCCGGCGAGCCTCGGGACCTCTGAAAGCCTTGAGGAGGCGCGGGGACACCATGGC 
                        ****************************************** 
 
ERK5  CGAGCCTCTGAAGGAGGAAGACGGCGAGGACGGCTCTGCGGAGCCCCCCGGGCCCGTGAA 
HeLa  CGAGCCTCTGAAGGAGGAAGACGGCGAGGACGGCTCTGCGGAGCCCCCCGGGCCCGTGAA 
HDMEC CGAGCCTCTGAAGGAGGAAGACGGCGAGGACGGCTCTGCGGAGCCCCCCGGGCCCGTGAA 
      ************************************************************ 
 
ERK5  GGCCGAACCCGCCCACACCGCTGCCTCTGTAGCGGCCAAGAACCTGGCCCTGCTTAAAGC 
HeLa  GGCCGAACCCGCCCACACCGCTGCCTCTGTAGCGGCCAAGAACCTGGCCCTGCTTAAAGC 
HDMEC GGCCGAACCCGCCCACACCGCTGCCTCTGTAGCGGCCAAGAACCTGGCCCTGCTTAAAGC 
      ************************************************************ 
 
ERK5  CCGCTCCTTCGATGTGACCTTTGACGTGGGCGACGAGTACGAGATCATCGAGACCATAGG 
HeLa  CCGCTCCTTCGATGTGACCTTTGACGTGGGCGACGAGTACGAGATCATCGAGACCATAGG 
HDMEC CCGCTCCTTCGATGTGACCTTTGACGTGGGCGACGAGTACGAGATCATCGAGACCATAGG 
      ************************************************************ 
 
ERK5  CAACGGGGCCTATGGAGTGGTGTCCTCCGCCCGCCGCCGCCTCACCGGCCAGCAGGTGGC 
HeLa  CAACGGGGCCTATGGAGTGGTGTCCTCCGCCCGCCGCCGCCTCACCGGCCAGCAGGTGGC 
HDMEC CAACGGGGCCTATGGAGTGGTGTCCTCCGCCCGCCGCCGCCTCACCGGCCAGCAGGTGGC 
      ************************************************************ 
 
ERK5  CATCAAGAAGATCCCTAATGCTTTCGATGTGGTGACCAATGCCAAGCGGACCCTCAGGGA 
HeLa  CATCAAGAAGATCCCTAATGCTTTCGATGTGGTGACCAATGCCAAGCGGACCCTCAGGGA 
HDMEC CATCAAGAAGATCCCTAATGCTTTCGATGTGGTGACCAATGCCAAGCGGACCCTCAGGGA 
      ************************************************************ 
 
ERK5  GCTGAAGATCCTCAAGCACTTTAAACACGACAACATCATCGCCATCAAGGACATCCTGAG 
HeLa  GCTGAAGATCCTCAAGCACTTTAAACACGACAACATCATCGCCATCAAGGACATCCTGAG 
HDMEC GCTGAAGATCCTCAAGCACTTTAAACACGACAACATCATCGCCATCAAGGACATCCTGAG 
      ************************************************************ 
 
ERK5  GCCCACCGTGCCCTATGGCGAATTCAAATCTGTCTACGTGGTCCTGGACCTGATGGAAAG 
HeLa  GCCCACCGTGCCCTATGGCGAATTCAAATCTGTCTACGTGGTCCTGGACCTGATGGAAAG 
HDMEC GCCCACCGTGCCCTATGGCGAATTCAAATCTGTCTACGTGGTCCTGGACCTGATGGAAAG 
      ************************************************************ 
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ERK5  CGACCTGCACCAGATCATCCACTCCTCACAGCCCCTCACACTGGAACACGTGCGCTACTT 
HeLa  CGACCTGCACCAGATCATCCACTCCTCACAGCCCCTCACACTGGAACACGTGCGCTACTT 
HDMEC CGACCTGCACCAGATCATCCACTCCTCACAGCCCCTCACACTGGAACACGTGCGCTACTT 
      ************************************************************ 
 
ERK5  CCTGTACCAACTGCTGCGGGGCCTGAAGTACATGCACTCGGCTCAGGTCATCCACCGTGA 
HeLa  CCTGTACCAACTGCTGCGGGGCCTGAAGTACATGCACTCGGCTCAGGTCATCCACCGTGA 
HDMEC CCTGTACCAACTGCTGCGGGGCCTGAAGTACATGCACTCGGCTCAGGTCATCCACCGTGA 
      ************************************************************ 
 
ERK5  CCTGAAGCCCTCCAACCTATTGGTGAATGAGAACTGTGAGCTCAAGATTGGTGACTTTGG 
HeLa  CCTGAAGCCCTCCAACCTATTGGTGAATGAGAACTGTGAGCTCAAGATTGGTGACTTTGG 
HDMEC CCTGAAGCCCTCCAACCTATTGGTGAATGAGAACTGTGAGCTCAAGATTGGTGACTTTGG 
      ************************************************************ 
 
ERK5  TATGGCTCGTGGCCTGTGCACCTCGCCCGCTGAACATCAGTACTTCATGACTGAGTATGT 
HeLa  TATGGCTCGTGGCCTGTGCACCTCGCCCGCTGAACATCAGTACTTCATGACTGAGTATGT 
HDMEC TATGGCTCGTGGCCTGTGCACCTCGCCCGCTGAACATCAGTACTTCATGACTGAGTATGT 
      ************************************************************ 
 
ERK5  GGCCACGCGCTGGTACCGTGCGCCCGAGCTCATGCTCTCTTTGCATGAGTATACACAGGC 
HeLa  GGCCACGCGCTGGTACCGTGCGCCCGAGCTCATGCTCTCTTTGCATGAGTATACACAGGC 
HDMEC GGCCACGCGCTGGTACCGTGCGCCCGAGCTCATGCTCTCTTTGCATGAGTATACACAGGC 
      ************************************************************ 
 
ERK5  TATTGACCTCTGGTCTGTGGGCTGCATCTTTGGTGAGATGCTGGCCCGGCGCCAGCTCTT 
HeLa  TATTGACCTCTGGTCTGTGGGCTGCATCTTTGGTGAGATGCTGGCCCGGCGCCAGCTCTT 
HDMEC TATTGACCTCTGGTCTGTGGGCTGCATCTTTGGTGAGATGCTGGCCCGGCGCCAGCTCTT 
      ************************************************************ 
 
ERK5  CCCAGGCAAAAACTATGTACACCAGCTACAGCTCATCATGATGGTGCTGGGTACCCCATC 
HeLa  CCCAGGCAAAAACTATGTACACCAGCTACAGCTCATCATGATGGTGCTGGGTACCCCATC 
HDMEC CCCAGGCAAAAACTATGTACACCAGCTACAGCTCATCATGATGGTGCTGGGTACCCCATC 
      ************************************************************ 
 
ERK5  ACCAGCCGTGATTCAGGCTGTGGGGGCTGAGAGGGTGCGGGCCTATATCCAGAGCTTGCC 
HeLa  ACCAGCCGTGATTCAGGCTGTGGGGGCTGAGAGGGTGCGGGCCTATATCCAGAGCTTGCC 
HDMEC ACCAGCCGTGATTCAGGCTGTGGGGGCTGAGAGGGTGCGGGCCTATATCCAGAGCTTGCC 
      ************************************************************ 
 
ERK5  ACCACGCCAGCCTGTGCCCTGGGAGACAGTGTACCCAGGTGCCGACCGCCAGGCCCTATC 
HeLa  ACCACGCCAGCCTGTGCCCTGGGAGACAGTGTACCCAGGTGCCGACCGCCAGGCCCTATC 
HDMEC ACCACGCCAGCCTGTGCCCTGGGAGACAGTGTACCCAGGTGCCGACCGCCAGGCCCTATC 
      ************************************************************ 
 
ERK5  ACTGCTGGGTCGCATGCTGCGTTTTGAGCCCAGCGCTCGCATCTCAGCAGCTGCTGCCCT 
HeLa  ACTGCTGGGTCGCATGCTGCGTTTTGAGCCCAGCGCTCGCATCTCAGCAGCTGCTGCCCT 
HDMEC ACTGCTGGGTCGCATGCTGCGTTTTGAGCCCAGCGCTCGCATCTCAGCAGCTGCTGCCCT 
      ************************************************************ 
 
ERK5  TCGCCACCCTTTCCTGGCCAAGTACCATGATCCTGATGATGAGCCTGACTGTGCCCCGCC 
HeLa  TCGCCACCCTTTCCTGGCCAAGTACCATGATCCTGATGATGAGCCTGACTGTGCCCCGCC 
HDMEC TCGCCACCCTTTCCTGGCCAAGTACCATGATCCTGATGATGAGCCTGACTGTGCCCCGCC 
      ************************************************************ 
 
ERK5  CTTTGACTTTGCCTTTGACCGCGAAGCCCTCACTCGGGAGCGCATTAAGGAGGCCATTGT 
HeLa  CTTTGACTTTGCCTTTGACCGCGAAGCCCTCACTCGGGAGCGCATTAAGGAGGCCATTGT 
HDMEC CTTTGACTTTGCCTTTGACCGCGAAGCCCTCACTCGGGAGCGCATTAAGGAGGCCATTGT 
      ************************************************************ 
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ERK5  GGCTGAAATTGAGGACTTCCATGCAAGGCGTGAGGGCATCCGCCAACAGATCCGCTTCCA 
HeLa  GGCTGAAATTGAGGACTTCCATGCAAGGCGTGAGGGCATCCGCCAACAGATCCGCTTCCA 
HDMEC GGCTGAAATTGAGGACTTCCATGCAAGGCGTGAGGGCATCCGCCAACAGATCCGCTTCCA 
      ************************************************************ 
ERK5  GCCTTCTCTACAGCCTGTGGCTAGTGAGCCTGGCTGTCCAGATGTTGAAATGCCCAGTCC 
HeLa  GCCTTCTCTACAGCCTGTGGCTAGTGAGCCTGGCTGTCCAGATGTTGAAATGCCCAGTCC 
HDMEC GCCTTCTCTACAGCCTGTGGCTAGTGAGCCTGGCTGTCCAGATGTTGAAATGCCCAGTCC 
      ************************************************************ 
 
ERK5  CTGGGCTCCCAGTGGGGACTGTGCCATGGAGTCTCCACCACCAGCCCCGCCACCATGCCC 
HeLa  CTGGGCTCCCAGTGGGGACTGTGCCATGGAGTCTCCACCACCAGCCCCGCCACCATGCCC 
HDMEC CTGGGCTCCCAGTGGGGACTGTGCCATGGAGTCTCCACCACCAGCCCCGCCACCATGCCC 
      ************************************************************ 
 
ERK5  CGGCCCTGCACCTGACACCATTGATCTGACCCTGCAGCCACCTCCACCAGTCAGTGAGCC 
HeLa  CGGCCCTGCACCTGACACCATTGATCTGACCCTGCAGCCACCTCCACCAGTCAGTGAGCC 
HDMEC CGGCCCTGCACCTGACACCATTGATCTGACCCTGCAGCCACCTCCACCAGTCAGTGAGCC 
      ************************************************************ 
 
ERK5  TGCCCCACCAAAGAAAGATGGTGCCATCTCAGACAATACTAAGGCTGCCCTTAAAGCTGC 
HeLa  TGCCCCACCAAAGAAAGATGGTGCCATCTCAGACAATACTAAGGCTGCCCTTAAAGCTGC 
HDMEC TGCCCCACCAAAGAAAGATGGTGCCATCTCAGACAATACTAAGGCTGCCCTTAAAGCTGC 
      ************************************************************ 
 
ERK5  CCTGCTCAAGTCTTTGAGGAGCCGGCTCAGAGATGGCCCCAGCGCACCCCTGGAGGCTCC 
HeLa  CCTGCTCAAGTCTTTGAGGAGCCGGCTCAGAGATGGCCCCAGCGCACCCCTGGAGGCTCC 
HDMEC CCTGCTCAAGTCTTTGAGGAGCCGGCTCAGAGATGGCCCCAGCGCACCCCTGGAGGCTCC 
      ************************************************************ 
 
ERK5  TGAGCCTCGGAAGCCGGTGACAGCCCAGGAGCGCCAGCGGGAGCGGGAGGAGAAGCGGCG 
HeLa  TGAGCCTCGGAAGCCGGTGACAGCCCAGGAGCGCCAGCGGGAGCGGGAGGAGAAGCGGCG 
HDMEC TGAGCCTCGGAAGCCGGTGACAGCCCAGGAGCGCCAGCGGGAGCGGGAGGAGAAGCGGCG 
      ************************************************************ 
 
ERK5  GAGGCGGCAAGAACGAGCCAAGGAGCGGGAGAAACGGCGGCAGGAGCGGGAGCGAAAGGA 
HeLa  GAGGCGGCAAGAACGAGCCAAGGAGCGGGAGAAACGGCGGCAGGAGCGGGAGCGAAAGGA 
HDMEC GAGGCGGCAAGAACGAGCCAAGGAGCGGGAGAAACGGCGGCAGGAGCGGGAGCGAAAGGA 
      ************************************************************ 
 
ERK5  ACGGGGGGCTGGGGCCTCTGGGGGCCCCTCCACTGACCCCTTGGCTGGACTAGTGCTCAG 
HeLa  ACGGGGGGCTGGGGCCTCTGGGGGCCCCTCCACTGACCCCTTGGCTGGACTAGTGCTCAG 
HDMEC ACGGGGGGCTGGGGCCTCTGGGGGCCCCTCCACTGACCCCTTGGCTGGACTAGTGCTCAG 
      ************************************************************ 
 
ERK5  TGACAATGACAGAAGCCTGTTGGAACGCTGGACTCGAATGGCCCGGCCCGCAGCCCCAGC 
HeLa  TGACAATGACAGAAGCCTGTTGGAACGCTGGACTCGAATGGCCCGGCCCGCAGCCCCAGC 
HDMEC TGACAATGACAGAAGCCTGTTGGAACGCTGGACTCGAATGGCCCGGCCCGCAGCCCCAGC 
      ************************************************************ 
 
ERK5  CCTCACCTCTGTGCCGGCCCCTGCCCCAGCGCCAACGCCAACCCCAACCCCAGTCCAACC 
HeLa  CCTCACCTCTGTGCCGGCCCCTGCCCCAGCGCCAACGCCAACCCCAACCCCAGTCCAACC 
HDMEC CCTCACCTCTGTGCCGGCCCCTGCCCCAGCGCCAACGCCAACCCCAACCCCAGTCCAACC 
      ************************************************************ 
 
ERK5  TACCAGTCCTCCTCCTGGCCCTGTAGCCCAGCCCACTGGCCCGCAACCACAATCTGCGGG 
HeLa  TACCAGTCCTCCTCCTGGCCCTGTAGCCCAGCCCACTGGCCCGCAACCACAATCTGCGGG 
HDMEC TACCAGTCCTCCTCCTGGCCCTGTAGCCCAGCCCACTGGCCCGCAACCACAATCTGCGGG 




ERK5  CTCTACCTCTGGCCCTGTACCCCAGCCTGCCTGCCCACCCCCTGGCCCTGCACCCCACCC 
HeLa  CTCTACCTCTGGCCCTGTACCCCAGCCTGCCTGCCCACCCCCTGGCCCTGCACCCCACCC 
HDMEC CTCTACCTCTGGCCCTGTACCCCAGCCTGCCTGCCCACCCCCTGGCCCTGCACCCCACCC 
      ************************************************************ 
ERK5  CACTGGCCCTCCTGGGCCCATCCCTGTCCCCGCGCCACCCCAGATTGCCACCTCCACCAG 
HeLa  CACTGGCCCTCCTGGGCCCATCCCTGTCCCCGCGCCACCCCAGATTGCCACCTCCACCAG 
HDMEC CACTGGCCCTCCTGGGCCCATCCCTGTCCCCGCGCCACCCCAGATTGCCACCTCCACCAG 
      ************************************************************ 
 
ERK5  CCTCCTGGCTGCCCAGTCACTTGTGCCACCCCCTGGGCTGCCTGGCTCCAGCACCCCAGG 
HeLa  CCTCCTGGCTGCCCAGTCACTTGTGCCACCCCCTGGGCTGCCTGGCTCCAGCACCCCAGG 
HDMEC CCTCCTGGCTGCCCAGTCACTTGTGCCACCCCCTGGGCTGCCTGGCTCCAGCACCCCAGG 
      ************************************************************ 
 
ERK5  AGTTTTGCCTTACTTCCCACCTGGCCTGCCGCCCCCAGACGCCGGGGGAGCCCCTCAGTC 
HeLa  AGTTTTGCCTTACTTCCCACCTGGCCTGCCGCCCCCAGACGCCGGGGGAGCCCCTCAGTC 
HDMEC AGTTTTGCCTTACTTCCCACCTGGCCTGCCGCCCCCAGACGCCGGGGGAGCCCCTCAGTC 
      ************************************************************ 
 
ERK5  TTCCATGTCAGAGTCACCTGATGTCAACCTTGTGACCCAGCAGCTATCTAAGTCACAGGT 
HeLa  TTCCATGTCAGAGTCACCTGATGTCAACCTTGTGACCCAGCAGCTATCTAAGTCACAGGT 
HDMEC TTCCATGTCAGAGTCACCTGATGTCAACCTTGTGACCCAGCAGCTATCTAAGTCACAGGT 
      ************************************************************ 
 
ERK5  GGAGGACCCCCTGCCCCCTGTGTTCTCAGGCACACCAAAGGGCAGTGGGGCTGGCTACGG 
HeLa  GGAGGACCCCCTGCCCCCTGTGTTCTCAGGCACACCAAAGGGCAGTGGGGCTGGCTACGG 
HDMEC GGAGGACCCCCTGCCCCCTGTGTTCTCAGGCACACCAAAGGGCAGTGGGGCTGGCTACGG 
      ************************************************************ 
 
ERK5  TGTTGGCTTTGACCTGGAGGAATTCTTAAACCAGTCTTTCGACATGGGCGTGGCTGATGG 
HeLa  TGTTGGCTTTGACCTGGAGGAATTCTTAAACCAGTCTTTCGACATGGGCGTGGCTGATGG 
HDMEC TGTTGGCTTTGACCTGGAGGAATTCTTAAACCAGTCTTTCGACATGGGCGTGGCTGATGG 
      ************************************************************ 
 
ERK5  GCCACAGGATGGCCAGGCAGATTCAGCCTCTCTCTCAGCCTCCCTGCTTGCTGACTGGCT 
HeLa  GCCACAGGATGGCCAGGCAGATTCAGCCTCTCTCTCAGCCTCCCTGCTTGCTGACTGGCT 
HDMEC GCCACAGGATGGCCAGGCAGATTCAGCCTCTCTCTCAGCCTCCCTGCTTGCTGACTGGCT 
      ************************************************************ 
 
ERK5  CGAAGGCCATGGCATGAACCCTGCCGATATTGAGTCCCTGCAGCGTGAGATCCAGATGGA 
HeLa  CGAAGGCCATGGCATGAACCCTGCCGATATTGAGTCCCTGCAGCGTGAGATCCAGATGGA 
HDMEC CGAAGGCCATGGCATGAACCCTGCCGATATTGAGTCCCTGCAGCGTGAGATCCAGATGGA 
      ************************************************************ 
 
ERK5  CTCCCCAATGCTGCTGGCTGACCTGCCTGACCTCCAGGACCCCTGAGGCCCCCAGCCTGT 
HeLa  CTCCCCAATGCTGCTGGCTGACCTGCCTGACCTCCAGGACCCCTGAGGCCCCCAGCCTGT 
HDMEC CTCCCCAATGCTGCTGGCTGACCTGCCTGACCTCCAGGACCCCTGAGGCCCCCAGCCTGT 
      ************************************************************ 
 
ERK5  GCCTTGCTGCCACAGTAGACCTAGTTCCAGGATCCATGGGAGCATTCTCAAAGGCTTTAG 
HeLa  GCCTTGCTGC-------------------------------------------------- 
HDMEC GCCTTGCTGCCACAGTAGACCTAGTTCCAGGATCCATGGGAGCATTCTCAAAGGCTTTAG 
      **********                                                   
 
ERK5  CCCTGGACCCAGCAGGTGAGGCTCGGCTTGGATTATTCTGCAGGTTCATCTCAGACCCAC 
HeLa  ------------------------------------------------------------ 
HDMEC CCCTGGACCCAGCAGGTGAGGCTCGGCTTGGATTATTCTGCAGGTTCATCTCAGACCCAC 




ERK5  CTTTCAGCCTTAAGCAGCCACCTGAGCCACCACCGAGCCATGGCAGGATCGGGAGACCCC 
HeLa  ------------------------------------------------------------ 
HDMEC CTTTCAGCCTTAAGCAGCCACCTGAGCCAC------------------------------ 
                                                                   
ERK5  AACTCCCCCTGAACAATCCTTTTCAGTATTATATTTTTATTATTATTATGTTATTATTAC 
HeLa  ------------------------------------------------------------ 
HDMEC ------------------------------------------------------------ 
                                                                   
 
ERK5  ACTGTCTTTTTGCCATCAAAATGAGGCCTGTGAAATACAAGGTTCCCTTCTGCACCTGAA 
HeLa  ------------------------------------------------------------ 
HDMEC ------------------------------------------------------------ 
                                                                   
 
ERK5            AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
HeLa            -------------------------------- 
HDMEC           -------------------------------- 
                                                 
Appendices 
203 
Appendix IV - Subcellular protein fractionation controls 
HDMEC were seeded on 10 cm plates for 24 h prior to overnight serum starvation and stimulation 
with 50 ng/mL VEGF for 10, 30 and 60 min. Cells were then lysed with the appropriate buffers from 
the Thermo Fischer Subcellular Fractionation Kit. Lysates were separated on a 4-12% NuPAGE gel as 
well as a 7% (w/v) acrylamide, 70 µM Phos-tag™ gel, followed by Western blotting (WB) with 
antibodies against CD31 (membrane control), Lamin (nuclear control) and GAPDH (cytoplasm 
control). Densitometric analysis of protein expression relative to the whole cell lysate of each 
subcellular region, is displayed beneath each blot to highlight protein enrichment. The whole cell 








Appendix V – Readout of ERK5-interacting proteins in HDMEC discovered by LC-MS/MS 
Proteins discovered in the untransduced, basal condition after LC-MS/MS, in Run 1 (blue), Run 2 (green) and Run 3 (pink) 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides # Peptides # PSMs # AAs 
MW 
[kDa] calc. pI 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
208.47 11.61 5 1 1 5 112 12.0 9.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
48.24 10.52 1 2 7 7 637 72.6 6.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
65.66 10.52 1 2 8 8 637 72.6 6.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
61.81 13.50 1 2 9 9 637 72.6 6.29 
O60814 Histone H2B type 1-K OS=Homo sapiens 
GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] 
56.54 19.05 14 1 2 2 126 13.9 10.32 
O60814 Histone H2B type 1-K OS=Homo sapiens 
GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] 
70.59 11.90 14 1 1 1 126 13.9 10.32 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
195.39 11.61 5 1 1 5 112 12.0 9.29 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
181.96 11.61 5 1 1 5 112 12.0 9.29 
P01859 Ig gamma-2 chain C region OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 - [IGHG2_HUMAN] 
38.74 2.76 1 1 1 1 326 35.9 7.59 
P01859 Ig gamma-2 chain C region OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 - [IGHG2_HUMAN] 
39.79 2.76 1 1 1 1 326 35.9 7.59 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 
SV=2 - [ALBU_HUMAN] 
80.28 8.21 1 2 6 9 609 69.3 6.28 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 
SV=2 - [ALBU_HUMAN] 
66.39 8.21 1 3 5 5 609 69.3 6.28 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
62.83 9.47 6 2 6 6 644 66.0 8.12 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
344.82 27.64 6 13 17 17 644 66.0 8.12 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 




P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB 
PE=1 SV=2 - [TBB5_HUMAN] 
71.09 9.68 11 2 4 4 444 49.6 4.89 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
41.16 6.34 17 1 4 4 584 58.8 5.21 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
156.28 24.32 10 6 14 14 584 58.8 5.21 
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo 
sapiens GN=TRIM21 PE=1 SV=1 - [RO52_HUMAN] 
42.08 1.89 1 1 1 1 475 54.1 6.38 
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo 
sapiens GN=TRIM21 PE=1 SV=1 - [RO52_HUMAN] 
45.39 1.89 1 1 1 1 475 54.1 6.38 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 
161.52 27.61 7 7 14 15 623 62.0 5.24 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
92.24 15.18 12 3 9 9 639 65.4 8.00 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
53.75 5.32 1 1 3 3 639 65.4 8.00 
P52732 Kinesin-like protein KIF11 OS=Homo sapiens 
GN=KIF11 PE=1 SV=2 - [KIF11_HUMAN] 
41.48 2.08 1 1 2 2 1056 119.1 5.64 
P52732 Kinesin-like protein KIF11 OS=Homo sapiens 
GN=KIF11 PE=1 SV=2 - [KIF11_HUMAN] 
35.87 10.70 1 1 12 12 1056 119.1 5.64 
P53999 Activated RNA polymerase II transcriptional 
coactivator p15 OS=Homo sapiens GN=SUB1 PE=1 
SV=3 - [TCP4_HUMAN] 
59.85 8.66 1 1 1 1 127 14.4 9.60 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB 
PE=1 SV=1 - [ACTB_HUMAN] 
0.00 13.87 14 1 5 5 375 41.7 5.48 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 
SV=2 - [H4_HUMAN] 
42.26 29.13 1 1 3 3 103 11.4 11.36 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 
SV=2 - [H4_HUMAN] 
44.41 29.13 1 1 3 3 103 11.4 11.36 
P68363 Tubulin alpha-1B chain OS=Homo sapiens 
GN=TUBA1B PE=1 SV=1 - [TBA1B_HUMAN] 
114.63 22.17 8 5 7 8 451 50.1 5.06 
P68371 Tubulin beta-4B chain OS=Homo sapiens 
GN=TUBB4B PE=1 SV=1 - [TBB4B_HUMAN] 
68.61 14.83 11 1 6 6 445 49.8 4.89 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 
SV=3 - [CASPA_HUMAN] 
36.56 0.96 2 1 1 1 521 58.9 7.33 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 
SV=3 - [CASPA_HUMAN] 
36.61 0.96 2 1 1 1 521 58.9 7.33 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 




Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 
47.34 12.57 1 1 3 3 342 36.7 5.17 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 
57.60 16.96 1 2 4 4 342 36.7 5.17 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens 
GN=TUBA1C PE=1 SV=1 - [TBA1C_HUMAN] 
43.07 17.37 5 1 5 5 449 49.9 5.10 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens 
GN=TUBA1C PE=1 SV=1 - [TBA1C_HUMAN] 
92.55 12.69 8 3 4 4 449 49.9 5.10 
 
Proteins discovered in the transduced, basal condition after LC-MS/MS, in Run 1 (blue), Run 2 (green) and Run 3 (pink) 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides # Peptides # PSMs # AAs MW [kDa] calc. pI 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 
SV=1 - [KV203_HUMAN] 
244.54 11.61 5 1 1 6 112 12.0 9.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo sapiens 
GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
81.94 14.60 1 3 10 10 637 72.6 6.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo sapiens 
GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
83.57 20.72 1 4 13 13 637 72.6 6.29 
O60814 Histone H2B type 1-K OS=Homo sapiens GN=HIST1H2BK 
PE=1 SV=3 - [H2B1K_HUMAN] 
36.69 19.05 14 1 2 2 126 13.9 10.32 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 
SV=1 - [KV203_HUMAN] 
198.69 11.61 5 1 1 5 112 12.0 9.29 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens PE=1 
SV=1 - [KV203_HUMAN] 
246.65 11.61 5 1 1 9 112 12.0 9.29 
P01700 Ig lambda chain V-I region HA OS=Homo sapiens PE=1 
SV=1 - [LV102_HUMAN] 
34.08 4.46 8 1 1 1 112 11.9 8.91 
P01859 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 - [IGHG2_HUMAN] 
36.59 2.76 1 1 1 1 326 35.9 7.59 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
145.41 8.21 1 2 6 17 609 69.3 6.28 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 




P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
50.79 3.61 1 1 2 2 609 69.3 6.28 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
301.08 26.86 5 14 16 16 644 66.0 8.12 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
70.76 8.39 2 3 6 6 644 66.0 8.12 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 
SV=2 - [TBB5_HUMAN] 
69.44 10.36 11 3 4 4 444 49.6 4.89 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 
SV=2 - [TBB5_HUMAN] 
61.90 17.57 11 2 7 7 444 49.6 4.89 
P08238 Heat shock protein HSP 90-beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 - [HS90B_HUMAN] 
46.19 2.21 4 1 2 2 724 83.2 5.03 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
220.72 22.60 21 8 13 13 584 58.8 5.21 
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo sapiens 
GN=TRIM21 PE=1 SV=1 - [RO52_HUMAN] 
43.49 1.89 1 1 1 1 475 54.1 6.38 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 
PE=1 SV=3 - [K1C9_HUMAN] 
123.58 18.78 2 5 8 9 623 62.0 5.24 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
106.25 16.28 10 5 10 10 639 65.4 8.00 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
40.11 3.44 1 1 2 2 639 65.4 8.00 
P52732 Kinesin-like protein KIF11 OS=Homo sapiens GN=KIF11 
PE=1 SV=2 - [KIF11_HUMAN] 
37.07 7.95 1 1 9 9 1056 119.1 5.64 
P53999 Activated RNA polymerase II transcriptional coactivator 
p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 - 
[TCP4_HUMAN] 
63.64 8.66 1 1 1 1 127 14.4 9.60 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 
SV=1 - [ACTB_HUMAN] 
40.65 18.93 10 1 6 6 375 41.7 5.48 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 
SV=1 - [ACTB_HUMAN] 
43.22 21.87 10 1 8 8 375 41.7 5.48 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 
- [H4_HUMAN] 
44.71 29.13 1 1 3 3 103 11.4 11.36 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 
- [H4_HUMAN] 
50.58 29.13 1 1 3 3 103 11.4 11.36 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B 
PE=1 SV=1 - [TBA1B_HUMAN] 
101.64 20.62 6 4 6 6 451 50.1 5.06 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B 
PE=1 SV=1 - [TBA1B_HUMAN] 




Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
80.09 18.87 1 2 14 20 816 88.3 5.88 
Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
264.73 28.43 3 12 21 26 816 88.3 5.88 
Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
309.01 32.84 1 12 26 33 816 88.3 5.88 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 SV=3 - 
[CASPA_HUMAN] 
33.80 0.96 2 1 1 1 521 58.9 7.33 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 SV=3 - 
[CASPA_HUMAN] 
0.00 0.96 2 1 1 1 521 58.9 7.33 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens GN=WDR77 
PE=1 SV=1 - [MEP50_HUMAN] 
70.73 9.94 1 2 3 3 342 36.7 5.17 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens GN=WDR77 
PE=1 SV=1 - [MEP50_HUMAN] 
86.33 9.94 1 3 3 3 342 36.7 5.17 
Q9BQE3 Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C 
PE=1 SV=1 - [TBA1C_HUMAN] 
55.09 7.57 5 1 3 3 449 49.9 5.10 
Q9UHT4 Putative uncharacterized protein PRO1854 OS=Homo 
sapiens GN=PRO1854 PE=5 SV=1 - [YG001_HUMAN] 






Proteins discovered in the transduced, 30 min VEGF stimulated condition after LC-MS/MS, in Run 1 (blue), Run 2 (green) and Run 3 (pink) 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides # Peptides # PSMs # AAs 
MW 
[kDa] calc. pI 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
87.37 19.31 1 4 13 13 637 72.6 6.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
71.42 18.68 1 3 13 13 637 72.6 6.29 
O14744 Protein arginine N-methyltransferase 5 OS=Homo 
sapiens GN=PRMT5 PE=1 SV=4 - [ANM5_HUMAN] 
68.57 15.86 1 3 11 11 637 72.6 6.29 
O60814 Histone H2B type 1-K OS=Homo sapiens 
GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] 
59.52 19.05 14 1 2 2 126 13.9 10.32 
O60814 Histone H2B type 1-K OS=Homo sapiens 
GN=HIST1H2BK PE=1 SV=3 - [H2B1K_HUMAN] 
61.77 19.05 14 1 2 2 126 13.9 10.32 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
234.26 11.61 5 1 1 6 112 12.0 9.29 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
200.82 11.61 5 1 1 5 112 12.0 9.29 
P01616 Ig kappa chain V-II region MIL OS=Homo sapiens 
PE=1 SV=1 - [KV203_HUMAN] 
249.65 11.61 5 1 1 7 112 12.0 9.29 
P01859 Ig gamma-2 chain C region OS=Homo sapiens 
GN=IGHG2 PE=1 SV=2 - [IGHG2_HUMAN] 
36.95 2.76 1 1 1 1 326 35.9 7.59 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
- [ALBU_HUMAN] 
50.62 2.46 1 1 1 1 609 69.3 6.28 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 
- [ALBU_HUMAN] 
45.91 5.09 1 1 3 3 609 69.3 6.28 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
116.09 11.96 2 4 8 8 644 66.0 8.12 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
177.97 21.27 5 9 13 13 644 66.0 8.12 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens 
GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN] 
81.82 11.80 2 4 8 8 644 66.0 8.12 
P07437 Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 
SV=2 - [TBB5_HUMAN] 
61.09 13.06 11 2 5 5 444 49.6 4.89 
P08670 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 - 
[VIME_HUMAN] 




P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
43.92 9.59 1 1 6 6 584 58.8 5.21 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
137.35 16.61 17 5 10 10 584 58.8 5.21 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens 
GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 
41.49 9.59 8 1 6 6 584 58.8 5.21 
P19474 E3 ubiquitin-protein ligase TRIM21 OS=Homo sapiens 
GN=TRIM21 PE=1 SV=1 - [RO52_HUMAN] 
43.25 1.89 1 1 1 1 475 54.1 6.38 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 
63.55 6.58 1 1 4 4 623 62.0 5.24 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 
88.04 11.40 1 3 6 6 623 62.0 5.24 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
87.65 8.14 4 3 5 5 639 65.4 8.00 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo 
sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 
52.16 5.32 1 1 3 3 639 65.4 8.00 
P52732 Kinesin-like protein KIF11 OS=Homo sapiens 
GN=KIF11 PE=1 SV=2 - [KIF11_HUMAN] 
55.70 2.46 1 1 3 3 1056 119.1 5.64 
P53999 Activated RNA polymerase II transcriptional coactivator 
p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 - 
[TCP4_HUMAN] 
66.77 8.66 1 1 1 1 127 14.4 9.60 
P53999 Activated RNA polymerase II transcriptional coactivator 
p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 - 
[TCP4_HUMAN] 
41.88 8.66 1 1 1 1 127 14.4 9.60 
P53999 Activated RNA polymerase II transcriptional coactivator 
p15 OS=Homo sapiens GN=SUB1 PE=1 SV=3 - 
[TCP4_HUMAN] 
53.42 8.66 1 1 1 1 127 14.4 9.60 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB 
PE=1 SV=1 - [ACTB_HUMAN] 
62.25 13.87 14 2 5 5 375 41.7 5.48 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB 
PE=1 SV=1 - [ACTB_HUMAN] 
56.30 16.00 10 1 6 6 375 41.7 5.48 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB 
PE=1 SV=1 - [ACTB_HUMAN] 
36.82 16.00 14 1 6 6 375 41.7 5.48 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 
SV=2 - [H4_HUMAN] 
42.55 17.48 1 1 2 2 103 11.4 11.36 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 
SV=2 - [H4_HUMAN] 
55.72 17.48 1 1 2 2 103 11.4 11.36 
P62805 Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 
SV=2 - [H4_HUMAN] 




P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B 
PE=1 SV=1 - [TBA1B_HUMAN] 
114.98 14.86 8 5 5 5 451 50.1 5.06 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B 
PE=1 SV=1 - [TBA1B_HUMAN] 
75.52 16.63 5 2 5 5 451 50.1 5.06 
P68363 Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B 
PE=1 SV=1 - [TBA1B_HUMAN] 
123.83 18.63 8 5 6 6 451 50.1 5.06 
P68371 Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B 
PE=1 SV=1 - [TBB4B_HUMAN] 
59.41 15.73 11 2 6 6 445 49.8 4.89 
Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
266.01 28.19 1 9 22 27 816 88.3 5.88 
Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
223.86 34.68 1 9 26 30 816 88.3 5.88 
Q13164 Mitogen-activated protein kinase 7 OS=Homo sapiens 
GN=MAPK7 PE=1 SV=2 - [MK07_HUMAN] 
292.05 30.15 1 11 25 30 816 88.3 5.88 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 
SV=3 - [CASPA_HUMAN] 
33.89 0.96 2 1 1 1 521 58.9 7.33 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 
SV=3 - [CASPA_HUMAN] 
36.55 0.96 2 1 1 1 521 58.9 7.33 
Q92851 Caspase-10 OS=Homo sapiens GN=CASP10 PE=1 
SV=3 - [CASPA_HUMAN] 
36.52 0.96 2 1 1 1 521 58.9 7.33 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 
68.68 9.94 1 3 3 3 342 36.7 5.17 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 
40.92 5.56 1 1 2 2 342 36.7 5.17 
Q9BQA1 Methylosome protein 50 OS=Homo sapiens 
GN=WDR77 PE=1 SV=1 - [MEP50_HUMAN] 
58.19 12.57 1 2 3 3 342 36.7 5.17 
Q9UHT4 Putative uncharacterized protein PRO1854 OS=Homo 
sapiens GN=PRO1854 PE=5 SV=1 - [YG001_HUMAN] 
36.63 7.46 6 1 1 2 67 8.3 10.08 
 
